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Abstract 
 
Background 
 
Depression is a common, disabling condition for which psychological treatments, in 
particular cognitive behavioural therapies are recommended. Promising results from 
randomised trials has renewed interest in behavioural therapy, which may be suitable 
for delivery by non-specialist therapists.     
 
Aims 
 
To deliver a phased research programme to examine the clinical and cost 
effectiveness of behavioural therapy for depressed adults, and in particular the 
suitability of the intervention for delivery by non specialists.     
 
Research design 
 
A systematic review and meta-analysis examined randomised trials of behavioural 
treatments for depression compared to controls or other psychotherapies. Data on 
symptom level, recovery/dropout rate and study level moderators (study quality, 
number of sessions, severity and level of training) were extracted and analysed.  
Based upon results of the meta-analysis a randomised controlled trial of clinical and 
cost effectiveness comparing BA delivered by non-specialist with treatment as usual 
in a primary care setting was conducted.  
 
Results 
 
Meta-Analysis: Seventeen randomised controlled trials including 1109 subjects were 
included. A meta-analysis of symptom level post-treatment showed behavioural 
therapies were superior to controls (SMD -0.70 CI -1.00 to -0.39, k=12, N= 459), 
brief psychotherapy (SMD -0.56 -1.0 to-0.12, k=3, N=166), supportive therapy 
(SMD -0.75 CI –1.37 to -0.14, k=2, N=45) and equal to cognitive behavioural 
therapy (SMD 0.08 CI -0.14 to 0.30, k=12, N=476).  
 
Randomised controlled trial: Intention to treat analyses indicated a difference in 
favour of BA of −15.79 (95% CI −24.55 to −7.02) on the Beck Depression 
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Inventory-II, −11.12; (95% CI = −17.53 to −4.70), on the Work and Social 
Adjustment Scale and a 0.20 (95% CI 0.01 to 0.39) improvement in quality adjusted 
life year. An incremental cost effectiveness ratio of £5756 per QALY indicates with 
a 97% probability that BA delivered by non-specialists is more cost effective than 
usual primary care at a threshold value of £20,000. 
 
Conclusion 
 
Behavioural Activation is an effective psychological treatment for depression that 
appears suitable for delivery by non-specialists. Further research with larger sample 
sizes and longer follow up is required to expand on the findings reported in this 
thesis.    
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Introduction 
 
This work is an evaluation of Behavioural Activation (BA) for depression in a 
practical setting. Having reviewed the literature to understand the theoretical 
background of the therapy and its existing evidence base, the next step was to 
explore whether this therapy was suitable to be adopted in a UK setting and 
specifically whether it could be delivered by non specialist therapists.  
Embedded within these aims are a number of different objectives and research 
questions. The structure of the research and therefore the thesis follows guidance set 
out by the Medical Research Council in relation to complex interventions (Medical 
Research Council 2000, Medical Research Council 2008) (see fig 1).  
 
 
 Figure 1: MRC Framework for development and evaluation of complex 
interventions. 
 
The work presented in this thesis follows a logical progression through the phases of 
development, feasibility and piloting and into the first stages of evaluation. Results 
from this work have been subsequently used to inform the design of a large scale 
multi centre randomised controlled trial to estimate the clinical and cost effectiveness 
of BA delivered by non specialists with short training vs. CBT, thereby furthering the 
journey around the MRC framework circle. 
The research for this thesis was conducted over 4 to 5 years and conducted in the 
context of the increasing drive to deliver effective talking therapies in the UK health 
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environment that offer good value for money and improve accessibility (Layard 
2006). By placing research in this context and disseminating findings from the thesis 
as the research progressed, it was hoped that the results could help inform practice 
and future policy. 
 
In this research I endeavoured to consider the durability of BA through evaluation of 
its delivery by non specialist qualified mental health workers. Key figures in the 
development of behaviour therapy have forwarded assertions that, due to its 
parsimony, BA was suitable for wide dissemination (Jacobson et al. 1996) however 
at the time of embarking on this research there was no indication such research had 
been conducted or was in progress (Ekers et al. 2008).   
 
Intervention development phase  
 
Following Figure 1, the research in this thesis can be put into the different stages 
required for evaluating complex interventions.  The intervention development phase 
of this research is reported in chapters one to three of this thesis. Firstly the 
epidemiology of depression and its impact on individuals and society was reviewed 
(see Chapter One). The difficulties of access to treatment were then considered in 
relation to the need for the development of an effective single strand psychological 
therapy that lends itself to wide dissemination.   
 
Chapter Two then examines the theoretical underpinning of behavioural activation 
through reference to published materials. This examination was used to reflect upon 
BA‟s adaptability across health care settings. Variants of the approach are considered 
and linked to the design of an intervention relevant for this research. This allowed for 
appropriate adaptation of BA for delivery by non-specialists in contrast to highly 
trained psychological therapists.  
 
Chapter Three describes detailed analysis of the evidence base through a systematic 
review with meta-analysis of randomised trials of behavioural therapies for 
depression. This is used to establish the effectiveness of the approach from all 
published and unpublished randomised trial evidence and to ascertain gaps in the 
research literature.  
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This development phase is an essential component of the MRC approach (Campbell 
et al. 2000) allowing the development of a behavioural activation research agenda 
based upon need, theory and all currently available evidence.  
 
Feasibility and Piloting Phase 
 
Chapter four outlines the development, design and delivery of an exploratory 
randomised trial design based upon findings from the development phase outlined in 
Chapters Two and Three. Information from the meta-analysis was used to inform 
sample size calculation and intervention design. A new treatment manual suitable for 
non-specialist therapists and application in a generalised setting was written 
incorporating the theory explored in Chapter Two.  As value for money is an 
important consideration in accessibility, both clinical and cost effectiveness were 
explored in this study. Results are outlined and discussed, relating to the potential 
benefit BA may offer. This process aimed to develop a new approach to the delivery 
of BA and present an evaluation of its feasibility in the UK. This has subsequently 
been used to inform the design of a large scale randomised controlled trial for the 
next evaluation phase in the MRC cycle of complex intervention development.  
 
Introduction summary  
 
This thesis contributes to the current evidence base of behavioural activation for 
depression by following a structured approach to exploring complex interventions. It 
is envisaged that findings will be disseminated widely to improve knowledge of 
behavioural activation and its use in the treatment of depression. The structure of the 
remainder of the thesis is as follows: 
 Chapter 1: Epidemiology of Depression and issues in the delivery of 
psychological therapies. 
 Chapter 2: BA and its theoretical background. 
 Chapter 3: A systematic review and meta-analysis of behavioural therapies 
for depression. 
 Chapter 4: A randomised controlled trial of clinical and cost effectiveness of 
behavioural activation for depression delivered by the non specialist. 
 Chapter 5: Summary and conclusion. 
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Chapter One: Depression, epidemiology, impact and access 
to treatment 
 
  
18 
 
1.1 Depression  
1.1.1 Prevalence 
 
Mental health problems are common among the adult population. More than a 
quarter of all people are likely to be affected at some time in their lives by such 
difficulties, which contribute 43% of years lived with disability (YLD) (World 
Health Organisation 2001). Point prevalence rates of all mental disorders range 
between 10-15% (McManus et al. 2009). The most prevalent mental health 
conditions are made up of a range of anxious and depressive symptoms. They 
indicate a breakdown in „normal‟ functioning, are commonly found in community 
settings and cause substantial distress and disability (Goldberg and Huxley 1992). 
Anxiety and depression diagnostic categories combined have been seen to contribute 
over 50% of all disability associated with mental health disorders, in contrast to less 
than 10% associated with schizophrenia (Henderson et al. 2001).  
 
Depression is one of the most prevalent common mental health disorders seen 
globally (World Health Organisation 2001). The level of severity and disability 
associated with depression varies from a relatively mild fluctuating condition to 
major depressive disorder. There are two main classification tools used for the 
diagnosis of depression: in Europe the ICD-10 (World Health Organisation 1992)  
and in the USA the DSM-1V(American Psychiatric Association 1994). Depression 
can be categorised based upon severity using a symptom count approach: not 
depressed (fewer than four symptoms), mild depression (four symptoms), moderate 
(five to six symptoms) and severe (seven or more symptoms). Differences between 
the two classification tools (see Table 1) have been present since their development 
more than 50 years ago (DSM I 1952 and ICD 1948).  The tools were developed on 
each side of the Atlantic by the American Psychiatric Association and World Health 
Organisation (WHO) respectively. Despite attempts to foster international 
consistency, slight discrepancies have remained. The development of multi-axial 
approaches to diagnosis in DSM III was a dramatic departure from the approaches 
used in ICD-9 and its predecessor DSM-II.  
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Table 1: Diagnostic criteria for DSM-IV and ICD10 
 DSM-IV ICD-10 
Clinical 
significance 
Symptoms cause clinically significant  stress or  
impairment in social, occupational or other important 
areas of functioning. 
 
Some difficulty in continuing with ordinary work  and social activities, but will 
probably not cease to function completely in mild depressive episode; 
considerable difficulty in continuing with social, work or domestic activities in 
moderate depressive episode; considerable distress or agitation, and 
unlikely to continue with social, work, or domestic activities, except to a very 
limited extent in severe depressive episode. 
 
Duration Most of day, nearly every day for at least 2 weeks. 
 
Duration of at least 2 weeks is usually required for diagnosis for depressive episodes 
of all three grades of severity. 
 
Classification of 
severity 
Five or more of following symptoms; at least one 
symptom is either depressed mood or loss of interest 
or pleasure: 
(1) Depressed mood 
(2) Loss of interest 
(3) significant weight  loss or gain or decrease or  
increase in appetite 
(4) Insomnia or hypersomnia 
(5) Psychomotor agitation or retardation 
(6) Fatigue or loss of energy 
(7) Feelings of worthlessness or excessive or  
inappropriate guilt 
(8) Diminished ability to think or concentrate, or 
indecisiveness 
(9) Recurrent thoughts of death, recurrent suicidal 
ideation without a specific plan, or suicide attempt or 
a 
specific plan 
Depressed mood, loss of interest and enjoyment,   and reduced energy leading to 
increased fatigability and diminished activity in typical depressive episodes; other 
common symptoms are: 
(1) Reduced concentration and attention 
(2) Reduced self-esteem and self-confidence 
(3) ideas of guilt and unworthiness (even in mild type of episode) 
(4) Bleak and pessimistic views of the future 
(5) Ideas or acts of self-harm or suicide 
(6) Disturbed sleep 
(7) Diminished appetite 
Typical examples of “somatic” symptoms are: loss of interest or pleasure in 
activities that are normally enjoyable; lack of emotional reactivity to normally 
pleasurable surroundings and events; waking in the morning 2 h or more before the 
usual time; 
depression worse in the morning; objective evidence of psychomotor retardation or 
agitation; marked loss of appetite; weight loss; marked loss of libido.  
 Mild depressive episode, two of most typical symptoms of depression and 
two of the other symptoms are required. If four or more of the somatic 
symptoms are present, the episode is diagnosed: With somatic symptoms.  
20 
 
 Moderate depressive episode, two of three of most typical symptoms of 
depression and at least three of the other symptoms are required. If four or 
more of the somatic symptoms are present, the episode is diagnosed: With 
somatic symptoms.  
 For severe depressive episode, all three of the typical symptoms noted for 
mild and moderate depressive episodes are present and at least four other 
symptoms of severe intensity are required. 
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Despite the variance in approach to diagnosis, relatively consistent pictures 
emerge regarding the epidemiology of depression and its impact on the 
individual and society. 
 
Those suffering from depression are likely to experience significant 
distress, impaired daily functioning and an increased risk of suicide 
(Hirschfeld et al. 1997). The UK national psychiatric morbidity survey 
used a sample of close to 10,000 individuals to estimate the prevalence of 
mental health problems using the Revised Version of the Clinical Interview 
Schedule (CIS-R) (Lewis et al. 1992) to assign diagnosis. Mixed 
depression and anxiety was identified as the most common mental disorder 
with a prevalence of 8.8%, depressive disorder alone having a prevalence 
of  2.6% (Singleton et al. 2001). This picture did not change markedly 
when the survey was repeated in 2007 with 8.8% of adults found to have 
mixed anxiety and depression and 2.3% a depressive episode in the week 
prior to the survey (McManus et al. 2009) (see Figure 2). The co-
occurrence of depression and anxiety disorders is long established. In the 
United States 58% of those with major depression  have an additional 
anxiety disorder and two thirds of those with generalised anxiety and or 
panic disorder have a history of depression (Kessler et al. 1998).  This 
pattern is a consistent finding in epidemiological studies of working age 
adults, older adults (Beekman et al. 2000) and those exploring sub 
threshold disorders (Pollack 2005). 
 
Such point prevalence rates indicate the scale of common mental health 
problems and in particular depression and mixed anxiety and depression at 
any given time. This is expanded if we look beyond point prevalence and 
examine the rates of these conditions in a population over a longer time 
span. Using the DSM-IV in a sample of 9282 adults in the USA,12-month 
and lifetime prevalence of major depression was explored (Kessler et al. 
2005). In this survey, rates of 6.7% for 12 month depression and 16.6% for 
lifetime depression were observed, with 23.3% and 37.3% of those 
identified experiencing severe and moderate levels of symptoms 
respectively. This survey identified higher rates of depression than the UK 
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surveys, which may be explained by the use of 12 months‟ and lifetime 
time spans.  
 
In summary it is reasonable to assume that more than one in ten people in 
the community are likely to be experiencing depression or mixed anxiety 
and depression at any given time. These numbers are likely to increase 
when viewed over a longer period with approximately half of these 
experiencing significant symptoms that warrant intervention (National 
Institute for Health and Clinical Excellence 2011).  
 
 
 
 
Figure 2: Prevalence of common mental health disorder in the week before 
assessment. Taken from psychiatric morbidity survey 2007  
1.1.2 Treated depression 
 
The majority of depression is treated within primary care (Fletcher et al. 
2006) with the cost for such treatment being estimated at twice that of all 
inpatient psychiatric services (Pincus and Pettit 2001). Prevalence of 
treated depression in primary care in 1998 was 29/1000 for males and 
70/1000 for females (Office for National Statistics 2000). Such data, 
however, is based upon a recording of diagnosis and drug treatment on 
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primary care systems. As such they are indicators of healthcare cost and 
demand, but should be viewed with caution as valid indicators of true 
disorder prevalence. Numbers are likely to be biased by factors such as 
variance in help seeking behaviour of patients and correct diagnosis, 
coding and prescription by practitioners.  
1.1.3 Onset and Prognosis 
 
The mean age of onset for depression is 30 years (Wilhelm et al. 2006, 
Kessler et al. 2005) with a strong likelihood of a recurring and chronic 
course. However wide variation can be seen, with a substantial proportion 
of people having a first episode in childhood or adolescence (Fava and 
Kendler 2000).  At one year 60% of those treated routinely in primary care 
and 50% of milder depressions meet criteria for caseness (Von Korff and 
Goldberg 2001). It has also been observed that approximately half of 
people with depressive illness will experience recurrence, with further 
relapse being associated with poorer prognosis, following a third 
recurrence such risk of relapse raises to 90% (Kupfer 1991). Biological 
factors, social stress and life events appear related to increased duration of 
depressed episodes (Singleton et al. 2001). Such poor prognosis (Lloyd et 
al. 1996, Kennedy et al. 2004, Judd et al. 1998), reflected in older adults 
also (Cole et al. 1999), has led to suggestions that depression is best 
managed as a chronic condition rather than a series of acute episodes 
managed separately (Andrews 2001). 
1.2 Determinates of depression  
1.2.1 Socioeconomic status and depression 
The association between poor socioeconomic status and ill-health has long 
been acknowledged and reflected in mental health conditions (Office for 
National Statistics 2000, Taylor et al. 1997). Low economic status is 
associated with increased morbidity rate of depression (Lorant et al. 2003). 
In common mental health conditions in general across Europe and North 
America, a near two-fold increase of morbidity between lowest and highest 
socioeconomic groups is observed (WHO International Consortium in 
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Psychiatric Epidemiology 2000, World Health Organisation 2001). In the 
United Kingdom poverty and unemployment is associated with longer 
duration of common mental health problems and increased financial strain 
(Weich and Lewis 1998, Lorant et al. 2003). The strongest predictor of the 
prevalence and persistence of depression in a large-scale depression 
management study was seen to be the measure of social deprivation of the 
GP practice location (Ostler et al. 2001). This was reflected in observed 
rates of treated depression prevalence in England and Wales. Highest rates 
of treated depression were found in deprived industrial areas (76.9 female, 
33.5 male per 1000)  (Office for National Statistics 2000) (Figure 3). It is 
of note that in this study those categorised from metropolitan professional 
areas had higher prevalence rates of treated depression than those from 
inner-city estates/deprived city areas. This is an interesting finding in and 
would appear to be at odds with other evidence linking increased rates of 
depression with poverty. It may be related to the use of treated depression 
to measure prevalence in this study. A number of potential factors may bias 
these results; in particular they  may reflect the possibility of inverse care 
law factors in relation to treatment uptake, i.e. that good quality medical 
care is seen to vary inversely to population needs (Tudor Hart 1971). That 
is, those in metropolitan professional areas may be more likely to seek help 
and to be treated by professionals more likely to identify need and offer 
help. This then rewards and increases help-seeking and giving in those 
areas, hence increasing the treated prevalence estimate.  
Changing socioeconomic status has an impact on the diagnosis and severity 
of depression (Lorant et al. 2007). In a sample of 11,909 individuals in 
Belgium, associations were noted over seven year follow-up that indicated 
a negative effect from worsening socioeconomic status. The impact of 
negative associations were far greater than positive effects from improving 
conditions and impacted on females and those in low income households 
more. 
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Figure 3: Prevalence of treated depression in primary care by ONS area 
classification, age standardised and aggregated 1994-1998 (Office for 
National Statistics 2000) 
 
 
1.2.2 Gender and depression 
 
As indicated in fig 3 gender has a significant effect of the prevalence rate 
of depression in the United Kingdom. In a large UK study (N=9792) 
working age women experienced 1.5-2 times more depression than is 
observed in males. Differences are not explained by the effect of 
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motherhood, employment or marital status (Bebbington et al. 2003) see fig 
4. This picture has remained relatively constant across the 15 years the 
survey with the largest increase in prevalence across all common mental 
health disorders of one fifth seen in women between 45-64 (McManus et 
al. 2009). 
 
 
 
Figure 4: Common mental disorder by age and sex: Adult Population of 
Great Britain 2000  
    
1.2.3 Ethnicity and depression 
 
Higher rates of depression have been found in middle-aged Irish and 
Pakistani men and older Indian and Pakistani women (Weich et al. 2004). 
Results however are inconsistent and many confounding factors exist. 
Difference in cultural attitudes to mental health help-seeking behaviours 
and pathways to care influence findings (Bhugra and Mastrogianni 2004) 
alongside somatic description of depression symptoms in non-European 
cultures and an association between ethnic grouping and unemployment, 
low income, social class and support (Brugha et al. 2004). This makes it 
hard to define clearly any links between ethnicity and increased rates of 
depression compared to the general population. It is likely that depression 
is under-diagnosed in this group (Bhugra and Mastrogianni 2004), but any 
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potential indication of higher prevalence rates may be a result of other 
socio-economic factors commonly associated with black and minority 
ethnic grouping rather than ethnicity itself.     
1.3 Economic factors and disease burden of 
depression 
 
In the UK over 900,000 adults are claiming incapacity benefits for mental 
health disorders, this accounts nearly 50% of all claimants, with 38% 
having a mental health condition as their main disability and a further 10% 
as an additional disability (Layard 2004) (see Figure 5). Depression either 
alone of mixed with anxiety makes up a substantial proportion of this and 
resulted in prescribing costs of  antidepressants in 2005 of £338 million 
(Bird 2006).  This cost is only a small figure when placed against the 
estimates of the economic impact of common mental health disorders as a 
group (depression, anxiety and stress). The Confederation of British 
Industry assessed this cost at £25 billion, roughly 2% of the gross domestic 
profit, with £4 billion due to time of sick and direct loss of output, £9.4 
billion due to lost output associated with economic inactivity, £4 billion 
time for carers and £8 billion public services cost (Layard 2006, Layard 
2005). Mixed anxiety and depression have been estimated to cause on fifth 
of all sick days in Britain (Das-Munshi et al. 2008), with the impact of lost 
productivity and employment due to depression estimated at 23 times that 
of  the direct treatment cost of these conditions (Thomas and Morris 2003). 
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Figure 5: UK incapacity benefits recipients by medical conditions, 2004. 
Layard R (2005)  
 
Depression is also associated with high levels of quality adjusted life year 
loss. In a large general population survey including 8028 people living in 
Finland depression contributed 55% of all such losses measured in the 
study (Saarni et al. 2007). Globally depression accounts for 4.4% of the 
global disease burden and 65 million disability adjusted life years annually 
and is set to become the second largest cause of disease burden in 
developed countries by 2020 (World Health Organisation 2002).  
 
Depression is also commonly associated with chronic physical disease with 
a two to three fold increase in prevalence over an equivalent healthy 
sample (National Institute for Health and Clinical Excellence 2009). It 
worsens health outcomes and costs and increases the risk of death 
(Nicholson et al. 2006, Moussavi et al. 2007). Depression also leads to a 
fourfold increase in the risk of suicide compared to the general population 
(Bostwick and Pankratz 2000).  
 
With signs of increasing prevalence (McManus et al. 2009) and demand for 
treatment  (Hollinghurst et al. 2005), it has been suggested that the 
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estimates of the societal burden of depression have been underestimated 
(The Sainsbury Centre for Mental Health 2003).  
 
1.4 Access to effective treatment for depression 
 
It can be seen that depression is a chronic and disabling condition. It 
increases the risk of premature death either by suicide or worsened physical 
health outcome and has a high cost to society. In the decade up to 2002 a 
2.8-fold increase in antidepressant prescription and a doubling of recorded 
GP consultations for depression were recorded (Hollinghurst et al. 2005). 
A number of both pharmacological and psychological treatments are 
effective (National Institute of Clinical Excellence 2009); however most 
treatment remains within primary care, and half of those with depression 
are likely to receive no treatment. Of those that do receive an intervention, 
the most common intervention is medication, with a psychological 
intervention being delivered in 25% of cases (McManus et al. 2009). It is 
of note that, while CBT is the recommended first line psychological 
intervention, only 7% received this treatment. Even with the roll-out of 
Improving Access to Psychological Therapy Services nationally in the UK 
aimed at increasing the availability of CBT, relatively small numbers are 
accessing such interventions (Glover et al. 2010). This indicates continued 
difficulty relating to accessibility of these treatments. Training a CBT 
therapist takes 1-2 years and is costly, making swift local adjustments to 
service provision difficult.  Briefer „single strand‟ interventions have for 
some time been seen as a possible beneficial additions to standard 
treatment options (Lovell and Richards 2000). These approaches may lend 
themselves to wider and swifter dissemination, and if effective compliment 
the choice of psychological interventions for depression. Behavioural 
activation (BA) presents itself as such an approach and for some time has 
been seen in randomised controlled trials to be effective and potentially 
suitable for wider dissemination (Jacobson et al. 1996).   
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 This thesis will explore the background and evidence base for BA and its 
potential suitability for meeting some of the demands of providing widely 
accessible effective psychological interventions for depression raised in 
this first chapter.    
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Chapter Two: Behavioural Therapy and its 
application in the treatment of depression 
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2.1 What is behavioural activation? 
 
Behavioural activation (BA) is a term now commonly used to describe 
treatments that use behavioural theory to explain depression onset and 
maintenance. BA views depression as a natural response to life events that 
interfere with a person‟s contact with naturally occurring positive 
reinforcement. This results in behavioural reductions, as behaviours are no 
longer positively reinforced. To cope with the feelings of sadness or 
anxiety which subsequently arise as a result of isolation from positive 
reinforcement, avoidance occurs. This further removes people from the 
environment in which where they have previously attained positive 
reinforcement, hence the context of the person-environment relationship is 
fundamentally changed. This is described as a contextual approach; 
depression is based in the context of the person‟s world and how they 
interact with it.  The behavioural therapist is interested in the manipulation 
of these person-environment interactions to create a situation non-
conducive to a depressed state. In behaviourist terms, this means 
reintroducing contact with regular and stable positive reinforcement from a 
range of sources in the person‟s environment. Behavioural therapists 
therefore are not seeking to manipulate internal states prior to change; 
rather they manipulate person-environment interactions, resulting in 
subsequent internal change. This is contrast to other approaches such as 
cognitive and biochemical therapies which could be described as internal 
deficit models, they seek to change faulty internal states (such as 
thoughts/serotonin levels) to then facilitate behavioural change.  
The first use of the term behavioural activation in relation to psychotherapy 
would appear to be in 1990 as a description of the behavioural components 
in cognitive therapy (Hollon and Garber 1990). Prior to that time 
behavioural therapy was the commonly used umbrella term for this set of 
clinical interventions. It would appear however that behavioural activation 
(BA) has become the commonly adopted description over the past two 
decades (Martell et al. 2010). BA can be defined as a brief 
psychotherapeutic approach that seeks to: 
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 Increase activities that are associated with a sense of value to the 
person 
 Reduce activities that result in isolation from a sense of value for 
the person 
 Solve problems and change behaviour that limits access to a sense 
of value to the person. 
Treatments are collaborative and focussed in the here and now. Many 
differing techniques are incorporated into treatment; however all use self-
monitoring of a mood-environment link and scheduling of new or adaptive 
behaviours to meet targets (Kanter et al. 2010). BA strategies are 
commonly seen in other therapies (Dimidjian and Davis 2009) such as 
CBT and mindfulness, and were present in the early stages of cognitive 
therapy; they also sit well alongside the modification of interpersonal 
context seen in brief interpersonal therapy (Klerman et al. 1984). 
2.1.1 Theoretical explanation of BA 
 
A functional analytic perspective is used in behavioural activation to 
understand the development and maintenance of depression (Martell et al 
2001). The function of the presenting behaviour is explored in order to 
understand its role in ameliorating distress and therefore how it is more 
likely to be repeated. The form of a behaviour (what it looks like) is of less 
interest in the development of a behavioural perspective and individual 
formulation. Skinner‟s writings on reinforcement (Skinner 1953) provide 
the basis of the behavioural understanding of depression. A reinforced 
behaviour is one that increases; BA seeks to understand how negatively 
reinforced avoidance has replaced positively reinforced „healthy 
behaviours‟.  
 
Positive reinforcement occurs when an action is followed by a rewarding 
consequence. It is to be noted this is not a necessarily a pleasurable 
consequence although that may be the case. An example of positive 
reinforcements is the taste of a particular food. A person will see the food 
and take a bite which is perceived as pleasurable, hence making a second 
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bite and a repeat of the behaviour more likely next time the person 
encounters that food. This exemplifies those instances where pleasure is the 
reinforcing consequence. Another example is opening a door; the goal of 
the behaviour is to get to the other side; the behaviour is turning the handle 
and pushing which achieves free movement through the door, a positive 
outcome. While this may not be experienced as pleasure, the behaviour is 
likely to be repeated the next time the person is confronted by a door, since 
the same consequence is sought. It is of note that if one is confronted 
regularly with a particular „sticky‟ door that requires a „turn-lift-push‟ 
sequence of behaviour, in that particular context (by that door) the 
previously learnt behaviour is rapidly modified to achieve the same 
outcome. Soon this new behaviour is incorporated and requires no pre- 
thought; the new positively reinforced behaviour has replaced the previous 
one in this context to achieve the function of moving about the house.  
 
Negative reinforcement occurs when an action is followed by the removal 
of a negative experience. An example is when a thirsty person takes a drink 
of water. The water removes the negative experience of thirst and therefore 
is likely to be repeated in the same or similar context. After time the 
drinking behaviour is seen to be repeated to prevent the experience of 
thirst. Therefore a negatively reinforced behaviour is designed to remove a 
direct or anticipated negative consequence. 
 
There are two other important determinants of behaviour important to the 
behavioural therapist. Punishment reduces behaviour, as it is followed by a 
direct negative consequence. A child being shouted at as he or she put out a 
hand to touch a fire is seen to reduce that behaviour since shouting is 
perceived as unpleasant. Frustrative non-reward occurs when expected 
rewards do not occur. This also leads to a reduction in behaviour; an 
example would be stopping working when it is not followed by the 
expected payment, the expected positive consequence. Table 2 
 outlines the relationship between each of these learning conditions.   
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Table 2: Summary of operant conditioning 
 Presented Omitted 
Positive Positive reinforcement Frustrative no reward 
Negative Punishment Negative reinforcement 
 
Ferster (Ferster 1973) was the first to hypothesise depressed behaviour will 
be maintained via operant conditioning. If a child requires a large amount 
of activity before positive reinforcement is achieved alongside behaviours 
being frequently negatively reinforced this will lead to the development of 
a passive approach to life. When in later life circumstances become 
difficult, such as after a relationship break-up or the loss of a job, this 
passive style then makes that individual more likely to respond by 
avoidance. This is due to historical learning being adopted in the current 
context. The person becomes isolated from positive reinforcement from 
their environment and increasingly avoids with the function of ameliorating 
distress in the short term but long term maintenance of problems.  
 
Viewed from this perspective, behaviours that are displayed in depression 
appear logical, or to be more precise functional, in the context of the whole 
of the person‟s life and experience at that point in time. When formulating 
the maintenance of depression within a behavioural framework, five 
particular environmental contingencies are important to explore: (1) an 
increase in negative reinforcement of avoidant behaviour, (2) a reduction in 
positive reinforcement of non-depressed behaviour, (3) an increase in 
positive reinforcement of depressed behaviour, (4) a punishing/aversive 
environment and, (5) response cost factors. 
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1. An increase in negative reinforcement of avoidant 
behaviour 
 
Much of the behaviour change in depressed patients functions as attempts 
to reduce aversive experiences. That is, either to directly ameliorate 
discomfort or to prevent aversive experience worsening. This process of 
negative reinforcement explains the increase of avoidance behaviours, 
since the action reduces discomfort. Withdrawal from work, social contact, 
family and friends can then be seen as a natural response to feeling low in 
mood, anxious, or physically lethargic, and become consistent responses to 
sources of discomfort. When, due to a significant event in a person‟s life, 
they feel the wide range of physical, emotional and cognitive symptoms 
that typify low mood, these avoidant responses become more than 
temporary coping. They become the primary method of responding to daily 
experiences in an attempt to cope with distress; each time the distress is 
felt, the avoidance reduces it. This results in increased isolation from 
sources of positive reinforcement hence reversal of the pattern is unlikely 
and depression results. 
2. A reduction in positive reinforcement of non-depressed 
behaviour 
 
Life events can occur to anyone. One consequence of this is that people 
become naturally isolated from positive reinforcement from their 
environment. This is clear in terms of a negative life event, such as the 
death of a partner. Following such a distressing event the person no longer 
has the direct contact with the partner, but also does not perform some of 
the shared activities previously enjoyed, i.e. walking. In consequence they 
will no longer be obtaining reinforcement from the person lost, and in 
addition will have discontinued the shared activities previously enjoyed.  It 
is important to also consider how depression may also follow an apparent 
positive life event. A new baby, for example, may be seen to be a positive 
life event for a mother who was keen to conceive. The subsequent 
reduction in previously valued activities, such as socialising and work, 
however may result in her feeling somewhat isolated, a negative feeling. If 
in addition the care of the baby is more problematic than anticipated, there 
 37 
arises a significant reduction in positive reinforcement from the mother‟s 
environment. If attempts at coping are (as Ferster suggested) passive, then 
negatively reinforced avoidance results and depression is more likely to 
occur. The behavioural activation therapist must therefore consider a range 
of events occurring at the time of onset or worsening of the episode of 
depression, and consider the impact of these on a person‟s interaction with 
environmental positive reinforcements.    
 
As an additional consequence of their increasing avoidance the person is 
likely to become further removed from contact with naturally occurring 
positive reinforcements in their environment. This will lead to an 
exacerbation of their depression as the person gains less reward from their 
behaviours in daily life. For example, social contact or work may become 
more challenging and provoke anxiety as a consequence of symptoms of 
depression such as worsened concentration and memory. This results in a 
reduction in positive reinforcement from such behaviours, therefore they 
begin to decline or stop altogether, being replaced by negatively reinforced 
avoidant behaviours. This then explains the process by which the person 
becomes increasingly depressed. 
3. An Increase in positive reinforcement of depressed 
behaviour 
 
Alongside increased avoidance the depressed person may receive positive 
reinforcement of depressed behaviour. Behaviours like resting, missing 
work, and reduced general activity become common. These behaviours 
initially are seen as attempts to cope with distressing symptoms and can be 
encouraged in that person‟s environment. Actions may be initially 
positively reinforced directly by friends, relatives, work colleagues and 
health professionals who encourage them to „slow down‟ or „take some 
time out and get some rest‟. This positive reinforcement for behaviour 
change as the person struggles to cope is also negatively reinforced by the 
amelioration of distress. These two factors combined can explain the how a 
person gets into a cycle of behaviour in depression that increases their 
isolation. 
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4. A punishing or aversive environment 
 
It is likely that the depressed person will experience their environment as 
increasingly punishing. Continued efforts to manage symptoms through the 
methods already described may lead to environmental contingencies 
changing in function if not in form. Work may become increasingly 
problematic, and attempts to cope as outlined above worsen performance, 
thereby making work even more difficult. In addition, where the person‟s 
depressed behaviour was initially positively reinforced by friends and 
relatives, over time this behaviour stops being viewed as understandable; 
some people may become impatient or  irritable when faced with a 
person‟s distress and avoidance, thus resulting in punishment of their social 
interactions, leading to a further reduction in behaviour and increased 
isolation.   
5. Response cost factors 
 
Once a depressed pattern of behaviour is primarily reinforced by avoidance 
of discomfort, attempts to reverse those behavioural patterns are more 
difficult than previously experienced. These attempts to change then have a 
greater cost than benefit and become aversive experiences in themselves. 
As an example one could take a person‟s efforts to reverse physical 
inactivity by re-starting a previously well-practised exercise routine. 
Initially this leads to a greater effort being needed than before the period of 
physical inactivity for the same goal (such as running one kilometre). The 
person feels physically worse after the exercise alongside the reduced 
ability to perform at previously held levels, thus the new behaviour induces 
despondency. This in turn results in the new behaviours (response), which 
were aimed at positive change, being punished (cost) and therefore their 
frequency is reduced. 
2.1.2 Behavioural model of depression 
 
The above factors combined lead us then to an understanding of depression 
based upon a behavioural theory. Life events initially result in a reduction 
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of naturally occurring positive reinforcement. This results in feeling bad, 
which leads to negatively reinforced avoidance. This then further isolates 
the person from positive reinforcement; new attempts to change are often 
punished, and so the cycle is maintained (see Figure 6). 
 
 
 
Figure 6: Behavioural Model of Depression 
 
Early research supported the link between a reduction in positive 
reinforcement (Lewinsohn and Graf 1973) and higher rates of punishing 
environments (Rehm 1978) in depressed subjects compared to non 
depressed subjects. These early studies were used to inform the 
development of behavioural therapies for depression based upon this 
operant conditioning framework.  
2.2 Historical development of BA as a treatment for 
depression 
 
As seen above Behavioural activation (BA) is a treatment for depression 
which has its roots in the writings of Skinner (Skinner 1953), being 
focused on the role of the environment and on people‟s responses to it. 
Behavioural models of depression put forward by Ferster (Ferster 1973)  
and Lewinsohn (1974) took the principles of operant conditioning and used 
them to improve understanding of depressed behaviour (as outlined above). 
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Interventions based upon these principles were focused on increasing 
access to positive reinforcement, with the aim of interrupting the cycle seen 
in Figure 6. Early adopters of this model monitored the links between 
behaviour and mood to develop an initial understating of a person‟s 
depression. They then used activity scheduling, social skills training and 
problem-solving to modify a person‟s relationship with their environment. 
This aimed to increase contact with potentially „anti-depressant‟ 
experiences, and was often focused upon „pleasant events‟ (MacPhillamy 
and Lewinsohn 1982). Initial evaluations of these reasonably 
straightforward approaches showed encouraging results in early trials 
(Brown and Lewinsohn 1984); however, research found that the use of  
pleasant events did not sufficiently explain patterns seen in depression 
(Amenson and Lewinsohn 1981). This led Lewinsohn to review his 
approach, to consider a more complete understanding of reinforcement 
schedules and understanding of thinking as a covert behaviour that can in 
turn be modified. The new model identified environmental stressors as a 
primary trigger for depression that disrupted individuals‟ behavioural 
repertoire and resulted in negative affect and reduced positive 
reinforcement. It incorporated the person‟s efforts to cope with the stressor 
by avoidance and subsequent deterioration resulting in depressed „cycles‟ 
emerging (Lewinsohn et al. 1985). This model again resulted in positive 
results in early studies (Lewinsohn et al. 1980), providing a therapeutic 
intervention for depression based within a conceptual framework of 
behavioural theory.  
 
Early trials of these approaches resulted in promising findings; however 
purely behavioural treatments lost favour in the 1980s. The development of 
cognitive interventions for depression, most notably Beck‟s cognitive 
therapy (CT) (Beck et al. 1979) replaced interest in behavioural 
approaches. This dominance occurred despite a lack of compelling 
evidence demonstrating the superiority of cognitive-based treatments. For 
example, Zeiss, Lewinsohn and Muñoz (Zeiss et al. 1979)  found no 
differences between cognitive and behavioural treatments on reduction in 
depression symptoms. Despite some exceptions (e.g. Shaw 1977), there 
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was very little evidence of the dominance  of cognitive over behavioural 
approaches. The new cognitive approaches nonetheless resulted in reduced 
interest in behavioural models which were no longer commonly accepted 
as adequate explanations of human behaviour and functioning. The focus 
on the importance of thinking then became the main psychological 
approach to formulation and treatment of depression. Cognitive Behaviour 
Therapy (CBT) or Cognitive Therapy thus became the main focus of 
research agendas, and was considered the first-line psychological treatment 
for depression. Cognitive treatments still included self monitoring and 
activity scheduling in their treatment packages (Beck et al. 1979). These 
were used as experiments to modify assumptions relating to control of 
mood in contrast to re-establishing contact with positive reinforcement, and 
the central behavioural theory as such was lost. Throughout the 1980s and 
early 1990s CBT‟s dominance was maintained in the research literature 
and the early promise of a simple and effective behavioural intervention for 
depression was mostly forgotten.  
 
Interest in a purely behavioural approach to treating depression returned 
with the trial of Jacobson et al. (Jacobson et al. 1996). Jacobson noticed 
when involved in trials of CT that a large amount of change in participants‟ 
symptom levels occurred early in treatment. This appeared to be at the time 
when the behavioural techniques (i.e. activity scheduling) were used 
(Jacobson and Gortner 2000). Cognitive theory asserts that modifying 
underlying cognitive structures were responsible for the effects of CT. 
Improvements however appeared prior to modification of cognitions, 
suggesting a possible alternative explanation: changes could be due to 
basic behavioural interventions which bring back contact with positive 
reinforcement from the person‟s environment. Jacobson‟s study used a 
component analysis design to compare full CT with thought challenging 
and behavioural techniques and with behavioural activation alone. The 
main finding of the study that caused controversy (Jacobson and Gortner 
2000),  was that there were no differences in reduction in depression 
symptom level between the three treatments. Results were maintained 
through a two- year follow up period (Gortner et al. 1998). This indicated 
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that BA was potentially as effective as CT in acute response, but also 
provided a durable intervention for consideration. This finding triggered a 
renewed interested in purely behavioural approaches, particularly as they 
might potentially offer the possibility of providing a simple effective 
treatment that would be more amenable to dissemination than other more 
complex psychological interventions (Jacobson et al. 1996).  Interest in this 
finding has grown particularly following a replication and extension of the 
initial Jacobson et al. trial (Dimidjian et al. 2006) which again 
demonstrated long term durability (Dobson et al. 2008). Other researchers 
were also looking at the potential of behavioural theories to guide the 
development of depression treatment and were developing separate 
treatment packages, notably Behavioural Activation Treatment for 
Depression BATD (Lejuez et al. 2001).  
 
Much of the research and development of behavioural treatments for 
depression have come from the USA. The UK had taken behavioural 
theories and developed their use in anxiety disorders over a number of 
years (Marks 2000); however this development did not extend to 
depression, where CT remained the focus of clinical and research activity.  
More recently, with the interest in single-strand treatments and stepped 
care increasing, BA has become increasingly used in the UK and is now 
recognised as an effective and valuable treatment of depression (National 
Institute of Clinical Excellence 2009).  
2.3 Relating behavioural theory to intervention 
 
As highlighted above, behavioural theory places the person‟s depressed 
condition firmly within an interrupted relationship with their environment. 
in contrast to other approaches that explain depression as an internal deficit 
due to faulty thinking, neurotransmitter problems or unconscious conflict 
(Martell et al. 2001). Behaviourists do not believe depression to be due to 
something being „wrong‟ inside but that it is an understandable pattern 
emerging based upon events changing reinforcement contingencies; thus if 
these are explored, understood and manipulated, then the depression will 
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remit. Therefore treatment does not endeavour to resolve internal feelings 
or thoughts prior to behavioural change, but instead uses behavioural 
change to manipulate person-environment interactions, with the aim of 
subsequently improving those internal feelings. Simply put, behavioural 
therapy asks people not to „wait to feel right to do things‟ but „to do things 
to feel right‟. When planning BA treatment, the goal is to develop sources 
of positive reinforcement in a person‟s life that are stable (the activity and 
reinforcing effects are repeatable) and diverse (what Kanter describes as 
„not putting all of one‟s eggs into one basket‟)  (Kanter et al. 2009). If this 
is achieved, it is more likely that the person will maintain contact with one 
or more sources of value/positive reinforcement, even in the face of future 
problematic life events. 
2.3.1 The therapeutic relationship in BA  
 
Across all cognitive behavioural therapies establishing a good therapeutic 
alliance is essential. The patient is being asked to give up well-practised, 
safe and reinforced behaviours and to replace them with activities of 
uncertain outcome. Results are then evaluated and reflected upon in an 
approach to develop new meanings or beliefs. This collaborative 
empiricism is also present in BA via the patient‟s dropping of negatively 
reinforced coping, replacing it with an alternative response and observing 
the consequences.  It is crucial, then, that the therapist develops trust early 
in the treatment by demonstrating empathic understanding of the patient‟s 
experience. These non-specific factors are common across therapies 
(Rogers 1961) and reflect good clinical skills. The therapist also offers a 
clear understanding of the patient‟s problem, developing a behavioural 
formulation that is non-judgemental and derived collaboratively. This 
behavioural case formulation is then linked to a clear rationale for the 
treatment proposed. This approach helps the patient to realise that they can 
have an influence on how they feel, which can provide positive 
reinforcement within sessions and thus increase ongoing engagement with 
therapy (Kanter et al. 2009). Throughout the course of behavioural 
activation the therapist will observe and identify behaviours within the 
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session that may be examples of the patient‟s problem, and use their own 
behaviour (verbal and non-verbal) to try to decrease the frequency of these 
behaviours through operant methods. Similarly the therapist will attempt to 
identify desired changes in the patient‟s behaviour within sessions and to 
reinforce these.  This is an approach used commonly in Functional 
Analytical Therapy (FAP) and models behavioural principles which are the 
basis of the treatment within each session (Kanter et al. 2010).   
2.3.2 BA models of delivery  
 
Kanter et al (Kanter et al. 2010) conducted a narrative review of 
behavioural therapy studies and  identified several key techniques which 
have commonly been incorporated into treatment packages since the 1970s. 
The techniques used in these studies were activity monitoring, assessment 
of goals and values, activity scheduling, skills training, relaxation training, 
contingency management, procedures targeting verbal behaviour (i.e. 
cognition) and procedures that target avoidance. It is of note that the only 
components appearing consistently over all seven treatment manuals 
reviewed were activity monitoring and scheduling. This raises some 
interesting questions, which are yet to be addressed, as to the „active‟ 
components in BA (Kanter et al. 2010).  While Kanter‟s helpful narrative 
review was not published at the time of the development of the intervention 
study outlined later in this thesis those studies it highlights were.  
 
There are two main approaches to the application of behavioural theory as 
described earlier in this chapter used currently that have a body of 
published data on their use in clinical settings; these are outlined below.  
 
The first is known commonly as Behavioural Activation (BA) (Martell et 
al. 2001). This approach was derived from the BA intervention in the 
Jacobson (1996) study. The treatment focuses on the functional aspects of 
depressive behaviour, identifying environmental triggers to ineffective 
coping responses which are then linked to the maintenance of depression.  
Primary symptoms as such (tiredness, low mood) are not the key focus of 
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BA. Instead,  the patient is directed to pay attention to their responses to 
such symptoms and to their negatively reinforced attempts to cope; these 
are the targets of BA techniques. Thus in this model behavioural avoidance 
and its function is central. Treatment is delivered in 24 sessions over 16 
weeks (Dimidjian 2006). 
 
The second approach, Behavioural Activation Treatment for Depression 
(BATD) was developed by Lejuez and colleagues (Lejuez et al. 2001).  
BATD is based on behavioural matching theory (Hernstein 1970). This 
model focuses on increased contact with the reinforcement of healthy (non-
depressed) behaviour and reduced contact with reinforcers of depressed 
behaviour with the aim of decreasing depressed behaviour and increasing 
non-depressed behaviour. (Hopko et al. 2003). The BATD model is 
delivered in a 8-15 session protocol (Hopko et al. 2003).  
2.3.3 Components of BA interventions 
  
Behavioural Activation (Martell et al. 2001, Martell et al. 2010). The first 
sessions of BA are used to develop a therapeutic relationship with the 
patient, introduce the formulation and link to the treatment rationale. This 
aims to develop an increased awareness on the part of the patient of their 
attempts to cope with symptoms of depression, resulting in only short-term 
relief and longer-term maintenance of the condition. Initially BA uses 
activity and mood monitoring to build on this awareness and 
understanding. Patients keep a daily diary of their activities on an hourly 
basis with a corresponding statement and rating of mood. This information 
is gradually incorporated into the initial case formulation and is used to 
assess general activity level and range of emotion. Associations between 
specific activities and mood are explored through functional analysis and 
related to development of understanding of the maintenance of depression. 
This antecedent-behaviour-response (ABC) is developed and an acronym 
TRAP: Trigger, Response, Avoidance Pattern used to facilitate a shared 
language between the therapist and patient. Once patterns of avoidance are 
understood, the focus of treatment moves to re-establishing healthy 
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behaviours by developing new alternative coping mechanisms aimed at 
contact with valued goals. The BA goal is to create new opportunities for 
encountering positive reinforcement from the person‟s environment, again 
using an acronym, TRAC: Trigger, Response, Alternative Coping. BA then 
uses scheduling and functional analysis to reduce avoidance and increase 
contact with positive reinforcement throughout treatment. Identification of 
specific goals and alternative coping strategies are collaborative, seeking to 
link the patient to their particular set of values. To support this process, BA 
incorporates techniques such as grading activities, therapist modelling, 
skills training, problem-solving and mental rehearsal as methods of 
connecting with positive reinforcement and replacing avoidance with 
„healthy behaviours‟ which is the aim of BA. 
 
BATD (Lejuez et al. 2001, Hopko et al. 2003). As in BA, initial sessions of 
BATD are used to help establish a therapeutic relationship. It again seeks 
to identify the changes in reinforcement patterns, using these to describe 
the treatment rationale. BATD then employs “systematic activation” with 
the goal of increasing frequency and reinforcement of healthy behaviour. 
As in BA, patients are asked to monitor their activities but not mood. 
Activity monitoring is used to emphasise the quality and quantity of a 
patient‟s range of activities, and from this to provide possibilities for new 
behaviours to focus on in treatment. BATD then identifies goals in valued 
areas such as relationships, education, employment, hobbies and recreation, 
general health issues, spirituality etc. Within these areas, patients select 15 
activities which are organised into a hierarchy of difficulty of achievement, 
and are then supported to work progressively through the hierarchy. 
Specific weekly goals are set in relation to frequency and duration of each 
activity. Additional positive reinforcement is integrated by introducing 
rewards for completing weekly goals. 
2.3.4 Using behavioural theory to improve concordance  
 
Often problems are encountered in activation approaches, moving people 
from patterns of negatively reinforced avoidance. Functional assessment 
 47 
procedures can be used to explore obstacles to client progress and resolve 
problems (Kanter et al. 2009). By returning to basic behavioural principles 
it is possible to develop an understanding of the difficulties that may arise 
in therapy and developing approaches to resolve these. 
In all approaches to behavioural treatments of depression all patients have 
clearly defined goals that reverse patterns of avoidance and introduce a 
sense of pleasure or accomplishment. Values differ from goals in that the 
term is used to describe a direction for life rather than an end point or target 
(Hayes et al. 1999). In order to reintegrate positive reinforcement, goals 
need to be linked to an individual‟s particular set of values, or they will not 
achieve that purpose. This means that, in order to effectively overcome 
potential obstacles, each set of goals used in therapy must be individually 
negotiated in order to correspond with each patient‟s particular set of 
values.  
2.4 BA and improving access to the psychological treatment of 
depression 
 
As highlighted in chapter one of this thesis depression is a highly prevalent 
condition with high cost to the individual and society. In the UK recent 
efforts have been made to improve access to psychological treatments 
through major investment in the IAPT programme (Improving Access to 
Psychological Therapies).  IAPT uses treatments approved by NICE and 
has yielded some rewards in terms of the numbers of people offered a  
treatment (Clark et al. 2009, Glover et al. 2010). BA has been incorporated 
to some degree in this programme and would seem to lend itself to this 
model of delivery. Central to the delivery of IAPT is the concept of 
„stepped care‟, that is, delivering the least intrusive and costly intervention 
that is likely to provide a health gain. Stepped care aims to optimise the use 
of the same level of resources to deliver more effective treatment aiming to 
make improvements in meeting demand. BA would seem to lend itself to 
such an approach. Some have suggested that a stepped BA delivery may be 
used (Kanter et al. 2009) where initial self-monitoring and scheduling are 
the interventions used, and only if no improvement is seen does the 
therapist move to delivery of the more complex functional analysis. This 
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would appear attractive; however, it requires further study.  The other 
promise of BA is the relative parsimony of the approach, which has been 
suggested for some time (Jacobson et al. 1996). If this is shown, it may 
suggest that a single-strand BA intervention would lend itself to delivery 
by a wide range of therapists. Such therapists would be at a lower grade 
and require less timely training than the one year currently needed to train a 
CBT therapist, thereby reducing the costs of both training and treatment 
delivery. The approach of including single-strand therapies in stepped care 
has long been thought to show promise (Lovell and Richards 2000), but is 
rarely routinely incorporated into service design. The reason for this is 
unclear; however, to date it would appear that only limited evidence has 
supported BA‟s use in this way. While BA clearly is built on sound 
theoretical foundations and has an apparent evidence for its use, no studies 
appear to support the parsimony leading to effective dissemination 
assertion. It is an area of research that would be very beneficial for 
supporting effective service redesign.   
2.5 Summary of chapter and research focus 
 
Behavioural approaches to the treatment of depression are based in 
behavioural theory, and have over the past four decades shown promise in 
providing an effective psychological treatment for depression. They appear 
to be simple in design and delivery and as such suggest an approach that is 
suitable for wide dissemination. While these ideas have for some time been 
suggested as an option to increase availability of effective acceptable 
psychological treatments, clarity regarding the evidence that supports this 
approach is needed. Two individual trials (Dimidjian et al. 2006, Jacobson 
et al. 1996) offer strong support for BA, but both used experienced 
therapists and so have not demonstrated its durability beyond delivery by 
this staff group. Narrative reviews develop strong arguments supporting 
increased use of BA (Jacobson and Gortner 2000, Jacobson et al. 2001, 
Martell et al. 2001, Hopko et al. 2003) but are written by key protagonists 
of the approach, and are hence subject to bias.  
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In subsequent chapters this thesis will therefore seek to develop knowledge 
by exploring the evidence for BA, and in particular whether its parsimony 
makes it suitable for dissemination, in a structured and scientific manner. It 
is of note that the terms „behavioural therapy‟ (BT) and „behavioural 
activation‟ (BA) are often used interchangeably. As highlighted in Chapter 
Two, the term BA was first used in the description of psychological 
treatments of depression in 1990 (Hollon and Garber 1990); prior to this 
date the term BT was normally used.  BA offers a more specific description 
of a particular intervention developed since that time. Taking into account 
the gradual shift over the last two decades to the use of BA as the common 
term, we will conduct a systematic review and meta-analysis of available 
evidence. This will identify gaps in knowledge and inform the design and 
delivery of appropriate primary research to explore such gaps. This will 
develop new knowledge regarding BA and its evidence base, with a 
particular focus on the challenges of providing effective treatment for 
depression as highlighted in Chapter One. 
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Chapter Three: Evidence base for Behavioural 
Activation for depression; systematic review and 
meta-analysis 
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3.1 Introduction 
 
As we have seen in Chapter Two behavioural treatments, such as 
behavioural activation (BA) and behavioural activation for depression 
(BATD) are theory-driven collaborative treatments with randomised 
controlled trial evidence to support their implementation. The considerable 
mismatch between the prevalence of depression and the availability of 
evidence-based psychological treatments outlined in Chapter One creates 
significant problems for society (Centre for Economic Performance's 
Mental Health Policy Group 2006). In health care systems such as the 
National Health Service (NHS), behavioural therapy may offer the 
possibility of meeting some of this demand due to its single-strand nature 
(Lovell and Richards 2000) and simplicity. While the evidence cited in 
support of such propositions is attractive, it is far from definitive as it is in  
narrative reviews (Jacobson and Gortner 2000) that may only provide a 
selected section of the overall picture and can be misleading to the reader 
(Glanville and Sowden 2002).   
In order to counter these problems and develop a clear picture regarding 
the effectiveness of an approach all available evidence should be reviewed. 
This process, termed systematic review, uses clearly predefined protocols 
to generate balanced inferences using all available evidence (Glanville and 
Sowden 2002). Systematic reviews, in contrast to narrative reviews, have 
the following characteristics (Higgins and Deeks 2008): they 
 Clearly state a set of objectives with pre-defined eligibility criteria 
for studies; 
 Use an explicit, reproducible methodology; 
 Deliver a systematic search that attempts to identify all studies that 
would meet pre-defined eligibility criteria; 
 Offer an assessment of the validity of the findings of the included 
studies, for example through the assessment of risk of bias;  
 Produce a systematic presentation, and synthesis, of the 
characteristics and findings of the included studies.  
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Behavioural therapy has been included as a comparator in a number of 
systematic reviews that evaluated the effectiveness of CBT compared to 
other therapies (Churchill et al. 2001, Dobson 1989, Gloaguen et al. 1998). 
Initial searches were conducted in the Database of Reviews of 
Effectiveness (DARE) and the Cochrane Database of systematic Reviews. 
No systematic reviews were found that had examined BT/BA as the 
primary intervention against which other therapies were compared. The 
first step to conducting a comprehensive review of a clinical question is to 
ensure that such a body of work does not already exist that is suitable for 
updating (Glanville and Sowden 2002). The reviews cited above were not 
capable of providing  a comprehensive overview of all trials using 
behavioural therapy, as the search terms used would have been designed to 
examine the subject areas addressed specifically in those reviews, such as 
cognitive therapy (Dobson 1989, Gloaguen et al. 1998) and brief 
psychological therapy (Churchill et al. 2001). This would therefore be 
problematic if we were expecting those reviews to provide a 
comprehensive picture of behavioural therapy (and/or BA). Searches would 
not identify studies specifically examining behavioural therapy where it 
was not indexed using „brief therapy‟ or „CBT‟ or associated terminology.  
Another potential problem of using those reviews looking at CBT for the 
purposes of this research was that they were relatively old and not 
conducted using the most up-to-date guidance on review design (Moher et 
al. 1999, Moher et al. 2009). Study selection would not have been related 
to the specific objectives of examination of the effectiveness of behavioural 
therapies of depression, so that even if a highly sensitive search strategy 
identified relevant studies, the review methodologies may not have 
included them. If such reviews were to be used as the basis of this research 
they would therefore potentially introduce bias at the first stage. In 
summary, while reviews up to the date of our work had used behavioural 
therapy as a comparator, relying on them would be problematic. They 
would potentially introduce bias and methodological limitations. 
Considering these limitations it was decided that a sufficiently rigorous 
examination of the effectiveness of behavioural therapy had not been 
conducted upon which appropriate primary studies could be designed. It 
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was therefore decided that a new systematic review of the evidence, 
focussing on the effectiveness of behavioural therapies in the treatment of 
depression, was required. The review would collate all empirical 
information linked to a research question via a clear pre-determined 
systematic approach and provide an evidence synthesis. This would 
minimise bias and produce a reliable estimate of the effectiveness of 
behavioural therapy in its own right, which could be used to inform future 
research based upon gaps in knowledge (Higgins and Deeks 2008).  
 
This chapter outlines the methods used to conduct a systematic review of 
evidence regarding the effectiveness of behavioural therapy for depression 
and discusses its findings. This approach was used to contribute new 
knowledge regarding behavioural therapy and highlight any gaps in the 
evidence base. This was related to the issues summarised in Chapters One 
and Two of the prevalence of depression, limited access to effective 
psychological interventions and the potential of BA as a single-strand 
intervention to fill some of that gap.  The review follows a transparent 
process to appraise and summarise all randomised controlled trials, with 
effectiveness explored where possible via meta-analysis. Meta-analysis 
provides a statistical approach to combining the results from a number of 
studies exploring the same construct, in this case change in level of 
depression symptoms.  It provides a natural extension of a systematic 
review following the logical process of gathering all the evidence in a 
specific area, reviewing and appraising the quality of studies and 
combining overall findings. It thus provides a comprehensive picture of the 
true effect of an intervention compared to a particular comparator. Through 
its combining of study results, meta-analysis increases the precision of 
estimates of effectiveness of an intervention, since often individual studies 
may be too small and underpowered to differentiate true difference from 
chance findings (Moher et al. 1999). Meta-analysis increases such power, 
and hence the chance that observed effects of an intervention are correctly 
assessed. A consistency of effects from studies in differing populations or 
environments can be observed which is not possible through the use of an 
individual study or narrative reviews. This provides a more scientific 
 54 
approach to exploring possible reasons for inconsistency across primary 
study findings, if present, as potential moderators of effect can be explored 
within meta-analysis. Therefore in this research a well-conducted and 
transparent systematic review combined with a detailed meta-analysis was 
used to improve statistical power, often a problem in psychotherapy trials, 
and produce a broader understanding of the potential benefits which 
behavioural therapy for depression might offer.    
3.2 Development of the review question 
 
Question development is a key first stage of the review process. It 
determines the review‟s focus, and as such is potentially most important 
decision which those conducting a review will take (Light and Pillemer 
1984). The review protocol will be derived directly from the question 
asked (Counsell 1998), which guides the  eligibility and search criteria, 
approach to data extraction and statistical methodology (Higgins and Deeks 
2008). Initial literature scoping had been conducted, as outlined in 
Chapters One and Two, to highlight areas of uncertainty required to focus 
the review and identify objectives and appropriate methodology (Khan et 
al. 2002). Questions require clarification of several key components to 
provide clarity (Counsell 1997, Richardson et al. 1995): the type of 
population, the intervention, the comparison and the outcome. This set of 
markers, often referred to as PICO (Higgins and Deeks 2008) allows the 
development of a well formed clinical questions and subsequent objectives. 
 
 Participants. Due consideration of the participant group is needed in 
the definition of a clear question. Criteria set must be broad enough 
to allow the inclusion of sufficient studies, but specific enough to 
allow for meaningful collation.  If such clarity is not developed a 
priori, reviewers may be left with decisions regarding the inclusion 
of a study that may introduce selection bias into the review. Pre-
specifying criteria will limit such risks. It is important to include 
both the group of interest and also the method of dealing with any 
unforeseen issues that emerge during the review regarding inclusion 
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of studies related to participants. An example may be the age of 
participants: for example, in this review the population of interest 
was adults. However further clarification is required within the 
methods section as to what age this would mean and how to deal 
with studies with populations spanning such criteria (i.e. age set at 
18, what approach would be used to deal with a study including 
participants from 16 upwards).  In broad terms, when considering 
the population, or participants to be included in the review it is 
useful to clarify the condition under investigation (in this case 
depression) and the broad population (in this case adults in 
community or inpatient settings). Table 3 outlines the questions 
considered in defining the population grouping in this review (for 
detailed information regarding the handling of issues, refer to 
methodology section). 
Table 3: Factors to considered in the development of  „types of  
participants‟ (Higgins and Deeks 2008) 
 How is the disease/condition defined? 
 What are the most important characteristics that describe these people 
(participants)? 
 Are there any relevant demographic factors (e.g. age, sex, ethnicity)? 
 What is the setting (e.g. hospital, community etc.)? 
 Who should make the diagnosis? 
 Are there other types of people who should be excluded from the review 
(because they are likely to react to the intervention in a different way)? 
 How will studies involving only a subset of relevant participants be 
handled? 
  
 
 Intervention: In consideration of the intervention type, both the 
target intervention of the review and any potential comparators are 
clarified. It is important to consider the key intervention and how 
any variance will be handled. For example, through scoping we are 
aware that techniques central to BT, such as scheduling, are 
commonly present in other approaches, most notably CBT. 
Consideration of this aspect of the question shows us the 
importance of outlining how such issues will be addressed a priori 
 56 
rather than making decisions during the review which could lead to 
bias.  
 Comparators: From this position also it is clear that the definition 
of potential comparator groups are also key to the question 
development, as methodology follow directly from a well-
structured question. Comparison against an inert, or control 
condition will allow estimation as to the effect of the intervention of 
interest. Comparison against other forms of active intervention will 
allow estimation of the performance of the intervention of interest 
benchmarked against other approaches. Table 4 outlines issues for 
consideration in development of intervention and comparison. 
Table 4: Factors considered in the development „types of intervention and 
comparison‟ (Higgins and Deeks 2008) 
 What are the experimental and control (comparator) interventions 
of interest 
 Does the intervention have variations (e.g. dosage/intensity, mode 
of delivery, personnel who deliver it, frequency of delivery, 
duration of delivery, timing of delivery)? 
 Are all variations to be included (for example is there a critical dose 
below which the intervention may not be clinically appropriate)? 
 How will trials including only part of the intervention be handled? 
 How will trials including the intervention of interest combined with 
another intervention (co-intervention) be handled? 
  
 Outcomes: Outcomes should be identified in a well-formed 
question in a way that guides the objectives of the review and the 
methodology to findings of importance to clinicians, patients and 
policy makers (Higgins and Deeks 2008, Sutton et al. 1998). While 
they will not be able to be defined within the question beyond a 
broad outline, such as depression symptom level, the consideration 
a priori is important to the subsequent delivery of the review. In 
addition to the event that will be observed (i.e. depression symptom 
level), the timing of  observations such as post-treatment and 
follow-up will also have a major impact of review findings, and 
hence must also be considered (Gøtzsche et al. 2007). Table 5 
outlines issues for consideration in deciding outcomes for a review.  
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Table 5: Factors considered when developing criteria for „types of 
outcomes‟ 
 Main outcomes, for inclusion in the „Summary of findings‟ table, 
are those that are essential for decision-making, and should usually 
have an emphasis on patient-important outcomes. 
 Primary outcomes are the two or three outcomes from among the 
main outcomes that the review would be likely to be able to address 
if sufficient studies were identified, in order to reach a conclusion 
about the effects (beneficial and adverse) of the intervention(s). 
 Secondary outcomes include the remaining main outcomes (other 
than primary outcomes) plus additional outcomes useful for 
explaining effects. 
 Ensure that outcomes cover potential as well as actual adverse 
effects. 
 Consider outcomes relevant to all potential decision makers, 
including economic data. 
 Consider the type and timing of outcome measurements. 
  
In summary, the preparation of a review question requires detailed 
preparation, as the question is a fulcrum for the subsequent delivery of the 
review. Whist the above considerations may not be explicitly mentioned in 
a brief question, reflection on them facilitates the development of a 
question that is „fit for purpose‟ (Counsell 1998). 
3.2.1 Review question 
 
The review question in this thesis was developed by D Ekers based upon 
the factors outlined above. This was then circulated to the research 
advisory team of Professor David Richards, Professor Simon Gilbody and 
Professor Christine Godfrey. Comments were received and incorporated in 
the design of the review question, which was subsequently agreed by email 
communication and face-to-face discussion between D Ekers and D 
Richards. The final agreed question for the review was: 
 
 
What is the relative effectiveness of individual 
behavioural psychotherapy on depression symptom level, 
recovery and dropout when compared with usual care, 
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inert controls and other psychosocial treatments in 
depressed adults?  
3.2.2 Objectives 
 
To conduct a systematic review to identify all randomised controlled trials 
comparing behavioural therapies with treatment as usual, control 
conditions and/or other brief psychotherapy (CBT, IPT, brief 
psychodynamic therapy and supportive counselling). 
 
To assess the overall effectiveness, using meta-analysis where possible, of 
behavioural therapies for depression compared to treatment as usual, 
control conditions and/or other brief psychotherapy (CBT, IPT, brief 
psychodynamic therapy and supportive counselling). 
 
To assess the quality of trials using a transparent process that is replicable 
and reliable. 
 
To assess the internal validity, external validity and statistical power of 
identified trials. 
 
To consider the effect of study level moderators on primary outcomes. 
3.3 Methodology of review 
3.3.1 Review team 
 
The systematic review was led at all stages by David Ekers (DE) who 
produced the protocol, developed the review tools and analysed the main 
findings. Good reviews require a team with a range of experience to 
maintain quality (Green and Higgins 2008). The review team for this 
research consisted of DE, who had knowledge and experience of 
behavioural activation and the challenges of providing psychological 
therapies for depression; David Richards (DR), who brought extensive 
health services research experience alongside being a national advisor to 
the Improving Access to Psychological Therapies programme; and Simon 
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Gilbody (SG), who brought extensive health service research skills and 
expert knowledge of review methodology, in particular the use of meta 
regression as seen in a previous meta-analysis of collaborative care 
(Gilbody et al. 2006).  
 
It is also recommended that an advisory board is established; however due 
to the financial limitations of this research this was not possible. It was 
agreed that the review team would act together as a steering group for the 
project, and that if specific advice was required this would be sought. 
 
Additional expertise was brought into the review team for particular 
purposes. At the search design phase Janet Menton (JM), a librarian and 
information skills trainer working within the local NHS trust, was 
consulted to provide expert advice in the design of searches. She also 
conducted the searches used in the review and provided results to DE for 
analysis. SG brought experience of meta-regression and analysis of 
publication bias, and conducted these analyses included in this thesis. 
3.3.2 Inclusion criteria study design.  
 
The type of study included in a review should be guided by the question 
rather than the perceived values of the design itself (Sackett and Wennberg 
1997). As this review focussed on the effectiveness of behavioural 
psychotherapy in comparison to other interventions, the appropriate study 
design for inclusion was randomised controlled trials (RCT). Scoping 
suggested that a number of such trials existed but had not been formally 
appraised or combined in meta-analysis. Randomised trials allow for the 
balancing of groups following inclusion in a study in a way that reduces the 
impact of confounders and bias and reduces overestimation of  treatment 
effects (Higgins and Deeks 2008).  Inclusion of non-randomised trials may 
be an acceptable in reviews of subject areas where there is a lack of RCTs 
and the endeavour is to examine the case for and design of such a trial, or 
where the subject under review does not lend itself to that study design 
(such as qualitative evaluation of a treatment approach). Also a review 
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including non-randomised studies may be useful to study the effects of 
interventions that are unlikely to be randomised (such as certain surgical 
procedures) or where the condition under examination is particularly  rare 
(Higgins and Deeks 2008). In this review it was considered that BT did 
lend itself to randomised controlled methods, hence it was decided to 
include all randomised controlled trials published and unpublished in any 
language. The importance of inclusion of unpublished trials and all 
languages was emphasised as a priority due to the potential for a positive 
result bias if they were excluded (Khan and Kleijnen 2002). The decision 
to include all randomised trials identified in searches was taken after 
consultation with the review steering group. Study quality would be 
assessed (control for selection, recruitment and measurement bias) and the 
impact explored through sensitivity analysis. This approach would allow 
for the gathering of all suitable evidence which could then be assessed and 
graded, with findings managed accordingly. It was anticipated through 
scoping that several older trials would be found which were not subject to 
the standards that have been applied to RCTs in recent years.  If, at 
identification, those studies were to be rejected based upon such 
methodological problems it was felt this review would be weakened. The 
objective was to identify and analyse all studies to give the most 
comprehensive review possible of behavioural therapies‟ effectiveness. 
One approach used to limit the potential biasing of results from the 
inclusion of low quality studies is to exclude such studies from the meta-
analysis in a review (for an example see NICE depression update (National 
Institute of Clinical Excellence 2009). In this review, it was decided an 
adequate compromise between controlling for confounding of results by 
low study quality and weakening of findings due to study exclusion and 
subsequent low numbers would be most appropriately managed via the use 
of sensitivity analysis. Through this, the impact of lower quality studies on 
overall results could be ascertained and considered alongside overall 
findings.    
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3.3.3 Exclusion criteria: study design 
 
Based upon the above decisions exclusion was broadly defined as non-
randomised controlled trials.  
3.3.4 Inclusion criteria: type of participants 
Age 
 
It was decided to focus this review upon the treatment of adults of either 
sex. The lower cut off age for inclusion was set at 16 years old. Studies that 
included participants in age categories below this would be excluded.  It 
was considered that while BT may be a suitable intervention for this 
population, the purpose of the review, as defined in the question, was to 
consider its effectiveness in adults. Inclusion of studies with participants 
below the age of 16 would introduce heterogeneity which would be 
unhelpful in addressing the main question; while behavioural interventions 
may be useful for those under 16 years of age this question would require a 
review in its own right. Such trade-offs between reductions in wider  
generalisability and facilitating comparison and synthesis that deliver 
meaningful results are common in review design, ultimately requiring 
informed decision making by the researcher (Horwitz 1995).  No upper 
limit was placed upon age. Depression and anxiety is a common condition 
in older adults affecting between 10-17% of this population (Chew-Graham 
et al. 2004). Scoping suggested trials existed in this age group, and such 
information would be of relevance to service providers.  
Treatment settings 
    
Studies including participants treated in community or inpatient settings 
were accepted into the review. The aim was to explore the efficacy of 
behavioural interventions rather than the settings in which they are applied, 
hence all treatment settings were considered relevant.  
Diagnosis 
 
Studies with participants with a primary diagnosis of depression were the 
main target of the review. It was anticipated, through previous narrative 
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reviews in this area (Martell et al. 2001), that we would identify a number 
of trials in this review which were published in the 1970s and 1980s. 
During this time the use of validated instruments to formally diagnose 
clinical conditions was less frequent. Based upon this expectation, studies 
were included if participants were identified as depressed when assessed 
according to standardised criteria at the time of the trial (ICD, DSM) with 
the use of structured diagnostic interview/validated diagnostic instruments 
or valid and reliable clinician/self-rated measures assessing level of 
depressive symptoms. 
 
Studies including participants with a diagnosis of mixed depression and 
anxiety were also included. Based upon findings outlined in Chapter One, 
the most prevalent diagnosis seen in clinical settings is a mixed 
presentation of anxiety and depression. It was therefore decided to include 
studies that included such mixed diagnosis if the primary problem treated 
was depression. It was considered that, while inclusion of anxiety may 
introduce confounders that impact on the overall outcome within the 
selected study, this would be preferable to potentially losing a significant 
number of relevant trials. If such studies were identified their impact on 
overall outcome would be explored through sensitivity analysis. 
3.3.5 Exclusion criteria: types of participants 
 
Diagnosis 
 
Related to the above inclusion criteria it was anticipated that trials would 
be identified that specified a mixed diagnosis of anxiety and depression 
when investigating a behavioural therapy approach to the treatment of 
anxiety. Such trials may make reference to depression symptom level as 
part of their overall battery of measurement. If an exposure-based rationale 
for the treatment of anxiety was the main intervention the study would be 
excluded.  
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In common with many other reviews, we excluded studies with participants 
experiencing psychosis, bipolar disorder, substance misuse problems or 
cognitive impairment.  
3.3.6 Types of intervention 
Main intervention – behaviourally-based interventions for 
depression 
 
The review included studies using behavioural interventions if the 
underlying theoretical framework guiding the protocol related to operant 
conditioning approaches (Skinner 1974) as outlined in Chapter Two. 
Interventions would typically be based upon a formulation exploring and 
readjusting the participants‟ engagement with contextual positive 
reinforcement (Jacobson et al. 2001) with subsequent related behaviour 
change.  It was anticipated that a number of trials would include a 
behavioural component as part of an overall intervention based upon 
cognitive theories (Beck 1976). Such an approach is common, and 
therefore required the review protocol to guide the researcher. The deciding 
factor in this case is the theoretical underpinning of the intervention. 
Behavioural theory would suggest that the focus of the intervention is the 
reconnection with positive reinforcement and the reduction of negatively 
reinforced avoidant behaviour. The use of behaviour scheduling and self-
monitoring commonly found in cognitive interventions has a different goal. 
It is aimed to allow the patient to explore their ability to control their mood, 
thus is used as a behavioural experiment to modify thinking. As such, 
where behavioural techniques were incorporated in cognitive therapy 
interventions to modify beliefs, these would be classed as CBT rather than 
BT.  
Comparators 
 
Comparators were classed into two broad categories, those testing BT 
against an inactive or usual care control condition and those testing against 
an alternative active psychological treatment. From this approach, the 
review aimed to examine if behavioural therapy is effective compared to no 
intervention, an inert intervention or the care usually received. Also it was 
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intended to consider the relative effectiveness of behaviour therapy 
compared to other psychotherapies. Using direct comparisons in studies at 
post-treatment in meta-analysis is more likely to control for the influence 
of individual study variations (such as length of treatment, severity etc.) 
and hence be likely to provide a clearer picture of the superiority of one 
psychotherapy treatment over another (Spielmans et al. 1980).  
Control conditions 
 
Control conditions in this review included: 
 Those with no contact: controls such as waiting list will include no 
contact with the participant for the duration of the control period. 
 Placebo interventions: such interventions are designed to have no 
„active component‟; however they deliver an „inert‟ treatment to 
provide control for non-specific influences such as therapist time 
and personal contact. 
 Treatment as usual: this control condition generally offers those not 
randomised to the intervention arm the usual care they would 
receive from standard care (i.e. from their primary care 
practitioner). As it is assumed that those in the „active‟ arm would 
be having such usual care with the addition of the active 
intervention under study, the differences post-treatment are 
assumed to be attributable to the active ingredient.  
It was decided in incorporate these three „control‟ groupings under one 
heading to provide a realistic estimate of the likely effect of BT in the 
treatment of depression.  
Active comparator interventions 
 
 Cognitive behavioural therapy (CBT): an intervention generally 
based upon the work of Aaron T Beck (Beck 1976) that identifies 
cognitive responses to situations and the emotional consequences of 
these as a central component of treatment. Treatment is time limited 
and is likely to include both behavioural and cognitive components. 
The treatment is psycho-educational, with therapists developing a 
collaborative formulation, shared with the participant, which 
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identifies new ways of coping. The essential difference to the 
behavioural model that is the main intervention is the focus towards 
the challenging of such thoughts and underlying belief structures. 
Any intervention that includes thought catching and challenging, 
either through thought diaries of behavioural experiments, was  
considered to be a CBT intervention. 
 Brief Psychotherapy (BP): other brief psychotherapy approaches 
that utilise the interpersonal relationship with the therapist to 
explore the problem areas of the patient such as Brief Interpersonal 
Therapy (IPT)  (Klerman et al. 1984) or brief psychodynamic 
therapy (Luborsky et al. 1995).  These approaches focus on 
developing insight and subsequent character development. Any 
structured psychotherapy not included in the CBT or behavioural 
categories will be included in this comparison grouping. 
 Supportive Counselling (SC): Generally based upon the work of 
Carl Rogers (Rogers 1961), supportive counselling is focused upon 
the therapist‟s use of core relationship conditions (genuineness, 
unconditional positive regard and empathy) to develop self-
awareness by the participant leading to symptom improvement. 
Treatments in this category will not follow a „structured‟ or 
protocol-led format as they are classed as non-directive however 
they remain brief and time limited. 
Dose/mode of intervention 
 
In the review we included studies examining „brief therapy‟; the definition 
of „brief‟ used was up to twenty-four sessions. No clear definition has been 
set regarding what constitutes a brief therapy; previous reviewers have 
used twenty sessions (Churchill et al. 2001) however no clear rationale was 
provided for the choice of this number. Scoping for this review, however, 
had highlighted key studies described as „brief psychotherapy‟, delivering a 
twenty-four session protocol, which were of significant relevance to this 
review. The researchers in this study provided a rationale regarding the 
number of sessions, which was aimed at giving an adequate „dose‟; this 
was based upon other researchers‟ observations regarding possible failings 
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of previous RCTs of behavioural therapy compared to other 
psychotherapies (Dimidjian et al. 2006). It was clear that such a decision 
could impact on review findings, therefore meta-regression was used to 
explore the relationship between the number of sessions and overall 
effectiveness of the intervention. 
Scoping also indicated that studies would be likely to be identified 
delivering therapy to participants through both individual and group 
approaches. In this review the focus was specifically on individual 
treatments. It was considered that the inclusion of groups could bring in 
additional confounders (such as the role of the group support etc.) that 
might impact on interpretation of findings. While there is a view that 
inclusion of such modes of therapy would assist in the generalisation of the 
review findings to treatment settings, this study was specifically interested 
in the efficacy of individual psychotherapy. In discussions of the steering 
group it was felt the delivery of a separate review on the role of group 
delivery of psychotherapy would be the most appropriate approach for 
exploring this area further, rather than combining both delivery models in 
this review. It was also anticipated that the trials identified could include 
behavioural marital/couple therapy for the treatment of depression. Again it 
was considered that, while such approaches may be based upon a 
behavioural framework, the interventions which focussed upon the 
depressed individual, their partner and centrally their relationship would be 
best dealt with within a separate review.  
3.3.7 Outcome measures 
 
Psychotherapy studies often use multiple outcome measures relating to 
many factors such as symptoms, functioning and cognitive chance. These 
can be categorised into continuous or dichotomous data. As there is a 
paucity of economic analysis in this area (Churchill et al. 2001), trials were 
not required to include cost data for inclusion. 
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Continuous data 
 
Studies that measured depressive episode by validated depression symptom 
level assessment comparing between group outcomes post-treatment and or 
at follow-up were included. Usual assessment consists of either self-rated 
measurement using scales such as the Beck Depression inventory (Beck et 
al. 1961) or clinician rating using a structured assessment tool such as the 
Hamilton Rating Scale (Hamilton 1960). Such scales commonly translate 
the frequency of a range of depression symptoms into a single score, with 
increasing scores reflecting more severe symptoms. For inclusion in the 
review the scales used the within studies must have been subject to validity 
and reliability testing. Outcomes are usually presented by means and 
standard deviations. As psychotherapy trials often present multiple 
measures, an algorithm was developed with self-report measures taking 
precedence over clinician-rated measures. As there is no clear standard 
approach to guide such a hierarchy, the review steering group had to 
consider available options and make a decision in consultation (Khan and 
Kleijnen 2002). Based upon the reviewers‟ experience in the field, the 
initial scoping of the frequency of each approach used and discussion, 
agreement was reached to give validated self-report measures precedence. 
The impact of this decision on overall results would be explored via 
sensitivity analysis.  
Dichotomous data 
 
Recovery is often reported in psychotherapy trials and was included as a 
dichotomous measure. Recovery reflects to what degree the participants in 
the study move from a clinical sample (based upon either symptom level 
measures supported by validated cut of points, or structured clinical 
interviews) to a non-clinical sample.   
 
Dropout was used as a proxy for treatment acceptability. Dropout was 
considered an important comparison to assess the effectiveness of an 
intervention outside the research setting. Acceptability of treatments is an 
important consideration, as if there is increased attrition for a particular 
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intervention compared to other standard treatments this would lead to 
overall questions relating to overall effectiveness. Such analysis was 
included as it provides important information for clinicians. 
3.3.8 Search strategy  
 
The delivery of an unbiased comprehensive literature search is central to a 
well-designed systematic review. Results will be compromised if the 
search misses relevant primary studies, as it will not provide a 
comprehensive overview and the level of precision of the effect estimates 
will reduce with insufficient statistical information (Higgins and Deeks 
2008). The difference between a narrative review and a systematic review 
is the search process involved. A systematic review delivers a 
comprehensive search of the literature based upon an established and 
piloted search strategy. The exclusion of bias through such comprehensive 
strategies sets the platform for the review and meta-analysis by identifying 
all relevant studies regardless of outcome of those studies (Easterbrook et 
al. 1991).  
In order to deliver as comprehensive and unbiased review as possible, the 
search strategy used in this review was developed in partnership with an 
expert in the field (JM, a librarian employed within Tees, Esk and Wear 
Valleys NHS Foundation Trust with extensive experience in delivery of 
searches and of training in literature searching at a NHS trust and strategic 
health authority).  
In designing the search strategies used in this review, the potential biases I 
wished to exclude were: 
 Publication bias: it has long been known there is a tendency to 
publish studies showing a significant difference in results 
(Rosenthal 1979). In psychology journals it has been estimated that 
95.6% of articles reported significant results (Sterling et al. 1995).  
Such a trend persists today, with estimates that studies with 
statistically significant results are up to four times as likely to be 
published (Hopewell et al. 2008) and those with negative results 
taking up to two or three years longer (Loannidis 1998). This leads 
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to a potential over-estimation of the effectiveness of the therapies 
included in a review. Therefore search strategies used in this review 
were designed to cover a multitude of databases aimed at 
identifying both published articles and „grey literature‟ (i.e. material 
not formally or commercially published). This approach was aimed 
at optimising the chances of identifying studies with both positive 
and negative results. 
 Duplicate publication bias: It is relatively common for results from 
an individual study to be presented in a number of publications 
(Higgins and Deeks 2008). This problem is particularly associated 
with trials with positive results, and can result in over-estimation of 
effectiveness in meta-analysis due to multiple inclusion of the same 
data set (Tramèr et al. 1997).  It creates particular problems in 
identification, as often publications are written by different authors, 
or report different measures incorporated in the same study. While 
it was felt that this could pose a significant risk to the outcome of 
the meta-analysis in this research, it was decided that this problem 
would be better managed at the study selection phase rather than 
though search strategy modification. The risk would be that limiting 
the scope of the search could have the unintended consequence of 
eliminating potentially important findings.  
 Citation bias: While using reference lists to identify research to be 
included in meta-analysis is commonly accepted (Glanville 2002),  
this can lead to bias in itself. Authors of book chapters and journal 
articles will commonly select evidence to support their view. This is 
particularly the case if the findings are positive (Carter et al. 2006) 
and hence a problem is posed for the review if such reference lists 
are to be used. In order to balance these findings we searched 
reference lists in those studies identified from our electronic 
searches of all databases to ensure adequate sensitivity for studies 
with negative findings. 
 Language bias: There remains considerable debate as to the impact 
of language bias on review findings (Moher et al. 2003, Jüni et al. 
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2002). More recently there is some evidence that randomised trials 
are more likely to be published in English-language journals 
(Galandi et al. 2006). In this review however it was anticipated, 
based upon literature scoping, that a number of trials from the 
1970s and 1980s would be identified. Therefore to exclude non-
English-language articles would potentially introduce unacceptable 
levels of bias. Often trials are indexed and abstracted in English 
despite being in a non-English journal. We therefore took the 
approach of including non-English language articles and adopting a 
case by case approach to balancing the resource requirements of 
translation vs. the relevance and impact any non-English language 
paper was likely to make to the review findings.    
Sensitivity vs. specificity 
 
Sensitivity refers to the proportion of articles on a subject the search is 
likely to deliver. It is often expressed or measured as a percentage and 
measures the comprehensiveness of a search strategy. Specificity (or 
precision) refers to the ability of a search to exclude irrelevant articles 
(Glanville 2002). The balance between each of these approaches is 
important, especially taking into account the diminishing returns in relation 
to additional searching beyond a certain stage. In this strategy it was opted 
to employ a highly sensitive approach in designing the search strategy to 
ensure that a high proportion of relevant reports were identified in relation 
to the number in existence. It was decided that the relatively swift process 
of scanning results in relation to the total time employed upon the review 
and meta-analysis as a whole made this approach advisable. As is 
recommended, the inclusion of an experienced librarian in the planning and 
execution of the search strategy assisted in these decisions, with the search 
being developed over a number of meetings where pilot searches were 
constructed and conducted and reviewed as recommended (Glanville 
2002).  
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Sources  
 
It is recommended that a minimum for a comprehensive search would 
include the Cochrane Central Register of Controlled Trials (CENTRAL), 
MEDLINE and EMBASE (Glanville 2002). While the CENTRAL 
database searches MEDLINE and EMBASE for controlled trial data, there 
may be a lag time in that process and also some of the free text terms, 
particularly in EMBASE, may have been missed with older studies. To 
ensure that a comprehensive picture was established it was decided to 
search both those databases in addition to CENTRAL for this review. This 
approach is not necessarily recommended (Higgins and Deeks 2008) 
however within the discussions of the research group it was felt to be 
appropriate based upon the scoping of literature for this review. The search 
was specifically widened to include databases that include dissertations 
(CINAHL), specific databases of mental health research (PsycINFO), those 
of allied health professionals (AMED) and nursing (British Nursing Index).  
In addition, searches were conducted within the Database of Abstracts of 
Reviews of Effects (DARE) and the Cochrane Database of Systematic 
Reviews to identify any reviews of evidence not previously identified. 
Searches were conducted from inception of each database to ensure a 
comprehensive record was gathered. It is noted that this approach may 
have resulted in increased work, as MEDLINE and EMBASE results 
would have been already included in CENTRAL prior to 2001; however, 
as outlined above, it was felt that the exclusion of duplicated work would 
be achieved at study selection. The benefit of the delivery of a thorough 
search outweighed the risk of any potential unrewarded effort of duplicate 
searching. Appropriate filters to capture randomised controlled trials were 
be included in all searches other than in those in the Cochrane Library, 
which only includes studies using this methodology (see 
http://www.york.ac.uk/inst/crd/search.htm). 
Hand searching 
 
Key journals in the field of psychological interventions for depression were 
hand-searched for the year prior to the review to identify recently published 
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trials. It can take up to this time for studies to be indexed in electronic 
databases (Glanville 2002). Reference lists from identified trials were also 
searched to highlight any trials not identified by the above search strategy. 
This process was repeated until no new relevant reports were identified. 
Grey literature 
 
Grey literature (conference abstracts etc.) were examined via hand and 
internet searching for the year prior to the review, as it was anticipated 
those presented prior to this time would be identified through published 
data searching. Databases containing references to these data sources such 
as SIGLE (system for information on grey literature) were searched 
alongside the Dissertation Abstracts International database, the NHS 
National Research Register (NRR) (to identify current and recent relevant 
research), and were cross-referenced with other findings.  
 
Key authors in the field of behavioural therapies of depression were 
contacted to identify any other relevant studies, which were then checked 
against results. 
Controlled vocabulary and free text 
 
Controlled terms such as MeSH in MEDLINE and EMTREE in EMBASE 
allow indexed terms to be collated in those source databases. However as 
these change across databases it is necessary to ensure the appropriate 
strategy is adopted for each database. In addition, controlled terms are 
indexed in subject trees and hence can be „exploded‟ to widen the search 
scope. One difficulty of controlled vocabulary searches, however, is the 
variability of indexing, particularly in relation to older studies (Higgins and 
Deeks 2008), some of which we were expecting to identify in this review. 
This emphasised the requirement of the free text section of searches to be 
robust and that all searches were adapted to a relevant format for the search 
platforms used. Where relevant, search filters were employed to capture 
randomised trials. See Table 6 for an example search strategy for the 
Cochrane Database. 
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Table 6: Example search strategy for Cochrane database. 
#1 MeSH descriptor Depression explode all trees in MeSH products 
#2 MeSH descriptor Depressive Disorder explode all trees in MeSH products 
#3 MeSH descriptor Dysthymic Disorder explode all trees in MeSH products 
#4 (#1 OR #2 OR #3) 
#5 depress* in All Fields in all products 
#6 dysthym* in All Fields in all products 
#7 (#4 OR #5 OR #6) 
#8 MeSH descriptor Behavior Therapy explode all trees in MeSH products 
#9 behav* next therapy in All Fields,  in all products 
#10 (#8 OR #9) 
#11 behav* near/3 activation in All Fields in all products 
#12 (event* or activit*) near/3 schedul* in All Fields in all products 
#13 positive next reinforc* in All Fields in all products 
#14 coping near/2 depression in All Fields in all products 
#15 (#10 OR #11 OR #12 OR #13 OR #14) 
#16 (#15 AND #7) 
 
MeSH terms for depression and dysthymia have been combined with free 
text searches for depression and depressive disorders ( combines both in 
free text via the use of truncation) and dysthymia to provide the diagnostic 
field. The MeSH term for behaviour therapy is exploded and combined 
with free text search of behaviour therapy ( behav is again truncated to 
obtain all spellings, is combined using „next‟ as the search is interested in 
the particular term). Duplication is removed to provide the intervention 
results. The search strategies from #11 to #14 are specific terms relevant to 
this intervention (combined using relevant search operators to optimise 
specificity); these have been combined with wider behavioural therapy 
terms to increase sensitivity of the search. Interventions are then combined 
with the diagnostic field  to provide the final set of results.  
 
The above outlines an extensive search strategy that was developed in 
partnership with JM. This information specialist was then contracted, based 
upon negotiation with the host employer, to conduct the search in 
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partnership with myself to deliver a mix of expertise in search delivery and 
behavioural theories.  
 
Details of the main search strategies used, dates conducted and results are 
included in the search report in Appendix I for transparency as per 
recommended procedures (Moher et al. 2009). 
3.3.9 Selection of Studies 
 
Studies in this review were selected following the stages outlined below: 
 
1. Merging the results of the numerous searches within a reference 
manager software programme (Endnote, (Thompson 2005) 
removing duplicate reports. 
2. Examine the identified titles and abstracts to remove obviously 
irrelevant articles. 
3. Obtain full text of potentially relevant reports; examine to exclude 
further duplication and assess relevance to inclusion criteria. 
4. Review findings of searches with research team and clarify 
approach to studies where uncertainty existed. 
5. Decide on inclusion and move studies to data extraction phase. 
Merging results 
 
Data from searches was downloaded to EndNote where possible and 
duplicate results searched for using the „find duplicates‟ command. Each 
example of identified duplication was reviewed to ensure a correct 
decision, then one citation was deleted. This process was repeated until the 
master data set no longer  included any duplications.  
Selecting studies 
 
Study selection is one of the most important stages in the review process, 
therefore it is beneficial to have a transparent process involving more than 
one reviewer (Glanville 2002). This helps to exclude bias as those 
conducting reviews may have preformed opinions that influence their 
decision making (Higgins and Deeks 2008). In this review, obviously 
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irrelevant research was excluded by title examination by one reviewer 
(DE). This was a pragmatic decision based upon the expectation that, due 
to the highly sensitive search strategies used, a high number of such reports 
would be included (i.e. studies identified looking at depressed thyroid 
gland may well be identified if RCT and the term „depressed‟ were  
captured). Following this the reduced list was examined at abstract level by 
two reviewers independently (myself and DR), following which a 
comparison of results was conducted and a list of articles for further full 
text review generated.  
Studies were then selected based upon their relevance to the question and 
inclusion criteria. Blinding of author and source details of studies may 
reduce bias in the selection process. Due to the resource limitations 
alongside the uncertain level of benefit this produces (Berlin 1997), in this 
study author and source details were included.  Full text of selected studies 
were obtained and screened for relevance independently by two reviewers 
(myself and DR) as a measure against bias. It was outlined a priori that any 
disagreements regarding suitability were to be resolved by discussion in the 
first instance. If agreement was not reached, a third reviewer (SG) would 
be asked to independently screen the article for acceptability and relevance. 
A flow chart would be used to outline the numbers of studies 
included/excluded at any given stage with summary rationales for decisions 
as per recommendations (Moher et al. 1999).  
Quality assessment  
 
Two reviewers (DE & DR) rated study quality using criteria to explore bias 
(Khan et al 2002). Other than concealment of allocation, evidence 
demonstrating aspects of study quality that directly influence outcomes is 
unclear (Jadad et al 1996, Schultz & Grimes 2002). Many quality 
assessment scales have been developed however all would seem to have 
individual weaknesses (Moher et al. 1995). An example of problems with 
quality assessment tools is highlighted in a study that used 25 scales, 
previously adopted in published reviews, to measure the quality of 17 
studies included in a meta-analysis of heparin use in the prevention post-
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operative thrombosis. The association of quality and effect estimates were 
so varied that the authors recommended assessing individual 
methodological aspects of trial quality in relation to effect estimate (Jüni et 
al. 1999). Based upon discussions between the review steering group, it 
was decided to use a simple measure of quality devised for this review that 
rated studies against two standards relating to selection, measurement, 
performance and attrition bias. This would result in a possible quality score 
of between 0-8. Study quality assessment forms were developed and 
piloted by DE and finalised in collaboration with SG and DR (see 
Appendix 1 for quality assessment tool). A protocol regarding decision 
making on study quality was agreed: that disagreements were dealt with 
through discussion initially between myself and DR, and if required, 
passed to SG with issues for final scoring. In order to explore the 
relationship between methodological aspects of trials (study quality) and 
effect size, regression analysis was performed; for details see below.  
3.3.10 Data Extraction and synthesis 
 
Data were extracted from each trial at post-treatment and follow-up (six 
months or nearest available data set). Data extraction forms used in a 
previous meta-analysis of collaborative care and guided self-help for 
depression (Gilbody et al. 2006, Gellatly et al. 2007) were reviewed and 
adapted  for this research.  These were then tested for ease of use (see 
Appendix I for blank data extraction form). Forms were designed to allow 
identification of the unique study and the person extracting the data. Forms 
allowed for collection of data in relation to study populations, 
interventions, quality and statistical data (Higgins and Deeks 2008). Final 
forms were completed for each study included in the review. Ideally data 
should be extracted by independent reviewers, as this reduces errors 
(Buscemi et al. 2006). In this study, however, a balance was considered in 
relation to capacity and an ideal approach. There was no funding to support 
the systematic review, hence double data extraction, while preferred, was 
not possible. We approached this by initial data being extracted by DE and 
subsequently checked in meetings with DR. This process was conducted 
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with an understanding of the increased risk associated with extraction error 
using this approach, which was rigorously checked for in such meetings. 
While blinding of some study details has been suggested to remove the risk 
of bias from review authors, as outlined in the abstract review stage, this is 
not generally accepted as necessary (Berlin 1997) and, due to resource 
limitations was not adopted.  Data were then entered into the Cochrane 
Collaboration Revman programme (Cochrance Collaboration 2003) for 
synthesis. Where missing data were identified, author contact details were 
sought through published papers or via the World Wide Web.  Contact was 
attempted via email, as often authors were based in the USA. If, after two 
attempts no less than four weeks apart, no response was received, no 
further contact was attempted. Statistical data were extracted to facilitate 
analysis of continuous (depression symptom level) and dichotomous 
(recovery, dropout) variables. For continuous data the mean score of the 
behavioural interventions (Mba) and of the comparator (Mc), standard 
deviation (SDba) and (SDc) and number (Nba) and (Nc) were extracted.  If at 
this point missing standard deviation scores were identified, which was 
anticipated due to the number of older studies identified in scoping for this 
review, these were imputed from relevant studies as per accepted protocols 
(Furukawa et al. 2006). Such approaches appear to have minimal impact on 
the overall findings of meta-analysis and are considered safe, hence were 
deemed appropriate in this review. In the case of missing standard 
deviation values  it was agreed that SG would identify and supply for 
imputation these extracted from a comparable primary study reviewed in a 
large meta-analysis of collaborative care for depression (Gilbody et al. 
2006). For dichotomous data the count of events in each arm were 
extracted alongside the numbers in each arm. 
3.3.11 Data pooling 
Continuous data-depression symptom level 
 
Two approaches to data pooling of continuous data are commonly used and 
were considered for this review. Weighted Mean Difference (WMD), more 
correctly described as „difference in means‟ and standardised mean 
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difference (SMD). WMD measures the mean difference between the 
intervention under investigation compared to the comparator on a 
continuous scale. It is a measure that can be used when measurements to be 
analysed in meta-analysis are of the same scale (e.g. kilograms or points on 
a BDI scale). Weighted mean difference therefore combines data from each 
study and gives a combined mean difference in across all studies in the 
specific unit of measurement. This approach is possible only when the 
continuous data under investigation as stated is on the same scale or can be 
converted to the same scale (e.g. trials using kilograms and trials using 
ounces measuring the continuous variable of weight). In this meta-analysis 
this would prove problematic, as depression symptom level studies use a 
range of measurement scales to measure this same construct. In contrast 
with scales measuring weight, there is no consistent relationship between 
units used in depression symptom level measurement: one unit on the Beck 
Depression Inventory (BDI) is not constantly related to one unit on the 
Patient Health Questionnaire (PHQ-9) across all possible ranges on the 
scales. While they both asses overall depression symptoms, the BDI used a 
21 item scale with each item scoring 0-3 rating feelings over the past week 
thus producing a possible score range of 0-63. The PHQ-9 in contrast 
measures depression on a nine-item scale, with each item scoring 0-3 in 
rating feelings over the past two weeks, producing a possible score range of 
27.  This results in no rational approach to convert all scales to one single 
„unit of depression symptom‟. While it would be possible to multiply the 
PHQ-9 score by 2.33 to convert it to a 63-point scale, this produces many 
problems, as each scale asks different questions with the BDI scoring more 
depression symptoms (21 vs. 9) over half the time. This would therefore 
clearly lead to problems in validity. For this reason the use of WMD was 
not possible in this meta-analysis if we wished to combine as many studies 
as possible rather than only those using a single scale for measurement. 
The alternative approach is to assess the difference in relation to the 
standard deviations of the means of scales used in the included studies. The 
standardised mean difference (SMD, sometimes described as Cohen‟s d or 
effect size) is commonly calculated by subtracting the mean of the control 
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group from the mean of the intervention group and dividing by the pooled 
standard deviation. 
 
What is being produced is a summary statistic of the giving the difference 
in means between groups relative to the variance (SD) in the study. This 
produces a measurement of the number of standard deviation units between 
the two means. Although the number has no quantifiable value, it allows 
for comparison across a number of scales as long as they are measuring the 
same construct (depression symptom level). In the case of the BDI and 
PHQ-9, the variance around the mean reflected in the standard deviation 
should be the same ratio even though the actual range of possible scores on 
the BDI scale is 2.33 times more than the PHQ-9. For example, if a 
moderately depressed group had a mean BDI score of 21 (SD 7) and a 
mean PHQ 9 score of 15 (SD 5), the ratio of the SD to mean is constant. 
This then allows comparison across scales using the SMD calculation 
outlined above. It is important to consider the use of SMD with care, 
ensuring that units of measurement included are measuring the same 
construct (such as depression symptom level) and that results viewed with 
reflection on the degree of heterogeneity of included participant samples. 
This can impact on SMD, as the pooled standard deviation may be directly 
related to the inclusion criteria of the study: the tighter the inclusion criteria 
the smaller the pooled SD. In this case the same treatment effect may result 
in a different SMD. Therefore a measure of heterogeneity (see later in this 
section) should be used to estimate its effect on results. The SMD is the 
only option in meta-analysis where differing scales of continuous variables 
are used (Deeks et al. 2009) and hence was considered appropriate in this 
review bearing in mind the considerations outlined above.  
 
We assigned effect sizes values according to the standard convention 
where the SMD is small (0 – 0.32), medium (0.33 - 0.55) and large (0.56 
and above) (Lipsey and Wilson 1993, Cohen 1988).  
 80 
3.3.12 Statistical considerations 
 
An additional issue addressed in our methodological design was related to 
studies that included two comparisons under the same category (i.e. CT and 
CBT vs. BT). Through the initial scoping it was clear this problem would 
be encountered. Simply entering the BA results in two separate rows would 
appear to be the simplest solution to this problem. This however would 
lead to double counting of the numbers in the BA arm of the meta-analysis, 
thus resulting in an over-estimation relating to the weighting of trials. That 
is a trial with 50 participants in a BA arm would be doubled up to 100 
participants suggesting twice as many people received the approach 
resulting in a unit of analysis error (Deeks et al. 2009). Several options 
exist in relation to such problems (Higgins et al. 2008). One option 
commonly adopted approach is to combine groups to form a single pair-
wise comparison. It was felt in this review such combinations would lose 
the individuality of the separate intervention arms in question. For 
example, in one study (Jacobson et al. 1996) both CBT and CT were 
compared to BA. In this case each comparator to BA was different in 
construct and thus merited comparison in its own right. An alternative (but 
slightly less favoured) approach is to enter comparisons separately but to 
halve numbers in the behavioural arm to avoid double counting and 
inaccurate weighting of trials (Higgins et al. 2008). In this review the latter 
approach was adopted, as it was felt more suited to the varied nature of the 
comparisons that may be encountered. 
 
 Where studies presented results using sub-categories (e.g. high/low 
depression severity), data were entered as two separate trials, provided that 
stratification occurred prior to randomisation. This approach was a 
pragmatic decision reducing the need to contact authors for combined data 
sets where these were not reported in publications. 
Dichotomous data - recovery rate and dropout 
 
Dichotomous (binary) data are presented when each individual in a study is 
in one of two states. This review analysed if patients were either 
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recovered/not recovered at post-treatment and follow-up and if they 
dropped out/ did not drop out at post-treatment.  These data were presented 
as odds ratios, the chance of an event (improvement or dropout) in the 
intervention group compared to the comparison group. An odds ratio of 1 
indicates no difference between an event occurring in each group, less than 
one a reduced chance of such an event and greater than one an increased 
chance. It is important to be mindful as to the preferred directions when 
interpreting odds ratios (Deeks et al. 2009). In this review for recovery a 
score of greater than one was a positive finding and for dropout less than 
one would be positive. Odds ratios are calculated by dividing the number 
of events in the intervention/control group by the number of participants in 
each group. This firstly establishes odds of the event happening in each 
arm, then to establish the odds ratio dividing the odds of the event in the 
control by the odds of the event in the treatment group. 
 
  
Effects modelling 
 
The aim in meta-analysis is to present the combined effect of an 
intervention across a number of varied studies. If all studies carried an 
equal level of precision this would be a simple calculation: the mean of 
effect sizes across all included studies. Some studies, however, may be 
more precise in the effect estimate than others due to a number of factors, 
such as sampling, size and possible bias. Therefore in meta-analysis it is 
important to decide how the findings of each study contribute to the overall 
effect size. There are two approaches based upon differing assumptions 
that are commonly used: fixed effect and random effect modelling (Deeks 
et al. 2009, Hedges and Vevea 1998). 
Fixed effects 
 
Fixed effects models assume there is one true effect that underlies all 
studies in the meta-analysis. Therefore, if each study were infinitely large, 
they would all produce the same effect size. Each study is as a result 
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allocated a weight dependent on the degree of information that is captured. 
The only error assumed in this model is random error, which is reduced as 
sample size increases; hence weight is calculated according to study size. 
Therefore calculations in fixed effects models assume that all studies have 
a shared effect size and that all observed effects are normally distributed 
around this, with observed variance dependent on sample size (see Figure 
7). 
 
Figure 7: Fixed effect model.  
The observed effects are sampled from a distribution with true effect μ, and 
variance σ
2
. The observed effect T
1 
is equal to μ+ε
i
 (Borenstein et al. 2007) 
 
Random Effects 
 
Random effects modelling, in contrast, assumes that each included study is 
estimating slightly different treatment effects. The model estimates the 
distribution assuming that effects are related and have a central value, but 
due to the heterogeneity of studies (i.e. age of participants, duration of 
treatment measurement reliability) the true effect within each study varies. 
The meta- analysis using this model therefore reports the mean effect 
estimate in this distribution.  As each study is estimating a different effect 
size from a sample of a population, the weight of each study in a 
calculation is more balanced, with larger studies less dominant than they 
would be in a fixed effect model. This results in two levels of variance, 
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firstly within each study and secondly across studies, to give an estimate of 
the mean of the effects of studies (see Figure 8).    
 
 
Figure 8: Random effects model.  
The observed effect T
1 
(box) is sampled from a distribution with true effect 
θ
1
, and variance σ
2
. This true effect θ
1
, in turn, is sampled from a 
distribution with mean μ and variance τ
2
. In turn, θ
1
, is determined by the 
mean of all true effects, μ and the between-study error ζ
1
.(Borenstein et al. 
2007) 
 
From scoping prior to this review, it was clear that studies would have 
heterogeneity in clinical populations (age and level of depression), and 
sampling methods. In addition, interventions would vary in terms of 
therapist experience, session number, setting and duration. As it was 
wished to make inferences about how results may generalise outside of the 
studies observed in the meta analysis, a random effects model was the most 
appropriate method to use (Hedges and Vevea 1998). This assumes that 
results would provide an estimate of the mean of a distribution of varied 
effects of behavioural therapy vs. comparators. 
Summary of statistical issues  
 
Based upon discussion within the review steering group of the above 
issues, it was decided to present pooled data of continuous outcomes by 
 84 
standardised mean difference and dichotomous outcomes by odds ratios 
with 95% confidence intervals using a random effect model (Sutton et al. 
1998),  taking into account both within and between study variance.  
3.3.13 Exploration of heterogeneity 
 
Heterogeneity is a term used to describe the variability between studies in a 
review. Such variability can be due to clinical differences in populations or 
interventions (clinical heterogeneity), or the methodological approaches, 
such as risk of bias and study design (methodological heterogeneity). These 
factors alone or in combination may result in intervention effects that vary 
more than would be expected by chance; such variation is described as 
statistical heterogeneity.  Scoping for this review suggested that while 
some clinical heterogeneity within each comparison group (differences in 
baseline severity and doses of intervention) was expected, this would not 
be sufficient to preclude meta-analysis. While slightly differing 
intervention results may be observed  due to the impact of clinical 
differences in individual studies, these were assumed to be distributed 
around a central „true‟ intervention effect (hence the use of random effects 
modelling). This assumption emphasised the need for estimation and 
reporting of heterogeneity within the review.     
 
To maintain scientific rigour in a review, the identification of potential 
sources of heterogeneity should be identified a priori and be conservative 
in number (Deeks et al. 2009). Multiple post hoc analysis is more likely to 
result in spurious findings and should be avoided (Anello and Fleiss 1995).  
From scoping exercises three potentially important sources of clinical 
heterogeneity were identified: 
(1) Baseline severity of depression;  
(2) Training level of the therapist (graduate versus 
postgraduate/experienced therapist qualification);  
(3) Number of treatment sessions.   
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Study quality was also considered a source of potential methodological 
heterogeneity, incorporating a cut-off point of 6 on the 8-point quality scale 
which had been agreed in discussions of the review steering group.  
Measurement of heterogeneity  
 
It is possible to view the variance between studies by observing the degree 
of overlap in confidence intervals on a forest plot. Such approaches provide 
a simple observation; however further formal testing is advised (Centre for 
Reviews and Dissemination 2009). Chi-square tests examine if the variance 
observed in results across studies is likely to be as a result of chance alone. 
Caution has been advised in the use of chi-square tests especially in          
meta- analysis with few studies and low numbers in some trials. This 
results in low power of the test, which may provide misleading results 
(Deeks et al. 2009). This can be adjusted for in the increase of the P value 
to 0.10 rather than 0.05; however the problem remains that non-significant 
results cannot be assumed to guarantee no heterogeneity.        
An alternative approach is to assume that heterogeneity is always present in 
meta-analysis and the important factor to assess is the degree to which it 
influences results (Higgins et al. 2003). This approach uses the I
2 
statistic to 
estimate inconsistency. The I
2 
statistic uses the chi-square statistic (Q) and 
its degrees of freedom to describe the percentage of variability in the meta-
analysis due to heterogeneity rather than chance (Higgins et al. 2003, 
Higgins and Thompson 2002);  
 
Interpretation of the I
2 
statistic is as follows: 
 0% to 40%: might not be important; 
 30% to 60%: may represent moderate heterogeneity; 
 50% to 90%: may represent substantial heterogeneity; 
 75% to 100%: considerable heterogeneity. 
 
Based upon scoping it was decided to adopt the I
2 
statistic approach, as it 
was expected that a number of small studies of behavioural activation 
would be identified which could have resulted in difficulty with the 
interpretation if significance testing via chi-square approaches.  
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3.3.14 Sensitivity analysis 
 
The impact of these sources of heterogeneity and study quality was 
explored via sensitivity analyses and meta-regression where possible 
(Thompson and Higgins 2002). Meta-regression examines how an outcome 
variable (SMD) may be predicted by pre-defined study characteristics or 
„potential effect modifiers‟.   In comparisons with ≥10 studies, outcomes 
were analysed using meta-regression, specifying sources of heterogeneity 
as predictive co-variates.  A permutation test (using 1000 Monte Carlo 
simulations) was used to calculate p-values, and to reduce spurious false 
positive findings (Higgins and Thompson 2004). The amount of 
heterogeneity explained by predictive co-variates was examined by 
reductions in the I
2
 inconsistency statistic within our model. This approach 
was discussed between DE and SG to agree the rationale for the approach. 
SG had previous experience of conducting meta-regression in exploration 
the impact of study level moderators in a large meta-analysis of 
collaborative care interventions for depression (Gilbody et al. 2006).  
Analyses were conducted using the metan and metareg commands in Stata 
8 (Stata Corporation 2003) by SG.   
3.3.15 Publication and small study bias 
 
Although the search strategies described earlier in this chapter were 
designed to reduce the possibility of reporting bias, they cannot eliminate 
the risk of it impacting on the review findings, therefore formal assessment 
is essential (Song et al. 2000, Rothstein et al. 2005). In this review the 
possibility of publication bias was assessed through a Begg funnel plot 
graph (Begg et al. 1994). These graphs are simple scatterplots that initially 
compared sample size on the vertical axis vs. intervention effect estimates 
of the horizontal axis. As effect estimates will be more precise as sample 
sizes increase, smaller studies will be more widely distributed towards the 
bottom of the graph. This results in the distribution representing a funnel in 
the absence of publication bias. If such bias is present and studies with 
non-significant effects are missing, the funnel will appear asymmetrical 
(see Figure 9). As statistical power is related to more than pure sample size 
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(such as standard deviation of responses in continuous outcomes), it is now 
recommended that standard error of intervention effect rather than sample 
size is plotted on a vertical axis (Sterne and Egger 2001). This places 
standard errors on a reversed scale, placing the most powerful studies at the 
top of the scale with the additional benefit of allowing the plotting of a 
triangular region within which 95% of studies would fall in the absence of 
bias or heterogeneity. Small studies, often found in psychotherapy, can still 
impact on the distribution of plots in a funnel plot graph. They may offer 
less precision and appear and introduce a positive bias in interpretation. 
They may also include a particularly severe or treatment resistant sample 
and introduce a negative bias to interpretation.     
Some problems therefore exist with a reliance on funnel plots alone in 
estimating publication and small study bias. Firstly the subjective approach 
relies on the researcher‟s ability to identify funnel plots reflecting bias, 
which is unreliable (Terrin et al. 2005, Tang and Liu 2000) and SMD is 
naturally correlated with its standard error and can therefore produce 
spurious asymmetry (Deeks et al. 2009).     
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Figure 9: Examples of funnel plot graphs showing symmetrical (1) and 
asymmetrical (2) distribution (Deeks et al. 2009) 
 
A sufficient number of studies are required for this approach to achieve 
significant power to detect real asymmetry from chance and be interpreted 
in light of the visual inspection (N≥10). To counter these problems, in 
addition visual examination of funnel plots we tested for asymmetry using 
Egger weighted regression test (Egger et al. 1997)  where the intercept is 0 
if no bias is present.  Egger regression testing was conducted using Stata 8 
(Stata Corporation 2003) by SG.   
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3.4 Results of systematic review and meta- analysis  
 
Searches conducted between October 2005 and February 2006 identified 
3353 potential studies for inclusion within the review. Following title 
review, 3268 reports were excluded as not relevant. Abstracts of the 
remaining 85 studies were reviewed, of which 52 were rejected. Of these, 9 
studies included participants who did not fall within the review criteria, 30 
studies reported interventions did not fall within the review criteria, two 
studies did not report relevant outcomes and 11 were not randomised 
controlled trials. A total of 33 full papers was then reviewed, of which 13 
were rejected. Of these, nine studies included participants who did not fall 
within the review criteria, in one study the comparator did not fall within 
the review criteria, and three studies were not randomised controlled trials. 
A total of 20 relevant randomised controlled trials were finally identified as 
meeting the criteria for the review, which included a combined total of 
1215 participants (Taylor and Marshall 1977, McLean and Hakstain 1979, 
Gallagher and Thompson 1982, Maldonado Lopez 1982, Wilson 1982, 
Wilson et al. 1983, Maldonado Lopez 1984, Skinner 1984, McNamara and 
Horan 1986, Thompson et al. 1987, Scogin et al. 1989, Jacobson et al. 
1996, McKendree-Smith 1998b, Hopko et al. 2003 , Dimidjian et al. 2006, 
Cullen et al. 2006, Padfield 1976, Zeiss et al. 1979, Gardner and Oei 1981, 
Cole 1983).  Three studies were excluded from the meta-analysis due to 
insufficient statistical data being available (Padfield 1976, Zeiss et al. 1979, 
Gardner and Oei 1981). All studies are listed in table 7. Each was allocated 
a number used for identification throughout the remainder of this chapter. 
In all, 17 randomised controlled trials, including a combined total of 1109 
participants, were included in the meta-analysis. For further details of study 
selection processes see Figure 10. For details of included studies see Table 
7. For study quality assessment scores see Table 8. 
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Figure 10: Flow chart of study identification 
 
Studies identified n = 3353
Excluded at title review n = 3268
Abstract reviewed n = 85  
Papers reviewed n = 33   
Included in narrative review n = 20
Included in meta analysis n = 17 
13 rejected (9 intervention, 1 
comparison, 3 design)
52 rejected (9 participants, 30 
interventions, 2 outcomes, 11 
design.  Not within review criteria)
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Table 7: Details of identified studies 
Authors and year (study no.) 
Sample/setting 
Mean age (SD/range) 
Sex (% female) 
Interventions 
 (n) 
Depression 
level at 
baseline 
Concurrent 
Pharmacolog
y 
Therapist level. 
Session number (duration) 
Taylor and Marshall. 1977. (1) 
university students 
22.4(2.6) 
71 
behavioural  (7) 
cognitive (7) 
cognitive 
Behavioural (7) 
wait List (7) 
mild/moderate 
(21.2 BDI) 
 
no 
graduate student 
experience as counsellor 
6 (40) 
McLean and Hakstein. 1979. (2) 
community 
outpatient39.2(10.9) 
72 
behavioural (42) 
brief Psychotherapy 
(44) 
drug Therapy (49) 
relaxation (43) 
within or 
beyond 
moderate 
depression 
range 2 out of 
3 measures 
used at 
baseline 
 
no (other than 
DT arm) 
licensed psychologists, 
physicians or psychiatrists. 
At least 2 years of 
experience as therapist 
10 (1hour) not drug 
therapy 
Gallagher and Thompson. 1982. 
(3) 
older adult community. 
67.76 (6) 
76 
behavioural (10) 
cognitive (10) 
psychotherapy (10) 
RDC Criteria  
MDD 
 
no 
advanced PhD or post-
doctoral therapists 
experience in modality 
16 (90mins) 
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Maldonado Lopez. 1982. (4) 
community outpatient. 
NA 
NA 
behavioural (8) 
cognitive (8) 
drug Therapy (8) 
psychiatrist 
diagnosis 
reactive 
depressive 
disorder 
no (other than 
DT arm) 
psychology dept, level of 
training not reported 
10 (1 hour) 
Wilson, P. 1982. (5) 
general population media 
announcements. 
38.8(20-55) 
66 
drug therapy and 
behavioural (12) 
drug therapy and 
relaxation (10) 
drug therapy and 
minimal contact (10) 
placebo and 
behavioural (9) 
placebo and 
relaxation (11) 
placebo and  
minimal contact(12) 
BDI>19 
 
in DT arm 
graduate psychologist 
7 (1hour) 
2 (1hour) in min. contact 
arm 
Wilson, P et al. 1983. (6) 
general population media 
announcements. 39.5 (20-
58) 
80 
behavioural (8) 
cognitive (8) 
wait list (9) 
BDI >17  
(moderate 
depression) 
yes (5 
subjects in 
trial) 
not clear, university 
psychology clinic 
8 (1hour) 
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Cole, M. 1983 (7) 
community outpatient 
veterans. 
56(24-71) 
0 
behavioural (15) 
treatment as usual 
(15) 
psychiatrist 
diagnosis 
major 
depression. 
BDI>24 
yes if stable 
doctoral clinical psychology 
student 
7(1hour) 
Maldonado Lopez. 1984. (8) 
community outpatients. 
NA 
NA 
behavioural and 
pharmacology (8) 
cognitive and 
pharmacology (8) 
pharmacology (8) 
psychiatrist 
diagnosis 
reactive 
depressive 
disorder 
 
all Subjects 
psychology dept, level of 
training not reported 
10 (1hour) 
Skinner, A. 1984. (9) 
community volunteers. 
20-61 (34) 
67.5 
behavioural (8) 
cognitive(7) 
control (9) 
BDI>12 yes 
doctoral clinical psychology 
Student 
5(1hour) 
McNamara, K and Horan, J. 
1986. (10) 
university students. 
23(19-31) 
73 
behavioural (10) 
cognitive (10) 
cognitive 
Behavioural (10) 
supportive (10) 
 
 
BDI>17 
HRSD>20 
 
not reported 
doctoral interns in clinical 
psychology/masters level 
social worker 
8 (50mins) (10 sessions in 
CBT arm) 
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Thompson, L et al. 1987. (11) 
older adults community. 
67.07 (5.8) 
67 
behavioural (25) 
cognitive (27) 
psychotherapy (24) 
delayed (19) 
RDC major 
depressive 
disorder 
 
if stable dose 
for 3 months 
doctoral level 
psychologists plus 1 year 
specialised therapy training 
16-20 (duration of each 
session not reported) 
Scrogin, F et al. 1989. (12) 
older adults community. 
68.3(6.7) 
85 
behavioural 
bibliotherapy (23) 
cognitive 
bibliotherapy (22) 
delayed (22) 
 
>9 on HRSD 
 
if stabilised 
prior to trial 
NA as bibliotherapy was 
main intervention 
4 (5min) phone contacts to 
support exercises 
Jacobson et al. 1996. (13) 
community (80% HMO, 20% 
volunteer) 
38 (not reported). 
72 
behavioural (56) 
thought challenging 
(43) 
full Cognitive (50) 
major 
depression 
(DSM-IV) >19 
BDI 
 
No 
experienced therapists 
(mean 9.5 years CT 
practice) 
20 sessions (NA) 
McKendree Smith. 1998. (14) 
community volunteer. 
913.17) 
75 
behavioural 
bibliotherapy (13) 
cognitive 
bibliotherapy (13) 
delayed  (14) 
mild-moderate 
depression 
 
if stabilised 
for 3 months 
NA as bibliotherapy main 
intervention 
8(10 mins) 
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Hopko, D et al. 2003. (15) 
inpatients. 
30.5(9) 
36 
behavioural (10) 
supportive (15) 
principle 
diagnosis of 
major 
depression 
 
yes all 
patients 
not clear 
6 (20mins) 
Dimidjian, S et al. 2006. (16) 
community. 
39.9 (10.97) 
66 
behavioural (43) 
cognitive (45) 
pharmacology/Place
bo (153) 
major 
depression 
(DSM-IV) >19 
BDI 
 
only in ADM 
arm 
BA-licensed 
psychologists/social worker 
(7 years’ practice. 
CT-Licensed Psychologists 
with CT training 
24(50mins) 
Cullen, J. 2006. (17) 
community. 
38.48(12.69) 
32 
behavioural (13) 
wait List (12) 
 
 
 
MDD (Mean 
BDI 
30.96(5.90) 
 
yes if stable 
>6 weeks 
previous experience in CT 
of depression plus 12 
hours training in BA 
10(50) 
Studies not included in Meta-Analysis 
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Padfield, M. 1976. (18) 
community female rural 
low socioeconomic status. 
21-56 
100 
behavioural (12) 
supportive (12) 
moderately 
depressed 
(diagnostic 
tool not clear) 
 
no 
counsellor (experience not 
clear) 
12 (NA) 
Zeiss et al. 1979. (19) 
community. 
33.9 (19-68) 
NA 
behavioural (22) 
cognitive (22) 
interpersonal (22) 
classed as 
depressed 
using 
Minnesota 
Multiphasic 
Personality 
Inventory and 
Grinkler 
Interview 
Rating 
 
not clear 
graduate students in 
clinical psychology and 
counselling psychologists 
(master’s level). At least 1 
year experience. 
12 (NA) 
Gardner, P and Oei, T. 1981.  (20) 
community. 
19-65 
77% 
behavioural (8) 
cognitive (8) 
mild 
depression 
(BDI) 
 
not Clear 
not clear 
NA 
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3.4.1 Study quality assessment 
 
Each study was measured against our 8 quality standards as outlined in the methods section (Table 8).  
Table 8: Study quality scores 
study 
number 
 
selection Bias 
 
performance 
bias 
measurement bias attrition bias 
overall 
quality 
score 
 
adequate 
randomisation 
concealment 
groups equal 
at baseline 
pre-specified 
eligibility 
adherence to 
treatment 
assessed 
independently 
assessment 
of outcome 
independent 
mean 
and SD 
reported 
ITT 
analysis 
loss to 
follow-
up  
reported 
1 0 1 1 0 1 1 0 1 5 
2 0 1 1 1 1 1 0 1 6 
3 0 1 1 1 1 1 0 1 6 
4 0 0 1 0 1 1 0 0 3 
5 0 1 1 0 0 1 0 1 4 
6 0 1 1 0 1 1 0 0 4 
7 0 1 1 0 1 1 0 0 4 
 8 0 0 1 0 1 1 0 0 3 
 9 0 1 1 0 1 0 0 0 3 
 98 
 10 0 1 1 0 1 1 0 1 5 
 11 0 1 1 1 1 1 0 1 6 
 12 0 1 1 1 1 1 0 1 6 
 13 0 1 1 1 1 1 1 1 7 
 14 0 1 1 0 1 1 0 1 5 
 15 0 1 1 0 1 1 0 1 5 
16 1 1 1 1 1 1 1 1 8 
 17 0 1 1 1 1 1 1 1 7 
Studies included not included in meta-analysis 
 18 0 0 1 1 0 0 0 0 2 
 19 0 0 1 0 0 0 0 1 2 
 20 0 0 0 0 1 0 0 0 1 
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3.5 Behavioural Therapy vs. control: comparison 1 
3.5.1 Scope 
 
Twelve studies with a total of 459 patients contributed data to this analysis 
(1, 2, 4, 5, 6, 7, 9, 11, 12, 14, 16, 17). Participants were taken from adult 
community sources consisting of outpatients (2,4,6,7,11,12,16,17), 
volunteers (5, 8,14) and students (1), two studies using older adults (11,12). 
Control interventions consisted of delayed treatment 
(1,3,9,11,12,14,16,17), treatment as usual (4,5,7) and relaxation (2,5). All 
comparisons were taken immediately after intervention. Interventions 
ranged from supported bibliotherapy (12, 14), brief therapy with six 40-
minute sessions (1) to 24 50-minute sessions (16). Facilitators were 
advanced graduate psychology/therapy students in five studies (1, 5, 6, 7, 
9), experienced psychotherapists in four studies (2, 11, 16, 17) and unclear 
in one study (4). Depression symptom level was assessed using either BDI 
self-report measure (1, 2, 4, 5, 7, 9, 17) or the HRSD assessor rating scale 
(12), or both (6, 11, 14, 16). Recovery was defined by clinical interview in 
one study (11) and by BDI score in 2 studies (2, 14).  
3.5.2 Depression symptom level post-treatment 
 
The effect size of behavioural interventions against control interventions 
was large, with a pooled SMD of −0.70 CI −1.00 to −0.39, demonstrating a 
highly significant difference in symptoms level scores favouring the 
behavioural group (P<0.001) (see Figure 11). There was no evidence of 
publication bias for this outcome, Egger‟s test = −1.04; 95% CI = −3.39 to 
1.29 P=0.35, a funnel plot showed no evidence of asymmetry (Figure 12). 
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Figure 11: Forest plot BA vs. control depression symptom level post-
treatment 
 
 
Review : Behavioural Activation for Depression
Comparison: 04 Behavioural vs control                                                                                     
Outcome: 01 SMD all studies BT vs Waitlist/Placebo Control/TAU                                                         
Study  Behavioural  Wait List  SMD (random)  SMD (random)
or sub-category N Mean (SD) N Mean (SD)  95% CI  95% CI
Wilson 1982 (relax)      6     12.42(9.38)          10      8.50(6.35)          0.49 [-0.54, 1.52]       
Wilson 1983              8      7.50(4.55)           9     21.44(5.52)         -2.60 [-3.98, -1.22]      
Taylor 1977              7     10.70(5.00)           7     20.10(5.80)         -1.63 [-2.89, -0.36]      
Mclean 1979             42      9.70(8.00)          43     14.95(8.00)         -0.65 [-1.09, -0.21]      
Maldonado Lopez 1982      8      7.38(3.74)           8     17.63(8.33)         -1.50 [-2.65, -0.35]      
Wilson 1982              6     12.42(9.38)          10     14.60(9.73)         -0.21 [-1.23, 0.80]       
Wilson 1982 (PLA)        5     11.89(10.87)         12     14.67(11.12)        -0.24 [-1.29, 0.81]       
Wilson 1982 (PLA/re)      4     11.89(10.87)         10     16.55(10.36)        -0.42 [-1.59, 0.76]       
Cole1983                15     26.40(8.00)          15     31.20(8.00)         -0.58 [-1.32, 0.15]       
Skinner 1984             8     14.62(5.90)           9     18.33(4.92)         -0.65 [-1.64, 0.33]       
Thompson 1987           30     12.40(7.80)          19     22.48(7.82)         -1.27 [-1.90, -0.64]      
Scogin1989              19      9.70(5.70)          21     15.90(6.90)         -0.96 [-1.61, -0.30]      
McKendree Smith 1998     13     12.00(13.15)         14     14.79(9.63)         -0.24 [-0.99, 0.52]       
Cullen 2006              6      3.83(3.31)           8     28.25(16.31)        -1.81 [-3.13, -0.49]      
Dimidjian 2006          22     16.82(8.56)          31     22.50(12.97)        -0.49 [-1.05, 0.06]       
Dimidjian 2006 (ls)     15     15.33(10.03)         19     14.68(7.81)          0.07 [-0.61, 0.75]       
Total (95% CI)    214                         245     -0.70 [-1.00, -0.39]
Test for heterogeneity: Chi² = 31.54, df = 15 (P = 0.007), I² = 52.4%
Test for overall effect: Z = 4.50 (P < 0.00001)
 -4  -2  0  2  4
 Favours Behavioural  Favours control
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Figure 12: Begg funnel plot symptom level BA vs. control   
 
Heterogeneity and sensitivity analysis 
 
Variation in effect size (I
2
) attributable to heterogeneity was moderate 
(55.1%).  Effect size was not significantly related to the level of baseline 
severity, (meta-regression beta-co-efficient = 0.04, 95% CI −0.04 to 0.12; 
I
2 
= 54%, P= 0.28); see Figure 13. Quality assessment indicated that seven 
studies fell below our quality threshold (1, 4, 5, 6, 7, 9, 14), and the pooled 
SMD was not affected by study quality (meta-regression SMDlow quality = 
−0.67; SMDhigher quality = −0.75, Pdifference = 0.77) see Figure 14.  Behaviour 
therapists with graduate and postgraduate qualifications produced similar 
effect sizes (meta-regression SMDgraduate = −0.82; SMDpost graduate = −0.59, 
Pdifference = 0.61; I
2
 = 59%) see Figure 15.  There was no clear relationship 
between effect size and number of sessions (meta-regression beta-
coefficient = 0.03, 95%CI −0.03 to 0.09; I2 = 0.49, P=0.27) (Figure 16). 
Prioritising clinician-rated assessment in precedence over self-rated where 
possible made no significant difference to overall effect size (SMD −0.68 
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CI −0.98 to – 0.38).
 
 
 
Figure 13: Meta-regression of baseline severity of depression (BDI score) 
versus effect size in studies comparing behaviour therapy versus control.  
(Regression weighted by within-study inverse variance, represented by size 
of graph data points.  Regression line fitted, SMD = −1.81 + 0.042*BDI 
score, P=0.28).  
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Figure 14: Study quality meta-regression 
 
 
 
 
 
 
Figure 15: Therapist level meta-regression 
 
 
 
  Standardised Depression Outcomes
 Favours BA  Favours usual care
 -3  -2  -1  0  1  2  3
 study
 Standardised Depression Outcomes
 (95% CI)
 low quality
 Skinner 1984  -0.65 (-1.64, 0.34)
 Wilson 1983  -2.60 (-3.98,-1.22)
 Wilson 1982adm  -0.21 (-1.23, 0.81)
 Wilson 1982pla  -0.42 (-1.59, 0.75)
 Taylor 1977  -1.63 (-2.89,-0.37)
 Wilson 1982adm   0.49 (-0.54, 1.52)
 Wilson  1982pla  -0.24 (-1.29, 0.81)
 Mckendree smith  -0.24 (-0.99, 0.51)
 Maldonado lopez  -1.50 (-2.65,-0.35)
 Cole 1983  -0.58 (-1.32, 0.16)
 Subtotal  -0.67 (-1.14,-0.19)
 high quality
 Cullen 2006  -1.81 (-3.13,-0.49)
 Mclean 1979  -0.65 (-1.09,-0.21)
 Scrogin 1987  -0.96 (-1.61,-0.31)
 Thompson 1987  -1.27 (-1.90,-0.64)
 Dimijian  -0.49 (-1.05, 0.07)
 Dimijian ls   0.07 (-0.61, 0.75)
 Subtotal  -0.75 (-1.16,-0.34)
 Overall  -0.70 (-1.00,-0.39)
 
  Standardised Depression Outcomes
 Favours BA  Favours usual care
 -3  -2  -1  0  1  2  3
 study
 Standardised Depression Outcomes
 (95% CI)
 graduate
 Skinner 1984  -0.65 (-1.64, 0.34)
 Wilson 1983  -2.60 (-3.98,-1.22)
 Wilson 1982adm  -0.21 (-1.23, 0.81)
 Wilson 1982pla  -0.42 (-1.59, 0.75)
 Taylor 1977  -1.63 (-2.89,-0.37)
 Wilson 1982adm   0.49 (-0.54, 1.52)
 Wilson  1982pla  -0.24 (-1.29, 0.81)
 Maldonado lopez  -1.50 (-2.65,-0.35)
 Cole 1983  -0.58 (-1.32, 0.16)
 Cullen 2006  -1.81 (-3.13,-0.49)
 Subtotal  -0.83 (-1.35,-0.31)
 post grad qualification
 Mclean 1979  -0.65 (-1.09,-0.21)
 Thompson 1987  -1.27 (-1.90,-0.64)
 Dimijian  -0.49 (-1.05, 0.07)
 Dimijian ls   0.07 (-0.61, 0.75)
 Subtotal  -0.60 (-1.07,-0.12)
 Overall  -0.72 (-1.07,-0.37)
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Figure 16: Meta-regression of number of sessions versus effect size in 
studies comparing behaviour therapy versus control. 
 (Regression weighted by within-study inverse variance, represented by 
size of graph data points.  Regression line fitted, SMD = −0.99 + 
0.03*sessions, P=0.27) 
3.5.3 Dropout Rate 
 
Three studies contributed data to this analysis (2, 14, and 16) on a total of 
119 subjects with an average dropout rate of 19.17%. There was no 
difference between rates of dropout between intervention and control: odds 
ratio = 0.58 CI 0.28 to 1.21 (P=0.86) (Figure 17). There were insufficient 
studies to check for publication bias for this outcome.  
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Figure 17: Forest plot of dropout data BA vs. control 
Heterogeneity and sensitivity analysis 
 
Variation in effect size (I
2
) attributable to heterogeneity was small (0%). 
There were insufficient studies and negligible heterogeneity to explore the 
impact of our a priori sources of clinical heterogeneity. 
3.5.4 Recovery rate 
 
Three studies contributed data to this analysis (2,11,14) on a total of 167 
subjects. There were greater rates of recovery in the behavioural 
intervention group (BT 52%, control 21.05%) with an odds ratio of 4.18 CI 
1.14 to 15.28 (P=0.03) (Figure 16). There were insufficient studies to test 
for publication bias for this outcome. 
 
 
 
Figure 18: Forest plot of recovery rate BA vs. control 
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Heterogeneity and sensitivity analysis 
 
Variation in effect size attributable to heterogeneity (I
2
) was medium 
(53%). There were insufficient studies to explore the underlying causes of 
this heterogeneity further or to conduct meaningful sensitivity analysis. 
3.6 Behavioural Therapy vs. CT/CBT: comparison 2  
3.6.1 Scope 
 
Twelve studies with a total of 476 patients contributed data to this analysis 
(1, 3, 4, 6, 8, 9, 10, 11, 12, 13, 14, 16). Participants were taken from adult 
community sources consisting of outpatients (3, 4, 8, 11, 12, 13, 16), 
volunteers (6,9,14) and students (1, 10), three studies using older adults 
(3,11,12). Interventions ranged from supported bibliotherapy (12, 14), brief 
therapy with six 40-minute sessions (1) to 24 50-minute sessions (16). 
Therapy was facilitated by advanced graduate psychology/therapy students 
in four studies (1, 6, 9, and 10), experienced psychotherapists in four 
studies (3, 11, 13, and 16); it was unclear who the facilitators were in two 
studies (4, 7).  Depression symptom level was assessed using either BDI 
self-report measure (1, 4, 8, 9, 10) or the HRSD assessor rating scale (12), 
or both (3, 6, 11, 13, 14, 16). Recovery was defined by diagnostic interview 
in two studies (3, 11) and by BDI score in three studies (10, 13, and 16). 
3.6.2 Depression symptom level post-treatment 
 
No difference in effect between behavioural interventions and CBT/CT 
was identified, with a pooled SMD of 0.08 CI −0.14 to 0.30 (P=0.46) (see 
Figure 19).  There was no evidence of publication bias for this outcome 
using Egger‟s test, (Intercept (0 if unbiased) = 1.07; 95% CI = −0.23 to 
2.38 P=0.10), and a funnel plot showed no evidence of asymmetry (Figure 
20). 
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Figure 19: Forest plot BT vs. CBT/CT post treatment and follow-up 
 
Review : Behavioural Activation for Depression
Comparison: 06 SMD BT vs CBT                                                                                              
Outcome: 01 BT vs CT Symptom Level                                                                                     
Study  Behavioural Therapy  Cognitive Therapy  SMD (random)  Weight  SMD (random)
or sub-category N Mean (SD) N Mean (SD)  95% CI  %  95% CI
01 Symptom Level post Treatment
Wilson 1983              8      7.50(4.55)           8      9.00(6.82)       4.93     -0.24 [-1.23, 0.74]       
Taylor 1977              4     10.70(5.00)           7     10.30(2.60)       3.56      0.10 [-1.13, 1.33]       
Taylor 1977 (CBT)        3     10.70(5.00)           7      5.60(4.70)       2.70      0.96 [-0.49, 2.42]       
Gallaher1982            10     12.62(11.97)         10      9.71(5.74)       5.71      0.30 [-0.59, 1.18]       
Maldonado Lopez 1982      8      7.38(3.74)           8      4.88(3.80)       4.75      0.63 [-0.38, 1.64]       
Maldonado Lopez 1984      8     16.35(5.37)           8      6.37(7.81)       4.05      1.41 [0.28, 2.54]        
Skinner 1984             8     14.62(5.90)           7     15.00(7.40)       4.73     -0.05 [-1.07, 0.96]       
McNamara 1986            5      5.50(3.56)          10      6.50(4.17)       4.33     -0.24 [-1.31, 0.84]       
MvNamara 1986 (CBT)      5      5.50(3.56)          10      4.80(3.55)       4.34      0.19 [-0.89, 1.26]       
Thompson 1987           30     12.40(7.80)          31     13.60(10.10)     10.09     -0.13 [-0.63, 0.37]       
Scogin1989              19      9.70(5.70)          21      7.50(3.60)       8.34      0.46 [-0.17, 1.09]       
Jacobson 1996           28      9.10(7.90)          50     10.10(9.60)      10.68     -0.11 [-0.57, 0.35]       
Jacobson1996  (AT)      28      9.10(7.90)          43     10.60(9.30)      10.47     -0.17 [-0.65, 0.31]       
McKendree Smith 1998     13     12.00(13.15)         13      5.62(4.33)       6.53      0.63 [-0.16, 1.42]       
Dimidjian 2006          16      8.75(7.96)          18     17.44(15.57)      7.55     -0.67 [-1.37, 0.02]       
Dimidjian 2006 (ls)     13     11.00(10.08)         17      9.76(8.15)       7.24      0.13 [-0.59, 0.86]       
Subtotal (95% CI)    206                         268 100.00      0.08 [-0.14, 0.30]
Test for heterogeneity: Chi² = 19.01, df = 15 (P = 0.21), I² = 21.1%
Test for overall effect: Z = 0.74 (P = 0.46)
02 Symptom level Follow  up
Wilson 1983              8      8.25(3.93)           8      9.75(7.46)       8.82     -0.24 [-1.22, 0.75]       
Taylor 1977              4      1.30(6.40)           7      8.00(3.00)       5.02     -1.38 [-2.81, 0.04]       
Taylor 1977 (CBT)        3     10.30(6.40)           7      2.90(2.70)       3.91      1.69 [0.03, 3.34]        
Gallaher1982             9      9.89(9.47)          10      9.78(5.67)       9.94      0.01 [-0.89, 0.91]       
Maldonado Lopez 1982      8     12.00(13.54)          8      5.50(3.46)       8.50      0.62 [-0.39, 1.63]       
Maldonado Lopez 1984      8     26.25(10.20)          8      3.87(3.56)       4.73      2.77 [1.29, 4.25]        
McNamara 1986            3      6.17(2.23)           7      4.71(1.70)       5.10      0.71 [-0.70, 2.13]       
MvNamara 1986 (CBT)      3      6.17(2.23)           5      4.75(1.89)       4.65      0.61 [-0.88, 2.11]       
Scogin1989              14      9.10(6.30)          15      8.90(6.00)      12.83      0.03 [-0.70, 0.76]       
Jacobson 1996           25      8.50(7.60)          47     10.30(8.60)      18.47     -0.22 [-0.70, 0.27]       
Jacobson1996  (AT)      25      8.50(7.60)          39      9.30(8.20)      18.04     -0.10 [-0.60, 0.40]       
Subtotal (95% CI)    110                         161 100.00      0.25 [-0.21, 0.70]
Test for heterogeneity: Chi² = 25.11, df = 10 (P = 0.005), I² = 60.2%
Test for overall effect: Z = 1.07 (P = 0.28)
 -4  -2  0  2  4
 Favours BT  Favours CT
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Figure 20: Begg funnel plot of BT vs. CBT  
Heterogeneity and sensitivity analysis 
 
Variation in effect size (I
2
) attributable to heterogeneity was small (21.1%). 
Seven studies fell below our quality threshold (1,4,6,7,9,10,14) and pooled 
SMD was not significantly affected by study quality (meta-regression 
SMDlow quality = +0.23; SMDhigher quality = −0.13, Pdifference = 0.12; I
2
 = 0%) 
(Figure 21).  Comparative effectiveness of BT versus CT/CBT varied 
according to baseline severity of depression, behaviour therapy associated 
with a greater level of effectiveness at more severe levels of depression 
(meta-regression beta-co-efficient = −0.05, 95% CI −0.10 to −0.01; I2 = 
0%; P = 0.04) (Figure 22).  
 
 
 
 
 
 
 
0
.2
.4
.6
.8S
ta
n
d
a
rd
 E
rr
o
r 
o
f 
S
ta
n
d
a
rd
iz
e
d
 M
e
a
n
 D
if
fe
re
n
c
e
-2 -1 0 1 2
Standardized Mean Difference
 
 109 
 
Figure 21:  Study quality meta regression BT vs. CBT 
 
 
 
 
 
Figure 22: Meta-regression of baseline severity of depression (BDI score) 
versus effect size in studies comparing BA versus CBT.  
(Regression weighted by within-study inverse variance, represented by size 
of graph data points.  Regression line fitted, SMD =  + BDI score, P=0.04).  
 
  Standardised Depression Outcomes
 Favours BA  Favours CBT
 -3  -2  -1  0  1  2  3
 study
 Standardised Depression Outcomes
 (95% CI)
 low quality
 Skinner 1984  -0.05 (-1.07, 0.97)
 Wilson 19838  -0.24 (-1.23, 0.75)
 Taylor 1977 cbt   0.96 (-0.49, 2.41)
 Taylor 1977ct   0.10 (-1.13, 1.33)
 Mcnamara & Horan ct  -0.24 (-1.31, 0.83)
 Mcnamara & Horan cbt   0.10 (-0.89, 1.09)
 Maldonado lopez 1982   0.63 (-0.38, 1.64)
 Mckendree smith 1998   0.63 (-0.16, 1.42)
 Subtotal   0.23 (-0.13, 0.59)
 high quality
 Thompson 1987  -0.13 (-0.63, 0.37)
 Gallaher 19982   0.30 (-0.59, 1.19)
 Jacobson 1996 ct  -0.11 (-0.57, 0.35)
 Jacobson 1996 at  -0.17 (-0.65, 0.31)
 Dimijian  -0.67 (-1.37, 0.03)
 Dimijian ls   0.13 (-0.56, 0.82)
 Scrogin 1989   0.46 (-0.17, 1.09)
 Subtotal  -0.06 (-0.29, 0.17)
 Overall   0.01 (-0.17, 0.20)
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Graduate level behaviour therapists produced slightly less favourable 
results compared to those with postgraduate qualifications in comparison to 
CBT, although this did not reach significance (meta-regression SMDgraduate 
= 0.28; SMDpost graduate =−0.135, Pdifference = 0.11; I
2
 = 0%) (Figure 23).  
There was no clear relationship between effect size and number of sessions 
(meta-regression beta-coefficient = −0.025, 95% CI −0.056 to 0.006; I2 = 
0.08, P= 0.11) (Figure 24). Prioritising clinician-rated assessment over self-
rated where applicable made no difference in overall effect size (SMD 0.09 
CI −0.12 to 0.29). 
 
 
 
Figure 23: Therapist level meta regression BA vs. CBT 
 
 
 
 
 
 
 
 
 
  Standardised Depression Outcomes
 Favours BA  Favours CBT
 -3  -2  -1  0  1  2  3
 study
 Standardised Depression Outcomes
 (95% CI)
 graduate
 Skinner 1984  -0.05 (-1.07, 0.97)
 Wilson 19838  -0.24 (-1.23, 0.75)
 Taylor 1977 cbt   0.96 (-0.49, 2.41)
 Taylor 1977ct   0.10 (-1.13, 1.33)
 Mcnamara & Horan ct  -0.24 (-1.31, 0.83)
 Mcnamara & Horan cbt   0.10 (-0.89, 1.09)
 Maldonado lopez 1982   0.63 (-0.38, 1.64)
 Maldonado lopez 1884   1.41 ( 0.28, 2.54)
 Subtotal   0.28 (-0.13, 0.68)
 post grad qualification
 Thompson 1987  -0.13 (-0.63, 0.37)
 Gallaher 19982   0.30 (-0.59, 1.19)
 Jacobson 1996 ct  -0.11 (-0.57, 0.35)
 Jacobson 1996 at  -0.17 (-0.65, 0.31)
 Dimijian  -0.67 (-1.37, 0.03)
 Dimijian ls   0.13 (-0.56, 0.82)
 Subtotal  -0.13 (-0.37, 0.10)
 Overall  -0.01 (-0.23, 0.21)
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Figure 24: Meta regression number of sessions BA vs. CBT 
 
3.6.3 Depression symptom level at follow-up 
 
Eight studies contributed data to this analysis (1, 3, 4, 6, 8, 10, 12, and 13) 
on a total of 271 subjects with an average follow-up period of four months. 
Overall there was no difference in effect of BT compared to CBT/CT with 
a pooled SMD of 0.25 CI –0.21 to 0.70 (P=0.28) (Figure 19).  
Heterogeneity and sensitivity analysis 
 
Variation in effect size (I
2
) attributable to heterogeneity was 60.2%. After 
exclusion of low-qualitystudies (1, 4, 6, 8, 10) and those with follow up of 
less than three months (1, 6) in a sensitivity analysis, there remained no 
difference in effect size between BT and CBT with a pooled SMD of −0.11 
CI −0.41 to 0.19 (P=0.47).  There were insufficient studies to explore the 
underlying causes of this heterogeneity further. 
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3.6.4 Dropout rate 
 
Eight studies contributed data to this analysis (1, 3, 6, 11, 12, 13, 14, and 
16) on a total of 436 subjects with an average dropout rate of 15.36%. 
There was no difference in rates of dropout with an odds ratio of 1.17 CI 
0.57 to 2.41 (P= 0.67) (Figure 25). There were insufficient studies to check 
for publication bias for this outcome.  
 
 
 
 
Figure 25 Forest plot of dropout rates BA vs. CBT 
Heterogeneity and sensitivity analysis 
 
Variation in effect size attributable to heterogeneity (I
2
) was moderate 
32%. Low-quality studies (1, 6, 14) were excluded in sensitivity analysis, 
resulting in an odds ratio of 1.47 CI 0.60 to 3.61 (P = 0.40) with an I
2 
statistic of 42.9%. There were insufficient studies to explore the underlying 
causes of this heterogeneity further. 
3.6.5 Recovery rate 
 
Five studies contributed data to this analysis (3, 10, 11, 13, and 16) on a 
total of 346 subjects. There was a pooled recovery rate of 55% with no 
difference between the two treatment approaches: odds ratio 0.92 CI 0.59 
to 1.44 (P = 0.72) (Figure 26). There were insufficient studies to check for 
publication bias in this outcome. 
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Figure 26: Forest plot BA vs. CBT recovery rates 
Heterogeneity and sensitivity analysis 
 
Variation in effect size attributable to heterogeneity (I
2
) was 0%. Low-
quality studies (8) were excluded in a sensitivity analysis, resulting in an 
odds ratio of 0.93 CI 0.59 to 1.47 (P=0.77) with an I
2 
statistic of 0%.  
3.7 Behavioural Therapy vs. Brief Psychotherapy: 
comparison 3 
3.7.1 Scope 
 
Three studies, with a total of 166 patients, contributed data to this analysis 
(2, 3, and 11). Participants were from adult outpatient community sources, 
two studies using older adults (3, 11). Brief psychotherapy interventions 
were based upon a psychodynamic model in all studies. Interventions 
ranged from 10 to 20 sessions, and all studies used experienced therapists.  
Studies assessed depression symptom level using the BDI alone (2) or both 
BDI and HRSD (3, 11). Two studies assessed depression at intake using 
structured clinical interviews (3, 11), the third using cut-off points from 
validated self-report measures (2). Recovery was defined by clinical 
interview in two studies (3, 11) and by BDI score in one study (2). 
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3.7.2 Depression symptom level post treatment  
 
The effect size of BT compared to brief psychotherapy was large, with a 
pooled standardised mean difference of −0.56 CI −1.0 to −0.12 (P=0.01) 
(Figure 27).  There were insufficient studies to test for publication bias. 
 
 
Figure 27:  Forest plot BT vs. psychotherapy symptom level at post-
treatment  
Heterogeneity and sensitivity analysis 
 
Variation in effect size attributable to heterogeneity (I
2
) was moderate 
43.4%. All studies were above the quality threshold, hence we performed 
no sensitivity analyses related to study quality. There were insufficient 
studies to explore the underlying causes of this heterogeneity further. 
Further meta-regression to explore the impact of our potential effect 
modifiers was not possible due to the low number of studies in this 
comparison. Prioritising clinician-rated assessment over self-rated 
assessment where applicable made no difference in overall effect size 
(SMD −0.52 CI −1.01 to – 0.03). 
3.7.3 Depression symptom level follow up  
 
Two studies contributed data to this analysis (2, 3) on a total of 96 subjects 
with an average follow-up period of 4.5 months. The effect size of 
behavioural interventions compared to brief psychotherapy was medium, 
with a standardised mean difference of −0.50 CI –0.90 to −0.09 (P=0.02).  
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Heterogeneity and sensitivity analysis 
 
Variation in effect size attributable to heterogeneity (I
2
) was 0%. Both 
studies collected follow-up beyond the three-month point and were above 
the quality threshold, so we performed no sensitivity analyses. No further 
meta-regression or testing for publication bias was undertaken due to the 
low number of studies in this comparison. 
3.7.4 Dropout  
 
Three studies contributed data to this analysis (2, 3 and 11) on a total of 
166 subjects with an average dropout rate of 14.45% across studies. No 
difference in dropout was observed, with an odd ratio of 0.94 CI 0.22 to 
3.96 (P = 0.11) (Figure 28). There were insufficient studies to test for 
publication bias. 
 
 
Figure 28: Forest plot BT vs. psychotherapy dropout post-treatment 
Heterogeneity and sensitivity analysis 
 
Variation in odds ratio attributable to heterogeneity (I
2
) was 54.1%. All 
studies were above quality threshold so no sensitivity analysis was 
performed. 
3.7.5 Recovery rate  
 
Three trials contributed data to this analysis (2, 3 and 11) on a total of 164 
subjects (note 2 subjects deceased). Greater rates of recovery were 
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observed in BT (56.79%) compared to brief psychotherapy (36.14%), with 
an odds ratio of 2.37 CI 1.23 to 4.57 (P= 0.01) (Figure 29). There were 
insufficient trials to test for publication bias. 
 
 
 
 
 
Figure 29: Forest plot BA vs. psychotherapy recovery rate 
Heterogeneity and sensitivity analysis 
 
Variation in odds ratio attributable to heterogeneity (I
2
) was 0%.  All 
studies were above quality threshold, so no sensitivity analysis was 
performed. No further meta-regression or testing for publication bias was 
undertaken due to the low number of studies in this comparison. 
3.8 Behavioural Therapy vs. supportive therapy: 
comparison 4    
3.8.1 Scope 
 
Two studies with 45 subjects contributed data to this analysis (10, 15). 
Participants were university students (10) and inpatients (15). 
Interventions ranged from six 20-minute sessions (10) to eight, 50-minute 
sessions (15), delivered by doctoral clinical psychology students (10) or a 
clinical psychologist (15). Both studies measured depression symptom 
levels by self report measures (BDI), with one (10) using HRSD also. 
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Depression at baseline was assessed by self report measures (10) or clinical 
interview (15). 
 
3.8.2 Depression symptom level post-treatment. 
 
The positive effect in favour of BT compared to supportive therapy was 
large: SMD −0.75 CI –1.37 to −0.14 (P=0.02) (Figure 30).  There were 
insufficient studies to test for publication bias. 
 
 
 
Figure 30: Forest plot BA vs. Supportive therapy post-treatment 
 
Heterogeneity and sensitivity analysis 
 
The variation in effect size attributable to heterogeneity (I
2
) was 0%. Both 
studies fell below quality threshold, therefore no sensitivity analysis was 
performed. No further meta-regression was undertaken due to the low 
number of studies in this comparison. 
3.9 Summary of meta-analysis findings 
 
Behavioural therapies for depression have a large effect size difference 
compared to control interventions at post-treatment. When compared to 
CT/CBT there appears to be no difference in effect size at post-treatment or 
follow up. Behavioural therapies also appear to have a medium to large 
effect when compared to brief psychodynamic therapies and supportive 
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counselling; however the number of studies is small. A summary of the 
main statistical findings is presented in Table 9.
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Table 9: Results of meta Analysis of randomised controlled trials of behavioural activation for depression (
 a
  indicates odds ratio) 
 
Comparison 
Number 
of studies 
Number 
subjects 
Standardised 
mean difference 
 
95% CI P I2 
BT vs. Control/TAU 
Symptom level  
Dropouta 
Recovery ratea 
 
12 
3 
3 
 
459 
119 
167 
 
−0.70  
  0.58   
  4.18  
 
−1.00 to  −0.39 
   0.28 to 1.20 
   1.14 to 15.28 
 
<0.001 
0.86 
0.03 
 
55.1% 
0% 
52.6% 
BT vs. CT/CBT 
Symptom level Post-
treatment  
Symptom level Follow Up 
Dropouta 
Recovery ratea 
 
12 
8 
8 
5 
 
476 
271 
436 
346 
 
 
  0.08 
  0.25 
  1.17 
  0.92 
 
 
−0.14 to 0.30 
−0.21 to 0.70 
   0.57 to 2.41 
   0.59 to 1.44 
 
 
0.46 
0.28 
0.67 
0.94 
 
 
21.1% 
60.2% 
32.4% 
0% 
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BT vs. Brief Psychotherapy 
Symptom level post-
treatment 
Symptom level follow-up   
Dropouta 
Recovery ratea 
 
3 
2 
3 
3 
 
166 
96 
166 
164 
 
−0.56  
−0.50  
0.94  
2.37  
 
−1.0 to −0.12  
−0.90 to −0.09 
  0.22 to 3.96 
  1.23 to  4.57 
 
0.01 
0.02 
0.11 
0.01 
 
43.4% 
0% 
54.1% 
0% 
BT vs. Supportive Therapy 
Symptom Level Post-
treatment 
 
2 
 
45 
 
−0.75  
 
 –1.37 to −0.14 
 
0.02 
 
0% 
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3.10 Studies not included in meta-analysis 
 
It was not possible to include study numbers 17-20 in the meta-analysis 
due to insufficient statistical reporting. Study 18 (Padfield 1976) reported 
an empathy-based counselling approach compared to the same intervention 
with the addition of activity scheduling. A total of 24 women were 
recruited and randomised into two groups of 12. The study scored two in 
the quality assessment scale, indicating a number of methodological 
concerns. Results were excluded from meta-analysis, as data presented 
only supplied information on the mean (SD) change on the self-rated 
depression symptom measure. No raw scores could be extracted for 
baseline or post-treatment analysis. With the limited statistical and 
methodological approach outlined, findings were inconclusive. Study 19  
(Zeiss et al. 1979) reported a comparison of a social skills-based, pleasant 
event-based and cognitive-based interventions. A total of 66 participants 
were randomised to one of the three conditions. The study scored two in 
the quality assessment. Results were excluded from the meta-analysis as 
only means were presented for the depression symptom level tool. While in 
other cases this had been managed by imputation methods following 
discussion with the review steering group it was not felt to be suitable for 
this study. The depression measure in use was a subscale from the 
Minnesota Multiphasic Personality Inventory (Hathaway and McKinley 
1943). We were not confident about  the imputation approaches relating to 
this measure, as no other studies in this review or other relevant 
populations could be found. Results showed a general improvement across 
all interventions reflective of meta-analysis results. Study 20 (Gardner and 
Oei 1981) reported a comparison of a basic activity scheduling approach 
with a basic cognitive restructuring intervention; 16 subjects were 
randomised. The study scored one on the quality assessment scale. Results 
were excluded from the meta-analysis as no raw data were presented. The 
Beck Depression Inventory was used as the main symptom measure, 
presented in a graphical format with no reference to specific mean and 
standard deviation. Therefore it was not possible to extract relevant 
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information from the document. Findings were consistent with the review 
that no significant difference was identified between the interventions. 
 
It was felt after discussion within the review team that the chance of 
retrieving relevant information through the finding and contacting of study 
authors was low due to the age of the source material. As the three studies 
were relatively small and of low quality, and were unlikely to significantly 
impact results the decision was made to exclude them from the meta-
analysis and include them in the narrative of the review only. 
3.11 Evaluation of review against recommended 
standards  
 
This meta-analysis was designed and conducted in 2006 and 2007. At that 
time the recommended conduct and reporting of reviews was based upon 
the QUOROM (quality of reporting of meta analysis) guidelines (Moher et 
al. 1999). This review was designed taking into account that guidance.  
In recent years the science of systematic reviews and meta-analysis has 
advanced, resulting in updated recommendations. The preferred reporting 
items for systematic reviews and meta analysis (PRISMA) (Moher et al. 
2009) has replaced QUOROM  taking into account conceptual and 
practical advances. This therefore provides a standard against which this 
current review and meta-analysis can be measured. In Table 10 this review 
is considered against all 27 factors. 
The review meets the majority of standards set by PRISMA. A protocol 
was not logged prior to commencing the study, which would be advisable 
as it prevents subsequent adjustments which cannot be traced by the reader. 
In addition a record was not kept of numbers of duplicates removed during 
the merging of search strategy results, which would have added to study 
selection transparency. In addition details of the rejected studies at both 
review of abstract and full report were not logged. It is not possible to 
return to these at the present time, but the information will be incorporated 
in future reviews. 
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The clarity of selection and analysis processes allows for a transparent 
approach to the review question which could be replicated. It has led to a 
clearer understanding of the current knowledge of the efficacy of BT with 
depressed adults, and has indicated areas for further research which will be 
followed in the subsequent chapters of this thesis.  
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Table 10: Review measured against PRISMA standards based upon chapter and publication (Ekers et al. 2008)  
 
Section/topic # Checklist item Reported  
TITLE 
Title 1 Identify the report as a systematic review, meta-analysis, or both. Yes in title of chapter 
ABSTRACT 
Structured summary 2 Provide a structured summary including, as applicable: background; 
objectives; data sources; study eligibility criteria, participants, and 
interventions; study appraisal and synthesis methods; results; limitations; 
conclusions and implications of key findings; systematic review registration 
number. 
Yes in publication 
(Ekers et al. 2008) 
INTRODUCTION 
Rationale 3 Describe the rationale for the review in the context of what is already known.  Yes introduction 
Objectives 4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design 
(PICOS).  
Yes  Introduction 
METHODS 
Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed (e.g., 
web address), and, if available, provide registration information including 
registration number.  
No registration of 
protocol 
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used as 
criteria for eligibility, giving rationale. 
All included and 
expanded in chapter 
methods section 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, 
contact with study authors to identify additional studies) in the search and 
Detailed description of 
search and dates 
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date last searched.  conducted included 
Search 8 Present full electronic search strategy for at least one database, including 
any limits used, such that it could be repeated. 
Search summary 
used examples given 
in appendices (online 
for publication) 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in 
systematic review, and, if applicable, included in the meta-analysis).  
Yes  
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, 
independently, in duplicate) and any processes for obtaining and confirming 
data from investigators. 
Yes reported in 
chapter under data 
extraction-limited 
reporting of this in 
publication 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, 
funding sources) and any assumptions and simplifications made. 
Yes in methods 
section 
Risk of bias in individual 
studies 
12 Describe methods used for assessing risk of bias of individual studies 
(including specification of whether this was done at the study or outcome 
level), and how this information is to be used in any data synthesis. 
Details description of 
approach to study 
level bias in quality 
assessment and 
publication bias 
included 
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means).  Yes SMD and odds 
ratio 
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if 
done, including measures of consistency (e.g., I2) for each meta-analysis. 
Yes detailed 
description and 
rationale provided 
Risk of bias across 
studies 
15 Specify any assessment of risk of bias that may affect the cumulative 
evidence (e.g., publication bias, selective reporting within studies).   
Yes for publication 
bias only 
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Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup 
analyses, meta-regression), if done, indicating which were pre-specified. 
Details of sensitivity 
analysis and meta-
regression provided 
with as pre-specified  
RESULTS 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in 
the review, with reasons for exclusions at each stage, ideally with a flow 
diagram. 
Yes, however no 
reporting of studies 
excluded by 
elimination of 
duplicates 
Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., 
study size, PICOS, follow-up period) and provide the citations. 
Yes table 6 
Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome-
level assessment (see Item 12). 
Yes in study quality 
assessment and 
where possible in 
publication bias 
Results of individual 
studies 
20 For all outcomes considered (benefits or harms), present, for each study: (a) 
simple summary data for each intervention group and (b) effect estimates 
and confidence intervals, ideally with a forest plot. 
yes 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals 
and measures of consistency. 
yes 
Risk of bias across 
studies 
22 Present results of any assessment of risk of bias across studies  (see Item 
15). 
Yes publication bias 
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup 
analyses, meta-regression [see Item 16]). 
yes 
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DISCUSSION 
Summary of evidence 24 Summarize the main findings including the strength of evidence for each 
main outcome; consider their relevance to key groups (e.g., health care 
providers, users, and policy makers). 
Yes limited in 
publication expanded 
in chapter 
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at 
review level (e.g., incomplete retrieval of identified research, reporting bias). 
Yes 
Conclusions 26 Provide a general interpretation of the results in the context of other 
evidence, and implications for future research. 
Yes –related to other 
similar studies and 
further research 
based upon findings 
recommended  
FUNDING 
Funding  27 Describe sources of funding for the systematic review and other support 
(e.g., supply of data); role of funders for the systematic review. 
Not specified as no 
funding received-
would have been 
beneficial in 
publication to express 
with more clarity 
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3.12 Discussion of review findings 
3.12.1 Main findings 
 
Review question:  
What is the relative effectiveness of individual behavioural psychotherapy 
on symptom reduction, recovery and dropout when compared with usual 
care, inert controls and other psychosocial treatments in depressed adults?  
 
In this review a detailed systematic review of all published and 
unpublished research examining the efficacy of behavioural therapies for 
depression was conducted. In all 20 studies (including 1215 participants) 
were identified, 17 of which (with 1109 participants) were able to be 
included in meta-analysis.  
Comparison 1. BA vs. controls 
 
BT was found to be an effective treatment for depression in adults. Meta-
analysis of 12 studies  (including 459 participants) demonstrated superior 
outcomes to controls with a large effect size. BT also achieved improved 
recovery rates, with no difference in dropout. This indicates that, while BT 
is an active treatment, it would appear to be acceptable to those receiving 
it. 
Comparison 2. BT vs. CBT 
 
BT was found to be as effective as CBT in the treatment of depressed 
adults. Meta-analysis of 12 studies, including 476 participants, 
demonstrated that BT provided equivalent results, with no statistically 
significant differences in depression symptom level at post-treatment and 
follow-up. BT also demonstrated equivalence in recovery rate and dropout 
at post-treatment.  
 
Comparison 3. BT vs. brief psychotherapy  
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BT was found to be superior to brief psychotherapy in the treatment of 
depressed adults. Three studies were identified, including 166 participants, 
with BT showing advantage in symptom level and recovery post-
intervention. The effect size in this comparison was large and statistically 
significant despite low statistical power. 
Comparison 4. BT vs. supportive counselling 
 
BT was found to be superior to supportive counselling in the treatment of 
depressed adults. Two  studies were identified, including 45 subjects, with 
BT showing advantage in symptom level post-intervention. The effect size 
was large in this comparison and statistically significant despite low 
statistical power.   
 
These findings indicate that BT is an effective when delivered as a „single 
strand‟ treatment. The addition of other components, such as cognitive 
restructuring, to this intervention does not provide additional benefits post-
treatment or at follow-up. BT is as effective as CBT when all randomised 
trials are combined in a meta-analysis. It also would appear to provide 
improved clinical outcomes over other forms of psychotherapy and 
counselling, although caution is recommended regarding this finding due to 
the low numbers of studies.   
3.12.2 Impact of study variables 
 
The studies in this meta-analysis varied considerably in design and delivery 
approaches. It was possible to utilise this variability to explore factors 
relating to magnitude of effectiveness where sufficient studies were 
available (BT vs. Control and BT vs. CBT). Meta-regression analysis 
makes observational associations between study variables and effect. It is 
exploratory in nature, and as such loses the power of causal inference 
(Higgins and Thompson 2004). This approach provides a viable and 
efficient method of considering the impact of such study level variables on 
outcome. It increases the depth of the analysis, and highlights potential 
issues that may require further research.  While caution is needed in such 
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interpretation, as associations in no way suggest definitive explanations, 
the alternative of planning large-scale prospective trials with many arms is 
costly, time-consuming and unrealistic in most cases. Therefore the meta-
analysis incorporating regression provides a timely and informative 
association without such constraints, and at least provides quantitative data 
around which subsequent research questions may be built. 
 
Meta-regression BA vs. controls. 
 
The meta-regression found that, when compared to controls, baseline 
severity, length of treatment and level of qualification were not related to 
the overall effect size of BT. Such findings may indicate that BT is a 
durable approach that can be delivered in a number of ways. Therapist 
level is of particular interest here. The suitability of BA for wider 
dissemination (Jacobson et al. 1996) requires further exploration, as we 
found that no studies used therapists below the level of doctorate 
psychologists.  
 
Meta-regression BT vs. CBT 
 
The meta-regression found that, when BT was compared to CBT, length of 
treatment and therapist level were not  related to the overall effect size. A 
statistically significant association between higher baseline severity and a 
larger effect size in favour of BT compared to CBT was found. This was 
the only significant association observed, and raises interesting clinical 
considerations. It may be that BT does not rely on high levels of cognitive 
engagement to mediate benefit. The benefit, according to the theory, will 
emerge when the person has re-connected with contextual relationships that 
provide positive reinforcement. CBT requires people to identify and 
challenge thinking styles and beliefs. In severe depression cognitive 
functioning deteriorates, hence engagement with „thinking‟ may be 
increasingly difficult as severity increases. It may be that this that accounts 
for the association found in this study; however further review and research 
would be essential to explore this finding, with relevant approaches being 
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defined a priori. Further conclusions based upon this finding would be 
unwise and are beyond the scope of this review.   
Summary of findings from meta-regression 
 
Following this review it remains unclear what is the optimum delivery 
approach of behavioural therapy for depression. This review is the first to 
explore a number of pre-defined factors and their association with effect 
size. Further exploration is required in relation to ideal treatment duration 
and improving outcome in more severely depressed patients using this 
intervention. No association was identified between therapist level and 
outcomes of BT. Few studies in the review described the training and 
supervision therapists received in depth making detailed analysis of this 
factor difficult. It was possible to extract core training levels, and findings 
showed that all studies used relatively expensive senior grade staff to 
deliver a potentially simple treatment.  The simple nature of BT has for 
some time suggested its suitability for wider training and dissemination 
(Jacobson et al. 1996) however no empirical support for this assertion was 
found in this review.  
3.12.3 Strengths and limitations of this meta-analysis 
 
This meta-analysis complements and concurs with other publications that 
include behavioural interventions as part of wider CBT reviews (Churchill 
et al. 2001, Gloaguen et al. 1998, Dobson 1989). In addition, two new 
reviews also focussing on BT as the primary intervention, which were 
published shortly before and after this work, came to similar conclusions: 
that BT is an effective treatment for depression (Cuijpers et al. 2007, 
Mazzucchelli et al. 2009). In contrast to these reviews, we chose to focus 
on individual rather than group interventions, and included dropout and 
recovery rate analyses. More studies were included in the review reported 
in this chapter than in previous reviews (apart from (Mazzucchelli et al. 
2009), due to broader inclusion criteria and the inclusion of recent and 
unpublished data. Studies drew patients of varying types from a range of 
settings such as inpatient, psychiatric outpatient and volunteer cohorts in 
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adult, older adult and student settings. Interventions varied considerably 
across studies, from supported self-help using minimal therapist contact to 
full psychotherapy. The quality of included trials varied considerably, with 
some of low quality delivering results that deviated considerably from the 
overall picture (4, 8). It was attempted to account for this to by the use of 
sensitivity analysis, random effects modelling and meta-regression of a 
priori variables. Interpretation of the results must be made with such 
factors in mind. Caution must also be exercised in interpreting the 
comparisons of behavioural interventions with brief psychotherapy and 
supportive therapy, due to the low numbers of studies and/or small sample 
sizes that informed such findings. 
 
The searches conducted identified a number of studies directly comparing 
BT with drug therapy; this was not included as an a priori comparator, and 
as such was outside the scope of this review. It might have been possible to 
incorporate the comparator when this omission became apparent. It was, 
however, felt that inclusion of relevant terms could have been missed in 
searches, hence it was not advised, as being prone to bias. It is clear, 
however, that such a comparison would be a useful addition in any future 
review. In the studies identified it appeared that BT produced at least 
equivalent results to drug therapy. A more formal protocol-based review 
would be needed to confirm these observations to reduce the chance of 
omitting relevant studies. 
3.13 Implications for practice and future research 
 
Of particular interest is the observed equivalence between BT and the more 
complex CBT/CT interventions recommended as the primary 
psychological intervention for depression (National Institute of Clinical 
Excellence 2009). In addition to similar levels of symptom improvement, 
we observed no difference in recovery or dropout. These combined 
findings indicate that behavioural interventions are as effective and 
acceptable as CBT/CT. Such findings partially endorse the BA parsimony 
hypothesis advanced by Jacobson and colleagues (Jacobson 1996, Jacobson 
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et al 2001). They question the utility of adding „complex‟ cognitive 
techniques to simpler behavioural interventions to improve clinical 
outcome. One of the attractions of behavioural interventions is simplicity 
and dissemination, thus assisting the current scarcity of therapists  and 
overwhelming demands outlined in Chapter One. There was no direct 
evidence identified in this review to support this assumption as no studies 
used non-psychology or psychotherapy-trained individuals to deliver BT. It 
may be that the effectiveness of BT is due to the therapist‟s skill and 
experience rather than the specific factors of the intervention. The impact 
of level of training of those who had delivered BT was examined, and no 
association was found between „higher level‟ of qualifications and effect 
size. This may support the assertion that BT is be suitable for delivery by 
non-specialists with shorter training; however further research is clearly 
needed.  
Another shortfall in the evidence base is the lack of economic analysis. 
While clinical effectiveness is a necessary consideration it is not wholly 
sufficient. New interventions must also be seen to provide value for money. 
While there is evidence that BT is effective the cost of this effectiveness 
has not been benchmarked against accepted threshold values, such as the 
£20,000 per Quality Adjusted Life Year (QALY) recommended by the 
National institute of Health and Clinical Excellence (National Institute for 
Health and Clinical Excellence 2008).  
 
Taking into account the need to widen the availability of effective 
psychological interventions for depression outlined in Chapter One of this 
thesis, further research is required to explore these factors. Of particular 
note is the need to test the suitability for dissemination of BA and to begin 
to estimate the potential value for money that single-strand behavioural 
therapies might offer. 
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3.14 Summary of chapter 3 
 
In summary, behavioural therapy for depression is an effective intervention 
that has outcomes comparable with, if not better than, those of alternative 
and currently recommended therapies. This review adds substantially to the 
literature regarding behavioural therapy for depression, as it provides a 
broad overview of the current evidence, reports data on recovery and 
dropout, and explores the effect of baseline co-variants in relation to 
depression symptom change. It is recommended that further research be 
undertaken into the clinical and cost-effectiveness of behavioural 
treatments of depression, in particular of Jacobson‟s (1996) parsimony 
leading to suitability to disseminate hypothesis, where the intervention is 
delivered by non-specialist mental health staff with specific training rather 
than by highly specialised psychotherapists. 
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Chapter Four: Randomised controlled trial of the 
clinical and cost effectiveness of Behavioural 
Activation for depression delivered by non specialist 
mental health workers 
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4.1 Introduction 
4.1.1 Background to study 
 
As outlined in Chapter One, depression will be the second largest cause of 
disease burden by 2020 (World Health Organisation 2001), affecting 
between 5-10% of the population and is the third most common reason for 
primary care consultation (Singleton et al. 2001). It is associated with 
significant distress, impairment of functioning, disturbance to interpersonal 
relationships and an increased risk of suicide (Hirschfeld et al. 1997). 
Psychological treatments, particularly cognitive behavioural therapy 
(CBT), are recommended to treat depression (National Institute of Clinical 
Excellence 2009, Hollon et al. 2002b); however less than 10% overall of 
those affected receive such treatment (McManus et al. 2009). Despite 
recent English investment in „Improving Access to Psychological 
Therapies‟ (IAPT) services (Clark et al. 2009), the limited availability of 
suitably trained therapists remains a significant brake on patient access to 
treatment. CBT remains the standard approach to depression (National 
Institute of Clinical Excellence 2009), commonly based upon Beckian 
Cognitive Therapy (Beck 1976). This incorporates both behavioural and 
cognitive strategies to identify, question and modify maladaptive thought 
processes, life rules and core beliefs. This is in contrast to single strand 
behavioural interventions, as outlined in Chapter Two, that use an operant 
conditioning model to develop a structured daily action plan. Although 
CBT is recommended as a main treatment option in the treatment of 
depression as seen in Chapter Three of this thesis, it is unclear whether the 
cognitive strategies are a necessary component of the intervention. As 
outlined in Chapter Two the landmark study in 1996 by  Jacobson et al. 
(Jacobson et al. 1996), comparing the full version of CBT with a reduced 
version including some cognitive techniques and a third intervention 
behavioural activation (BA), led the way to this research. There was no 
evidence of any differences in effectiveness between treatments at post-
treatment or follow-up (Gortner et al. 1998)  which led Jacobson (Jacobson 
et al. 1996, Jacobson and Gortner 2000) to put forward a parsimony 
argument in favour of BA: if CBT and behavioural interventions are 
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equally effective, then behavioural ones may be preferable because they are 
simpler and can therefore be delivered more economically by professionals 
with less training. Were this to be the case it may have substantial 
implications for the organisation and delivery of treatments (Jacobson and 
Gortner 2000). This is a somewhat provocative finding albeit one 
supported by the meta-analysis outlined in Chapter Three of this thesis. It 
indicates that much of what occurs in this leading psychological treatment 
for depression may be an unnecessary complication. A series of meta-
analyses including the one outlined in this thesis (Cuijpers et al. 2007, 
Ekers et al. 2008, Mazzucchelli et al. 2009) are now published all reaching 
the same conclusion. Although a main impetus for the renewed interest in 
BA is the possibility of developing a simple and effective treatment for 
depression, it is notable that no study reviewed in the meta-analyses has 
explored this approach in a controlled clinical trial. As seen in Chapter 
Three in earlier studies the treatments were delivered by clinicians with 
previous experience of delivering therapy often amounting to several years. 
While behavioural activation may indeed by simpler to deliver, it may be 
the experience of the therapist that counts. If this were to be the case 
despite BA offering a more simple intervention it would still rely of the 
same set of experienced and highly trained therapists to deliver it 
effectively. This while possibly broadening the skills of such therapists, 
would be unlikely to markedly improve accessibility or value for money. 
The aim of this current study is to examine whether non-specialist mental 
health workers, without previous experience in therapy, can deliver 
effective behavioural interventions and if so estimate the cost utility of 
such an approach. This research is based upon findings of the meta-
analysis reported in Chapter Three and is the first study to directly assess 
the parsimony leading to suitability for dissemination argument offered in 
favour of BA.  
4.2 Research Questions 
 
As outlined in Chapter Three the development of a clear question is 
essential in the research process. As in systematic reviews having a 
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focussed question to inform study design is essential. Again this should be 
based upon the PICO (participants, interventions, comparisons, outcome) 
format.   
 
Our two research questions for this study are:  
 
1. What is the impact on depression symptom level, functioning and 
treatment satisfaction of BA delivered by generic mental health 
workers to depressed adults compared to usual primary care 
management? 
 
2. What is the estimate of cost utility of BA delivered by generic 
mental health workers to depressed adults? 
 
These questions mapped against the PICO structure below: 
 Participants-depressed adults; 
 Interventions-BA delivered by generic mental health workers; 
 Comparisons-BA and usual care; 
 Outcomes-depression symptom level, functioning, service use/cost 
and health state. 
4.3 Method 
4.3.1 Choice of study design 
 
Depression is a disorder that is likely to wax and wane over time (Kennedy 
et al. 2004) and it is also likely that participants would be at a significant 
point of severity in their depression at baseline which then led to seeking 
help and therefore are likely to „regress to the mean‟. Another potential 
confounder is that those accepting of treatment and in particular entering a 
research trial may be an over representation of motivated individuals who 
are potentially more likely to improve. Therefore any study design must 
control for such confounders as far as possible giving a reasonable 
assumption the intervention is accounting for any differences observed. 
The randomised control trial (RCT) is designed for this purpose; it provides 
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an experimental design to decide the relative effectiveness of two or more 
treatment groups. The use of the randomisation balances confounders 
between groups, reduces the potential to come up with an incorrect finding 
and controls for numerous types of bias (Everitt and Wessley 2008, Altman 
and Bland 1999b).  The RCT is based upon three main components: 
 
 A comparison of a group of participants who have been given the 
intervention under investigation with a group of participants who 
have been given a standard treatment or inert treatment.  
 
 An approach that assigns people to each intervention under 
investigation in an equal manner. 
 
 An approach to assessing effectiveness is used. Commonly a 
number of outcomes will be considered. 
 
There remains some debate about when the first randomised trial was 
conducted in medicine but consensus tends to cite a streptomycin trial in 
the treatment of tuberculosis reported in 1948 (Doll 1998). The idea may 
however have been considered some centuries before when a Flemish 
physician named Jean Baptiste van Helmot advocated casting lots to decide 
who received the intervention of bloodletting. The outcome was to be the 
number of funerals in each group. No physician appeared to have accepted 
the challenge, which is unfortunate as it might have sowed the seeds of 
effective research design and prevented numerous interventions of 
questionable benefit being continued over many years (Chalmers 2001). It 
would appear that the first randomised controlled trial in psychiatry was in 
the mid-1950s (Healy 1997). Since then the RCT has become the accepted 
standard to measure clinical effectiveness and is commonly used across all 
areas of medicine including psychological treatment of depression 
(National Institute of Clinical Excellence 2009). As such the RCT was 
considered the suitable study design for our research question. 
 
 140 
The study design used in this research is parallel treatment group two arm 
randomised controlled trial of BA facilitated by non-specialists compared 
to usual care for adult participants with depression.  
4.3.2 Ethical issues  
 
While randomisation provides a solution to the problems of selection bias it 
poses possible ethical dilemmas that require careful consideration. The trial 
has to consider the overall benefit of potential findings against the 
individual benefit for participants. This is a difficult balance in an RCT. 
Individual considerations relate to the need for a person to receive 
treatment that is likely to offer benefit (certainly to do no harm) against the 
need of collective consideration of evaluating competing therapies for 
future use. This delicate balance can also be influenced by clinicians pre-
determined views. Clinicians should always act in the best interest of the 
patient even during clinical trials, as stated in the Declaration of  Helsinki 
(World Medical Association 2008). The use of chance in the determination 
of which intervention is delivered can prove problematic for some 
clinicians, leading them to refuse to suggest that their patients participate in 
studies. Clinicians‟ unwavering belief in their own experience being all-
important has been the subject of some debate and humour, being termed 
„eminence based medicine‟ (Isaacs and Fitzgerald 1999), listing the 
following traits: 
“The more senior the colleague, the less importance he or she 
placed on the need for anything as mundane as evidence. 
Experience, it seems, is worth any amount of evidence. These 
colleagues have a touching faith in clinical experience, which has 
been defined as „making the same mistakes with increasing 
confidence over an impressive number of years‟. The eminent 
physician's white hair and balding pate are called the “halo” 
effect.” 
Clearly the trial has to counter these issues by ensuring that it is delivered 
in a way that is scientific and beneficial. To do so the trial must (Everitt 
and Wessley 2008): 
 141 
 Ensure it is based in science to produce meaningful results to justify 
the need for the trial. 
 Use a control arm that is reflects current accepted practice where 
available, and at worst be designed to do no harm. 
 Be subject to scrutiny prior to recruiting participants. 
 Provide potential participants with good information on which to 
base their decision to participate. 
 Receive informed consent from all that take part. 
 Follows the protocol and report any deviation in compliance. 
 
These factors will be considered in more detail in relation to the current 
trial in the section below. 
Ethical process and considerations in the current trial 
 
The purpose of this trial was to examine if BA could be delivered by            
non-specialists and thus possibly provide another evidence based 
alternative in the psychological treatment of depression. In order to ensure 
a scientific robustness the trial protocol developed by DE was placed on 
the International Standard Randomised Controlled Trials Registry and 
allocated number (ISRCTN27045243). The protocol was then sent for 
independent scrutiny by DE. This allowed the scientific rigour to be 
assessed. The trial was reviewed by Professor M Bland (MB) to review the 
statistical methods. Dr Chris Williams a clinical expert in CBT who is a 
previous chair of the British Association of Behavioural and Cognitive 
Psychotherapists and researcher in CBT to review trial design and 
relevance and Professor David Richards. Their reports can be found in 
Appendix II. A trial steering committee was established as recommended 
(Medical Research Council 1998) with David Ekers (DE), Professor Simon 
Gilbody (SG), Professor Christine Godfrey (CG) and Professor David 
Richards (DR). Additional statistical rigour was provided by Professor 
Martin Bland (MB) who advised on statistical approaches incorporated in 
the protocols.  The steering group approved the study protocol and received 
bi-monthly updates of trial progress by email. 
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The choice of comparator was a central ethical consideration for this study. 
While we had substantial evidence from our meta-analysis that BA was 
effective we had not seen it delivered by non-specialists. The choices 
considered were a waiting list control, usual care or the current main 
recommended psychological treatment for depression, CBT (National 
Institute of Clinical Excellence 2009). It was felt that a waiting list control 
had ethical problems. This would involve no treatment over a period of 
three months which was likely to result in untreated distress and disability. 
As there were treatment options commonly in use for depression that were 
likely to have benefit over no treatment, it was felt this option was 
unethical. The choice of face-to-face CBT would have provided a high 
quality active comparator. It was considered for the current trial but was 
felt to be beyond the resources available to this unfunded study, as 
availability of CBT was very limited at the time of the trial delivery. So 
while this comparator would have provided a robust alternative to            
non-specialist BA, offering CBT was not a realistic possibility or reflective 
of the current care most people received for depression. Usual care as 
offered in primary care services provided our third option. It appeared 
feasible and is the most commonly received treatment for depression 
(Office for National Statistics 2000, McManus et al. 2009). This approach 
could also provide cost comparisons based upon total service use in each 
arm with the BA costs added in the intervention arm. As this was a 
feasibility study regarding non-specialist delivery of BA long-term follow 
up was not required and we could also offer those randomised to usual care 
BA after three months. Based upon these factors usual GP care was 
adopted as the comparator.  
 
The study developed patient information sheets and consent forms based 
upon good practice guidance (National Research Ethics Service 2007). I 
sought consent firstly to contact potential participants; this was completed 
by either the general practice staff or the primary care mental health team. 
If agreed, we then sought further consent to enter the trial prior to 
conducting any assessments. Potential participants were provided with 
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information sheets at each stage and contact details for further information. 
The information sheet provided study information and also details on what 
would happen if they consented, declined or withdrew from the study. 
Copies of the information sheet and consent forms can be found in 
Appendix II.  
 
The study was then presented to the Northumberland local research ethics 
committee, the University of York research ethics committee and local 
NHS research governance departments. All approved this study prior to 
commencement. Approval letters from the above can be can be found in 
Appendix II. 
 
Therefore in relation to the scientific and beneficial criteria outlined above: 
 The trial was based upon a scientific design and had been reviewed 
by experts in therapy for depression, trial design and statistics. 
 It used the standard treatment received for depression as the 
comparator. 
 It was scrutinised by independent experts and two research ethics 
departments. 
 It provided information based on best practice. 
 It received consent prior to contact and prior to entry to trial. 
 It placed the protocol on a public international database and had a 
steering group monitoring progress. 
 4.3.3 Recruitment  
 
Potential participants aged 18 or over were recruited from either general 
practice directly or from primary care mental health services over a nine 
month period. Practices were based in a mix of rural and urban settings and 
following receiving information about the trial requested to participate.   
Recruitment often poses problems in clinical trials in primary care, even in 
conditions with high prevalence such as depression (Hunt et al. 2001). This 
may be due to a desire to protect the patient, lack of confidence in research 
practise by GPs and prioritising clinical administration over research 
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(Mason et al. 2007). Several recommended methods were used to enhance 
recruitment to the trial (Bower et al. 2009, Ward et al. 1999, Everitt and 
Wessley 2008). Meetings were arranged in each practice/primary care 
mental health team with DE to discuss the trial and the details of 
interventions, process and outcomes. Key partners were identified in each 
practice/team and DE maintained contact with them for the duration of the 
study, sending regular email updates of progress and benchmarking their 
contribution to recruitment against the average. A small number of 
practices/teams were identified initially to pilot recruitment with an 
additional set to add if targets were not achieved. Positive feedback was 
received regarding planned use of the trial as formal psychological therapy 
for depression at the time of the study had a wait time of well over six 
months. This process was felt to incorporate the major factors identified for 
supporting recruitment and piloting processes within the constraints of an 
unfunded feasibility study. 
4.3.4 Participants 
 
Participants identified by a general practitioner or primary care mental 
health worker were supplied with the study information sheet and asked to 
consider inclusion in the trial. Participants were required to have been on 
no antidepressant medication or a stable dose for six weeks prior to 
inclusion. This ensured that no crossover effect from treatment adjustment 
would be recorded within the trial and attributed to interventions. 
Following consent, eligibility was confirmed by the use of a standardised 
computer-based assessment tool, the Clinical Interview Schedule Revised 
(CSIR)(Lewis et al. 1992). Confirmation of a diagnosis and hence 
eligibility is an important quality measure of a trial therefore a reliable tool 
was required (Schulz et al. 2010). The CSIR had been extensively used for 
this purpose in large scale surveys in the UK population and hence was 
considered suitable (Singleton et al. 2001, McManus et al. 2009). 
Exclusion criteria were those commonly adopted in randomised trials of 
depression in primary care. They were aimed to limit contamination of 
results with factors not directly attributable to the intervention under 
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investigation. Exclusion criteria consisted of suicidal risk, psychotic 
symptoms, diagnosis of bipolar disorder, organic brain disease or the use 
alcohol/non-prescription drugs requiring clinical intervention. If suitable, 
written consent was obtained and baseline measures (outlined below) were 
taken prior to randomisation. 
4.3.5 Allocation concealment and randomisation  
 
While the RCT design improves objectiveness in trials there are conditions 
that are fundamental in the protection against bias. Allocation concealment 
is central to this and the degree to which it is achieved has been shown to 
influence trial outcome (Jadad et al. 1996). Concealment prevents any 
interference by researchers with the assignment of particular participants to 
a treatment condition and hence limits allocation bias. Clinicians will often 
hold a view as to which intervention is preferable and will wish for a 
patient to get the intervention they believe is the best (Schulz and Grimes 
2002) an issue that has been discussed in the running of previous trials of 
BA (Jacobson and Gortner 2000). If the sequence of assignment is altered 
this will undermine the trial findings as random allocation can no longer be 
assumed and there is a risk that selected participants received the 
intervention under investigation. It is therefore essential that the trial design 
placed great emphasis of concealment of allocation. 
 
Following assessment, if suitable for inclusion, participants in this trial 
were randomly allocated to two arms. A block randomisation system was 
used in blocks of four to enable a close balance between the numbers 
allocated to each group at any given time. In a small trial this is helpful due 
to the potential impact on resource if a simple randomisation sequence 
results in a high number of allocations sequentially to a single arm. It is 
also possible in a small trial to generate a randomisation sequence that 
would be weighted towards a particular arm. Block randomisation ensures 
a matched number within blocks that are a multiple of the number of arms 
in the trial and then randomly varies the sequence over consecutive blocks 
(Altman and Bland 1999a).  
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Baseline depression severity has been seen to be associated with 
differential effects of psychological treatments of depression (Elkin et al. 
1995). With the small sample sizes in this study there was an increased risk 
of unequal distribution of depression severity levels across each treatment 
arm post randomisation. This was countered by stratifying participants by 
baseline depression severity prior to randomisation an acceptable approach 
where such imbalance could impact on interpretation of study results 
(Altman and Bland 1999a). Participants were allocated into two groups 
prior to randomisation based upon Beck Depression Inventory (BDI-
II)(Beck et al. 1996) scores using the midpoint of the moderate category  
(≤25 & ≥26).  
 
Allocation bias was controlled by an allocation concealment process 
independent of the study team. Randomisation lists for high and low 
severity were generated independently of the study team by MB using the 
computer statistical software Clinstat (Bland 2004). These lists were 
supplied directly to an administration team within Tees Esk and Wear 
Valleys NHS Foundation Trust who were not involved in the running of or 
referral to the study. Lists were held in a locked location and following 
assessment and stratification the study team contacted and requested the 
next allocation code assigned. At no point did the study team have any 
influence on list development, communication of the list to those providing 
the allocation service nor any involvement in the allocation of participants 
to treatment arm. An ideal system of allocation is commissioning of a 
complete allocation service but this is often costly. As this trial had no 
external funding this procedure offered a suitable alternative maintaining 
standards of allocation concealment within study resources.  
 
Following randomisation GPs and patients were informed of allocation 
automatically by letter from the study team.  
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4.3.6 Sample size 
 
No previous study of BA delivered by non-specialists was available to give 
a precise estimate of the sample size required in this study. The present 
exploratory study would provide such information to future researchers 
however at the time of the study design such information was not available. 
It was decided by discussion with the trial steering group to calculate 
sample size based upon those studies from our meta-analysis that reflected 
the study design we were to use (Ekers et al. 2008). While it was accepted 
that this approach was not ideal, it incorporated and reflected the best 
available evidence at the time of planning. The studies used incorporated a 
range of BA approaches, and all were delivered by more senior therapists 
than the non-specialists being used in this study. There was a possibility 
that this would result in biasing sample size calculations on an over 
estimation of difference resulting in underestimation of numbers required if 
senior therapists achieve better results than non-specialists. This would 
potentially increase the chances of a type II error (accepting the null 
hypothesis when it is in fact false) in this study.  In the absence of any 
more suitable alternative evidence calculations were based on those studies 
in our meta-analysis that incorporated a delayed start to psychological 
interventions with variable levels of concurrent usual care. It was decided 
this was preferable to not using a sample size calculation for the current 
trial.  
 
Statistical advice on the calculation of sample size for this study was 
sought from MB. The current standard of 80% power at a 5% significance 
level was used as the basis for sample size calculations. This indicated the 
number of participants needed to have an 80% chance of finding a true 
difference between groups if with a 5% chance of a type I error. Sample 
size calculations were based upon standardised between-group effect size 
(Cohen‟s d) of −0.84 (CI −1.27 to −0.41) observed in a sample of nine 
studies including 282 subjects. Using the PS sample size calculator 
(Dupont and Plummer 2009) calculations based upon a continuous 
response variable (BDI-II) from independent control and experimental 
 148 
subjects with 1 control(s) per experimental subject were used.  Calculations 
assumed response within each subject group was normally distributed with 
standard deviation 1.  If the true difference in the experimental and control 
means is 0.84 calculations indicated 23 experimental and 23 control 
subjects we required to be able to reject the null hypothesis with 
probability (power) 0.8 with a Type I error probability associated with this 
test of 0.05 (see Figure 31). 
 
Figure 31: Sample size calculation 
4.3.7 Measures 
Depression symptom level 
 
The primary clinical outcome of depression symptom level was assessed in 
this study using a commonly applied validated self report measure in 
psychotherapy studies the Beck Depression Inventory second edition (BDI-
II) (Beck et al. 1996). In our meta-analysis the BDI was applied in 16 of 
the 17 studies of BA analysed. There is no clear correct position regarding 
the preference of self-rated over clinician-rated measurement tools for 
depression symptom level. The most frequently applied clinician rated tool 
found in the meta-analysis was the Hamilton Rating Scale for Depression 
(HRSD)(Hamilton 1960) which was used on its own in one study and 
combined with the BDI in 11 studies. It was decided to use the BDI-II in 
this study as it was the most frequently used measure identified in the 
meta-analysis and was practical to use with the limited resources available 
(no requirement for assessor training and less time needed for 
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assessments). The BDI-II has a score range of 0 to 63 (0-13 minimal, 14-19 
mild, 20-28 moderate, 29-63 severe). It has strong concurrent validity (r= 
0.71 between BDI-II and HRSD, r= 0.93 between BDI-II and BDI-I)  and 
reliability (coefficient alpha 0.92) in an sample of 500 depressed 
outpatients (Beck et al. 1996).   
Functioning 
 
Functioning was measured using the Work and Social Adjustment Scale 
(WASA) (Munt et al. 2002). It consists of a five item scale measuring self 
rated impairment of functioning in relation to work, relationships, home 
management, social leisure and private leisure. Each item is scored on an 
eight point Likert scale (with anchors of 0 meaning no impairment and 8 
meaning severe impairment). It has been tested for use with a depressed 
sample of outpatients, and has demonstrated strong reliability (Cronbach‟s 
alpha 0.80-0.94) and validity (correlation 0.76) in a sample of  380 
depressed outpatients (Munt et al. 2002). The WASA also represents a 
commonly used measure of functioning adopted in the Improving Access 
to Psychological Therapies (IAPT) services across the UK. This gave an 
additional benefit of using this scale as results will be meaningful and 
familiar for the IAPT workforce. 
Satisfaction 
 
Satisfaction was measured using the Client Satisfaction Questionnaire 
(CSQ8) (Attkisson and Greenfield 2004). The CSQ8 is evaluates 
satisfaction over eight areas of service provision: The quality of the 
service; if it was what was wanted; if it met needs; if would recommend to 
others; satisfaction with amount of help; helped to deal with problems; 
overall satisfaction; if would use service again if needed. The CSQ8 gives a 
score range of 0-32. The CSQ8 was adopted for use in this study as it has a 
UK English version and, unusually for satisfaction questionnaires, has 
published validity and reliability studies related to it. Internal reliability as 
demonstrated across nine studies, with Cronbach‟s alpha ranging from 
0.83-0.93 is very positive, and construct validity has been demonstrated 
with high correlations with other satisfaction instruments (Spearmans rank 
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correlation coefficient 0.6-0.8) (Attkisson and Greenfield 2004). It has 
been used previously in the UK in research settings (Lovell et al. 2006) and 
in multicentre trials of depression (see CADET trial ISRCTN 32829227). 
 Health State  
 
General health state utility was assessed using the EQ-5D (EuroQol Group 
1990, Brooks 1996). The EQ-5D provides a standard measure of general 
health status for use in clinical and economic evaluations. It is a tool that is 
suitable for use across a wide range of health conditions.  The EQ-5D is the 
accepted approach to measuring health utility, and is appropriate for use in 
major depression in primary care settings (Sapin et al. 2004). Using the 
general health state measures such as the EQ-5D is increasingly 
recommended (Bosmans et al. 2008, Barton et al. 2009), as it allows 
mental health studies to be viewed in a decision making context alongside 
all fields of health care. The EQ-5D measures health across five 
dimensions of mobility, self care, usual activities, pain/discomfort and 
anxiety depression. Each state is divided into 3 levels of perceived 
problems self rated by the participant: 
 Level 1 No problems 
 Level 2 Some problems 
 Level 3 Extreme problems. 
This results in 243 possible health state values ranging from 11111 
indicating no problem in each area to 33333 indicating severe problems in 
all areas. The EQ-5D is then converted to a single health state by applying 
a formula that assigns weights to the levels within each dimension resulting 
in a single summary score.  Health state values were assigned from these 
scores using standard UK population values (Dolan P et al. 1995) for 
quality adjusted life years (QALY) between 0 (death) and 1 (full health). 
Specialist health economics guidance was received from Dr Steve Parrott 
(SP) who assigned health states using STATA (Stata Corporation 2003).  
4.3.8 Costs 
BA treatment costs 
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BA costs were calculated from therapists hourly pay rates (mid scale 
Agenda for Change band 5) for the year of the study plus 30% overhead 
costs. Overhead costs incorporate those services that serve many different 
departments in the health service and also management costs.  In this study 
it was decided that overhead costs of therapist time were unlikely to make a 
substantial influence on the overall cost of the intervention. After 
consultation with health economists CG and SP and the finance department 
of Tees Esk and Wear Valleys NHS Foundation Trust where the trial was 
hosted it was decided to take the simple commonly adopted approach of 
assigning 30%. The effort put into overhead cost allocation should be 
related to the likely importance in relation to the overall analysis 
(Drummond et al. 2005). It was felt this was a balanced, acceptable and 
pragmatic way of addressing the issue of overhead costs in this study since 
it was unlikely there would be significant variation from the 30% value, 
used in the NHS hosting organisation and other cost utility studies of 
depression in primary care (Katon et al. 2005). In a small study it could be 
said variance would have a larger influence on final results. This study was 
considered exploratory and would include sensitivity analysis to inform 
potential future large definitive trials. Taking this into account, the extra 
resource needed to perform more detailed calculations of overhead costs 
was not considered necessary.    
All twelve planned sessions were included regardless of attendance rates. 
This study was exploratory and likely to be underpowered to provide an 
accurate estimate of attendance. Calculating costs for only those sessions 
attended could therefore introduce potential bias into findings as it is 
unlikely observed attendance in this study would reliably translate to 
routine care settings. By including only those sessions attended BA costs 
may have been underestimated.  It was therefore decided in consultation 
with health economists CG and SP to adopt the conservative approach of 
including the cost of all sessions regardless of actual attendance rate. This 
would provide the basis of a cost utility analysis of BA by the non 
specialist based upon a 12 session treatment programme and reduce the 
chances of underestimation.  
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BA training and supervision costs 
 
Training and clinical supervision was delivered on local NHS trust 
premises by the DE and were considered a major factor in cost estimates. 
Training costs were calculated by facilitators hourly rate for the duration of 
the training (35 hours) plus 30% overhead cost. The hourly rate was 
obtained in consultation with the NHS trust‟s finance department. The 
figure obtained was then divided by the number of participants attending 
the training, in this case ten. BA is already an accepted intervention for 
depression, and as such training for such interventions as CBT, BA etc. is 
common within routine care. If our training costs were allocated only to the 
two therapists operating in the intervention arm of the trial this would have 
added unrealistic increased costs influencing overall economic evaluation.  
Based upon clinical judgement and the experience of the author a training 
group size of ten was considered appropriate. This group size would allow 
role play and feedback and be able to address any emerging issues. Those 
participants in the training were then asked to provide treatment to study 
participants finishing the usual care arm. Training costs do pose problems 
in economic evaluation and require balanced decisions on their 
management. Exploratory trials in particular, due to their small size, would 
carry an unrealistic cost burden of training if distribution of such costs 
were to be limited to the trial therapists and participants alone.  
Supervision costs were based upon one hour per fortnight of supervision 
for each therapist and supervisor plus 30% overhead costs as outlined 
above.   
Training and supervision costs were then adapted to reflect activity levels 
expected in NHS settings. As outlined above, training and supervision can 
burden costs in small studies in a way that limits translation into routine 
care. One purpose of cost-effectiveness analysis is to inform decision 
makers (Fenwick et al. 2001) therefore decisions are required as to how to 
handle training costs both in terms of per trainee and also the degree to 
which this influences cost per participant. Psychotherapy trials are 
commonly small, and if training were only assumed to have an impact on 
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those in the study, the distribution of such costs would be limited and 
hence add a substantial amount per participant. To counter this, the costs of 
training in this study were based upon a distribution expected outside the 
trial setting. This is a common approach used in the costing of trials of 
depression in primary care (Kendrick et al. 2006, McCrone et al. 2004) and 
accepted by decision makers (National Institute for Health and Clinical 
Excellence 2008). Through discussion between DE and experts in BA and 
training in UK psychological health service delivery training costs for the 
trial were based on an assumption that competences gained through 
training would be maintained over three years and be used with patients 
outside the trial setting. The exact number of treatments a therapist would 
deliver over a year was unclear. Two different estimates of therapist 
workload based upon local Improving Access to Psychological Therapy 
(IAPT) service specifications were used. This provided a routine health 
service approach that represented the geographical location of the study. It 
also provided a real-life estimate of anticipated demand in a psychological 
therapy service designed to increase access which is where the BA under 
investigation is likely to be placed.  In the first estimate it was assumed 
each BA therapist would complete 65 treatments per year if employed in a 
depression-specific role (scenario A). The second scenario had a smaller 
estimate of the workload which was focussed specifically on depression of 
33 treatments per year assuming that the therapist was operating in a 
common mental health service role treating both depression and anxiety 
(scenario B).  Training and supervision costs were then distributed based 
upon each scenario over anticipated completed treatments for three years 
and added to direct BA treatment costs. This approach balanced a potential 
bias of overestimation of training costs in this study.    
General health service resource use  
 
As per recommendations all resource use from a health and personal social 
service perspective (PSS) were used for this study (National Institute for 
Health and Clinical Excellence 2008). As this was not intended to be a 
definitive study it was decided not to include cost savings that fell outside 
of these perspectives. Other studies have measured missed work days 
 154 
(McCrone et al. 2004, Kendrick et al. 2006) allocating costs to this. There 
is however a methodological debate regarding this approach (McCrone et 
al. 2004), and results should be reported separately and not incorporated in 
QALY calculations in line with guidance issued on the estimation and 
perspectives on costs issued by NICE (National Institute for Health and 
Clinical Excellence 2008).  Based upon these uncertainties it was decided 
in discussion with the trial steering group to focus on NHS and PSS costs 
in order to build a body of evidence usable by those designing larger scale 
definitive studies. Using a standard uncontroversial approach would 
facilitate clarity for this purpose. Direct intervention costs were calculated 
using total service use gathered from participants‟ primary care records 
augmented by self-report questionnaires and diaries. In the design of the 
cost-effectiveness protocol there was discussion regarding the method of 
collecting service use data. Use of self-report questionnaires and diaries is 
common in economic analysis; however members of the steering group 
who were experienced in this approach reported variable rates on reliability 
and completion. Based upon this it was decided to use a combination of 
self-report questionnaires, diaries and health service records in order to 
provide cross validation between methods. A questionnaire used in a 
previous trial of community alcohol treatment (Drummond et al. 2009)  
was modified for use in this study (see Appendix II). Particular alcohol 
related questions were adapted for depression service use and criminal 
justice sections removed as these were not deemed necessary for this 
population. The questionnaire was then taken to a local self-help group of 
people experiencing anxiety and depression and circulated. Verbal 
feedback was sought to ascertain if the questionnaire was acceptable. 
While it is acknowledged it would have been preferable to pilot the tool 
formally, this process was deemed to be an acceptable compromise and 
within the resources and time constraints of the study. Feedback indicated 
that the questionnaire would be appropriate and acceptable to use. Primary 
care records were used, as these were likely to include a comprehensive 
summary of all health care received from a variety of sources such as acute 
medical care and mental health care. Results from the two sources were 
combined and where discrepancies occurred the health service record was 
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used. Prioritising the health service records was agreed, as these were 
likely to have been recorded during or at about the time of an intervention 
rather than being a retrospective account based upon memory, and were 
therefore considered to be more reliable. The two approaches outlined were 
used to complement each other to supply a detailed picture of NHS and 
PSS service use for the six-month baseline and duration of this study.  
Research assistants blinded to allocation collected baseline service use both 
retrospectively for six months prior to entry to the trial and for the three-
month follow-up period using the above methods. They recorded all health 
service use including primary care, specialist services, inpatient stays and 
medication use, and any direct social service delivery including social 
worker, housing advisor, employment advisor etc. The baseline period used 
was beneficial to the trial due to the relatively short follow-up period. It 
allowed results to be balanced over a longer duration with baselines built 
into statistical analysis (see later under statistical methods).  The total cost 
per patient was ascertained by multiplying each resource use by its relative 
cost. Costs were allocated in British pounds at 2009 rates, the year of the 
study. Unit costs of health and social care (Curtis 2009) and the British 
National Formulary (British Medical Association & Royal Pharmaceutical 
Society of Great Britain 2009) were used as the primary source of cost 
information. These sources are considered reliable and have been used in 
other trials of depression in UK primary care (Kendrick et al. 2006, 
McCrone et al. 2004). Where costs were not available from these sources 
we searched  firstly from official listings (such as Department of Health) 
and then from other publicly available resources as per accepted guidance 
(National Institute for Health and Clinical Excellence 2008).  Full details of 
costs adopted in this study are outlined in Table 11.  
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Table 11 Costs used in study 
Services                         Cost              Source and details 
Acute medical care 
A and E visit 
 
 
 
 
 
£126/93 
Curtis (2009, p. 93) Accident and 
Emergency treatments (leading to 
admitted) £126. Accident and Emergency 
treatments (not leading to admitted) £93. 
A and E mental health 
liaison services 
£231 per 
episode 
Curtis (2009, p. 93) based on national 
average. 
Paramedic services £240 
Curtis (2009, p. 93): emergency transfers 
£240. 
Rapid response service £200 
£200 per low-cost episode (includes 
assessment and travel costs. 
Inpatient £493/day 
Curtis (2009, p. 93): non-elective inpatient 
stays (short stays) £493 national average 
Outpatient £126 
Curtis (2009, p. 93) weighted average of 
all outpatient procedures national average 
£126. 
Day case £638/case Curtis (2009, p. 93) 
Primary care services 
GP £35/ visit 
Curtis (2009, p. 121): per surgery 
consultation lasting 11.7 minutes £35. Per 
telephone consultation lasting 7.1 minutes 
£21. Per home visit lasting 23.4 minutes 
(includes travel time)  £117. 
PN £11/visit 
Curtis (2009, p. 118): £11 per 
consultation; £20 per home visit. 
Nurse advanced (includes 
lead specialist, clinical 
nurse specialist, senior 
specialist) 
£16 
Curtis (2009, p. 119): cost per hour of 
client contact £65; cost per surgery 
consultation £16 
Counsellor £42/visit 
Curtis (2009, p. 68) £42 per hour of client 
contact. 
Health visitor £40 
Curtis (2009, p. 115): £96 per hour of 
client contact; £81 per hour of clinic 
contact; £117 per hour spent on home 
visits; £40 per home visit. 
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Health Care Assistant 
£4.49 based 
on 11.7 
minutes 
contact time 
(as per GP) 
Curtis (2009, p.117): unit costs available 
2008/2009 
£14 per hour; £23 per hour spent with a 
patient; £18 per hour in clinic contacts; 
£23 per hour spent on home visits; £9 per 
home visit.. 
Based on the median full-time equivalent 
basic salary for Agenda for Change 
Band 2 of the January-March 2009 NHS 
staff earnings estimates for unqualified 
nurses. Median full-time equivalent total 
earnings, which include basic salary 
plus hours-related pay, overtime, 
occupation payments, location payments 
and other payments including redundancy 
pay or payment of notice periods were 
£17,200.1 See page 178 for information 
on mean salaries. 
 
Podiatrist £11 
Community chiropodist/podiatrist Curtis 
(2009, p. 108): £23 per hour; £21 per 
home visit; £11 per clinic visit. 
Dietician £34 
Curtis (2009, p. 150): £34 per hour client 
contact; £59 per hour of home visiting. 
Physiotherapist £17 
Community physiotherapist Curtis (2009, 
p. 105): £43 per hour of client contact; 
£48 per home visit; £17 per clinic visit. 
Hospital physiotherapist Curtis (2009, p. 
147): £40 per hour of client contact; £52 
per hour in home visiting. 
Radiographer £16 
Curtis (2009, p. 151): £29 per hour; £48 
per hour of client contact; £16 per 20- 
minute clinic visit. 
Psychiatry services 
CPN appointment £72 
Curtis (2009, p. 136): £72 per hour of 
face-to-face contact 
Psychiatrist appointment £322/hour 
Curtis (2009, p. 172): £322 per hour 
patient contact 
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Psychologist appointment £75 
Curtis (2009, p. 109): £75 per hour of 
client contact 
GMHW £32 
Unit costs available 2008/2009 (costs 
including qualifications given in brackets): 
£24 (£28) per hour; £45 (£53) per hour of 
face-to-face contact; £32 (£37) per hour 
of client related work. Based on a Agenda 
for Change band 5. 
Occupational therapist £43 
(Curtis 2009): NHS community 
occupational therapist £43 per hour of 
client contact; £47 per home visit; £17 per 
clinic visit. 
Hospital occupational therapist £44 per 
hour of client contact. 
Drug and alcohol services £90 
Curtis (2009, p. 93): drug and alcohol 
services £90 national average. 
Personal social services 
Social worker £38 
Curtis (2009, p. 126): £29 per hour; £38 
per hour of client-related work; £140 per 
hour of face-to-face contact. 
Debt advisor £9.50 
0.5 professional and 0.5 volunteer labour. 
Based on social worker Adult rate per 
hour of client-related work (£38 per hour) 
Curtis (2009, p. 126), 30 min. contact. 
Benefits advisor £19 
Based on social worker dult rate per hour 
of client-related work (£38 per hour) 
Curtis (2009, p. 126): 30 min contact 
Housing benefit advisor £19 As above 
Employment advisor £19 As above 
Other 
Alternative medical 
practitioner 
£11.43/visit 
Uprated to 2008/09 levels using the 
HCHS Pay and Prices Inflator. 
NHS walk-in centre £26 
Uprated to 2008/09 levels using the 
HCHS Pay and Prices Inflator. 
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GP out of hours £65 
http://www.hsj.co.uk/news/primary-
care/study-reveals-three-fold-cost-
variation-in-gp-out-of-hours-
services/5000264.article (Based on 
research from the research organisation 
Primary Care Foundation). Decision: 
worked out average. 
NHS Direct £25 
http://www.telegraph.co.uk/health/325324
5/Every-call-to-NHS-Direct-costs-25.html 
2008 
Post-Natal National 
Helpline 
£2.35 
http://www.nct.org.uk/info-centre/getting-
help/helplines  Accessed 12/04/2010 at 
10.38am 
999 call £240 
Curtis (2009, p. 93): emergency transfers 
£240 
Phlebotomist £9 
Based on the median full-time equivalent 
basic salary for Agenda for Change and 2 
Unit costs available 2008/2009 £14 per 
hour; £23 per hour spent with a patient; 
£18 per hour in clinic contacts; £23 per 
hour spent on home visits; £9 per home 
visit. 
 
RELATE £9.50 
0.5 professional and 0.5 volunteer labour. 
Based on social worker Adult rate per 
hour of client-related work (£38 per hour) 
Curtis (2009, p. 126), 30 min contact 
CAB £9.50 As above 
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4.3.9 Blinding 
 
Blinding is concerned with the minimisation of measurement bias in 
assessors and performance bias in participants and therapists. If achieved it 
ensures that investigators, patients and assessors are unaware of allocation 
and there can be no accusation of attempt to influence results. There are 
three possible levels of blinding in studies: 
 
 Single blind-the patient is unaware of which treatment is received; 
 
 Double blind-the patient and investigators (clinicians) are unaware 
of which treatment is received; 
 
 Triple blind-the patient, investigators and assessors are unaware of 
which treatment is received.  
 
Blinding poses particular problems in non-pharmacological trials such as 
those evaluating psychotherapy, as it would not be possible to disguise 
allocation to a particular intervention either from the patient or from the 
therapist (Boutron et al. 2007). In this study it was not realistic to suppose 
that we could blind participants between an allocation of usual care and 
BA; neither would we have been able to blind therapists. The accepted 
alternative commonly used in these scenarios is to use assessors who are 
unaware of allocation. All participants were asked not to disclose any 
details regarding the intervention received at the start of each appointment 
where measures were collected. Therefore all assessments were collected 
by a research worker blind to treatment allocation at each follow-up stage. 
Our use of self-report for clinical outcomes would also have reduced the 
risk of assessor bias; however it is possible that it increased the chance of 
performance bias by participants.  
We used an additional process to reduce the possible impact of 
measurement bias by using two research assistants who were unaware of 
allocation to enter data into SPSS (SPSS for Windows 2008) to create two 
independent data sets, which were then checked for inconsistencies.  
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Initial statistical analysis was checked by MB who was blind to allocation. 
This was achieved by allocation of subject group codes with two randomly 
selected numbers. Initial analysis was then conducted on the main 
outcomes (BDI-II, WASA and CSQ) prior to unmasking code labels. 
While this was not possible for all subsequent analysis it provided a 
baseline which was independently analysed and blinded to allocation. This 
then was used as a reference point for additional analysis by investigators 
unblinded to allocation.    
4.3.10 Interventions 
Behavioural Activation 
 
The theoretical basis for BA is outlined in detail in Chapter Two. In this 
study the aim was to test the dissemination of the approach when delivered 
in a way that was likely to be incorporated in routine NHS practice. An 
initial consideration was the duration of the intervention. While we 
required a protocol that included the key components, little evidence 
existed to inform us of the optimum number of sessions required. We 
endeavoured to address this through the use of meta-regression within our 
meta-analysis. The association between session number and effect size had 
been examined in our meta-analysis  (Ekers et al. 2008) finding no 
association within the comparison of BA and control to guide decision 
making (meta-regression beta-coefficient = 0.03, 95% CI −0.03 to 0.09; I2 
= 0.49, P = 0.27). The number of sessions recommended in guidance for 
the approach is 16-20 sessions over 3-4 months (National Institute of 
Clinical Excellence 2009). In reality, however, even in Improving Access 
to Psychological Therapies services where therapies are designed to 
replicate those delivered in trials session numbers tend to fall far short of 
such recommendations (Clark et al. 2009, Glover et al. 2010). In these two 
large scale evaluations high-intensity treatments reported a wide variance 
in number of sessions received by service users with median numbers of 
therapy sessions  8.2 and 8.5 respectively. In a sample of 7,825 patients of 
IAPT services only 1.38% received 16 or more sessions (Glover et al. 
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2010). While such data had not been not published at the time of this trials 
protocol  design, this pattern was emerging and influenced our intervention 
design. DR and DE had been involved in IAPT national rollout 
programmes and were privy to early audit data of sites. This, with 
additional substantial clinical experience, led to the agreement that a 
pragmatic approach was to have an intervention based upon session 
numbers falling short of those recommended in NICE guidance. A map of 
the components of BA was established and distributed across what was 
deemed realistic in one hour sessions leading to a 12-session protocol being 
developed (see Table 13, page 168). The  protocol was based upon two 
behavioural approaches developed in previous research (Martell et al. 
2001, Hopko et al. 2003). The BA in this study consisted of a structured 
programme aimed at participants increasing their contact with potentially 
antidepressant environmental positive reinforcement by scheduling and 
reducing the frequency of negatively reinforced avoidant behaviours.  A 
shared formulation was created based upon a behavioural model in the 
early stages of treatment which was developed with the patient throughout 
the 12 sessions. Subsequent specific techniques incorporated in the 12 
session protocol were self-monitoring, identifying „depressed behaviours‟, 
developing alternative goal orientated behaviours and scheduling. In 
addition the role of avoidance and rumination was addressed through 
functional analysis and alternative responses developed. The overall goal 
of BA was to re-engage participants with stable and diverse sources of 
positive reinforcement from their environment (Kanter et al. 2009) and to 
enable them to understand the BA rationale, thus developing depression 
management strategies for future use. 
Once developed, the BA treatment manual was shared with an international 
expert in behavioural activation (C Martell) who had been involved in two 
previous randomised controlled trials and was had written the most 
comprehensive book on the subject (Martell et al. 2001). His comments 
were incorporated into the manual which is presented in Appendix II.   
BA therapists  
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This study was designed to examine the suitability for wider dissemination 
of BA. In order to test this realistically, it was important to consider the 
most appropriate staff group from which to recruit therapists. Traditionally 
therapy has been the domain of psychology or experienced professionals 
with substantial post-registration qualifications. This may be one factor in 
the hitherto limited availability and dissemination of effective therapies 
(Lovell and Richards 2000).  This was reflected in our meta-analysis, 
where we were unable to find studies of BA delivered by non-specialists 
despite it being more than ten years since Jacobson had put forward the 
parsimony hypothesis (Jacobson et al. 1996, Ekers et al. 2008). Mental 
health nurses represent the largest section of the mental health workforce. 
They have the potential to deliver evidence-based interventions but require 
development to do so (Department of Health 2006). Based upon this it was 
decided therapists in this study would be drawn from the mental health 
nursing workforce. This would allow confidence in their level of baseline 
training and understanding of mental health. Also this workforce had been 
used in previous studies of psychological therapies in primary care 
(Kendrick et al. 2006). Two qualified mental health nurses with no 
previous formal psychotherapeutic training or experience were recruited to 
train and deliver the BA in the intervention arm of the study. This allowed 
a test of whether the brief training could develop sufficient skills, and 
would limit any potential bias of previous psychotherapy training 
influencing practise.  Funding was supplied by Tees, Esk and Wear Valleys 
NHS Foundation Trust to employ the two nurses for one year. It was 
decided to use two full-time nurses rather than a greater number released 
for small periods of time to complete interventions. While there would 
have been potential benefit in being able to evaluate BA delivery by a 
wider number of therapists, the practical problems would have been 
considerable. Releasing staff for short time periods weekly to deliver 
treatments would have required considerable co-ordination of appointments 
and therapy rooms. Local team managers were approached; although they 
were interested in the study, they felt that releasing staff with minimal 
backfill funds would have a detrimental effect on the management of their 
services. It was therefore decided to recruit two nurses who would work 
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full-time on the trial and treat all the intervention participants. Based upon 
local service performance frameworks, it was thought that the numbers 
needed for the trial could be managed with this number of full-time 
therapists both for the intervention group and for those in the control group 
opting for treatment after the three-month study period. A potential 
bottleneck of participants requiring treatment midway through the study 
year was anticipated, as those in the control group would be entering 
treatment after three months alongside those entering the intervention 
group at the same time. It was decided to counter this by offering the 
training for the intervention to services on the understanding that staff 
released to train would treat 1-2 trial participants from the control arm. 
This was discussed with the trial steering group and deemed appropriate; as 
it offered a safety net of additional capacity if needed and also reflected 
normal practice (training groups for this type of intervention are not usually 
two members of staff).   
 
Both trial therapists had worked in a range of services in inpatient and 
community settings, with three and six years' experience respectively since 
qualification. They were employed on Agenda for Change Band 5, the 
basic qualified nurse banding representing the largest section of the mental 
health nursing workforce. This was felt to be the most appropriate group 
from which to recruit, since if BA could be shown to be delivered 
effectively by basic grade nurses with no previous therapy experience, it 
would be likely that other more experienced nurses could achieve similar 
results. 
 BA training 
 
BA training was delivered over five days in consecutive weeks and was 
delivered by DE. Previous experience indicated the use of  „massed 
practise‟ would be more beneficial than a day release course of longer 
duration (Ekers 2010). The approach also reflected the study time 
constraints: needing to get therapists trained and seeing patients swiftly 
after appointment. The course content sought to provide participants with a 
basic theoretical understanding of the principles and evidence base 
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underpinning BA. It also aimed to emphasise the clinical delivery of 
various BA interventions through repeated role play.  The material was 
delivered using a range of learning methods including presentations and 
small and large group work, with a major component being intensive skills 
practice employing role-play with highly structured, constructive feedback 
(see Table 12). Training was structured around a typical course of 
treatment, initially outlining the theoretical basis and evidence base of BA. 
Assessment techniques were outlined which were aimed at gathering 
information on changes in the contingent relationships between the person 
and their environmental reinforcement. These were designed to facilitate 
the sharing of a BA rationale with the patient. This is an important skill in 
BA, which seeks to develop a collaborative approach, with the therapist 
acting as a coach to support the patient's goal attainment (Martell et al. 
2010). The use of self-monitoring was covered, with participants 
encouraged to use it on themselves during the first two days of the course. 
This allowed self-reflection on the challenges presented by this that could 
be used within treatment to generate an empathic response when this stage 
of homework is or is not completed. Information gathered was used to 
develop a functional analysis of depressed behaviour using antecedent, 
behaviour and consequence (ABC). The training then explored the role of 
valued goal setting and scheduling in reintroducing positive reinforcement 
in participants' daily lives. Various procedures were employed to develop 
skills in collaboratively addressing negatively reinforced avoidance, such 
as Trigger, Response, Avoidance Pattern (TRAP) and Trigger, Response, 
Alternative Coping (TRAC)  (Martell et al 2001). Problem-solving 
strategies were introduced, and then the training examined BA approaches 
to dealing with worrying thoughts or troubled thinking. Finally, relapse 
prevention planning was covered and the treatment protocol (following the 
same structure of the training) outlined. Participants were audio-taped for 
two role-play sessions (an initial assessment session and session four) to 
assess if a sufficient level of competency had been achieved.  Training 
content was mapped against the 12-session protocol to ensure that all 
aspects in treatment were covered (see Table 13).  
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Table 12: BA course outline 
 Day 1 Day 2 Day 3 Day 4 Day 5 
Session 1 
 
Introduction 
What is BA for 
depression? 
Theoretical 
underpinnings 
(reinforcement theory) 
 
 
 
Use of self-monitoring 
to facilitate 
engagement with 
model 
 
Skills practice 
 
Recognising helpful 
and unhelpful 
behaviours 
 
Using reduction in 
avoidance tools, skills 
practice continued 
 
 
Pulling it all together 
to this point 
 
Skills practice 
 
Thinking in BA 
 
How to deal with 
thoughts 
 
 
Attention training 
 
 
Whole case skills 
practice 
 
Competency 
assessment 
Session 2 
 
Evidence base for BA 
for depression (does 
it work?) 
 
 
A BA rationale for 
depression, 
application in 
practice, 
understanding the 
cycle 
 
Skills practice 
 
 
Valued goal setting 
and its link to 
scheduling 
 
 
Activity scheduling 
 
Recap, putting it 
together so far and 
skills practice 
 
Building in goal 
directed ACTION 
 
 
 
Skills practice, 
incorporating 
avoidance reduction 
in goal-directed 
scheduling 
 
Understanding 
recognising and 
dealing with 
rumination 
 
Skills practice 
 
Lunch      
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Session 3 
 
Assessment and 
functional analysis. 
How to get ABC 
 
 
Skills practice 
 
 
Assessing avoidance: 
its role and 
relationship to 
depression 
TRAP 
 
Skills practice using 
TRAP assessment 
Problem solving 
seven stages 
 
Practice 
Ending therapy and 
relapse prevention 
 
Building a relapse 
prevention plan 
 
Session 4 
 
 
 
Skill practice 
continued 
 
 
Summary and 
discussion 
 
 
Breaking avoidance, 
use of TRAC 
 
 
Summary and 
discussion 
Graded task 
assignment 
 
Practice 
 
Summary and 
discussion 
Any questions, 
repeated practice 
opportunity.  
 
Summary and 
discussion 
 
The research plan 
 
 
Summary and 
discussion 
 
 
  
   
 
 
 168 
Table 13: Training content mapped against 12 session protocol 
 
Session 
Number 
Content of session Diary sheets etc. for session Covered in training 
1 
Introduction  
Rational assessment 
Self-monitoring 
Day 1 
Day 1 afternoon 
2 
Behaviour mood link 
Identifying depressed behaviours  
ABC formulation 
Self-monitoring 
Goals 
 
ABC sheet 
Yes functional analysis 
Yes day 2 a.m. 
3 
Further exploration of depressed 
behaviours and consequence 
Develop goal list 
Scheduling to break cycle 
Behaviours that make me feel bad 
Breaking down goals sheet 
Scheduling sheet 
Day 2 p.m. 
 
Day 2 p.m. 
4 
Review of scheduling 
Avoidance recognition  
Scheduling 
Goals 
TRAP 
Day 2 p.m. 
 
Day 3 a.m. 
5 
Scheduling 
Breaking avoidance 
What I have learnt so far 
TRAP/TRAC 
What I have learnt sheets 
Day 3 a.m. 
6 
Scheduling 
Breaking avoidance continued 
Assessing response to situation 
and making choices 
Schedules 
Alternative behaviour worksheet 
Action 
Day 2 p.m. and day 3 a.m. 
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7 
Review of using schedules to 
reduce depressed behaviour and 
break avoidance 
How to deal with depressed 
thinking  
Schedules 
Monitoring rumination 
Day 2 and day 3 
 
 
 
 
Day 4 a.m. 
8 
Continued scheduling review using 
TRAP/TRAC approach 
Dealing with rumination 
Schedules 
RCA sheet  
Day 2 and day 3 
 
 
Day 4 a.m. 
9 
Review of treatment and any 
problem areas left 
Problem solving 
Problem-solving sheet Day 3 p.m. 
10 
Review scheduling and new 
patterns of behaviour and impact 
Acting ‘as if’ 
Prepare relapse prevention 
Relapse flash card -  
what I have learnt 
 
Day 4 p.m. 
 
 
 
11 
Review ongoing scheduling 
Relapse prevention 
 
Risk signs/response to risk card Day 4 p.m. 
12 
Review relapse prevention work 
Review progress to goals 
Summary and goodbye 
 Day 4 and all sessions 
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 Training evaluation 
 
Participants were provided with details of the evaluation, and written 
consent was obtained to report anonymous findings. Participants‟ 
experience of the training in terms of acceptability was measured on the 
final day via the „Training Acceptability Rating Scale‟ (Davis et al. 1989). 
Questionnaires were self-report and completed anonymously. 
 
Questions 1-6 asses acceptability and are scored on a six-point bipolar 
Likert format (1 = do not agree at all, 6 = strongly agree).  Questions 7-15 
refer to perceived effectiveness of the training are scored on a four-point 
unipolar scale (0= not at all, 1 = little, 2= quite a lot, 3= a great deal).  The 
opportunity for free text comments was also provided  at the end of the 
questionnaire. The TARS has good test-retest reliability (r = 0.83), internal 
consistency (0.99) and acceptable construct validity (Milne 2010, Milne et 
al. 2000). The TARS tool was chosen as it is commonly used to evaluate 
training in both physical and mental health settings, thereby facilitating 
meaningful dissemination of results. Total scoring provides a range of 6-
63, with a higher score reflecting increased training endorsement. In 
addition scores can be separated for the acceptability and effectiveness 
subscales (6-36 for acceptability and 0-27 for effectiveness). Raw data are 
presented as range and means and then converted to a percentage score for 
the total and each subscale for each participant. This is achieved by 
dividing the achieved score by the total possible score and multiplying by 
100. The mean  percentage scores achieved for the group results are then 
presented, with scores of 70-80% being satisfactory and scores of 80% and 
above suggesting exceptionally good training (Milne 2010, Milne et al. 
2000).  
Usual Care 
 
Usual primary care management was chosen as the comparator in this 
study as it reflects the most common intervention for depression (National 
Institute of Clinical Excellence 2009). There had been no previous 
evaluation of BA delivered by non-specialists, therefore the first question 
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would be: does it work? If so, how does it work compared to what most 
people receive, i.e. usual care? In usual care participants were followed up 
by their GP or primary care mental health worker and offered interventions 
deemed appropriate for their condition as per normal practice. At the three 
months follow-up, control participants were offered BA therapy as 
delivered in the intervention arm.  
4.3.11 Adherence to BA and competency levels of 
therapists 
 
Adherence is a complicated factor in psychotherapy trials. There are two 
levels of adherence that of interest to the investigator: that of the 
participants receiving the intervention and that of the therapists delivering 
the intervention.  
In this study it would have been impractical to assess the fidelity to the 
model of participants beyond how this is managed within therapy (using 
and reviewing homework diaries etc.). It was assumed through 
randomisation equal levels of adherence would be achieved in each group, 
which through therapy would result in increased activation in the 
intervention arm alone. Therefore evaluation would be observing the 
results of activation in any difference between groups on post-treatment 
outcome measures. It was therefore important to measure the adherence of 
the non-specialist therapist to the protocol/model under investigation, as 
this would be the catalyst to increased activation.  
For this purpose all treatment sessions were audio taped in the intervention 
arm of the study. Recordings were stratified for study phase (early, mid, 
late) and therapist. A sample of 20% of recordings was then randomly 
selected by a research assistant with no access to content. The number of 
sessions selected was felt by the study team to reflect a sufficient sample 
above the ratio used in previously reported studies of BA (Dimidjian et al. 
2006) and within the studies financial constraints (independent assessors 
required payment). We selected two independent assessors with substantial 
experience both in CBT and in behavioural activation, who reviewed 38 
sessions of BA therapy from the study intervention arm. 
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Adherence 
 
Treatment fidelity was measured against specific behavioural factors in 
session/homework content. As no established tool was available for this 
purpose, one was devised for the study. It was felt by the study team (DE in 
consultation with DR and SG) that this should be simple and lend itself to 
simple dichotomous evaluation. Was the treatment BA? Was the 
homework BA? Was any other therapeutic model in evidence? The tool 
designed was based upon those used in  manuals of therapeutic training 
within IAPT services (Richards and Whyte 2008) as these had been 
extensively used with minimal problems in clinical settings. Assessors 
specifically examined session content against treatment protocols, to 
determine whether behavioural activation was the overall modality applied 
and if other therapeutic models were prominent in the therapy (such as 
cognitive therapy); see Table 14 page 174. After reviewing each tape, 
assessors decided if the session could be classed as authentic BA and 
assigned values of 1 (yes) and 0 (no) to give a score of adherence to the 
model. While such rating would not be directly comparable across studies, 
it was felt to be an acceptable measure of performance bias in the absence 
of more formally validated tools. 
Competence 
 
While the evaluation of adherence measured the degree to which therapists 
maintained fidelity to the BA model, it did not measure the skill with 
which they did so. In CBT the commonly used tool for this is the Cognitive 
Therapy Scale Revised (CTS-R) (Blackburn et al. 2001). This tool 
measures competence across 14 areas. The tool is valid and reliable in the 
measurement of CBT, and is commonly used in clinical settings. The CTS-
R was reviewed for use in this study through discussion within the steering 
group and contributors' (DE and DR)  experience of applying it to BA. A 
number of the items (such as eliciting cognitions and guided discovery) 
were not felt to be relevant in BA. It was not felt this that tool would 
provide a suitably accurate measure of BA competence, especially as it had 
not been specifically validated for BA. An alternative was identified 
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through discussion with Sona Dimidjian, an experienced BA therapist and 
researcher in the USA. Her research group was developing a rating scale 
specifically for BA, adapted from the CTS-R, the Behavioral Activation 
Competence Scale (BACS). It was felt that, although this tool was still in 
development, it would provide a more accurate reflection of BA 
competence in this trial. It had been devised by an expert reference group 
and had been piloted and modified. It measures a range of BA competence 
across 15 categories on a six-point Likert scale. A score of 0 is poor, 1 
barely adequate, 2 mediocre, 3 satisfactory, 4 good, 5 very good and 6 
excellent. Guidance is given that a score of 6 would only be applied in 
exceptional instances of a particular skill. It was felt that this tool, despite 
its early stage of development and evaluation, would provide a more 
accurate measure of competence in this study. 
 
Use of both the BACS and the adherence measure was piloted on two 
therapy tapes by David Ekers and the independent assessors. Differences in 
interpretation were explored through discussion to develop a consistent 
approach to the use of each measure. 
 
Results from the BACS are presented as a combined score and then for 
each therapist individually. Any differences were compared using 
independent sample t-tests (Bland and Altman 1994).      
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Table 14: Adherence rating scale BA 
Tape ID 
 
Reviewer Date reviewed 
 
 
No evidence present Some evidence present Clear evidence present 
Was there evidence that a 
behavioural rational underpinned 
interventions within sessions 
 Reflection on shared BA 
rationale in session to 
explain exercises 
 Checking understanding of 
BA approach with patient 
 Self-monitoring of mood-
behaviour link 
 Activity scheduling 
 Using approaches to tackle 
avoidance (TRAP-TRAC, 
ACTION etc..) 
 Exploring values - goal 
setting 
 Dealing with ruminations by 
exploring consequence 
 Relapse prevention using a 
behavioural model 
No examples of the 
behavioural approach were 
present in the session 
There was a mix of 
behavioural approaches but 
these were not specific, nor 
were they linked to a clear 
shared rationale 
The interventions were clearly 
behavioural in orientation, 
shared, specific and linked to 
a collaborative rationale 
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Was there evidence that homework 
tasks were designed primarily to re-
introduce environmental positive 
reinforcement - reduce avoidance? 
 Shared understanding of 
homework tasks in place 
 Self-monitoring to draw 
mood-behaviour link 
 Developing meaningful goals 
linked from session to 
homework 
 Scheduling activities based 
upon session discussion 
 Exploring problems with 
scheduling and examples 
reviewed in session-
homework 
 Use of approaches to 
manage avoidance as 
homework (TRAP-TRAC 
Healthy –unhealthy 
behaviour sheets 
 Monitoring rumination and/or 
RCA sheets explained and 
used  
 Relapse prevention tasks 
specific and linked to model 
No examples of the 
behavioural approach were 
present in the homework-no 
homework discussed 
There was a mix of 
behavioural approaches but 
these were not specific, nor 
were they linked to a clear 
shared rationale for the 
homework task 
The homework interventions 
were clearly behavioural in 
orientation, shared, specific 
and linked to a collaborative 
rationale 
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Was there evidence that other 
therapeutic models (i.e. cognitive 
therapy) were central to session 
content or homework? 
(If so, please briefly note what was 
used and how.) 
There was no evidence that 
any other therapeutic models 
governed session content 
There appeared to be a mix of 
therapeutic models guiding 
the session, but BA was 
prominent 
There was clear evidence that 
the interventions used were 
primarily of a therapeutic 
model other than BA 
Overall would you say the session 
was authentic behavioural 
therapy/activation? 
yes no 
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4.4 Data analysis 
4.4.1 Data quality 
 
Two research assistants independently extracted  data from self-rated 
measures and entered into SPSS (SPSS for Windows 2008). Each data file 
was checked for errors and then any inconsistencies explored. Data quality 
was checked by producing descriptive reports of categorical and 
continuous variables. These were then checked to identify any outliers or 
values that appeared unusual; each example was examined, referring back 
to relevant measures as required. Once each data set appeared appropriate, 
descriptive statistics were produced on each variable for each data set and 
results compared across data sets. Any inconsistencies were examined to 
identify the data entry point explaining the difference between data sets. 
This was then referred back to the original measure and amended 
accordingly. Once each data set produced the same descriptive statistical 
results across all variables, one set was adopted as the final version and 
was used for statistical analysis in this thesis.  
 
Poor data quality is a major threat to the validity of randomised controlled 
trials and as a result can impact negatively upon subsequent patient care.  It 
is recommended that studies use systematic central statistical monitoring to 
counter this risk (Baigenta et al. 2008). In this study resources were not 
available to support such an approach and, as no external grant funding was 
received, no additional Mental Health Research Network assistance was 
available for this purpose. It was felt in discussion with the study steering 
group that the above approach provided an appropriate alternative to 
systematic central monitoring as a means of maintaining data quality.  
4.4.2 Descriptive statistics 
 
Baseline characteristics are presented as means and standard deviations for 
psychometric scales (BDI; WASS; CSQ) and counts and percentages for 
categorical variables (depressed/not depressed) as per current conventions 
(Schulz et al. 2010, Altman and Bland 1996). We analysed each group and 
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presented results in a table format for each group and for the overall 
sample.  
4.4.3 Statistical approaches 
 
Severity of depression as measured by the BDI-II, functioning as measured 
by the WASA and health state were compared at one-, two- and three- 
month follow-up between groups using analysis of covariance (ANCOVA), 
incorporating baseline measures from each tool respectively. The three-
month analysis represented the primary analysis point in this research. 
Analysis of covariance increases the power of studies to detect difference 
while controlling for baseline imbalance (Vickers and Altman 2001). 
Therefore it was considered the most appropriate statistical approach in this 
study, as the small sample sizes to be used would increase the potential for 
unequal groups post-randomisation.  
 
Satisfaction was measured using the CSQ-8 at three months and compared 
between groups using an independent two-sided t-test (Bland and Altman 
1994).  
 
For continuous variables between-group mean endpoint differences are 
presented, both in terms of scores on the instrument and as standardised 
effect sizes (Cohen‟s d) and assigned values to effect size as per normal 
convention (small 0 - 0.32, medium 0.33 - 0.55 and large 0.56 and above) 
(Lipsey and Wilson 1993). 
4.4.4 Clinical significance  
 
While the above approaches analysed the statistical significance of 
findings, they did not give a clear indication of the clinical importance. The 
level of clinical change would give a estimation of the importance of any 
findings from a clinician's perspective and would complement statistical 
findings. The study protocol incorporated  Jacobson and Truax's 
procedures (Jacobson and Truax 1991) for calculating reliable and 
clinically significance change to quantify clinical improvement in 
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depressive symptoms on the BDI-II. This is recommended as a standard 
reporting strategy for all published research involving psychological 
interventions (Evans et al. 1998).  Reliable and clinically significant 
change requires a pre- to post-treatment improvement in scores that is 
unlikely to be due to the inherent unreliability of the measure (reliable 
change), accompanied by a movement from a clinical range to a non-
clinical one (clinically significant change). In calculating reliable and 
clinically significant change criteria, the data from the BDI-II manual 
(Beck et al. 1996) was used for clinical means, standard deviations and the 
reliability estimate (Cronbach‟s alpha) and data from Dozois, Dobson and 
Ahnberg (Dozois et al. 1998) for the non-clinical mean and standard 
deviation. The Dozois et al. study was used for the latter due to the larger 
sample sizes used in that study.  On the basis of these data, a participant 
had to improve by ten points or more from pre to post-treatment to show 
reliable change, and in addition had to score 17 or above pre-treatment and 
16 or below post-treatment to meet criteria for clinically significant change.    
 
As an additional measure of clinical improvement, response and remission 
criteria used in a previous study of BA (Dimidjian et al. 2006) was 
examined. Response was defined as an improvement of at least 50% or 
more and remission as a score of ≤10 on the BDI-II.  
 
Odds ratios with 95% confidence intervals were used to compare clinically 
significant change in the two groups. 
4.4.5 Health state 
 
EQ-5D scores were converted to health state (QALY) values, and means of 
the BA and usual care groups were compared at three months using 
analysis of covariance with baseline health state incorporated as covariate.  
4.4.6 Cost data analysis 
 
Mean cost differences between BA and usual care were calculated for the 
intervention phase with 95% confidence intervals using analysis of 
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covariance, with six-month pre-treatment baseline cost values as 
covariates. This would allow for any potential baseline differences to be 
incorporated in calculations. 
4.4.7 Cost Utility 
 
Cost differences between BA and usual care were calculated and expressed 
as the ratio of cost per difference in QALY. To achieve this in a study 
measuring only a proportion of a year health state score differences 
between groups at post-treatment were divided by four to represent the 
three-month duration of the study. This figure would provide the 
proportion of a QALY benefit for the duration of this study. This was then 
multiplied any cost differences observed between BA and usual care over 
the three-month period of the study by the value required to convert the 
three month proportion of QALY benefit to a full QALY.  This approach 
provided the deterministic results for the cost of a QALY found in this 
study.    
An as additional observation the cost per point change on the BDI-II was 
calculated. While this is not the preferred approach to cost utility analysis, 
it allowed results to be considered alongside other studies using this 
method. 
4.4.8 Sensitivity analysis of cost utility calculations 
    
Cost effectiveness acceptability curves (CEAC) were generated to explore 
uncertainty around cost utility findings (Fenwick and Byford 2005). This is 
achieved by conducting 1000 non-parametric bootstrap replications placed 
upon an incremental cost-effectiveness plane, where cost is mapped against 
health state outcome on the y and x axis respectively. Cost-effectiveness 
planes are then used to map results of a sample across four quadrants: more 
costly and more effective, more costly and less effective, less costly and 
more effective and less costly and less effective (Briggs et al. 2002). 
Bootstrapping approaches are then used to re-sample based upon the 
original data set to explore uncertainty of results. This was achieved by re-
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sampling a set of observations of equal size to the original data for the 
treatment and usual care groups. The means of cost and effect were then 
used to estimate the incremental cost-effectiveness of each bootstrapped 
sample. This procedure was repeated 1000 times and results placed upon 
the cost effectiveness plane as per recommended approaches (Briggs et al. 
2002, Briggs 1999). This allows an estimation of the number of 
observations likely to fall below any particular value given to a QALY. 
Results were then used to generate a CEAC for scenario A and B as 
outlined in training costs section. The curve was created by plotting the 
proportion of observations indicating BA was cost-effective compared to 
usual care at a range of values for a QALY gain (Fenwick and Byford 
2005). This approach is preferred over incremental cost effectiveness ratios 
with 95% confidence intervals as it allows an estimate of the probability 
that one intervention is preferable at a range of values and thus supports 
decision making (Fenwick et al. 2001). As we have an acceptable value for 
a QALY set at £20,000 (National Institute for Health and Clinical 
Excellence 2008) the CEACs  used in this study would allow consideration 
of the probability that BA or usual care would be dominant at that value. 
Bootstrapping and the generation of the CEACs used in this study was 
conducted by SP in using data provided by DE.  
This process was not repeated for the value of a point reduction on BDI-II, 
as no equivalent accepted tariff exists to provide appropriate context to 
results.  
4.4.9 Missing Data 
 
Missing data presents a common threat to the results of many trials with 
over half commonly missing over 10% of results (Altman 2009). Excluding 
cases with missing variables cannot be justified as it has been seen to bias 
results with the degree and direction of such bias being unpredictable 
(Nuesch et al. 2009) and also results in reduced statistical power (Altman 
2009).  In this study missing data were anticipated as dropout from active 
psychotherapies such as BA is commonly high (Clark et al. 2009). This 
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alongside the relatively small sample sizes planned in this study meant any 
missing data would need to be carefully handled.  
Missing data can be categorised into one of three groups (Sterne et al. 
2009, Altman and Bland 2007): 
 Missing completely at random (MCAR) - this is where the reason 
for the missing observation cannot be assumed to be related to the 
outcome and available data. An example of this is when a 
sphygmomanometer machine breaks down. This explanation to the 
missing observations cannot be assumed to be associated with any 
factor other than random chance. 
 Missing at random (MAR) - The missing observation is predictable 
and related to other observations, but not specifically the missing 
observation. An example might be young people having more 
missed blood pressure measurements. While there is a pattern to the 
missing data, it cannot be assumed that this depends on the actual 
missing value.  
 Missing not at random (MNAR) – There is a relationship between 
the missing value and the fact it is missing. Using the above 
example this may be that people with high blood pressure are more 
likely to miss appointments due to headaches.  
 
MNAR is the most common reason, and poses problems as the lack of such 
observations will introduce bias into findings (Altman and Bland 2007). It 
was assumed that missing data in this study was most likely to fall into 
either the MAR or MNAR categories; hence it was necessary to use an 
intention to treat (ITT) approach examining results for all participants in 
the group to which they were randomised. ITT is seen to be the most 
appropriate way to handle missing data, but there is debate with regards to 
the most appropriate methodology (Streiner and Geddes 2001).  A 
commonly used approach to deal with missing data is carrying forward last 
observations (LOCF), as seen in previous trials of BA (Dimidjian et al. 
2006). This approach, however, can significantly bias results in either 
direction, since a single imputation of missing values fails to reflect the 
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uncertainty around missed observations (Nuesch et al. 2009, Streiner and 
Geddes 2001). LOCF assumes that the final value or missing value is equal 
to the last observed value. This is problematic; if observations are MNAR 
there is an explanation to their absence of which we are not aware. 
Examples of this may be clear deterioration (treatment not acceptable or 
working) or improvement (treatment has worked and person needs no 
more) or a dislike of the therapist. Therefore LOCF takes no account of any 
change from outside treatment settings (natural improvement/deterioration) 
or the trajectory prior to dropout maintaining post dropout. Missing data 
are therefore likely to be related to treatment and/or prognosis in some 
way, making LOCF implausible (Altman 2009).  To deal with such 
problems multiple imputation was used, where possible, for our intention 
to treat analysis (Sterne et al. 2009). Multiple imputation allows for 
uncertainty around missing data by creating many imputed data sets 
sampled from predictive distributions modelled on a relevant available set 
of observations. This does not give one replaced value but a range of 
replaced values reflecting the uncertainty around the missing observation 
based upon the variability of the observed data. The post-treatment 
differences of each imputed set are compared using ANCOVA and a mean 
of results provided. Thus results from multiple imputations do not supply 
individual post-treatment scores where observations are missing, nor do 
they provide means and standard deviations for each group. It is important 
where there is uncertainty as to the reason for missing data to use multiple 
imputation cautiously and to consider it against completer analysis, 
explaining any significant differences observed (Sterne et al. 2009).  An 
intention to treat analysis was conducted for this study replacing missing 
data using multiple imputation by chained equations, as described by 
Royston using 100 imputations (Royston 2004).  Baseline BDI-II, age, sex, 
problem duration and allocation was incorporated  in modelling.  Multiple 
imputation is a specialist statistical procedure, and becoming fully 
competent in its design and application is beyond the remit of this PhD. It 
is recommended to get expert advice and assistance in the procedure from a 
statistician (Sterne et al. 2009). MB advised in the design of this approach 
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and conducted the analysis using STATA with MVIS and MCOMBINE 
functions (Stata Corporation 2003). 
 
For the clinical significance analyses it was not possible to use the multiple 
imputations method, as it does not supply individual participant level data 
(post-treatment mean). The approach of using both completer and LOCF 
analyses for clinical significance was adopted, taking into account the 
reservations regarding LOCF outlined above. In the absence of any more 
suitable alternative this approach was considered suitable.  
 
An intention to treat approach (ITT) with health state data using multiple 
imputation, using 100 imputations incorporating baseline health state, age, 
sex, problem duration and allocation in modelling was used. As this 
approach does not replace post-treatment scores, the completer results were 
used for bootstrapping and production of CEACs as per recommended 
approaches to managing missing data in cost-effectiveness studies (Briggs 
et al. 2003).    
4.4.10 Mapping results against previous studies 
 
As this study was aimed at exploring the effective dissemination of BA it 
was felt to be important to map results against studies that had used senior 
therapists to deliver BA or BT. Mean and standard deviation scores for the 
BDI-II were entered into the meta-analysis database in review manager 
(Cochrance Collaboration 2003) used to produce the results in Chapter 
three. This was conducted for both completer analysis and ITT analysis 
using LOCF, as multiple imputation does not provide post-treatment mean 
and standard deviation scores for extraction. The results were then 
compared visually and by examination of their influence on SMD between 
groups. 
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4.5 Results  
4.5.1 The treatment manual 
 
The treatment manual used in the study is presented in Appendix II. It 
represents a major product of the research of potential use to future 
researchers and clinicians. Each session is laid out with an agenda, session 
content instructions and homework tasks. It provides the therapist with 
guidance on content of sessions and if followed covers all key elements of 
behavioural activation identified for reviewed trials. Session-by-session 
content is outlined in Table 13 page 168. 
.  
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4.5.2 Training evaluation 
 
Training was attended by 10 mental health professionals currently 
employed within Tees, Esk and Wear NHS Foundation Trust. Participants 
were mental health nurses or graduate primary care mental health workers.   
Brief characteristics of participants are outlined in Table 15. 
Table 15: Characteristics of training participants  
 
Characteristic Mean (SD) 
Age in years (SD) 41.7 (9.11) 
Years of health service employment 
(SD) 
13.4(9.95) 
Role 
Mental health Nurse-8 
Graduate primary care mental 
health worker-2 
Mean caseload number (SD) 30.5 (19.3) 
Percentage of caseload 
experiencing depression (SD) 
74.89 (21.30) 
 
Training Acceptability Rating Scale 
 
All participants (n=10) completed post training evaluation on the TARS 
questionnaire. Results are presented in Table 16.   
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Table 16: TARS Evaluation of  five day BA training  
 
Area (score range) 
Range 
(min-max) 
Mean 
1. General acceptability (0-6) 5-6 5.7 
2. Effectiveness (beneficial for staff) (0-6) 4-6 5.7 
3. Negative side effects for clients (0-6) 5-6 5.7 
4. Not appropriate intervention (0-6) 4-6 5.4 
5. Consistent with good practice (0-6) 5-6 5.9 
6. Most staff would approve of this training (0-6) 4-6 5.6 
7. Did the course improve your understanding? (0-4) 2-3 2.8 
8. Did the course help develop work related skills? (0-4) 3-3 3.0 
9. Has the course made you more confident? (0-4) 2-3 2.3 
10. Do you expect to make use of the course content in 
your workplace? (0-4) 
2-3 2.4 
11. Competency of course leaders (0-4) 2-3 2.9 
12. General satisfaction (0-4) 2-3 2.9 
13. Did the course meet its objectives? (0-4) 2-3 2.9 
14. Did course leaders relate to group effectively ?(0-4) 3-3 3.0 
15. Were the leaders motivating? 2-3 2.9 
 
 
A high level of perceived acceptability and effectiveness of the training 
was found from the questionnaires. All training participants‟ scores were 
above the 80% „very good' threshold of this measure (see Table 17 ). The 
mean percentage of acceptability for the training across all training 
participants was 94.4% (SD 6%) and for effectiveness 92.96% (SD 4.43%), 
with a combined rating of 93.81% (SD 4.76%).    
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Table 17: Percentage TARS scores for Participants in BA training 
 
Student 
evaluation 
Acceptability Effectiveness Total 
1 100.00 
 
96.30 
 
98.41 
 
2 100.00 
 
88.89 
 
95.24 
 
3 94.44 
 
96.30 
 
95.24 
 
4 94.44 
 
100.00 
 
96.83 
 
5 97.22 
 
96.30 
 
96.83 
 
6 94.44 
 
92.59 
 
93.65 
 
7 88.89 
 
88.89 
 
88.89 
 
8 100.00 
 
92.59 
 
96.83 
 
9 94.44 
 
92.59 
 
93.65 
 
10 80.56 85.19 82.54 
 
 
Free text comments are presented in Table 18. They reflect the overall 
positive evaluation of the training with clear reference to the repeated skills 
practice being an important factor.    
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Table 18: Free text comments from TARS regarding five day BA training 
Question 
 
Response 
 
Q16.  What was the most helpful part of the course for 
you personally? 
 Role play – to practice skills in safe environment and receive 
constructive feedback, albeit that dreaded role play at start. 
 Skills practice. 
 Helped me understand the model much more and gave the 
opportunity to put model into practice which gave confidence in 
delivery. 
 Practising the skills in small groups to experiment with different ways 
of presenting the information/worksheets. 
 Observing the assessment completed by the course leader. 
 Developing skills in funnelling questions to collect information. 
 Practising techniques through role play. 
 Group discussion. 
 Working in triads. 
 Trainer with excellent knowledge base and enthusiasm for the model. 
 The assessment tool and the formulation tool made it easy to explain 
how it is easy for us to maintain case depression. 
 Role play. 
 Group debates. 
 Feedback from course leader during monitoring of sessions. 
 Group work i.e. role play and open discussion. 
 The role play exercises were very helpful as a learning (aid) exercise. 
 Formulation of problem solving. 
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Q17.  What change, if any, would you recommend (e.g. to 
the content or teaching)? 
 Provide handout at start. 
 None. 
 Have slides printed for staff before training to make notes as we go 
along. 
 No changes other than the locations were not always easy to find. 
 Handouts of slides to be optional. 
 Use of ‘hand-outs’. 
 Change format of assessment form, feels all out of sync. 
 Some alternative titles for the formulation boxes. 
 
Q18.  Please make any other comments that you would 
like to offer 
 Enjoyed the training very much – relaxed atmosphere – increased 
confidence. 
 Thank you. 
 Thoroughly enjoyed the training despite initial apprehension – feel I 
have learnt all appropriate techniques in a well-structured and well 
planned way. 
 Overall I found the training to a high standard and I’m confident that it 
will guide my practice in the future. 
 The course has greatly contributed to my skills in clinical work. 
 An excellent delivery of a method of treating depression and I eagerly 
await putting it into practice. 
 The training was very enjoyable and I feel will be very useful in my 
daily working practice, supervision to be organised. 
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4.5.3 Data quality 
 
Prior to analysis 40 inconsistencies on comparison of the two independent 
data sets were identified. These generally related to data entry errors and 
they were resolved with reference to source records following which 
appropriate amendments were made.  Details of problems identified and 
approach taken can be found in Appendix II.  
4.5.4 Baseline characteristics and study attrition 
 
Sixty eight participants were referred to the trial, of whom 21 were 
excluded (17 did not meet diagnostic criteria, 2 refused randomisation, 2 
had significant suicidal ideation (as measured by a score of 2 ≥ on question 
9 of the BDI-II). Forty seven participants met the inclusion criteria and 
proceeded to randomisation. This rate (69% inclusion) is similar to other 
studies of BA which included 68% inclusion (Dimidjian et al. 2006) and 
UK primary care based problem solving (66%) (Kendrick et al. 2006).  
Twenty three patients were allocated to behavioural activation and 24 to 
control. No differences were observed in scores at baseline between the 
two groups on BDI-II (BA mean = 35.57 SD=9.60, usual care mean 
 35.08 SD=9.60), WASA (BA mean  26.39 SD 7.30, usual care mean = 
25.13 SD=7.30), CSIR (BA mean = 31 SD=10.99, usual care mean=33.13 
SD=8.22) or problem duration (BA mean = 186.91 weeks SD=358.49, 
usual care mean =195.21 weeks SD=404.64). Baseline participant 
characteristics are presented in Table 19 and indicate the participants in the 
trial represent a long term severely depressed group with substantial 
impairment of functioning. Data were collected from 38 participants at 
three month assessment, 16 in the BA arm and 22 in control. Of those 
opting out of the study 3 did so post randomisation (1 BA, 2 Usual care), 3 
at one month (3 BA), and 3 at two months (3 BA). There were no 
significant differences between completers and those dropping out of 
treatment on baseline BDI-II depression scores (dropout mean =36.55 
SD=10.77, no dropout mean =35.21 SD 9.43) or duration of problem 
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(dropout mean =182 weeks SD=439, no dropout mean=193 weeks 
SD=369). Of the 23 participants randomised to BA 11 received all 12 
sessions. Of those with missed sessions 3 received 1-3 sessions, 3 received 
4-6 sessions and 5 received 7-9 sessions. Study flow is presented in Figure 
32. 
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Table 19: Characteristics of participants at baseline  
 
 
Baseline Characteristic  BA (n=23) TAU (n=24) All (n=47) 
Age in years (range) 46.43 (24-
63) 
43.08 (28-63) 44.72 (24-63) 
Sex n (%) 
Male 
Female 
 
8 (35) 
15 (65) 
 
10 (41.7) 
14 (58.3) 
 
18 (38) 
29 (62)  
Employment n (%) 
Full time 
Part time 
House person 
Carer 
Retired 
Unemployed 
Incapacity benefit 
 
13 (56.5) 
1  (4.3) 
1  (4.3) 
0 
3  (13) 
4  (17.4) 
1  (4.3) 
 
8 (33.3) 
7 (29.2) 
1 (4.2) 
1 (4.2) 
3 (12.5) 
2 (8.3) 
2 (8.3) 
 
21 (44.7) 
8   (17) 
2   (4.3) 
1   (2.1) 
6   (12.8) 
6   (12.8) 
3   (6.4) 
 
Mean Duration of 
problem in weeks (SD) 
186.91 
(358.49) 
195.21(404.64) 191.15 
(378.61) 
Mean Baseline BDI-II 
score (SD) 
35.57 (9.60) 35.08 (9.60) 35.32 (9.50) 
Mean Baseline WASA 
scale score (SD) 
26.39 (7.30) 25.13 (7.70) 25.74(7.46) 
Mean Baseline CSIR 
score (SD) 
31 (10.99) 33.12 (8.22) 32.09 (9.63) 
Prescribed anti 
depressants (%) 
15 (65%) 17 (71%) 32 (68%) 
Baseline CSIR (ICD10) 
diagnosis n (%) 
Mild depression 
Moderate depression 
Severe depression 
Mixed anxiety and 
depression 
 
 
1   (4.3) 
13 (56.5) 
8   (34.8) 
1   (4.3) 
 
 
2  (8.3) 
9  (37.5) 
13 (54.2) 
0 
 
 
3 (6.4) 
22 (46.8) 
21 (44.7) 
1  (2.1) 
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Figure 32: Study flow chart 
 
 
  
Referred from general 
practice (n=41)  
Referred from PCMH 
teams (n=27) 
Excluded 
Diagnosis (n=13) 
Refused   (n=2) 
Excluded 
Diagnosis (n=4) 
Risk (n=2) 
47 participants accepted into trial from GP (n=26) from PCMH team (n=21) 
High severity (n=44) 
Low severity (n=3) 
Randomisation  
BA n=23 
HS n=21 
LS n=2 
Usual Care  n=24 
HS n=23 
LS n=1 
 
Opt out 
n=7 
Opt out 
n=2 
3 month assessment n= 38 BA (n=16)-TAU(n=22) 
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4.5.5 Assessment of normality of baseline data  
BDI-II 
 
The 5% trimmed mean of baseline BDI-II data was 35.20, indicating 
minimal impact of extreme scores on distribution (overall mean 35.32 SD 
9.50). Plots revealed a relatively normal distribution on a histogram, and 
the Kolmogorov-Smirnov statistic produced a non-significant result 
(P=0.13), indicating normal distribution of BDI-II scores: See Figure 33 
 
 
 
 
Figure 33: Histogram of baseline BDI-II pre scores combined 
 
WASA 
 
The 5% trimmed mean of combined baseline WASA data was 25.99, 
indicating minimal impact of extreme scores on distribution (overall mean 
25.74 SD 7.46). Plots revealed a relatively normal distribution on a 
histogram, and the Kolmogorov-Smirnov statistic produced a non-
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significant result (P=0.20), indicating normal distribution of BDI-II scores: 
See Figure 34. 
 
Figure 34: Histogram of Baseline WASA pre scores combined 
 
4.5.6 Treatment adherence  
 
Therapists closely adhered to the treatment protocol in all 38 sessions 
reviewed by independent specialists. A behavioural activation rationale 
underpinned all intervention content and homework, with all reviewed 
sessions scoring 1 (BA dominant) in relation to session and homework 
content. There was no evidence of alternative therapy models (such as 
cognitive therapy) being applied in any the reviewed sessions, with a score 
of 0 for all tapes (reflecting no other therapy modes being prominent). All 
sessions scored 1, being classed as an example of BA. 
4.5.7 Treatment competence 
 
Scores on the BACS scale are outlined in Table 20. They indicate a mean 
level of competence between satisfactory and good in all categories apart 
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from session structure, where the rating falls between mediocre and 
satisfactory. This is reflected in the overall rating of therapist competence 
score of 3.39 (SD 0.8239) indicating a satisfactory level BA ability across 
all sessions. 
 
BACS competence ratings were then compared between the two therapists 
in the study. Differences between the therapists are presented in Table 21. 
A significant difference was found across all domains, with therapist one 
achieving consistently higher levels of competency across both 
independent assessor ratings.   
 
  
 198 
Table 20: Combined BACS rating scores for therapist 1 and 2. 
BACS item N Minimum Maximum Mean 
Std. 
deviation 
Structure 38 1.00 5.00 2.89 0.92 
Focus BA 38 2.00 5.00 3.79 1.04 
Attends to 
understanding 
38 1.00 5.00 3.11 0.92 
Validates 38 2.00 5.00 3.24 0.75 
Non-judgemental 38 3.00 5.00 3.76 0.63 
Warm and genuine 38 3.00 5.00 3.84 0.68 
Collaborates 38 1.00 5.00 3.16 0.92 
Reinforces activation 38 2.00 5.00 3.24 0.82 
BA formulation 38 2.00 5.00 3.45 0.80 
Reviews homework 38 2.00 5.00 3.16 0.92 
Defines problems 
behaviourally 
38 2.00 5.00 3.60 0.89 
Selects appropriate 
targets 
38 2.00 5.00 3.53 0.69 
Appropriate change 
methods 
38 2.00 5.00 3.66 0.78 
Assigns homework 38 2.00 5.00 3.47 0.60 
Skilful application 38 2.00 5.00 3.39 0.79 
Overall rating 38 2.00 5.00 3.39 0.82 
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Table 21: BACs rating scale comparison between therapist 1 and 2 
BACS item 
thera
pist 
N Mean Std. deviation 
Mean 
difference 
P value 95% CI 
Structure 
1 18 3.33 0.84 
0.83 0.00 
 
0.28 to 1.38 
 2 20 2.50 0.82 
Focus on BA 
1 18 4.50 0.61 
1.35 0.00 
 
0.82 to 1.87 
 2 20 3.15 0.93 
Attends to 
understanding 
1 18 3.83 0.51 
1.38 0.00 
 
0.98  to 1.78 
 2 20 2.45 0.68 
Validates 
1 18 3.78 0.54  
1.03 
 
0.00 
 
0.67 to 1.39 
 2 20 2.75 0.55 
Non-judgemental 
1 18 4.22 0.43  
0.87 
 
0.00 
 
0.57 to 1.18 
 2 20 3.35 0.50 
Warm and genuine 
1 18 4.33 0.49  
0.93 
. 
0.00 
 
0.61 to 1.26 
 2 20 3.40 0.50 
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Collaborates 
1 18 3.79 0.55  
1.18 
 
 
0.00 
 
0.71 to 1.64 
 2 20 2.60 0.82 
Reinforces activation 
1 18 3.83 0.51  
1.13 
 
0.00 
 
0.74 to 1.52 
 2 20 2.70 0.66 
BA formulation 
1 18 3.83 0.71 
0.73 0.00 0.26 to 1.20 
2 20 3.10 0.72 
Reviews  homework 
1 18 3.78 0.65  
1.18 
 
0.00 0.77 to 1.59 
2 20 2.60 0.60 
Defines problems 
behaviourally 
1 18 4.28 0.67  
1.28 
 
0.00 
 
0.87 to 1.68 
 2 20 3.0 0.56 
Selects appropriate 
targets 
1 18 3.94 0.54  
0.79 
 
0.00 
 
0.42 to 1.17 
 2 20 3.15 0.59 
Appropriate change 
methods 
1 18 4.17 0.51 
0.97 0.00 
0.56 to 1.37 
 2 20 3.20 0.70 
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Assigns homework 
1 18 4.00 0.34  
1.00 
 
 
0.00 
 
0.78 to 1.22 
 2 20 3.00 0.32 
Skilful application 
1 18 4.06 0.42  
1.26 
 
0.00 
 
0.94 to 1.57 
 2 20 2.80 0.52 
BACS overall BA 
rating 
1 18 4.00 .59  
1.15 
 
0.00 
 
0.76 to 1.54 
 2 20 2.85 .59 
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4.5.8 Additional interventions 
 
Antidepressant medication was prescribed at baseline to 17 (71%) 
participants in usual care and 15 (65%) participants in BA compared to 
15/24 (62.5%) and 12/23 (52%) respectively during the intervention phase. 
Six participants in usual care had follow-up from a community psychiatric 
nurse. Two participants in BA had one session each with a psychiatrist. No 
other additional interventions for depression were received by participants 
during the study. 
4.5.9 Depression symptom level  
 
A one-way between groups analysis of covariance was conducted, with 
participants' scores on the BDI-II pre-treatment used as the covariate for 
those with completed post-treatment scores (BA n=16, control n=22). 
Preliminary checks were conducted to ensure there was no violation of 
assumptions of linearity or homogeneity of regression slopes. There was no 
significant interaction between BDI-II at baseline and allocation (P=0.404).  
After adjusting for baseline BDI-II scores, there was a significant 
difference in favour of BA of −15.65 (95% CI − 6.90 to −24.41) points on 
the BDI-II (F (1, 35) =13.18, P=0.001 n=38) representing a large effect 
size (Cohen‟s d = −1.15 95% CI − 0.45 to −1.85): See Table 22. 
Multiple imputation analysis of missing data BDI-II   
 
Intention to treat analyses with multiple imputation showed a mean 
difference on post BDI-II scores of −15.78 in favour of BA (95% CI 
−24.55 to −7.02, P= 0.001) with all randomised subjects (BA n=23, usual 
care n=24) included in analysis: See Table 22 
Difference in BDI-II scores over time 
 
One way between groups‟ analysis of covariance was conducted at 2 
additional time points, one month into treatment and 2 months into 
treatment. Multiple imputation was not used due to the similar findings 
between imputed data sets and completers at our primary analysis time 
point (3 months). 
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At one month we observed a mean BDI-II score for BA of 27.70 (SD 3.33 
n=20) and control 31.70 (SD 10.98 n= 23). After adjusting for baseline 
BDI-II scores, there was a non-significant difference in favour of BA of 
−3.90 points on the BDI-II (95% CI  −10.13 to 2.31  P=0.21). 
 
At two months, we observed a mean BDI-II score for BA of 21.31 (SD 
10.42 n=16) and control 28.96 (SD 14.63 n= 23). After adjusting for 
baseline BDI-II scores, there was a significant difference in favour of BA 
of  −8.47 points on the BDI-II (95% CI  −16.76 to −0.17  P= 0.046 BA): 
see Figure 35. 
 
 
 
Figure 35: Change over time by group BDI-II  
 
4.5.10 Clinical significance 
Clinically significant improvement on the BDI-II for those 
completing the intervention 
 
In the completer analysis (n = 38), 75% of participants in the Behavioural 
Activation group met the criterion for reliable improvement (improvement 
of 10 points or more) on the BDI-II compared to 36.4% of the control 
0
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group (OR = 5.35, 95% CI = 1.3 to 21.9). The treatment group was also 
more likely to meet criteria for reliable and clinically significant change 
(improvement by 10 points or the BDI-II and a move from ≥17  pre-
treatment to ≤16 post treatment) (56.3% vs. 22.7%; OR = 4.4, 95% CI = 
1.1 to 17.8). Response rates on the BDI-II were higher in the behavioural 
activation group (68.2% vs. 18.2%; OR = 9.9, 95% CI = 2.2 to 45.0) as 
were remission rates (56.3% vs. 13.6%; OR = 8.1, 95% CI = 1.7 to 39.1).  
Reliable and clinically significant change and response and remission for 
completers are presented in Figure 36 and Figure 37 respectively. 
 
 
Figure 36: Reliable and clinically significant change by group for study 
participants completing the intervention (n=38).  
Notes: reliable improvement requires a score below the lowest diagonal; 
scores below the lowest diagonal and below the horizontal reference line 
meet criteria for reliable and clinically significant change. 
   
 205 
 
Figure 37: Participants meeting response and remission criteria by group 
for study participants completing the intervention (n=38).  
Notes: Scores below the diagonal meet the criterion for response. Scores 
below the horizontal reference line meet the criterion for remission. 
Clinically significant improvement on the BDI-II using LOCF 
 
When the analysis of the BDI-II was repeated using last observation carried 
forward (n = 47), 65.2% of the behavioural activation group showed 
reliable improvement compared to 33.3% of the control group (OR = 3.8, 
95% CI = 1.1 to 12.5). Although more of the treatment group (43.5%) met 
criteria for reliable and clinically significant change than the control group 
(20.8%), the confidence interval for the odds ratio included one (OR = 2.9, 
95% CI = 0.8 to 10.6) hence this difference was not statistically significant. 
Response rates were higher in the treatment group (47.8% vs. 16.7%; OR = 
4.6, 95% CI = 1.2 to 17.7) and were on the border of significance for 
remission (39.1% vs. 12.5%; OR = 4.5, 95% CI = 1.0 to 19.6). Four 
participants (16%) in the usual care arm demonstrated deterioration at three 
months which was not observed in BA.  Figure 38 and Figure 39  
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summarise pre- to post-treatment change against reliable and clinically 
significant criteria and response and remission respectively.   
 
 
 
Figure 38: Participants meeting reliable and clinically significant change 
criteria by group (LOCF n= 47).  
Notes: reliable improvement requires a score below the lowest diagonal; 
scores below the lowest diagonal and below the horizontal reference line 
meet criteria for reliable and clinically significant change. 
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Figure 39: Participants meeting response and remission criteria by group 
(LOCF n=47).  
Notes: scores below the diagonal meet the criterion for response; scores 
below the horizontal reference line meet the criterion for remission. 
4.5.11 Functioning  
 
A one-way between groups analysis of covariance was conducted with 
participants' scores on the WASA pre-treatment used as the covariate. 
Preliminary checks were conducted to ensure that there was no violation of 
assumptions of linearity or homogeneity of regression slopes. There was no 
significant interaction between WASA at baseline and allocation (P=0.97).  
After adjusting for baseline WASA scores, there was a significant 
difference in favour of BA of  −11.56 (95% CI −4.79 to −18.33) points on 
the WASA (F (1,35) =12.01, P= 0.001 n=38) representing a large effect 
size −1.14 (−1.84 to −0.45): See Table 22. 
 208 
Multiple Imputation of missing data WASA scale   
 
Intention to treat analysis with multiple imputation showed a mean 
difference on post-WASA scores of −11.12 in favour of BA (95% CI 
−17.53 to −4.70, P= 0.001) with all randomised subjects (BA n=23, usual 
care n=24) included in analysis: See Table 22. 
Difference in WASA scores over time 
 
One-way between groups analysis of covariance was conducted at two 
additional time points, one month into treatment and two months into 
treatment. Multiple imputation was not conducted due to the similar 
findings between imputed data sets and completers at our primary analysis 
time point (three months). 
 
At one month, a mean WASA score for BA of 25.55 (SD 0.01 n=20) and 
control 27.09 (SD 7.08 n= 23) was observed. After adjusting for baseline 
WASA scores there was a non-significant difference in favour of BA of  
−2.35 points on the BDI-II (95% CI  −6.75 to 0.2.04 P=0.28). 
 
At two months, a mean WASA score for BA of 20.44 (SD 10.52 n=16) and 
control 25.83 (SD 9.11 n= 23) was observed. After adjusting for baseline 
BDI-II scores there was a non-significant difference in favour of BA of  
−6.34 points on the WASA (95% CI  −12.74 to 0.06 P= 0.05): see Figure 
40. 
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Figure 40: Change over time by group WASA 
4.5.12 Satisfaction  
 
Analyses were conducted on 38 participants (16 BA, 22 usual care) who 
completed CSQ questionnaires for post-treatment assessment. A mean 
difference in post treatment CSQ scores was found in favour of BA of 4.81 
(95% CI 2.23 to7.38, P= 0.001) showing a higher level of general 
satisfaction in the BA group. See Table 22 
4.5.13 Therapist differences 
 
A post hoc analysis of results by therapist was conducted to explore any 
differences observed. No differences were observed at baseline in the level 
of depression severity in those participants treated by each therapist (BDI-
II therapist 1= 38.75 SD 9.27, therapist 2= 32.09 SD 9.09) or functioning 
(WASA therapist 1 = 27.75 SD 6.80, therapist 2 24.91 SD 7.87). 
Independent samples t-tests were then conducted on post-treatment scores 
on the BDI-II, WASA and CSQ between therapist 1 and 2. Patients treated 
by therapist 1 showed a greater reduction and lower post-treatment score 
on the BDI-II (post-treatment BDI-II therapist 1 6.25 SD 7.09, therapist 2 
17.62 SD 12.81, P = 0.05) and WASA (post-treatment WASA therapist 1 
6.12 SD 4.64, therapist 2 16.12 SD 10.97, P = 0.03) using the completer 
analysis (N=16, N= 8 for each therapist).   
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When repeated using LOCF (N=23) (as multiple imputation data not 
available for this analysis) the differences reduced and were non-significant 
on the BDI-II  (post-treatment BDI-II therapist 1 14.41 SD 13.92, therapist 
2 19.90 SD 14.96, P = 0.366) and WASA (post-treatment WASA therapist 
1 13.33 SD 11.80, therapist 2 17.45 SD 10.72, P = 0.39). 
 
Therapist 1 achieved a higher satisfaction score post-treatment (CSQ 
therapist 1 31.37 SD 1.19, therapist 2 26.87 SD 4.05, P = 0.02 n=16). 
 
Findings reflect the improved competence scores found on the BACS for 
therapist 1; however it is of note that this was a post hoc analysis with no 
power calculation on a non- randomised allocation (to each therapist). As 
such, the findings are informative but must be treated with caution.  
4.5.14 Effect size findings mapped against meta-analysis 
 
Results from this study were incorporated into meta-analysis findings 
reported in Chapter Three. With the completer results added, the overall 
effect size of BA compared to controls increased slightly with a SMD  of 
−0.73 95% CI −1.02 to −0.44 P<0.001 observed against the reported a 
SMD of  −0.70 CI −1.00 to −0.39  P<0.001 in the meta-analysis. With 
LOCF data added, the overall effect size remained unchanged, with a SMD 
of  −0.70 (95% CI −0.98 to −0.42). These observations would indicate that 
BA delivered by non-specialists in this study achieved similar results to 
those achieved in studies using specialist therapists (see Figure 41 for 
visual comparison).  
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Table 22: Analysis of Outcome scores of BA vs. Usual Care at 3 month assessment 
a  ITT using multiple imputation incorporates repeated imputed values of post scores for analysis hence individual post mean (SD) values are not produced.  
 
 
Pre mean (SD) Post mean  (SD) 
Mean difference (95% CI) P value 
Standardised mean 
difference(95%CI) BA 
usual 
care 
BA 
usual 
care 
BDI-II 
 
Completers 
 
 
 
35.57 
(9.60) 
n=23 
 
 
35.08 
(9.60) 
n=24 
11.93 
(11.84) 
n=16 
27.40 
(14.01) 
n=22 
−15.65 (−24.41 to −6.90) 0.001 −1.15 (−1.85 to −0.45) 
 
ITT a 
 
N/A 
n=23 
N/A 
n=24 
−15.78 (−24.55 to  −7.02) 0.001 N/A 
WASA 
 
Completers 
 
26.39 
(7.30) 
n=23 
25.13 
(7.70) 
n=24 
11.12 
(9.64) 
n=16 
22.68 
(10.07) 
n=22 
−11.56 (−18.33 to−4.79) 0.001 −1.14 (−1.84 to −0.45) 
 
ITT a 
 
N/A 
n=23 
N/A 
n=24 
−11.12 ( −17.53 to −4.70 0.001 N/A 
CSQ 
 
Completers 
 
n/a n/a 
29.13 
(3.70) 
n=16 
24.32 
(3.96) 
n=22 
4.81 (2.23 to 7.38) 0.001 N/A 
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Figure 41: Forest plot of BA vs. Control with Ekers et al study included  
(N.B. forest plot includes both completer and LOCF data sets. This leads to 
double counting. The graph is presented for visual inspection of non 
specialist BA compared to other studies.  SMD calculations in text should 
be used for statistical results as these are based on analysis of each finding 
separately). 
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4.6 Economic evaluation 
4.6.1 Behavioural activation by the non-specialist 
intervention costs 
 
Individual therapist training costs for the five-day course were £641.55 and 
for delivery of the 12-session BA protocol £219.96. Training and 
supervisor costs for the five-day training and delivery of 40 hours of 
clinical supervision were £3059. Based upon scenario A, costs of delivery 
of a 12-session BA treatment, including therapist training and supervision, 
was £247 per participant, and for scenario B, £272.52 per participant. A 
breakdown of intervention cost calculations is presented in Table 23. 
. 
 
Table 23: BA intervention cost calculations 
BA costs training costs 
 
Therapist mid-point £14.10 + 
30%=£18.33 
Training for 35 hours =£641.55 
 
Trainer and supervisor basic costs 
£42.79 + 30%=£55.62 
Training 35 hours at £55.62=£1947 
Trained 10 people hence per 
therapist £194.7 
Supervision per therapist 1 hour 
each 2 weeks for 40 weeks (one 
year- leave and sickness etc.)=20 
hours of supervision per therapist  
£1112-supervsior, £366-therapist 
Trainer costs divided by 195 
treatments over three years  
assuming depression treatment 
alone 
£1.00 per patient (rounded up from 
0.99) 
Trainer costs divided by 98 
treatments over three years  
assuming half treated cases 
depression 
£1.99 per case 
Supervision costs one hour per 
fortnight divided by 65 cases per 
year (supervisor + therapist) 
£17.11 + £5.64=£22.75 per case 
Supervision costs one hour per 
fortnight divided by 33 cases per 
year 
£33.70 + £11.11= £44.01 per case 
BA costs for training-based upon 
mid-point Band 5 for 35 hours 
£641.55 
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BA training cost estimate per 
patient based upon 65 completed 
treatments per year (HI trained 
estimates from local IAPT 
specification) over three years 195 
£3.29 
BA training cost estimate per 
patient based upon 65 completed 
treatments per year (HI trained 
estimates from local IAPT 
specification) with 50% over 3 
years depression related 98 
£6.56 
Total add on costs to BA 
Treatment per patient (based 
upon195 treatments over three 
years total number treated per 
training) 
£1.00+£22.75+£3.29= £27.04 per 
case 
Add-on cost to BA for training and 
supervision (based upon 98 
treatments over three years 
treated per training) 
£1.99+£44.01+£6.56= £52.56 per 
case 
Cost per patient therapist time for 
treatment (assuming received all 
12 sessions) 
£219.96 
Cost of BA treatment plus 
training plus supervision (based 
upon 195 treatments  over three 
years assumptions) 
£219.96 + £27.04= £247 
Cost of BA treatment plus 
training plus supervision (based 
upon 98  treatments  over 3 
years assumptions) 
£219.96 + £52.56= £272.52 
 
4.6.2 Health care costs 
 
Complete resource use costs, excluding intervention costs, were available 
for all 47 recruited participants for both the six-month baseline and the 
three-month intervention phase (see Table 24). There were no differences 
in costs observed at baseline between the BA and usual care (BA mean 
£1050.12 SD = £1907.75, usual care mean £899.31 SD=£1131.33) or 
during the intervention phase (BA mean £336.01 SD = £434.48, usual care 
mean £412.81 SD=£380.29).  
4.6.3 Cost comparison between study arms 
 
With BA delivery costs included a one-way between groups analysis of 
covariance was conducted on health service costs during the intervention 
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phase, with baseline cost used as the covariate. In scenario A, after 
adjusting for baseline costs BA was £149.24 more costly than usual care 
(95% CI −£354.82 to £56.34 P= 0.15). In scenario B, after adjusting for 
baseline costs BA was £174.74 more costly than usual care (95% CI -
£380.34 to £30.82 P= 0.09) (see Table 25).  
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Table 24: Service use and cost BA vs. Usual Care 
Cost Category 
Treatment - Pre 
(n=23) 
Control - Pre 
(n=24) 
Treatment -  Post 
(n=23) 
Control - Post 
(n=24) 
 
Volume per 
patient 
Mean (s.d.) 
 
Cost 
per patient 
Mean (s.d.) 
Volume per 
patient 
Mean (s.d.) 
Cost per 
patient 
Mean (s.d.) 
Volume per 
patient 
Mean (s.d.) 
Cost per 
patient 
Mean (s.d.) 
Volume per 
patient 
Mean (s.d.) 
Cost per 
patient 
Mean (s.d.) 
Primary Care NHS 
(General) 
 
        
GP 
 
 
6.13 (4.911) 
 
 
£214.57 
(171.887) 
 
 
4.92 (2.812) 
 
 
£172.08 
(98.410) 
 
 
248 (1.648) 
 
 
£86.74 
(57.675) 
 
 
2.67 (2.869) 
 
£93.33 
(100.419) 
GP telephone 
 
 
0.83 (2.498) 
 
 
£17.35 
(52.463) 
 
0.46 
(1.285) 
£9.63 
(26.978) 
 
0.17 
(.388) 
 
 
£3.65 
(8.139) 
 
 
0.29 
(0.624) 
 
 
£6.13 
(13.106) 
 
GP out of hours 
 
 
0 
 
 
£0 
 
 
0.13 
(.338) 
 
 
£8.13 
(21.959) 
 
0 
 
£0 
 
 
0.08 
(.282) 
 
 
£5.42 
(18.351) 
 
GP home visit 
 
 
0.09 
(.288) 
 
 
£10.17 
(33.708) 
 
0.04 
(.204) 
 
£4.88 
(23.883) 
 
0 £0 0 £0 
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Nurse 
 
 
1.74 (2.684) 
 
 
£19.13 
(29.519) 
 
 
1.83 (2.297) 
 
 
£20.17 
(25.265) 
 
 
0.74 
(1.322) 
 
 
£8.13 
(14.539) 
 
 
0.96 
(1.429) 
 
 
£10.54 
(15.718) 
 
Nurse telephone 
 
 
 
 
0 
 
£0 
 
0.17 
(.381) 
 
 
£1.11 
(2.543) 
 
 
0 
 
 
£0 
 
 
0.04 
(.204) 
 
 
£0.28 
(1.364) 
 
Nurse home visit 
 
 
0.04 
(0.209) 
 
 
£0.87 
(4.170) 
 
 
0 
 
 
£0 
 
 
0 
 
 
£0 
 
 
0.08 
(0.282) 
 
 
£1.67 
(5.647) 
 
 
Health Care 
Assistant 
 
 
0.35 
(0.647) 
 
£1.56 
(2.906) 
 
0.17 
(0.482) 
 
£.75 (2.162) 
 
0.13 
(0.458) 
 
£0.59 
(2.055) 
 
0.25 
(0.676) 
 
£1.12 
(3.034) 
Health Visitor (HV) 
 
 
0 
 
 
£0 
 
 
0.21 
(1.021) 
 
 
£8.33 
(40.825) 
 
0 £0 0 £0 
HV In Surgery 
 
 
0 
 
 
£0 
 
 
0.08 
(0.408) 
 
 
£6.75 
(33.068) 
 
 
0 
 
 
£0 
 
0.08 
(0.408) 
 
£6.75 
(33.068) 
 
 
HV Telephone 
 
 
0 
 
 
£0 
 
0.08 
(0.408) 
 
£0.95 
(4.638) 
 
 
0 
 
 
£0 
 
 
0.13 
(0.612) 
 
 
£1.42 
(6.957) 
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HV Home 0 £0 0 £0 
 
0 
 
 
£0 
 
0.08 
(0.408) 
£3.33 
(16.330) 
NHS Direct 
 
 
0 
 
 
£0 
0 
 
 
0.17 
(0.482) 
 
 
£4.17 
(12.039) 
 
 
0 
 
 
£0 
 
 
0.08 
(0.408) 
 
 
£2.08 
(10.206) 
 
Walk-in Centre 
 
0.09 
(0.417) 
 
£2.26 
(10.843) 
 
0.04 
(0.204) 
 
£1.08 
(5.307) 
 
0 £0 0 £0 
 
Secondary Care 
NHS (General) 
 
        
 
Dietician 
 
 
0.04 
(.209) 
 
 
£1.48 
(7.089) 
 
0 
 
£0 
 
 
0 
 
 
£0 
 
 
0.13 
(0.612) 
 
 
£4.25 
(20.821) 
 
Ambulance 
 
 
0 
 
 
£0 
 
 
0.04 
(.204) 
 
 
£10.00 
(48.990) 
 
 
0 
 
 
£0 
 
04 
(.204) 
 
£10.00 
(48.990) 
 
 
Rapid Response 
 
0 £0 0 £0 
 
.04 
(.209) 
 
 
£8.70 
(41.703) 
 
0 
 
£0 
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Ambulance 
 
 
0 
 
 
£0 
 
 
.04 
(.204) 
 
 
£10.00 
(48.990) 
 
 
0 
 
 
£0 
 
 
04 
(0.204) 
 
£10.00 
(48.990) 
 
A&E 
 
 
0.30 
(0.559) 
 
£28.30 
(51.968) 
 
0.25 
(0.676) 
 
£23.25 
(62.837) 
 
0 
 
 
£0 
 
0.08 
(0.282) 
£7.75 
(26.257) 
In-Patient 
 
 
0.13 
(0.458) 
 
 
£63.00 
(221.067) 
 
0.29 
(1.429) 
 
£140.88 
(690.144) 
 
0 £0 0 £0 
 
Out-Patient 
 
 
1.35 (2.516) 
 
 
£169.83 
(316.961) 
 
 
1.21 (2.431) 
 
£152.25 
(306.344) 
0.61 
(1.234) 
 
£76.70 
(155.432) 
 
 
0.71 
(1.367) 
 
 
£89.25 
(172.199) 
 
 
Day-Patient 
 
 
0.43 
(1.376) 
 
 
£277.39 
(877.866) 
 
 
0.13 
(0.448) 
 
 
£79.75 
(286.097) 
 
 
0.09 
(0.288) 
 
 
£55.48 
(183.810) 
 
 
0.08 
(0.282) 
 
 
£53.17 
(180.126) 
 
Alternative Medical 
Practitioner 
 
 
0 
 
 
£0 
 
 
0.25 
(1.225) 
 
 
£2.86 
(13.999) 
 
 
0 
 
 
£0 
 
 
0.04 
(0.204) 
 
 
£0.48 
(2.333) 
 
Radiographer 
 
0.65 
(3.128) 
 
£10.43 
(50.043) 
 
 
0.04 
(0.204) 
 
 
£0.67 
(3.266) 
 
0 £0 0 £0 
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Phlebotomist 
 
 
 
0 
 
 
 
£0 
 
 
0.21 
(0.658) 
 
 
 
£0.94 
(2.961) 
 
 
0.04 
(0.209) 
 
 
£0.20 
(0.938) 
 
 
0.13 
(0.612) 
 
 
£0.56 
(2.756) 
 
Physiotherapist 
 
 
0.30 
(0.876) 
 
 
£12.17 
(35.027) 
 
 
0 
 
 
£0 
 
0.04 
(0.209) 
 
£1.87 
(8.966) 
 
0.04 
(0.204) 
 
£1.79 
(8.777) 
 
Occupational 
Therapist 
 
 
0 
 
 
£0 
 
0.13 
(0.612) 
 
£5.38 
(26.332) 
 
 
0.04 
(0.209) 
 
 
£1.87 
(8.966) 
 
0.04 
(0.204) 
 
£1.79 
(8.777) 
 
Total physical 
Medication 
prescribed (a) 
 
 
5.70 (8.657) 
 
£44.70 
(94.428) 
 
9.29 
(12.791) 
 
£53.36 
(120.437) 
 
2.91 (5.567) 
 
 
£28.52 
(83.066) 
 
 
2.96 (5.344) 
 
£29.57 
(70.266) 
Sub-total Primary 
Care 
 
 
 
£254.91 
(239.130 
 
 
£238.02 
(140.318) 
 
£99.11 
(64.610) 
 
£132.07 
125.673 
Sub-total Secondary 
Care 
 
£562.61 
(1431.361) 
 
£415.96 
1023.698 
 
£144.80 
(278.560) 
 
£169.04 
(277.616) 
 
Primary Care NHS: 
Mental Health 
Services 
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Link Worker 
 
 
0.87 
(1.392) 
 
 
£62.61 
(100.201) 
 
 
0.88 
(1.424) 
 
 
£63.00 
(102.513) 
 
 
0 
 
 
£0 
 
 
0.63 
(1.715) 
 
 
£45.00 
(123.459) 
 
Graduate Mental 
Health Worker 
 
 
0 
 
 
£0 
 
 
0.42 
(2.041) 
 
 
£9.38 
(45.928) 
 
0 £0 0 £0 
Counselling 
 
 
0.22 
(0.736) 
 
 
£9.13 
(30.906) 
 
 
0.17 
(0.816) 
 
 
£7.00 
(34.293) 
 
 
0.04 
(0.209) 
 
 
£1.83 
(8.758) 
 
 
0 
 
 
£0 
 
Post Natal National 
Helpline 
 
 
0 
 
£0 
 
0.04 
(0.204) 
 
 
£0.10 
(.480) 
 
0 £0 0 £0 
Psychologist 
 
 
0.04 
(0.209) 
 
 
£3.26 
(15.639) 
 
 
0 
 
 
£0 
 
0 £0 0 £0 
Psychiatrist 
 
 
13 
(0.626) 
 
 
£42.00 
(201.425) 
 
 
0 
 
 
£0 
 
 
0.13 
(0.458) 
 
 
£42.00 
(147.378) 
 
 
0 
 
 
£0 
 
Psychiatrist 
telephone 
consultation 
 
0 £0 0 £0 
.04 
(.209) 
£1.66 
(7.944) 
0 
 
£0 
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Liaison Psychiatry 
 
0 
 
£0 
 
0.08 
(0.408) 
£19.25 
(94.305) 
0 
 
£0 
 
0 
 
£0 
 
Sub-total (2) 
 
 
£117 
(225.73) 
 
£98.73 
(152.19) 
 
£45.49 
(154.20) 
 
£45 
(123.46) 
 
Secondary Care 
NHS Services: 
 
        
Nurse specialist 
 
 
 
0.04 
(0.209) 
 
£.70 (3.336) 
 
0 
 
 
£0 
 
 
0 
 
£0 
 
0 
 
£0 
Community 
Psychiatric Nurse 
 
 
0.17 
(0.491) 
 
£12.17 
(34.372) 
 
0.46 
(1.444) 
 
£32.08 
(101.080) 
 
 
0 
 
 
 
£0 
 
 
0.21 
(0.658) 
 
£15.00 
(47.376) 
Mental Health 
Medication 
prescribed (b) 
 
3.09 (4.833) 
£17.62 
(44.983) 
2.50 (2.207) 
£10.91 
(15.644) 
1.43 (1.950) 
£10.66 
(27.887) 
1.71 (1.876) 
£5.90 
(8.459) 
Total  Medication (a) 
+ (b) 
 
 
£62.32 
(19.15) 
 
£64.27 
(30.08) 
 
£39.18 
(12.62) 
 
£35.47 
(16.74) 
Sub-total (3) 
 
 
£12.87 
(34.28) 
 
£32.08 
(101.08) 
 
£0 
(.000) 
 
£15 
(47.38) 
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Community/Social 
Services: 
 
        
Social Work 
 
.04 
(.209) 
£6.09 
(29.192) 
.17 
(.816) 
£23.33 
(114.310) 
0 £0 0 £0 
Community Alcohol 
Service 
 
0.04 
(0.209) 
£3.91 
(18.766) 
.00 
(.000) 
£0 
(.000) 
0 £0 0 £0 
Employment Advisor 
 
 
0.83 
(2.933) 
 
£15.70 
(55.734) 
 
0.13 
(0.338) 
 
£2.38 
(6.419) 
 
0.26 
(0.752) 
 
£4.96 
(14.284) 
 
0.29 
(1.042) 
 
£5.54 
(19.792) 
Citizens Advice 
Bureau 
 
0.13 
(0.458) 
£1.24 
(4.348) 
0.12 
(0.338) 
£1.19 
(3.209) 
0 
 
£0 
 
0.08 
(0.282) 
£0.79 
(2.682) 
Relate 
 
0 
 
£0 
 
0.50 
(2.449) 
£4.75 
(23.270) 
0 
 
£0 
 
0.17 
(0.816) 
£1.58 
(7.757) 
Legal/Debt Advisor 
 
 
0.09 
(0.417) 
 
£0.83 
(3.962) 
 
0.13 
(0.448) 
 
£1.19 
(4.260) 
 
0 
 
 
£0 
 
 
0.37 
(1.173) 
 
£3.56 
(11.140) 
Benefit/Housing 
Advisor 
 
0.04 
(0.209) 
£0.83 
(3.962) 
0.37 
(1.279) 
£7.13 
(24.301) 
0.09 
(0.288) 
£1.65 
(5.474) 
0.17 
(0.482) 
£3.17 
(9.149) 
Job Centre 
 
0.04 
(0.209) 
£0.83 
(3.962) 
0.54 
(2.449) 
£10.29 
(46.533) 
0.04 
(0.209) 
£0.83 
(3.962) 
0.08 
(0.408) 
£1.58 
(7.757) 
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Sub-total (4) 
 
 
£29.43 
(68.22) 
 
£50.26 
(121.62) 
 
£7.44 
(17.88) 
 
£16.22 
(39.47) 
Total NHS (1+2+3) 
 
 
£958.38 
(1836.62) 
 
£784.80 
(1065.85) 
 
£289.39 
(400.29) 
 
£361.11 
(356) 
Total Mental Health 
(2+3) 
 
 
£129.87 
(226.74) 
 
£130.80 
(175.25) 
 
£45.48 
(154.20) 
 
£60 
(155.54) 
Total Cost of Care 
(1+2+3+4) 
 
£987.80 
(1866.43) 
 
£835.03 
(1113.67) 
 
£296.82 
(400.75) 
 
£377.34 
(374.71) 
Total Cost of Care 
(1+2+3+4) and 
Medication Cost 
(a+b) 
 
1050.12 
(1907.75) 
 
899.31 
(1131.33) 
 
336.01 
(434.48) 
 
412.81 
(380.29) 
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4.6.4 Health State comparison between study arms 
 
Preliminary checks were conducted to ensure there was no violation of 
assumptions of linearity or homogeneity of regression slopes. There was no 
significant interaction between Health state at baseline and allocation 
(P=0.85).  A one-way between groups analysis of covariance with 
participants‟ health state pre-treatment used as the covariate showed a 
significant difference at post-treatment in favour of BA (n=16) over usual 
care (n=22) of 0.24 (95% CI 0.052 to 0.437 P=0.01). 
 
Intention to treat analyses with multiple imputation showed a mean 
difference on post health state scores of 0.20 in favour of BA (95% CI 0.01 
to 0.39, P= 0.04) with all randomised subjects (BA n=23, usual care n=24) 
included in analysis (see Table 25). 
4.6.5 Economic deterministic results 
 
In scenario A, with BA £149.24 more costly than usual care and a health 
state difference of 0.20 generates a cost per QALY earned through BA 
valued at £2985 (0.20/4 = 0.05 QALY gain per year, £149.24 × 20 = 
£2984.8 per full QALY). 
 
In scenario B with BA £174.74 more costly than usual care, the resulting 
ratio is £3495per QALY (0.20/4 = 0.05 QALY gain per full year, 174.74 × 
20 = £3494.80 per full QALY). 
 
A cost per point reduction on the BDI-II earned through BA is calculated at 
£9.45 and £11.04 for scenarios A and B respectively. 
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Table 25: comparison of cost and health state at 3 month follow up 
a 
Using scenario B costs as these represent the most conservative analysis 
b 
Multiple imputation does not report individual mean (SD) scores 
 
  
 
Baseline Mean (SD) Post Mean  (SD) 
Mean difference post (95% CI) P value 
BA 
Usual 
Care 
BA Usual Care 
 
 
 
Costs 
 
 
£1050.12 
(1907.75) 
n=23 
£899.31 
(1131.33) 
n=24 
 
 
 
£608.53(4
34.48)a 
n=23 
 
 
 
 
 
£412.81 (380.29)a 
n=24 
 
 
 
 
 
£174.74 (-£380.34 to £30.82)a 
 
 
 
 
 
 
0.09 
 
 
 
Health 
State 
 
Completer 
 
 
 
0.40 (0.24) 
n=23 
 
0.46 (0.35) 
n=24 
 
0.79 (0.24) 
n=16 
 
0.58 (0.39) 
n=22 
 
0.24 (0.052 to 0.437) 
 
0.01 
 
ITT 
 
 
  
N/Ab 
n=23 
N/Ab 
n=24 
0.20 (0.01 to 0.39) 0.04 
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4.6.6 Exploration of uncertainty of economic evaluation 
 
One 1000 bootstrap replications were conducted for scenarios A and B 
which were mapped on a cost effectiveness plane see (Figure 42 and Figure 
43 respectively). To examine the uncertainty of the results these findings 
were placed upon a cost effectives and acceptability curve. At a threshold 
value of £20,000/QALY there was a 97.7% probability when adopting 
scenario A that BA delivered by generic mental health workers is more 
cost effective than usual care. Adopting the same threshold value there was 
also a 97% probability when adopting scenario B that BA delivered by 
generic mental health workers is more cost effective than usual care. At a 
value of £30,000/QALY the probabilities converged at 98.9% for both 
scenarios (see Figure 44). Results suggest an incremental cost effectiveness 
ratio of £5006 per QALY for scenario A and £5756 per QALY for scenario 
B. Both scenarios indicate  that the additional cost of BA over usual care 
per QALY gained is less than the current UK accepted value of £20,000 
(National Institute for Health and Clinical Excellence 2008).  
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Figure 42: Scenario A Cost effectiveness plane for BA vs. Usual Care 
(reference line indicates threshold value of £20000 per QALY) 
 
 
 
 
 
Figure 43: Scenario B Cost effectiveness plane for BA vs. Usual Care 
(reference line indicates threshold value of £20000 per QALY) 
 
 229 
 
 
 
 
 
Figure 44: Cost Effectivenss and acceptability curve of BA vs. Usual care 
scenario A and B 
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4.7 Discussion 
4.7.1 Main findings 
 
In this study behavioural activation was found to be an effective individual 
therapy for depression compared to usual care when delivered by non-
specialist mental health staff. This approach had significantly greater 
benefits over primary care management in terms of our primary outcome of 
depression symptom and our secondary outcomes of functioning and 
satisfaction. Detailed analysis of reliable and clinically significant change 
and response and recovery criteria also demonstrated significant levels of 
difference in favour of the BA group. Results appeared to reflect effect 
sizes found in our previous meta-analysis in which all studies had used 
therapists trained to the level of clinical psychologist or psychotherapist. 
Such an ad hoc approach to comparing specialist against non-specialist 
delivery of BA is not conclusive; this would require a randomised 
controlled trial. It does however provide a first observation based on data 
observed in practice of the potential benefit that the wider dissemination of 
BA may offer.  
 
This study represents an important addition to the BA evidence base. As 
discussed throughout this thesis repeated publications have made reference 
to the potential BA offers due to its relative simplicity (Jacobson et al. 
1996, Jacobson and Gortner 2000, Martell et al. 2001, Dimidjian et al. 
2006, Kanter et al. 2010). This potential in was explored in the meta-
analysis finding, reported in Chapter 3. No previously published 
randomised study that had scientifically examined this assertion. On this 
basis the findings reported here will be of interest to clinicians and 
researchers as they present new knowledge in this important area. While 
the systematic review illustrated that BA offers clinical benefit (Ekers et al. 
2008) we were not clear if this was the result of the senior therapists 
therapeutic skill and experience or the BA approach (Chapter 3). If it were 
the therapeutic experience and skill of the therapist that explained 
outcomes, this would indicate limited benefit of increasing the capacity of 
effective psychological therapies for depression. Therefore while small this 
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study would appear to be the first randomised controlled trial to test 
directly the feasibility of the parsimony-dissemination assertion put 
forward by Jacobson and colleagues well over a decade ago (Jacobson et 
al. 1996). Results would also appear timely related to evidence emerging 
from the Improving Access to Psychological Therapies (IAPT) initiative in 
the UK where much attention is given to increasing the numbers of people 
treated (Clark et al. 2009). Results also suggest that BA by the non-
specialist may offer an economically viable and rapid alternative to CBT 
which is currently the mainstay intervention of IAPT services for 
depression. These results, which represent the first economic evaluation of 
BA appear very promising and are discussed in more detail later in this 
section. With depression being cited as a primary problem in up to 95% of 
those referred to IAPT (Clark et al. 2009) or 30% by those diagnosed 
within the service (Glover et al. 2010)  a „semi high intensity‟ treatment 
that lends itself to rapid training and is effective would appear attractive. 
Commonly such services experience blocks in the stepped care system at 
access to step 3 (Glover et al. 2010) which is precisely where this BA 
intervention may sit. Training additional CBT therapists takes one year and 
produces therapists on senior clinical bandings. In this context results from 
this study suggesting BA by non specialists may offer both clinical and 
cost effectiveness should be of interest.  
 
Mental health nurses were used in this study as they represent the largest 
mental health workforce that require improved training in psychological 
interventions (Department of Health 2006). If this workforce can be trained 
then the possibilities for dissemination would therefore be substantial. 
Those trained in BA for this study appeared to find the training both 
acceptable and an effective approach to developing their skills. All trainees 
gave an exceptionally positive score on the TARS well above the 70-80% 
normally achieved (Milne et al. 2000). Further dissemination outside of 
mental health nurses specifically may offer additional benefit if results can 
be maintained. Large, adequately powered trials are required to examine 
this area further and to replicate these findings. 
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4.7.2 Clinical outcomes 
 
A large effect size of −1.15 on depression symptom level post-treatment 
favouring BA against usual care using intention to treat analysis was found. 
This compares favourably to an overall effect size of −0.70 of  twelve 
studies (459 participants) comparing BA to controls using experienced 
therapists in our previously reported meta-analysis (Ekers et al. 2008). The 
difference between BA and usual care at post-treatment of between 15 and 
16 points on a BDI-II measure is clearly clinically important. It reflects the 
difference between a minimal depression level score of 13 and below and a 
severe depression level score of 29 and above. The findings also compare 
favourably with a review of three studies with 208 participants where CBT 
has been compared to usual primary care where minimal difference was 
identified (National Institute of Clinical Excellence 2009).  This research 
may add to the evidence available to NICE when their depression guidance 
is further reviewed. Currently NICE identified no cost effectiveness 
evaluation for BA which they reported as a weakness of its evidence base. 
They recommended BA for mild to moderate depression with 16 to 20 
sessions over three to four months. This research adds to knowledge as if 
now provides the first cost utility analysis of BA with less sessions than 
previously recommended in a severely depressed sample. The research 
recommendations of the NICE depression guideline also indicate BA 
should be directly compared to CBT. This research would support the 
design of such a study if researchers were to look at non-specialists 
delivering the BA intervention.  
The various clinical significance criteria used in this study further 
strengthen the results. Differences between the groups were significant or 
close to significance for all comparisons using reliable and clinically 
significant change criteria (Jacobson and Truax 1991). These stringent 
approaches to data analysis provide further insight into the clinical 
meaning of the results. They use normative data from scales to inform the 
degree to which participants move from a clinical to a non-clinical group 
and the number whose changes during therapy are considered clinically 
meaningful. The results found in this study compare favourably with other 
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major studies of BA that achieve remission rates of around 50% (Jacobson 
et al. 1996) although they are below the exceptional and unusually high 
findings of one important trial (Dimidjian et al. 2006).   
 
Overall clinical findings in this study appear very positive and lend weight 
to the promise that BA may offer as a simple and effective psychological 
treatment. There are a number of limitations to the trial outlined later in 
this discussion section but as an initial exploration of the feasibility of non 
specialist delivery of BA this study has provided encouraging clinical 
results. 
4.7.3 Functioning 
 
Similar findings in functioning were observed to those found in depression 
symptom level; whilst both groups improved, in BA improvement was 
substantial whilst in usual care it was marginal. BA participants on average 
achieved a 15 point drop on the WASA scale compared to a 2 point drop 
for usual care. Both groups scored above 20 on this measure pre treatment. 
This score range reflects severe symptoms and functional impairment 
(Munt et al. 2002). While usual care remained in that category the BA 
group reduced to a mean WASA score of 11.12. This is slightly above the 
subclinical cut off point of 10 identified for this measure (Munt et al. 
2002). It would appear from these findings that BA delivered by non-
specialists also improves functioning alongside depression severity.  
The study  findings would support the view that BA may lend itself to 
improvement of functioning as this is a direct intervention target aimed at 
the reintroduction of positively rewarding environmental contingencies 
(Kanter et al. 2010). BA focuses specifically on the „outside in‟ approach 
of activating and accessing positive reinforcement which as a result 
increases functional behaviour. Those participants undertaking BA would 
be encouraged to reintroduce, or to develop new, behaviours that are 
personally viewed as meaningful and valued despite internal feelings. New 
behaviours are then paired with positive reinforcement and hence occur 
with increased frequency. In contrast, other standard treatments seek to 
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change internal deficits or to change internal feelings prior to functional 
change. This approach of seeking internal improvement prior to activity 
reflects the pattern of „I will do it when I feel better‟ is often seen in people 
with depression (Martell et al. 2001).  It may be that as BA is directly 
targeting the problems measured on the WASA as a component of the 
intervention this to some degree accounts for the large improvement in 
functioning in the BA group compared to usual care. It is of note that 
functioning improvement is consistent with symptom level findings, it 
would appear BA is not simply getting people more active whilst feeling as 
depressed. This supports the theoretical assumption that depression is 
unlikely to be paired with a high level of contextual positive reinforcement 
(Kanter et al. 2010). It was beyond the scope of this small study to test 
further the interpretation of these findings. Future researchers may be able 
to consider this rationale for BA‟s effectiveness in more detail with larger 
sample sizes. Following the MRC complex intervention guidance the 
feasibility and piloting in this research has identified this as a potential area 
of interest. With the introduction of relevant process measurements and 
qualitative analysis larger studies could explore this area further.  
4.7.4 Satisfaction 
 
Satisfaction with BA appeared extremely good with a mean of score of 29 
out of a possible 32. This is significantly better than usual care which 
received a reasonably positive evaluation score of 24. Across six United 
States based studies with 7838 participants using the CSQ8 the mean 
satisfaction level was 27.17 (Attkisson and Greenfield 2004). In the UK  
the CSQ 8 has been used in trials of both face-to-face and telephone based 
CBT with scores of 29 reported as indicative of very high satisfaction 
(Lovell et al. 2006).  Patients are able to distinguish between clinical 
benefit and satisfaction (Larsen et al. 1979) so it would appear from our 
results that BA may offer both a satisfactory and effective intervention.  
It is of note however that only those completing post-treatment evaluation 
completed the CSQ8 forms in this study. We were unable to use any 
method of imputation as no previous scores were collected to inform 
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calculations. No measure of satisfaction was made at baseline or at one and 
two month data collection points. This weakens our results in this area and 
future research should consider taking satisfaction measures throughout 
treatment at key stages to allow for ITT analysis in the event of dropout.  
4.7.5 Cost utility analysis 
 
Clinical effectiveness is necessary but not sufficient for policy makers who 
need to be sure that innovative treatments represent good value for money.  
To my knowledge this is the first study to examine cost effectiveness of 
BA and in particular this innovative approach to its delivery. Mental health 
economic analysis should be conducted to allow consideration within a 
general decision making context (Bosmans et al. 2008, Barton et al. 2009).  
NICE suggests that a QALY gain valued below £20,000 provides good 
value for money across the health care spectrum (National Institute for 
Health and Clinical Excellence 2008). It was in this context the economic 
evaluation of BA delivered by non-specialists was conducted using generic 
health outcome measures as recommended (Barton et al. 2009, Sapin et al. 
2004, Bosmans et al. 2008). BA delivered QALY gains significantly below 
accepted threshold values using the EQ5D generic health state 
measurement tool. Changes in health state were consistent with clinical, 
functioning and satisfaction benefits. The results indicate BA may offer 
lower cost per QALY or point reduction on the BDI-II than brief problem 
solving (Kendrick et al. 2006) or online CBT (Hollinghurst et al. 2010, 
McCrone et al. 2004), interventions also aimed at increasing accessibility. 
Both the baseline severity of the participants in this study and the lower 
grade staff used for treatment may have contributed to the strong indication 
of cost effectiveness we found when benchmarked against other trials.  
 
These gains were calculated using a short follow-up period of three 
months. At this point we identified a QALY difference of 0.20. In order not 
to overestimate the benefit of the intervention this difference was divided 
by four to provide a quarter of the QALY gain, a value of 0.05 and based 
our calculations on this figure. This approach was sufficient to demonstrate 
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QALY gains at a cost which falls below the threshold values set out by 
NICE. It makes no assumptions about what might happen to the health 
status of patients beyond the three month follow-up period. Previous 
studies have found BA to provide lasting benefit (Dobson et al. 2008, 
Gortner et al. 1998) with between 60% to 70% of those who show 
improvement maintaining gains a year following treatment. A similar 
pattern would be expected to emerge in this study however the analysis 
was restricted to observed results at 3 months building in no assumptions 
regarding any difference between groups following this point. If BA when 
delivered by non-specialists does provide any lasting benefit beyond the 
completion of therapy this would increase the QALY gain we used beyond 
0.05 and subsequently reduce the cost per QALY found.  
The economic findings were also modelled using a senior grade of 
therapist, Agenda For Change band 8c, to train and supervise workers and 
assumed all sessions were attended. This again reflects a conservative 
baseline from which further studies can design their economic models. 
Considerably less expensive staff are commonly used in the NHS to deliver 
training and supervise psychological treatments and not all patients needed 
all treatment sessions. If built into calculations the cost of a course of BA 
would have dropped, again reducing the cost assigned to a QALY gain. 
Costs were not based on actual number of sessions attended to prevent an 
underestimation of costs given the small sample size. The small numbers 
was likely to result in the study being underpowered to estimate attendance 
rates. Future studies with more participants may supply more clarity on the 
number of required sessions for optimal benefit and may provide greater 
precision on the true cost effectiveness of BA compared to usual care. 
4.7.6 Recruitment issues 
 
Recruitment rates to the study were well below those anticipated in 
planning. Despite developing communication links and regularly updating 
practices and primary care mental health teams on recruitment progress the 
rate of referral to the study was low. Monthly updates were sent to specific 
contacts within practices with their individual referral rate benchmarked 
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against the overall rate. This approach was unsuccessful in increasing 
recruitment rates even when supported by personalised email 
communication. The study was rolled out to additional general practice 
sites to compensate for this poor response. While the number of 
participants required as per our power calculations was achieved (23 in 
each arm) it would have been beneficial to have recruited to the target set 
in initial planning of 70 participants (35 in each arm). This would have 
allowed analysis of completers to have been above the 23 required in each 
arm.  
Explanations for these difficulties in recruitment are unclear. General 
practice clearly has many patients experiencing depression who would 
have been suitable for this study. The study offered a structured 
psychotherapy with a waiting time, even in the control arm, well below the 
local service average.  It is possible that the experience of referring 
participants who did not meet the study inclusion criteria was an aversive 
experience for their general practitioner. As this was the most common 
cause for potential participants being excluded, 13 out of 41 referrals 
(31%), this may have reduced their desire to pass subsequent suitable 
participants to the trial. While this is difficult to confirm it may have added 
to the existing problems encountered in encouraging general practitioners 
to refer to research (Mason et al. 2007). The exclusion rates were not 
particularly high when compared with the 40-45% exclusion found in other 
studies of primary care depression in the UK (Richards et al. 2008, 
McCrone et al. 2004) or the 32% found in  previous BA for depression 
studies (Dimidjian et al. 2006). Unlike those studies however the study was 
reliant solely on the behaviours of others such as GPs and mental health 
staff to refer to the trial. As this study did not have external funding it 
could not access the resource of clinical trial officers from research 
networks to support recruitment process. Therefore recruitment in this 
study was solely reliant on the behaviour of referrers which is known to be 
unreliable (Hunt et al. 2001, Mason et al. 2007). 
 
It is clear that future studies may require of a modified recruitment 
procedure in order to be successful. The use of patient electronic records 
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can be used to identify suitable participants through repeated in practice 
searches based upon depression coding. Potential participants can then be 
contacted by practice staff via letter and asked if they are willing to be 
contacted by the research team. This would allow study information sheets 
and consent forms to be forwarded directly to the participant and not be 
considered overly intrusive. Those that do not respond could be reminded 
by telephone as this has been seen to improve recruitment rates (Watson 
and Torgerson 2006). This approach has the benefit of removing variance 
in referral practice and hence would minimise the risk of selection bias and 
improve external validity. Such approaches have been used in trials and 
have improved recruitment rates (Richards et al. 2006); they would 
minimise the impact of  the behaviour of those referring on study 
recruitment or validity.  Externally funded trials would also have access to 
clinical study officers to monitor the process closely and to perform 
searches, which was outside the scope of this small unfunded trial.       
4.7.7 Participants 
 
Participants in this study had high baseline depression and functional 
impairment, scoring 35 on the BDI-II and 25 on the WASA. This score 
represents severe depression with high levels of disability equal to or 
greater than those studies included in the meta-analysis outlined in Chapter 
Three. The main diagnosis in allocated to those in the study by the CSIR 
was moderate or severe depression and these problems were of long 
duration, on average 3.5 years. The study therefore offered treatment to a 
cohort of participants with a higher proportion of severe problems and with 
longer mean duration of symptoms than those commonly seen in primary 
care therapy settings (Clark et al. 2009).  One of the criticisms of 
randomised controlled trials is that the populations treated often do not 
reflect clinical reality. This study would appear to go some way towards 
that in the group treated which contributes to the external validity of 
findings.  
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4.7.8 Randomisation and allocation concealment 
 
As outlined in the methods section of this chapter randomisation and in 
particular allocation concealment are fundamental aspects of trial quality 
(Altman and Bland 1999b). Owing to financial constraints, this study was 
unable to use a completely independent clinical trials unit to perform this 
task. Such services are ideal as they hold randomisation lists and 
automatically notify therapists GPs and trial coordinators of allocation. I 
was not able to use such services due to the costs associated and the 
unfunded nature of the study. It would have posed a problem of internal 
validity in the study, with the potential for selection bias, if the 
randomisation had been conducted or able to be influenced by those 
involved with the study. The approach of having a computer-generated 
stratified allocation sequence generated independently, as per 
recommended methods (Altman and Bland 1999a), and held by a medical 
secretary independent of the study team was a balanced compromise that 
maintained quality and allocation concealment. At no point in the study 
was the list able to be seen by those involved as it was held in an envelope 
in a locked location and viewed only by the secretary when asked for a 
participant allocation. 
The randomisation would appear to have been successful as the groups 
appeared equal in terms of age, severity, duration of symptoms and 
antidepressant use.     
 4.7.9 Therapist effects 
 
Therapists used in this study were representative of the vast pool of generic 
mental health workers in that they had no previous therapy training, were 
relatively recently qualified and were employed at the base level of 
registered psychiatric nurses. Two therapists were used and a consistent 
approach to BA was ensured by developing a structured 12-session 
protocol, assessing competence post training and providing fortnightly 
supervision. It is of interest that while overall measures on the BACS 
indicated a reasonable level of competence in the delivery of BA there was 
clear variation between therapists. These observations are reflected in 
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individual outcome scores on the BDI-II observed at post-treatment. So 
while it would appear based upon independent evaluation with very little 
training it is possible overall to equip staff with the skills to deliver BA 
effectively, there may be some variation to how this is delivered in practise 
between each therapist. This is not a new finding: in an early study 
comparing BA with CT there was clear variation between therapists scores 
on an established CT rating scale (Jacobson and Gortner 2000). Agreement 
on therapist competence level is hard to establish even when reviewed by 
those experienced in using the tool. In this study a competency scale was 
used that is new and unfamiliar and not currently supported by peer 
reviewed validation publications.  
There are several major risks in interpretation of these findings. This 
examination is a post-hoc analysis. The study was not powered to detect 
difference on the BACS nor any between-therapist variations. It is very 
likely that this would require a much larger trial and more background 
information on which to base any such calculations. Participants were not 
randomised between therapists, and in such a small trial we cannot with 
any confidence assume that confounding variables are equally distributed 
between the groups treated by different therapists. It is possible that 
therapist 2 received by chance a more challenging and treatment-resistant 
group of participants who were less amenable to such a structured BA 
protocol. This may have resulted in the inferior clinical outcome and ability 
to apply BA techniques in structured manner found with therapist 2. 
Therefore while it is important to observe the variation in therapist 
competence and outcome mindfully it cannot  be  considered  definitive. 
The debate between therapist and intervention effect in RCTs is 
longstanding (Wampold et al. 1997) and beyond the scope of this study to 
resolve.  
 
In general I have found BA to be amenable to dissemination in this study 
albeit with signs that there may be variation in competency and outcome 
between therapists requiring further examination in a larger study. 
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4.7.10 Study limitations 
 
This was an exploratory study and there are a number of limitations of 
note.  
 
Firstly the relatively small numbers of participants and therapists recruited 
limits the generalisability of our results. Sample numbers were based on 
power calculations from the meta-analysis, see Chapter 3,  suggesting a 
sample size of 23 in each arm was sufficient to detect previously observed 
effect sizes. Despite this, it would have been beneficial to have recruited 
more participants to allow for our completers analysis to reflect these 
numbers rather than our intention to treat analysis. The small sample sizes 
may account for the wide confidence intervals found on post-treatment 
measures. Due to the lack of previous economic analyses of BA, no power 
calculation was conducted for this cost effectiveness analysis. Power 
calculations for economic analysis within clinical trials are rare and usually 
based upon costs and effects separately. If results are directed at cost 
effectiveness then power calculations should be focussed on this directly 
(Briggs et al. 2002). The use of sensitivity analysis exploring uncertainty 
using CEAC goes some way to moderating this shortfall. BA was found to 
have a 97% probability of offering a cost effective intervention at currently 
accepted thresholds based upon 1000 bootstrap replications. This is a 
strong finding using conservative assumptions from our data (no 
assumption of benefit maintenance post three months and use of expensive 
staff to train and supervise). Improving recruitment and increasing sample 
sizes would have allowed more confidence in findings. I have now 
established baseline data from which future studies can conduct cost 
effectiveness power calculations based upon recommended approaches 
(Briggs et al. 2002). 
 
More people dropped out in BA than in usual care. This in itself is not 
surprising, as BA is an active intervention relying on the person receiving 
treatment to complete homework on a regular basis. Of those discontinuing 
treatment, three did so in the first month and three in the second. The 
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dropout rate in this study (of approximately 30%) is similar to those seen in 
large data sets of CBT provision in primary care (Clark et al. 2009), so 
viewed in this context our dropout rate for BA is not unusual. Usual care in 
contrast does not involve as much investment from the participant and is 
“nested” within a person‟s overall health care thereby reducing the 
likelihood of dropout. Larger sample sizes would have allowed a more 
precise estimate of this finding, as it is likely this limited sample was 
underpowered to accurately estimate dropout rates from BA delivered by 
this workforce. It is possible that BA was considered an aversive treatment 
by those that dropped out of therapy. This would be in marked contrast to 
the strong satisfaction found in those with post-treatment measures.  Future 
large scale studies would be better placed to explore this finding further 
and allow more precise estimates of likely dropout from BA. This is an 
important consideration as high dropout rate markedly influences a 
treatment‟s overall clinical effectiveness. 
  
The lack of follow-up is also a limiting factor in the interpretation of the 
study. This was due to the limitations of the study in terms of funding and 
available time scales. Previous studies of BA have demonstrated its 
durability to be equal to that of other therapies such as CBT (Dobson et al. 
2008, Gortner et al. 1998); however such studies have been delivered by 
experienced therapists. The aim of this study was to explore the feasibility 
of dissemination of BA; while we found results supporting this I was 
unable to conduct follow up assessments due to my financial and time 
constraints. The results showed comparable gains at post-treatment to those 
of previous BA studies. As those studies demonstrated prolonged 
improvement comparable to that of CBT, it is reasonable to assume that 
benefits in this study are likely to follow a similar maintenance pattern. 
This however has not been monitored and as such requires future testing. It 
is possible that improvement was due to the „Hawthorne Effect‟ , showing 
response due to being the subject of a study rather than the intervention 
being studied (McCarney et al. 2008). The Hawthorne effect first identified 
when methods of increasing productivity were examined in the Western 
Electrical Company‟s Hawthorne depot in Chicago in the 1920s and 1930s. 
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They observed that no matter what method of increasing productivity was 
used results increased, indicating that it was being the focus of such 
methods rather than the methods themselves that caused change (Mayo 
1993). Whilst the increased focus on participants in the current study was 
equal in terms of researcher attention the Hawthorne Effect should have 
been equally distributed in both groups. It may have resulted in an over-
inflation of the effect size, both groups showing more improvement than 
would be anticipated in usual care. While it is difficult to control for this in 
trials the short follow-up may not have provided sufficient time for these 
effects to settle, i.e. subjects to become habituated to the stimulus of being 
studied.  The impact of the Hawthorne effect may have been moderated in 
longer term follow-up; this requires consideration in the interpretation of 
our results and consideration in the design of further study. It is of note, 
however, that this study showed comparable differences to other studies 
(see Figure 41) and a number of those studies used longer follow up 
demonstrating continued improvement where one would have expected the 
of treatment to be reduced if the Hawthorne effect had been operating. It is 
not possible to be sure if and how much the Hawthorne Effect may have 
influenced our results however the potential impact should be considered.  
 
The lack of follow-up also limits the long term assessment of QALY gains 
and associated costs. While it is clear that treatment costs in BA would be 
front loaded in the first three months it is difficult to assess the differential 
effects on costs and health state of relapse from our methods. In the cost 
utility analysis the use of a six month retrospective cost measurement at 
baseline used as a covariate in our calculation of service use costs over the 
study duration helped redress this issue. Also only the proportion of QALY 
gained during the three months was used within our calculations, with no 
modelling of maintenance.  An ideal follow-up period of 18 months to 2 
years would allow for this limitation to be accounted for in future research. 
This would then pose ethical considerations for a study adopting usual care 
as the comparator. If BA offers clear clinical benefit at three months over 
usual care, following up as randomised would exclude those in the usual 
care arm from such benefit. While the durability of BA delivered by non-
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specialist is an important consideration this may require exploration in a 
study with an alternative therapeutic intervention.  
 
A self-report measure was used in the analysis of depression symptom 
level post intervention. This is a source of potential information bias as in 
psychological therapy trials participants will be aware of their treatment 
allocation and hence not blind to allocation. This may lead to an over 
reporting of benefit in those participants receiving the intervention under 
investigation. It is again difficult to assess the degree of impact, if any, that 
this limitation places on our results. The  BDI-II (Beck et al. 1996) was 
used as the primary outcome for several reasons. Firstly it is a well 
validated measure and fell within the financial and manpower limitations 
of the trial. It was felt that as it had been used very regularly in previous 
trials it was an acceptable solution to not having grant funding to support 
more detailed and costly assessor-rated depression outcomes. I also noted 
that in previous studies identified in the meta-analysis (Ekers et al. 2008) 
the BDI was the most commonly used measure, used in 16 of the 17 studies 
analysed. The alternative assessor-rated measure was the Hamilton Rating 
Scale for Depression (Hamilton 1960).  This was used on its own in only 
one study. Both measures were used in 11 studies and showed minimal 
difference in outcome between the tools. Sensitivity analysis was used to 
explore potential impact using our meta-analysis data which suggested that 
using an assessor rated measure would have minimal impact on the results 
(BA vs. Control prioritising BDI  SMD −0.70 CI −1.00 to −0.39 vs. 
prioritising HRSD SMD −0.68 CI −0.98 to – 0.38). It is unclear the degree 
to which this limitation may have influenced findings, but on balance the 
approach adopted appears justified, as  a commonly applied scientifically 
tested set of measures was used. The inclusion of the CSIR at end-point 
may have gone some way to moderating this possible limitation also; 
however this tool is generally used as a diagnostic tool to confirm 
eligibility, and as such serves its purpose at assessment. Repeating the 
CSIR at end-point may have been useful, but it is debatable whether it 
would have provided any additional scientific rigor over a well validated 
self rated measure of depression such as the BDI-II. While minimising the 
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number of measures used is advised, as it decreases the chance of a Type 1 
error of finding a difference when it is not there the use of both self-rated 
clinician and blind assessor measures should be given due consideration in 
future research. 
 
Another issue was the choice of the QALY approach for cost utility 
analysis. Some previous studies in depression have used the cost of a 
„depression free day‟ based upon depression symptom scores (Katon et al. 
2005, McCrone et al. 2004). However, no accepted cost threshold value for 
„depression free day‟ is available, whereas we have an accepted tariff for a 
QALY (National Institute for Health and Clinical Excellence 2008). While 
the cost per QALY approach may limit direct comparison with such studies 
I chose, in discussion with the trial steering group, the more conventional 
approach that allows BA to be contrasted with other interventions across 
the health services spectrum, as this is increasingly recommended for 
mental health economic research (Barton et al. 2009, Bosmans et al. 2008). 
A basic analysis of cost per point change on the BDI-II was included to 
allow comparison alongside other research that had used that approach.  
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4.8 Review of study design and reporting  
 
This study examined the impact of BA by non-specialists compared to 
usual primary care. The accepted method for such comparisons is the 
randomised controlled trial; however this methodology is subject to several 
forms of bias, as outlined in the methods section of this chapter, if not 
conducted and reported appropriately. The accepted benchmarks to review 
this methodology are included in the CONSORT statement (Schulz et al. 
2010). The trial will be reviewed against these standards below. 
CONSORT item 1: title and abstract 
 
Items 1a and 1b indicate the title should clearly report the study as an RCT 
with a structured abstract. The study is clearly identified as a randomised 
controlled trial with the second item being included as an abstract of the 
whole research process at the start of the thesis. 
CONSORT item 2: background and objectives 
 
Items 2a and 2b indicate a scientific background and rationale for the study 
should be included and clear objectives should be set. These criteria have 
been met as the study was based upon a meta-analysis and the need for 
investigation has been highlighted. Objectives for the study have been 
outlined and reviewed in the conclusion section.  
CONSORT item : reporting of methods (CONSORT item number 
included in brackets) 
 
 Trial design: the trial is described as a parallel design in methods 
section (3a). It is also recommended that any changes in methods 
after trial commencement are reported (3b). This is not relevant to 
this study, as no changes were made. 
 Participants:- eligibility criteria are clearly reported and justified 
in the methods section (4a), and the method of data collection from 
participants described (4b). 
 Interventions: interventions are clearly described in methods 
section with details of staff group used, training approach and 
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manual provided. This would allow for adequate replication as 
recommended (5). 
 Outcomes: outcome measures used are clearly outlined with 
justification for use in the methods section (6a). There were no 
changes to these so no requirement was needed to report variation 
(6b). 
 Sample size: sample size was justified in the methods section (7a) 
with details of calculations based upon our meta-analysis results. 
No interim analysis or stopping guidelines were used, so were not 
reported (7b).  
 Randomisation: the methods used to create the randomisation 
sequence are clearly reported (8a) and the rationale and approach to 
stratification and use of blocked randomisation reported (8b). The 
method of allocation concealment is explained in detail, with the 
computer program referenced (9) and the implementation of this 
outlined in terms of who generated the sequence, who enrolled and 
who allocated (10). 
 Blinding: the approach to blinding is clearly reported in the 
methods section alongside the challenges this poses in 
psychotherapy trials (11a). The interventions were clearly different, 
and descriptions of both have been reported in methods. There was 
no attempt to blind participants to interventions as in pill placebo 
trials as this is clearly not feasible, hence reporting similarity of 
interventions was not relevant (11b). 
 Statistical analyses: these are clearly outlined in methods with 
approaches to missing data outlined a priori (12a and 12b). 
CONSORT item: reporting of results  (CONSORT item number 
included in brackets) 
 
 Participant flow: the numbers of participants assessed, excluded, 
included, randomised, received treatment and were assessed or lost 
to follow-up at post-treatment was clearly reported including a 
diagram as recommended (13a and 13b). Recruitment study dates 
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are reported, as is trial duration (14a); the trial ran its duration, so 
reporting reasons for stopping (14b) was not relevant.   
 Baseline data: a table is included as recommended (15). 
 Numbers analysed: is clearly reported in text and tables in results 
section as recommended (16). 
 Outcomes and estimation: each outcome is reported with both SD 
and 95% confidence intervals as recommended (17a). Binary 
outcomes of recovery and clinical significant improvements are 
reported as odds ratios with 95% CI as recommended (17b). 
 Ancillary analysis: adjusted analysis (such as ITT) is clearly 
indicated at all stages, as is reporting of subgroup and exploratory 
analysis in the text when these were not pre-specified (such as 
results by therapist) (18). 
 Harms: no harm or unexpected events in the study were identified 
and as such these are not reported (19). 
CONSORT item: discussion of findings (CONSORT item number 
included in brackets)  
 
 Limitations: a section is included in the discussion outlining 
potential limitations of the study in terms of participants, follow-up, 
measures making reference to impact of potential precision (wide 
confidence intervals due possible to low numbers) and bias (issues 
of blinding and use of self-report measurement). This is as 
recommended (20). 
 Generalisability: issues and limitations to generalisability are 
considered in the discussion under participants and therapist 
sections and in terms of approach to cost utility analysis. Issues are 
also addressed in relation to number of participants in study 
limitation section (21). 
 Interpretation: interpretation of the results are balanced against 
limitations with findings benchmarked against other studies 
exploring BA to give context (22). 
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CONSORT item other information: (CONSORT item number 
included in brackets) 
 
 Registration and protocol: the trial was registered with the  
International Standard Randomised Controlled Trials Registry, 
number ISRCTN27045243 where the protocol is available (23, 24). 
 Funding:- funding sources and role of funders are important to 
report, as this study received no external funding this was not a 
focus. The support of Tees, Esk and Wear Valleys NHS Foundation 
Trust in funding the therapists was outlined (25). 
Summary of trial against CONSORT standards    
 
It can be seen from the above that while this was a small unfunded study it 
has been conducted and reported in line with the current recommended 
standards for randomised controlled investigations. 
4.9 Conclusion, clinical implications and future 
research 
 
The questions for this study were: 
 
1. What is the impact on depression symptom level, functioning and 
treatment satisfaction of BA delivered by non-specialist mental 
health workers to depressed adults compared to usual primary care 
management? 
 
2. What is the estimate of cost utility of BA delivered by generic 
mental health workers to depressed adults? 
 
This study is the first randomised controlled clinical trial to test feasibility 
of dissemination of BA to a wider mental health workforce than 
psychologists and psychotherapists and as such represents a major step 
forward in our understanding of the intervention. In answer to the first 
question I have demonstrated that with limited training, non-specialist 
mental health nurses can be trained to deliver clinically effective BA to 
people with severe long standing depression. In answer to the second 
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question results demonstrated an incremental cost ratio of between £5-
6,000 per QALY with 97% probability that this would fall below the 
currently recommended thresholds.  
 
If these findings can be replicated and translated into routine health care, 
then clinical and cost implications are substantial. Depression is a disabling 
condition of high prevalence (World Health Organization 2004) and 
finding and testing potentially effective new treatments should be 
considered a priority (Hollon et al. 2002a). Now such feasibility has been 
shown, future research with a larger sample and multiple therapists should 
investigate the longer-term durability of this approach. This would build on 
the limitations identified in this study. Comparison of this BA delivery 
mode against an active psychological treatment such as CBT would 
provide an ideal comparator. This would allow longer term follow-up and 
provide meaningful clinical and cost effectiveness results against the 
current gold standard psychological intervention for depression. Such 
findings could inform future decision making regarding service design for 
depression.  
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Chapter 5: Summary, dissemination and link to 
future research 
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Summary of thesis 
 
This research has followed a process recommended for the examination of 
complex interventions outlined in the introduction. The research has 
followed the development phase by identifying an area of need and scoping 
the evidence base. The demands for accessible psychological therapies for 
depression were highlighted in Chapter One. The theoretical basis of BA 
was examined in Chapter Two and its potential parsimony highlighted it as 
a single strand approach that possibly made it a suitable to explore in 
relation to needs outlined in Chapter One. In Chapter Three the available 
evidence base was scoped via a systematic review of all randomised trials 
in which BA has been used to treat depression. From this it became clear 
that while BA appeared effective and as effective as the current gold 
standard psychological treatment for depression, no research had 
adequately explored the dissemination of the approach. This was clearly an 
area of need highlighted in preparatory work outlined in Chapters One and 
Two of the thesis.  
 
As the development phase found no relevant studies that had adapted 
accepted BA approaches for use by non specialists, the research moved to 
the feasibility and piloting phase in the MRC cycle. In this phase the theory 
of BA was matched with information from the meta-analysis to create a 
short-term 12-session protocol that had potential to be delivered by non-
specialists. This approach had no previous trial evidence, so required 
feasibility testing in order to develop the intervention, to estimate effect 
size and ascertain potential recruitment and delivery issues. The trial 
outlined in Chapter Four was conducted over one year and measured 
clinical and cost outcomes, providing information that can now be used to 
design larger definitive trials beyond the scope of this thesis.  
 
By following this process the research outlined in this thesis has 
contributed both to a body of evidence and created a platform for future 
studies. It has explored the idea that the parsimony of BA makes it suitable 
for delivery by non-specialists. This was a surprising gap in the research 
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literature, as the first presumption of such an idea in relation to BA had 
been written a decade before we embarked on our meta-analysis. The study 
had limitations due to the sample size and duration. It was however able to 
provide a clear indication that BA may be an intervention that is relatively 
simple and suitable for dissemination. As highlighted in the trial results and 
discussion sections, there was some indication that variation in therapist 
effect requires further examination. Larger studies should include more 
therapists and the detailed examination of therapist effect should be clearly 
defined in future studies methods. As dissemination is a central factor in 
the advantage BA may offer variation between therapists is clearly an 
important factor. The post hoc methods viewed in this study require 
cautious interpretation but they do shed light on the need for further 
research.  The BA used in this study reflected a comprehensive model and 
there has been some discussion in literature as to the effective elements in 
BA which may indicate a simpler approach may be as effective (Kanter et 
al. 2010). The findings at one and two months in both the BDI-II and 
WASA demonstrated gradual improvement throughout the duration of the 
intervention. It was therefore unclear if any particular aspect of the 
intervention provides the benefit. Simplified models do exist (Lejuez et al. 
2011) that include a less complex BA model. Future research may benefit 
from exploring to what degree simplicity provides improved consistency in 
dissemination whist maintaining treatment benefit. The inclusion of a 
qualitative analysis would also benefit future research. Qualitative 
interviews may offer insight into how BA is perceived by those receiving 
the intervention and themes relating to key aspects of therapist and 
intervention effect. No well conducted qualitative examination of BA was 
found in the development or analysis of this thesis. This represents it is a 
clear gap in the evidence and therefore knowledge of BA that should be 
addressed in future research design.  The study is also the first to estimate 
the potential cost utility of the BA approach. Again a surprising finding in 
the review was that the cost effectiveness had not been investigated for BA. 
Initial results are promising and future study should build on these with 
larger sample sizes and longer term follow-up. It would also be of benefit 
to examine the cost effectiveness of BA delivered by non-specialists 
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against CBT, the current gold standard psychological treatment for 
depression. This would provide meaningful data for the design of clinical 
services aimed at improving access to effective depression treatment. 
 
While this study is limited by lack of follow-up and size, which is 
understandable of any unfunded research programme embarked on as a 
PhD, it has however made a meaningful contribution to the evidence 
providing new knowledge.  It has resulted in wide dissemination both by 
conference presentation and publications in peer-reviewed journals which 
have been widely cited. The research has formed the basis of a large multi-
centre trial funding application to the National Institute of Health Research 
(NIHR) under the Health Technology Appraisal (HTA) funding stream. 
The study Cost and Outcome of Behavioural Activation (COBRA) is 
currently in the second phase of the review process. This research formed 
the basis of the grant application informing the design of the research (see 
appendix III for relevant section of that protocol).  
 
This research suggests that BA may be an intervention that is important for 
clinicians and policy makers alike. The research highlighted in this thesis 
indicates BA may provide a clinically and cost effective psychological 
intervention for depression that can be widely disseminated. If larger trials 
are able to build on the results outlined here it is anticipated BA will 
become a standard treatment for depression used commonly across health 
care settings. Research outlined in this thesis will have made a significant 
contribution to such developments and hence have provided a meaningful 
and important addition to the evidence base for psychological treatment of 
depression.    
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Appendix I: Systematic review and meta-analysis of 
behavioural therapies for depression: additional 
materials   
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Search Reports 
 
 
14 February 2006 
 
 
To :  David Ekers 
 
 
Search Report 
 
Topic 
Comparison of Behavioral Treatments for depression with treatment as 
usual, placebo or other brief psychotherapy 
 
Date requested 
5 October 2005 
 
Date completed 
 8 February 2006 
 
Databases searched (all via Dialog DataStar except Cochrane) 
 Medline  1951 to date 
 Embase  1974 to date 
 Cinahl     1982 to date 
 PsycInfo  1806 to date 
 BNI  1994 to date 
 AMED  1985 to date 
 Cochrane Library Issue 2006-1 
 
Limits 
Adult or adolescent populations from age 16 upwards 
Randomised Controlled Trials 
 
Results 
 Results in ASCII tagged format (for import to EndNote) were 
emailed to david.ekers@blueyonder.co.uk and to your Trust email. 
You requested both Short format results for 
initial scan, and Medium format results to 
provide abstracts. 
 Search histories were provided for each database. For completeness, 
I include them in this report. The histories show numbers of results 
provided for each database.  
 Duplicates across databases were not removed.  
 
Issues 
 Search methodology was geared to a highly sensitive search. 
Guidance from the CRD was used in order to retrieve all RCTs.  
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 Full use was made of descriptors and other special options, as well as 
free text searching.  
 
Conclusion 
 
Comprehensive searches have been conducted in 7 databases. 
Please let me know if you discover any missed references or gaps in the 
search strategies.  
 
 
Janet Menton 
CDDPS Library Services Training Coordinator 
0191 333 3465 
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Allied & Complementary Medicine - 1985 to date (AMED)    (9 Nov 
05) 
 
 
Search history – Bold indicates results taken from this set 
 
No. Search term Results 
1 depression.ti. or depressive$1.ti. 1105 
2 depressive-disorders.de. 739 
3 dysthym$ 18 
4 1 or 2 or 3 1365 
5 behavio$ adj therapy 1044 
6 behavior-therapy.de. 853 
7 
treatment$1 or intervention$1 or therap$7 or activat$5 or psychotherap$9 or psycholog$7 or 
psychosocial$3 
88365 
8 behavi$7 with 7 2383 
9 positive adj reinforce$ or (event$1 or activ$6) near schedul$3 54 
10 9 same 7 31 
11 10 or 8 or 6 or 5 2402 
12 11 and 4 77 
13 (children or child or adolescen$3) not (adult$ or elderly or geriat$ or old adj age$1) 11480 
14 12 not 13 69 
15 rct or rcts 180 
16 randomized-controlled-trials.de. 1308 
17 random$ near (clinical or trial$ or control$ or allocat$) 4357 
18 pt=randomized-controlled-trial 542 
19 15 or 16 or 17 or 18 4365 
20 pt=controlled-clinical-trial 20 
21 pt=clinical-trial$ 679 
22 clinical-trials#.de. 2803 
23 (clinic$4 adj trial$1).ti,ab. 1752 
24 (single adj blind adj method).de. or double-blind-method.de. 352 
25 ((singl$1 or doubl$1 or tripl$1 or trebl$1) adj (blind$2 or mask$2)).ti,ab. 1239 
26 placebo$1.ti,ab. 1597 
27 placebos.w..de. 480 
28 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 7199 
29 14 and 28 12 
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BRITISH NURSING INDEX- 1994 to date (6 Feb 06) 
 
 
Search history (6 Feb 2006) 
 
Bold indicates results taken from these sets 
 
Comments 
 Search results have not been compared with results from other 
databases, i.e. there may be duplicates with results from Medline, 
Embase, Cinahl. 
 21 results from set 18 have been emailed in both short and 
medium formats. 
 
No. Search term Results 
1 RCT 22 
2 
RANDOM$ NEAR (CLINICAL OR TRIAL$ OR 
CONTROL$ OR ALLOCAT$ OR STUDY OR 
DESIGN$2 OR VOLUNTEER$ OR 
PROSPECTIVE) 
1095 
3 (CLINIC$4 ADJ TRIAL$1).TI,AB. 227 
4 
((SINGL$1 OR DOUBL$1 OR TRIPL$1 OR 
TREBL$1) ADJ (BLIND$2 OR 
MASK$2)).TI,AB. 
58 
5 PLACEBO$1.TI,AB. 80 
6 
RESEARCH-AND-DEVELOPMENT.DE. OR 
RESEARCH 
30116 
7 1 OR 2 OR 3 OR 4 OR 5 OR 6 30373 
8 
DEPRESSION OR DEPRESSIVE OR 
DEPRESSED 
1677 
9 Depression.W..DE. 1035 
10 DYSTHYM$ OR DYSPHOR$ 14 
11 8 OR 9 OR 10 1686 
12 
11 NOT (MATERN$3 OR INFANT OR BABY OR 
BABIES OR MIDWIF$4) 
1482 
13 BEHAVIO$7 ADJ THERAPY 311 
14 
TREATMENT$1 OR INTERVENTION$1 OR 
THERAP$7 OR TECHNIQ$3 OR ACTIVAT$5 
OR MODIF$8 OR PSYCHOTHERAP$9 OR 
PSYCHOLOG$7 OR PSYCHOSOCIAL$3 
20236 
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15 BEHAVI$7 WITH 14 642 
16 
POSITIVE ADJ REINFORCE$ OR (EVENT$1 
OR ACTIV$6) NEAR SCHEDUL$3 
2 
17 13 OR 15 OR 16 643 
18 17 AND 12 AND 7 21 
 
Search history – CINAHL 1982 TO DATE  (4 Jan 2006) 
Bold indicates results taken from these sets 
 
Comments 
 Search results have not been compared with results from other 
databases, i.e. there will be duplicates with previous results from 
Medline and Embase.  
 Medline has been reloaded in the intervening time and it gives 
different numbers of results compared with the original Medline 
search, so an attempt to remove duplicates within Dialog would be 
inappropriate.  
 275 results from set 26 have been emailed in both short and 
medium formats. 
 
No. Search term Results 
1 depression.ti. or depressive.ti. or depressed.ti. 7129 
2 
(depressive adj disorder$ or major adj depression or 
organic adj depression or reactive adj depression).ab. 
1064 
3 (dysthym$ or dysphor$).ti,ab,de. 409 
4 
depression.w..de. or depression-reactive.de. or 
dysthymic-disorder.de. 
13204 
5 1 or 2 or 3 or 4 14506 
6 behav$ adj therap$6 5399 
7 behavior-therapy.de. 2063 
8 behav$ near activat$3 167 
9 
behavi$ with (treatment or intervention or therap$7 or 
activat$5 or modif$8 or psychotherap$9 or psycholog$7 
or psychosocial$3) 
24259 
10 
positive adj reinforce$ or (event$1 or activ$6) near 
schedul$3 
520 
11 10 or 9 or 8 or 7 or 6 24621 
12 rct 3202 
13 
random$ near (clinical or trial$ or control$ or allocat$ or 
assign$ or study or design$2) 
63682 
14 random$8.ti. 8248 
15 12 or 13 or 14 64378 
16 pt=clinical-trial$ 16820 
17 clinical-trials#.de. 44186 
18 ((clinic$4 or control$) adj trial$1).ti,ab. 25182 
19 ((singl$1 or doubl$1 or tripl$1 or trebl$1) adj (blind$2 or 5736 
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mask$2)).ti,ab. 
20 placebo.ti,ab. 10795 
21 placebos.w..de. 3260 
22 15 or 16 or 17 or 18 or 19 or 20 or 21 84197 
23 5 and 11 1444 
24 23 and 22 470 
25 
adolescence.de. or adult.de. or middle-age or 
aged.de..w. or aged-80-and-over 
273576 
26 24 and 25 275 
Search history for Cochrane Library – performed on 8 Feb 2006 
Cochrane Library Issue 2006-1  
 
Comments 
 Search results have not been compared with results from other 
databases. 
 I have not limited results to any keywords for RCT 
 602 citations from set 14 have been emailed, divided up by 
database (see list beneath search history) 
When exporting results, abstracts are only available for items 
from CDSR and Central databases, so 581 items citations 
with abstracts have been emailed. 
 
 
ID Search Hits 
#1 
MeSH descriptor Depression explode all trees in MeSH 
products 
2599 
#2 
MeSH descriptor Depressive Disorder, Major, this term 
only in MeSH products 
575 
#3 
MeSH descriptor Depressive Disorder, this term only in 
MeSH products 
3305 
#4 dysthymic disorder in All Fields in all products 208 
#5 
dysthym* or dysphor* in Title, Abstract or Keywords in all 
products 
815 
#6 
depression or depressive or depressed in Record Title in all 
products 
7730 
#7 
MeSH descriptor Behavior Therapy, this term only in 
MeSH products 
2071 
#8 (event* or activ*) near schedul* in All Fields in all products 272 
#9 
behavio* near (therap* or treat* or techniq* or modif* or 
interven* or activat*) in Title, Abstract or Keywords in all 
products 
7649 
#10 positive next reinforc* in All Fields in all products 100 
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#11 coping near/3 depressi* in All Fields in all products 65 
#12 (#1 OR #2 OR #3 OR #4 OR #5 OR #6) 10944 
#13 (#7 OR #8 OR #9 OR #10 OR #11) 8013 
#14 (#12 AND #13) 602 
 
 
Results by database: 
Cochrane Reviews [10]  |   DARE [11]   |   CENTRAL [571]   |   HTA [6]   | 
  NHS EED [4]   |   
» There are 10 results out of 4200 records for: "(#12 
AND #13) in The Cochrane Database of Systematic 
Reviews"  
» There are 11 results out of 5859 records for: "(#12 
AND #13) in Database of Abstracts of Reviews of 
Effects"  
» There are 571 results out of 470139 records for: "(#12 
AND #13) in The Cochrane Central Register of 
Controlled Trials"  
» There are 6 results out of 5378 records for: "(#12 
AND #13) in Health Technology Assessment 
Database"  
» There are 4 results out of 17015 records for: "(#12 
AND #13) in NHS Economic Evaluation Database"  
Search history – EMBASE 1974 TO DATE (13 Dec 05) 
Bold indicates results taken from these sets 
 
no. database search term results 
46 embase   depression.ti. or depressive.ti. or depressed.ti. 47158 
47 embase   depressive adj disorder 8412 
48 embase   major-depression.de. 4363 
49 embase   dysthym$.ti,ab,de. 3065 
50 embase   depression.w..de. 102512 
51 embase   endogenous-depression.de. 791 
52 embase   46 or 47 or 48 or 49 or 50 or 51 117527 
53 embase   behav$ adj therapy 19129 
54 embase   behavior-therapy 17099 
55 embase   behavior-therapy.mj. 6716 
56 embase   behav$ near activat$3 2564 
57 embase   
behavi$ with (treatment or intervention or therap$7 
or activat$5 or modif$8 or psychotherap$9 or 
psycholog$7 or psychosocial$3) 
55494 
58 embase   
positive adj reinforce$ or (event$1 or activ$6) near 
schedul$3 
2621 
59 embase   58 or 57 or 56 or 55 or 54 or 53 58146 
60 embase   59 and 52 and human=yes 5434 
61 embase   rct 2351 
62 embase   randomized-controlled-trial$.de. 101719 
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63 embase   
random$ near (clinical or trial$ or control$ or allocat$ 
or study or design$2) 
193305 
64 embase   randomization.de. 17198 
65 embase   61 or 62 or 63 or 64 203604 
66 embase   clinical-trial#.de. 388595 
67 embase   (clinic$4 adj trial$1).ti,ab. 89647 
68 embase   single-blind-procedure 5667 
69 embase   double-blind-procedure 60529 
70 embase   crossover-procedure 17018 
71 embase   
((singl$1 or doubl$1 or tripl$1 or trebl$1) adj (blind$2 
or mask$2)).ti,ab. 
83851 
72 embase   placebo$1.ti,ab. 93718 
73 embase   placebo.w..de. 93940 
74 embase   prospective-study 51906 
75 embase   
65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 
74 
616257 
76 embase   75 and 60 1726 
77 embase   76 and animal=yes 7 
78 embase   77 not (76 and human=yes and animal=yes) 0 
79 embase   76 and adult=yes 624 
80 embase   adolescent.de. 351050 
81 embase   (76 and 80) not 79 126 
82 embase   79 or 81 750 
96 medline  40 or 42         these were the results from Medline 1685 
97 
embase   
medline  
combined sets 82, 96  combined results from Embase 
and Medline 
2435 
99 
embase   
medline  
unique records from 97 (dropped 250 duplicates from 
the databases) 
2185 
101 embase   
split set 99 (these are the unique records from 
EMBASE) 
522 
 
Search history – EMBASE 1974 TO DATE  PART 2 (19-12-05) 
Bold indicates results taken from these sets 
 
Objectives 
1. Include additional descriptors for types of depression (see set 16) 
2. Include additional study types (see set 33) 
3. Obtain results from these which are additional to results despatched on 
13 Dec 05 (set 82 before being compared with Medline for duplicates). 
About the Extra Results 
These have not been compared against Medline search results, i.e. may 
contain duplicates. 
 Set 35 equivalent to set 76 of initial search) contains an extra 4 
results due to database update – all emailed (medium format only) 
 Set 41 contains an extra 16 results due to additional descriptors for 
types of depression (from set 16) 
 Set 51 contains an extra 11 results which mention these study types: 
(controlled ADJ study OR major ADJ clinical ADJ study OR clinical 
ADJ article) combined with random$ and also combined with only 
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selected major terms/descriptors for depression and behaviour 
therapy 
 Set 53 contains an extra 53 results (compared with set 51) which 
mention those study types and random$ without limit to selected 
terms for depression and behaviour therapy. 
 
 
No. Search term Results 
1 DEPRESSION.TI. OR DEPRESSIVE.TI. OR DEPRESSED.TI. 47212 
2 DEPRESSIVE ADJ DISORDER 8424 
3 MAJOR-DEPRESSION.DE. 4391 
4 DYSTHYM$.TI,AB,DE. 3069 
5 DEPRESSION.W..DE. 102652 
6 ENDOGENOUS-DEPRESSION.DE. 792 
7 1 OR 2 OR 3 OR 4 OR 5 OR 6 117704 
8 BEHAV$ ADJ THERAPY 19150 
9 BEHAVIOR-THERAPY 17120 
10 BEHAVIOR-THERAPY.MJ. 6721 
11 BEHAV$ NEAR ACTIVAT$3 2569 
12 
BEHAVI$ WITH (TREATMENT OR INTERVENTION OR THERAP$7 OR 
ACTIVAT$5 OR MODIF$8 OR PSYCHOTHERAP$9 OR PSYCHOLOG$7 
OR PSYCHOSOCIAL$3) 
55573 
13 
POSITIVE ADJ REINFORCE$ OR (EVENT$1 OR ACTIV$6) NEAR 
SCHEDUL$3 
2626 
14 13 OR 12 OR 11 OR 10 OR 9 OR 8 58230 
15 14 AND 7 AND HUMAN=YES 5448 
16 (dysphoria OR melancholia OR major ADJ depression).TI,DE. 10559 
17 14 AND (7 OR 16) AND HUMAN=YES 5555 
18 RCT 2361 
19 RANDOMIZED-CONTROLLED-TRIAL$.DE. 101876 
20 
RANDOM$ NEAR (CLINICAL OR TRIAL$ OR CONTROL$ OR 
ALLOCAT$ OR STUDY OR DESIGN$2) 
193608 
21 RANDOMIZATION.DE. 17256 
22 18 OR 19 OR 20 OR 21 203937 
23 CLINICAL-TRIAL#.DE. 389428 
24 (CLINIC$4 ADJ TRIAL$1).TI,AB. 89823 
25 SINGLE-BLIND-PROCEDURE 5681 
26 DOUBLE-BLIND-PROCEDURE 60584 
27 CROSSOVER-PROCEDURE 17036 
28 
((SINGL$1 OR DOUBL$1 OR TRIPL$1 OR TREBL$1) ADJ (BLIND$2 OR 
MASK$2)).TI,AB. 
83915 
29 PLACEBO$1.TI,AB. 93806 
30 PLACEBO.W..DE. 94167 
31 PROSPECTIVE-STUDY 52053 
32 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 617381 
33 controlled ADJ study OR major ADJ clinical ADJ study OR clinical ADJ article 3717141 
34 32 OR 33 3920524 
35 32 AND 15 1730 
36 34 AND 17 3457 
37 32 AND 17 1774 
39 37 NOT 35 44 
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40 ADULT# OR AGED.DE. OR ADOLESCENT.DE. 2054682 
41 39 AND 40 16 
49 (36 AND 40 AND (10 OR 11 OR 13) AND (1 OR depression.MJ.)) NOT 37 181 
50 49 AND random$ 11 
51 49 AND (random$ OR 25 OR 26 OR 28 OR 30) 11 
52 (36 AND 40 AND random$) NOT 37 64 
53 52 NOT 51 53 
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MEDLINE  1951 TO DATE  Search history (30 Nov 05) 
Bold indicates results taken from these sets 
 
 
No. Search term Results 
1 depression.ti. or depressive.ti. or depressed.ti. 54179 
2 (depressive adj disorder$).ab. 7365 
3 depressive-disorder#.de. 47822 
4 dysthym$.ti,ab,de. 1937 
5 depression.w..de. 41033 
6 1 or 2 or 3 or 4 or 5 102398 
7 behav$ adj therapy 20048 
8 behavior-therapy.de. 17604 
9 behavior-therapy.mj. 10631 
10 behav$ near activat$3 2841 
11 
behavi$ with (treatment or intervention or therap$7 or 
activat$5 or modif$8 or psychotherap$9 or psycholog$7 or 
psychosocial$3) 
83625 
12 
positive adj reinforce$ or (event$1 or activ$6) near 
schedul$3 
2819 
13 12 or 11 or 10 or 9 or 8 or 7 86486 
14 13 and 6 and human=yes 4270 
15 rct or rcts 3397 
16 randomized-controlled-trials.de. 40249 
17 
random$ near (clinical or trial$ or control$ or allocat$ or 
study or design$2) 
229268 
18 pt=randomized-controlled-trial 209366 
19 random$8.ti. 49476 
20 15 or 16 or 17 or 18 or 19 336906 
21 pt=controlled-clinical-trial 69809 
22 pt=clinical-trial$ 420643 
23 clinical-trials#.de. 172371 
24 (clinic$4 adj trial$1).ti,ab. 97767 
25 
(single adj blind adj method).de. or double-blind-
method.de. 
93219 
26 
((singl$1 or doubl$1 or tripl$1 or trebl$1) adj (blind$2 or 
mask$2)).ti,ab. 
83013 
27 placebo$1.ti,ab. 95342 
28 placebos.w..de. 25241 
29 research-design.de. 42243 
30 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 687321 
31 comparative-study.de. 1247963 
32 evaluation-studies#.de. 540159 
33 follow-up-studies.de. 309308 
34 prospective-studies.de. 195627 
35 (control$3 or prospectiv$3 or volunteer$).ti,ab. 1640684 
36 31 or 32 or 33 or 34 or 35 3233487 
37 animals.de. not (human.de. and animals.de.) 2977974 
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38 (30 or 36) not 37 2678930 
39 38 and 14 2083 
40 39 and adult# 1377 
41 adolescent.de. 1090548 
42 (39 and 41) not 40 308 
 
PSYCINFO Search history – (20 Jan 2006) 
Bold indicates results taken from these sets 
 
Comments 
 In set 11, classification category 3312 covers Behaviour Therapy 
and Behaviour Modification; it falls within the hierarchy Health and 
Mental Health Treatment and Prevention. 
 Search results have not been compared with results from other 
databases, i.e. there will be duplicates with previous results from 
Medline, Embase, Cinahl. 
 592 results from set 33 have been emailed in both short and 
medium formats. 
 
no. search term results 
1 depression.ti. or depressive.ti. or depressed.ti. 45219 
2 (depressive adj disorder).ab. 8250 
3 dysthymic-disorder.de. 1119 
4 (dysthym$ or dysphor$).ti,ab. 5182 
5 major-depression.de. 44673 
6 1 or 2 or 3 or 4 or 5 65690 
7 behav$8 adj therapy 48875 
8 behavior-therapy#.de. 12773 
9 behav$8 near activat$6 4889 
10 psychological-interventions.kw. 276 
11 '3312'.cc. 13087 
12 behav$8.ti,ab,de,kw. and (10 or 11) 10563 
13 
positive adj reinforce$ or (event$1 or activ$6) near 
schedul$3 
1888 
14 13 or 12 or 9 or 8 or 7 56194 
15 14 and 6 4174 
16 rct or rcts 586 
17 
random$ with (clinical or trial$ or control$ or allocat$ or 
study or design$2 or volunteer or prospective) 
4919 
18 16 or 17 5485 
19 treatment-outcome-clinical-trial.at. 9992 
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20 clinical-trials#.de. 609 
21 (clinic$4 adj trial).ti,ab. 6105 
22 
((single or double or triple or treble) adj (blind$2 or 
mask$2)).ti,ab. 
10365 
23 placebo.ti,ab. 17423 
24 placebos.w..de. 1478 
25 18 or 19 or 20 or 21 or 22 or 23 or 24 36521 
26 prospective-studies.de. 274 
27 
at=followup-study or at=prospective-study or at=meta-
analysis or at=treatment$ 
39867 
28 25 or 26 or 27 65549 
29 animals.de. not (human.de. and animals.de.) 78090 
30 28 not 29 65074 
31 15 and 30 753 
32 
age=adolescence-13-17-yrs or age=adulthood-18-yrs-and-
older 
796544 
33 31 and 32 592 
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Study Quality Assessment tool 
 
 
Study quality checklist BA systematic review 
Describe briefly and allocate: yes, no,  not clear 
 
Study details (title author year)  
 
 
Adequate randomisation procedure used (computer generated/random 
number table, independent, describe) 
 
 
Assessment of outcome blinded to intervention arm (describe) 
 
 
Pre-specified eligibility criteria for study 
 
 
Groups equal at baseline 
 
 
Was adherence to treatment procedures monitored in each arm 
 
 
Mean and Standard Deviation recorded for primary outcome measure 
 
 
 
Power calculation  
 
 
loss to follow up reported 
 
 
Intention to treat analysis 
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Study Data Extraction Form 
 
Behavioural Activation SYSTEMATIC REVIEW DATA 
EXTRACTION FORM 
 
 
INSTRUCTIONS 
 
 
 Please enter data in each BLANK shaded data entry field 
 
 Use the TAB key to move DOWN from one data entry 
field to the next one 
 
 Use SHIFT+TAB together to move UP from one data 
entry field to the previous one 
 
 Boxes will expand to fit additional data  
 
 If data is not available, please enter ‘Not clear’ 
 
 When the data extraction is completed, please save the 
file with the following filename:   
 
o [First author] [Date] [Reviewer initials].doc  
o e.g. Scogin 2005 PB.doc 
o If two studies share the same identifier, please use 
2001a, 2001b etc 
 
 
 272 
 
General information 
 
 
Study ID (First author + Year) 
 
      
 
Title 
 
      
 
Source 
 
      
 
Diagnosis 
 
      
 
Population 
 
      
 
Country where data collected 
 
      
 
Recruitment context (e.g. primary care, specialist setting, community, 
other) 
 
      
 
Recruitment method (description of actual recruitment procedure) 
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Study population 
 
Target population (broad description e.g. depressed students) 
 
      
 
Inclusion criteria 
 
      
 
Exclusion criteria 
 
      
 
Baseline sex 
 
      
 
Baseline age 
 
      
 
Baseline social economic status 
 
      
 
Baseline education 
 
      
 
Baseline ethnicity 
 
      
 
Baseline other 
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Trial design 
 
Number of groups, conditions or arms 
 
      
 
Unit of randomisation (i.e. who was randomised? e.g. patient, group, 
class?) 
 
      
 
Method of randomisation (i.e. how was it conducted? e.g. coin toss, 
central telephone) 
 
      
 
Power calculation (i.e. was a power or sample size calculation 
reported?) 
 
      
 
Was a main aim identified a priori? 
 
      
 
Did they conduct an intention to treat analysis? (e.g. analysed all 
patients irrespective of adherence to treatment) 
 
      
 
What assessment of depression outcomes were included? (e.g. BDI, 
CES-D) 
 
      
 
Secondary outcomes measured 
 
      
 
How many patients were eligible for the trial? (i.e. met the criteria for 
inclusion) 
 
      
 
How many patients actually took part in the trial? (i.e. randomised) 
 
      
 
How many patients were lost to follow up? (e.g. failed to return outcome 
assessments, or left the trial) 
 
      
 
Lost patients reasons recorded 
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Blinding method adopted 
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Behavioural Intervention 
 
Description of the intervention (please enter a one sentence) 
 
      
 
Level of training of therapist (general) 
 
      
 
Level of specific training of therapist for BA intervention 
 
      
 
Number of sessions 
 
      
 
Duration of sessions 
 
      
 
Frequency of sessions 
 
      
 
Concurrent pharmacology 
 
      
 
Did the person providing the intervention receive supervision? 
 
      
 
Therapist/researcher independence? 
 
      
 
How was adherence to intervention assessed? 
 
      
 
Incentives for participants? 
 
      
 
Additional information not covered above 
 
       
 
 
 
 
 
 
 
Control Groups 
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Comparison group 1 
 
      
 
Level of training for comparison group intervention 
 
      
 
Balanced for non specific factors (describe eg time/contact) 
 
      
 
Comparison group 2 
 
      
 
Level of training for comparison group intervention 
 
      
 
Balanced for non specific factors (describe eg time/contact) 
 
      
 
Comparison group 3 
 
      
 
Level of training for comparison group intervention 
 
      
 
Balanced for non specific factors (describe eg time/contact) 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
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Were groups equal at baseline (comment) 
 
      
 
Study quality rating 
 
      
 
Post treatment measurement at what time point (post intervention, 
specific time following first assessment) 
 
      
 
Number of follow up assessments 
 
      
 
Time period of follow up assessments 
 
      
 
 
Additional comment 
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Results Table (n means sd)  
 
Intervention 
Pre 
Post 
      
Fu1 
      
Fu2 
      
Fu3 
      
Fu4 
      
Measure 1       
                                          
                                          
                                          
Measure 2       
                                          
                                          
                                          
Measure 3       
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Appendix II: A randomised controlled trial of 
clinical and cost effectiveness of behavioural 
activation for depression delivered by the non 
specialist: additional materials 
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Independent peer reviews of study protocol for ethics 
 Dr Chris Williams     MBChB   BSc  MMedSc   MD   FRCPsych 
Senior Lecturer and Honorary Consultant Psychiatrist  
  
Direct Line:  0141 211 3912 
Secretary:     0141 211 0685 
Fax:              0141 357 4899 
E-mail:          Chris.Williams@clinmed.gla.ac.uk  
http://www.gla.ac.uk/departments/psychologicalmedicine/index.html 
 
 
Re: CW/AG/Research 
 
22 February 2008 
 
Dear David 
 
Thank you for asking me to review your protocol entitled „Trial Protocol 
for Behaviour Therapy for Depression delivered by specifically trained 
generic mental health staff‟. 
 
This study is timely and will pave the way for a possible larger funded 
randomised controlled study.  There is a need to discover which sorts of 
staff best can deliver these sorts of interventions and it may well be the 
case that junior mental health staff with appropriate training and 
supervision are able to offer this very effective intervention. I am less 
convinced that 12 sessions of 30-45 minutes really saves so much time 
though compared to traditional CBT so maybe the issue is more about 
widening the scope of practitioners who may be able to offer this effective 
intervention. 
 
Please find my specific comments below: 
 
Methodology:  
It is very sensible at this stage to do a small randomised controlled study in 
order to establish the feasibility of recruiting, training, delivering and 
retaining both patients and staff in this approach.  The primary care sample 
is a logical group to focus on and the confirmation of diagnosis using the 
Clinical Interview Schedule Revised is very appropriate (though it is not 
stated who will do this).  It would be helpful to define exactly what you 
mean by currently actively suicidal (for example a score of 2 or more on 
the Beck Depression Inventory suicide item might be used for consistency). 
 
The main design aspect I would question is the control arm. In practice it 
might be better to compare BT + TAU with TAU + monitoring rather than 
monitoring alone. In practice many GPs will have prescribed/referred 
already but ethically both arms should be treated by G.P.s as they would 
usually do. If there is going to be advice/expectation that GPs don‟t offer 
other treatment for a time this may fit with watchful waiting initiatives but 
only for 3-4 weeks and I am concerned that TAU should be available to 
both arms as needed. 
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It is sensible to recruit from General Practice and to use two forms of 
recruitment.  A major feature that needs to be addressed is that of 
contamination as it is a small sample and a proportion will be already 
referred to other practitioners/may have new 
 
Sample size: this seems appropriate based on the previous research. 
 
Ethics of Recruitment: 
antidepressants etc. This needs to be recorded in detail.  
 
Recruitment:  For practice case-notes search it is not stated who will do 
this.  Will this be one of the G.P. practice staff or a member of the research 
team?  If it is a member of the research team it may not be appropriate for 
records or contact details to be taken away from the G.P. surgery (and if 
they are they need to be encrypted) and in the first instance it is probably 
sensible for the letter sending the patient information sheet to the person to 
come on behalf of the practice saying that the practice is interested in 
supporting this research and including the PIS.  I assume that a written 
consent form will then be returned as described in your protocol allowing 
the research team to provide further contact.  This seems very appropriate.  
There is no mention of whether an advert will also be used.   
 
The area that is not described in detail is the direct referral from the health 
care provider. Much depends on the severity of depression but there is a 
need to avoid any hints of coercion. A model that can work well is for the 
GP to provide the potential participant with the Participant Information 
sheet (PIS) and an opt-in card they can sign and either post off and/or drop 
in a box in reception to be collected by the research team who can then 
contact the person and proceed with recruitment or not.  
 
Overall I think this is a well-planned, detailed protocol which has a high 
chance of success and will add significantly to what is known. 
 
 
Yours sincerely 
 
 
 
Dr Chris Williams 
Senior Lecturer in Psychiatry & Honorary Consultant Psychiatrist 
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DEPARTMENT OF 
HEALTH SCIENCES 
 
Room 222, 2
nd
 Floor (Area 4) 
Seebohm Rowntree Building 
University of York 
Heslington 
York YO10 5DD 
 
Telephone  (01904) 321908 
Fax                   (01904) 321382 
Email              dr17@york.ac.uk 
 
www.york.ac.uk/healthsciences 
 
Sunday, 11 November 2007  
 
          
    
Re: Research Proposal from David Ekers 
 
I have been involved in considerable peer review of this proposal, which 
David Ekers has produced for his PhD studies. I am happy that all aspects 
of his background, methods and analysis plan are of high quality, having 
been rigorously scrutinised by myself, Professor Simon Gilbody and others 
in our department, not least Professors Godfrey (for the health economics) 
and Bland (for the statistical analysis plan). The proposal has been through 
several drafts and iterations and has been considerably edited as a 
consequence of this process. It is based on a published systematic review 
and meta-analysis of the literature which Mr Ekers has conducted and 
recently published to considerable acclaim from the scientific and 
psychology communities
1
. He has also taken advice on ethics and research 
governance. I have no doubt, therefore, that it is a suitably rigorous 
proposal. 
 
Yours sincerely, 
 
 
 
                                               
1
 Ekers, D, Richards, D and Gilbody S. (2007). A Meta Analysis of 
Randomised Trials of Behavioural Treatment of Depression. Psychological 
Medicine doi: 10.1017/S0033291707001614, published online 01 October 
2007. 
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David Richards 
Professor of Mental Health 
Sample size 
 
The difference to be detected is what is indicated by the meta-analysis as 
most likely, i.e. the point estimate of the difference.  The chosen power, 
80%, is accepted by funders such as MRC and HTA as acceptable for 
trials.  The power may be increased by the use of baseline depression as a 
covariate.  We have allowed for 30% dropout in this trial.  In the earlier 
meta-analysis, the dropout was 19% and in the collaborative care for 
depression trial is was 16%.  Hence 30% is, if anything, generous. 
 
Power calculations are most appropriate when the study is intended to be 
the final, definitive study.  This is an exploratory study, in that no other 
trials of this intervention have been done.  It will be used to help design a 
further, larger and definitive trial if the treatment appears promising. 
 
Martin Bland 
17 January 2008 
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Study information sheet and consent forms 
 
 
 
 
 
Behavioural Therapy for Depression Information sheet version 2 
(17.03.08) 
 
 
Treatment of Depression by Behavioural Therapy Participant Information 
Sheet  
 
You are being invited to take part in a research study.  Before you decide 
whether you want to take part or not it is important for you to understand 
why the research is being done and what it will involve.  Please take time 
to read the following information carefully and discuss it with others if you 
wish.  Ask us if there is anything that is not clear or if you would like more 
information.  Take time to decide whether or not you wish to take part. 
 
What is the purpose of the study? 
 
Depression causes misery to many patients and is a major health problem 
in the UK. Effective talking treatments are available however access to 
these is often difficult. The recommended treatment in the UK is Cognitive 
Behavioural Therapy. However Behavioural Therapy alone has been seen 
to be as effective as full Cognitve Behavioural Therapy, although these 
treatments have mainly been developed in the United States. We do not 
know who is best placed to deliver this treatment; therefore, this study will 
investigate this question further by training mental health workers to 
deliver behavioural therapy to approximately 35 people with depression. 
This treatment will then be compared with approximately 35 people being 
treated by their GP as per usual practice (with monthly brief phone calls 
from the research team) over 12 week period (who will then be offered the 
behavioural therapy).  
 
Why have I been chosen? 
 
Your health worker has identified you as suffering from depression. This 
letter asks you to consider taking part in the research study. 
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part.  If you do decide to 
take part you will be given this information sheet to keep and be asked to 
sign a consent form. If you decide to take part you are still free to withdraw 
at any time and without giving a reason.  A decision to withdraw at any 
time, or a decision not to take part, will not affect the standard of care you 
receive. 
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What will happen to me if I take part? 
 
This study is a randomised controlled trial. Sometimes, because we do not 
know which way of treating patients is best, we need to make comparisons. 
People are put into groups and then compared. The groups are selected by a 
computer which has no information about the individual – i.e. by chance.  
Patients in each group then have a different wait time before starting 
behavioural therapy and are compared before treatment and at 12 weeks.  
Firstly, we would like to interview you to make sure you are eligible for the 
trial and to ask you to fill in some questionnaires. We would then like to 
interview you again after three months to repeat the questionnaires. We 
may also need to collect some information from your medical records. The 
research study will last for approximately one year. You will be invited to 
commence behavioural therapy either immediately or at most 12 weeks 
after agreeing to take part in the study. We would also like to record the 
therapy sessions you attend, however if you do not wish us to do so your 
inclusion in the study will not be affected. A proportion (20% picked at 
random) of these recordings will be listened to by an expert in this field 
(bound by standard NHS confidentiality rules) outside of the core research 
group. This will allow independent verification of the content of the 
intervention. All recordings will treated as confidential information as per 
NHS standards and will be destroyed at the end of the study. No personal 
information (such as names & address) will be associated with the 
recordings.  
 
 
What do I have to do? 
 
There are no restrictions in your lifestyle from taking part in this research. 
You should continue to follow the advice of your GP as they will remain 
responsible for your overall medical care throughout your involvement in 
this study. In addition to the treatment offered from your GP you will be 
given access to 12 40-50 minute sessions of behaviour therapy for 
depression. This will be at a local health centre either straight away or 
following 12 weeks.  
 
 
What is the drug or procedure that is being tested? 
 
The treatment is called Behavioural Therapy for Depression. You will be 
allocated a therapist (a mental health worker) trained in this method of 
helping people with depression. Behavioural therapy helps you consider 
how what you do affects the way you feel. It considers any changes in your 
life and in partnership with your therapist you explore your response to 
these, trying out changes in agreement between you. In this way it is aimed 
to address those things that contribute to your depression and based on this 
consider changes to make to overcome this problem.  
 
Are there any side effects, disadvantages and risks of taking part? 
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We are not aware of any side effects, disadvantages or risks to you of 
taking part in this research. 
 
What are the possible benefits of taking part? 
 
You will have access to 12 weeks of a talking therapy aimed at improving 
your depression. We hope that this treatment will teach you techniques that 
can make you feel better. The information we get from this study may help 
us to treat future patients with depression more effectively. 
 
What will happen if I don’t want to carry on with the study 
 
You can withdraw from the study at any time and your GP will continue to 
treat you depression. We would like to keep in contact with you to check 
your progress however this will be with your consent.  
 
What happens when the research study stops? 
 
Throughout the study and afterwards, your GP will continue to treat your 
depression as s/he feels is best for you and with your agreement. 
 
What if something goes wrong? 
 
We do not anticipate any harm coming to you from involvement in this 
study. However, if you wish to complain, or have any concerns about any 
aspect of the way you have been approached or treated during the course of 
this study, the normal National Health Service complaints mechanisms are 
available to you. In the event that something does go wrong and you are 
harmed during the research and this is due to someone‟s negligence then 
you may have grounds for a legal action for compensation against (name of 
Sponsor Organisation, NHS Trust, Private Clinic) but you may have to pay 
your legal costs. 
 
Will my taking part in this study be kept confidential? 
 
All information collected about you during the course of the research will 
be kept strictly confidential.  Any information about you will have your 
name and address removed so that you cannot be recognised from it. As 
your GP/health care worker has suggested you might like to take part in 
this study and is involved in your treatment s/he will be informed of your 
progress as part of the research study with your permission. 
 
What will happen to the results of the research study? 
 
We will publish the results of this research study widely. As well as 
producing a research report and writing articles for health professionals to 
read you will be given a summary of the findings. We will ensure service 
organisations such as Depression Alliance are informed of the results of the 
trial. You will not be personally identified in any publications from this 
trial. 
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Who is organising and funding the research? 
 
The research is being supported by your local NHS mental health trust as 
part of is normal running costs, no additional funding has been provided. 
Your GP is not being paid any extra money for being involved in the study. 
  
Who has reviewed the study? 
 
All research in the NHS is reviewed by an independent group of people 
called a research ethics committee to protect your rights, safety, wellbeing 
and dignity. The Northumbria Research Ethics Committee of the NHS has 
reviewed the study and approved it. 
  
Next Steps 
 
If you would like to take part in this research study please fill in the 
attached consent form and send it off in the enclosed stamped envelope. If 
you need further information to help you decide, please contact David 
Ekers at the address below. Once the research team receives your consent 
form, a researcher will contact you and arrange to see you in the next few 
days.  
 
Thank you for reading this and for considering taking part in this study. 
 
You are welcome to keep this Information Sheet and if you agree to take 
part in the research study you will also be given a copy of a signed consent 
form to keep. 
 
 
Contact for Further Information 
 
If you need further information about this study please contact the research 
lead: 
David Ekers, 
Nurse Consultant Primary Care Mental Health  
Health Centre,  
Newcastle Road,  
Chester Le Street,  
Co Durham,  
DH3 3UR 
 
Telephone: 01913336038. 
 
Email: david.ekers@cddps.nhs.uk 
 
For independent advice re participation in the study please contact: 
 
Ms Jacqui Lovell 
R & D Manager 
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TEWV NHS Tust 
TAD Centre 
Ormsby Rd 
Berwick Hills 
Middlesbourgh 
TS3 7SF 
 
Telephone 01642 516981 
 
 
 
 
Permission to contact consent version 2 17.03.08 
 
GP Practice Letter Headed Paper 
 
 
 
Patient Identification Number for this trial: 
 
 
Permission for researcher to contact 
 
practice name 
 
 
Treatment of Depression by Behavioural Therapy 
 
I confirm that I have read and understand the information sheetfor the 
above study and am happy for a researcher to contact me. 
 
I understand that my participation is voluntary and that I am free 
to withdraw at any time without giving any reason, without my  
medical care or legal rights being affected. 
 
 
Name          
__________________________________________________________ 
 
Address      
__________________________________________________________ 
 
Signature    
__________________________________________________________ 
 
Telephone contact details  
 day__________________________________  
 Evening_______________________________ 
 Mobile 
 Email address 
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Return in enclosed pre-paid envelope to: 
David Ekers 
Treatment of Depression by Behavioural Therapy Trial 
Health Centre,  
Newcastle Road,  
Chester Le Street,  
Co Durham,  
DH3 3UR 
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Patient Identification Number for this trial: 
 
CONSENT FORM 
 
Treatment of Depression by Behavioural Therapy 
David Ekers, 
Nurse Consultant Primary Care Mental Health  
Health Centre,  
Newcastle Road,  
Chester Le Street,  
Co Durham,  
DH3 3UR 
 
Telephone: 01913336038. 
 
Email: david.ekers@cddps.nhs.uk 
 
 
       Please initial box 
 
1. I confirm that I have read and understand the information sheet 
dated 06/03/2008 (version 2) for the above study and have had the 
opportunity to ask questions           . 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected.   
 
I understand that sections of any of my medical notes may be looked at by 
research staff from Tees Esk & Wear Valleys NHS Trust.  I give 
permission for these individuals to have access to my records.  
 
4. I agree to take part in the above study       
 
5. I agree to my GP being informed of my participation in this study     
 
 
6. I agree to sessions being recorded and listened to by an independent 
expert to verify content of the intervention       
 
 
 
___________________________________________        
Name of Patient Date Signature 
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Copies of research ethics and governance approvals 
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Service use questionarres baseline and 3 months 
 
 
 
SERVICE USE QUESTIONNAIRE 
 
These questions refer to the previous 6 months. 
 
USE OF HEALTH SERVICES (excluding specific treatment for depression 
problem) 
 
1. Have you visited a hospital as a patient during the last six months?  Yes 
 
No 
 
Not Answered 
 
 
If “NO”, please skip to 1e. 
 
1a. Have you visited a hospital A & E dept in the last six 
months? 
 
Yes 
 
No 
 
Not Answered 
 
If “NO”, please skip to 1b. 
 
How many times?    
 
How many nights did you stay in total?    
 
How many times did you use an emergency  
(999 call) ambulance? 
   
 
1b. Have you visited hospital as an inpatient for a medical  
problem in the past 6 months?  (i.e. stayed overnight, but 
excluding A&E) 
Yes 
 
No 
 
Not Answered 
 
 
If “NO”, please skip to 1c. 
 
How many nights did you stay in total?    
 
1c. Have you visited hospital as an outpatient in the last 6 
months? 
Yes 
 
No 
 
Not Answered 
 
 
If “NO”, please skip to 1d. 
 
How many times?    
 
1d. Have you visited hospital as a day patient in the last 6 
months? 
Yes 
 
No 
 
Not Answered 
 
 
If “NO”, please skip to 1e. 
 
How many days?    
 
1e. Have you seen your GP or a practice nurse at the surgery in 
the last 6 months?   
Yes 
 
No 
 
Not Answered 
 
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If “NO”, please skip to 1f. 
 
How many times have you visited the GP?    
How many times have you visited the practice nurse? 
 
   
 
1f. Have you been visited at home in the last 6 months by a GP, 
practice nurse? 
Yes 
 
No 
 
Not Answered 
 
 
If “NO”, please skip to 1g 
 
How many times? GP    
 
Practice nurse    
 
 
1g. Have you contacted NHS Direct over the past 6 months? Yes 
 
No 
 
Not Answered 
 
 
If “NO”, please skip to 1h 
 
How many times?    
 
1h. Have you visited a walk in centre over the past 6 months? Yes 
 
No 
 
Not Answered 
 
 
If “NO”, please skip to 2 
 
How many times?    
 
MEDICATION 
 
2. Have you received any prescriptions in the last 6 months? Yes 
 
No 
 
Not Answered 
 
 
If “NO”, please skip to 3. 
 
How many?    
 
DEPRESSION SERVICES CONTACTS 
 
3. Have you received treatment for a depression over the last six 
months? 
Yes 
 
No 
 
Not Answered 
 
 
If “NO”, please skip to 4. 
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3a. Have you been prescribed medication? 
 
Yes 
 
No 
 
 If so what was the name of the medication   
If “NO”, please skip to 3b. 
 
 
What dose in mg per day?       
If current dose is 
unknown 
 
    tick this box.  
 
 
3b. Were you offered any other services for a problem with depression (such 
as seeing a counsellor, CPN, Psychiatrist etc)? 
 
Yes 
 
No 
 
If “NO”, please skip to 3c. 
 
Service  When and how long were the 
appointments 
 How many 
times 
       
 
       
 
       
 
       
 
3c. Were you prescribed any other medication for psychological problems 
(such as sleeping, anxiety etc)? 
 
Yes 
 
No 
 
If “NO”, please skip to 3d. 
 
Drug  Dose  No of 
prescriptions 
       
 
       
 
       
 
       
 
This section records other contacts with depression services over the last six months.   
 
3d. Have you been treated for a depression problem in the last 6 
months where you stayed in a hospital? 
Yes 
 
No 
 
Don‟t know 
 
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If “NO”, please skip to 3e. 
 
How many times were you admitted?    
 
How many nights did you stay in total?    
 
3e. Have you received specific counselling or advice in a 
specialist depression clinic? 
Yes 
 
No 
 
Not answered 
 
 
If “NO”, please skip to 3f. 
 
What type of counsellor did you see? Number of occasions 
seen 
Psychologist    
    
Keyworker/general counselling    
    
Social worker    
    
Psychiatrist    
    
Other (please specify):    
……………………………………………    
 
 
OTHER SERVICE RECEIPT 
 
4. Have you used any of the following services during the last 6 months? 
  Number of contacts 
(i) Advisor regarding state benefits or housing issues 
 
   
     
(ii) Social Worker (at home) 
 
   
     
(iii) Occupational Therapist (at home) 
 
   
     
(iv) Citizens Advice 
 
   
     
(v) RELATE 
 
   
     
(vi) Alternative medical practitioner 
 
   
     
(vii) Advisor on legal or debt issues 
 
   
     
(viii) A homeless persons agency 
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(ix) An employment advisor 
 
   
     
(x) Other  
(please specify………………………………….……….…………) 
   
 
EMPLOYMENT 
 
5a. Have you had a job in the past 6 months? Yes 
 
No 
 
Not Answered 
 
If “NO”, please skip to 5i. 
 
5b. How many weeks have you been working?   Not Answered 
 
 
5c. Have you been unemployed in the last 6 months? Yes 
 
No 
 
Not Answered 
 
 
5d. Do you currently have a job where you are on a contract and pay 
income tax?  
Yes 
 
No 
 
Not Answered 
 
 
If “NO” or “Not Answered”, please skip to 5e. 
 
If “Yes”, is it full time or part time?  
 
Full time 
 
Part time 
 
Not answered 
 
 
What is your weekly wage before tax?  
 
    
 
5e. Do you earn money from „cash in hand‟ work?  Yes 
 
No 
 
Not Answered 
 
If “NO” or “Not Answered”, please skip to 5f. 
 
 
If “Yes”, is it full time or part time?  
 
Full time 
 
Part time 
 
Not answered 
 
 
How much, approximately, do you earn per week from cash 
in hand work? 
    
 
5f. How many days have you been absent from work in the last 6 
months?  
   
 
5g. Do you think your performance at work has been affected by your 
depression in the past 6 months? 
Yes 
 
No 
 
Not Answered 
 
 
If “NO”, please skip to 5h. 
 
On how many days in the past 6 months has your 
productivity been affected? 
    
 
Was your productivity affected . . . . . .  Slightly  
 Moderately  
 Considerably  
 Extremely  
 
5h. Have you had an accident at work in the last 6 months? Yes 
 
No 
 
Not Answered 
 
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If Yes, how many times? 
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5i. If you have claimed benefits, which of the following have you claimed and for 
how long?  Please tick as many as apply. 
  Yes No Not Answered If Yes, no of weeks claimed in 
last 6 months 
 Income support 
 
       
     
 Invalidity benefit 
 
       
     
 Unemployment benefit 
 
       
     
 Sickness benefit 
 
       
     
 Housing benefit 
 
       
     
 Severe disablement allowance 
(DLA) 
       
     
 Mobility allowance 
 
       
     
 Family credit 
 
       
     
 Child benefit 
 
       
     
 Lone parent benefit 
 
       
     
 Attendance allowance 
 
       
     
 Other (specify below) 
 
       
 
 
 
EDUCATION 
 
6a. Please indicate which of the following qualifications you have achieved. 
 
  
  
Degree or equivalent  
Higher education below degree level 
 
 
GCE „A‟ Level or equivalent  
One   
Two  
Three or more  
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HND / HNC/ etc.  
5 or more GCSE Grades A-C or equivalent  
GCSE Grades D-G or equivalent/commercial/apprenticeship  
Foreign or other qualifications  
No qualifications  
  
 
 
 
 
LIVING ARRANGEMENTS and ACCOMMODATION 
 
7a. Which of the following best describes your current accommodation? 
 
Owner occupied - owner outright/with mortgage  
Rented from council/housing association  
Privately rented flat or house  
Rented flat or house shared with other people other than family  
Temporary accommodation  (B&B, hostel, etc)  
Temporary accommodation  (NHS or other treatment facility)  
 
 
7b.   Are you: 
 
 
 married or cohabiting with a partner?  . 
 married but not living with partner? . 
 single and in a current relationship?  
 single and not in a current relationship?  
 
7c.   Do you / your partner have children whom you live with? Yes   
No    
  
  
 How many children under 16?              1  2  3   4   5   6 
   
 What is your relationship to the children? Parent  
Legal Guardian 
 
 
 Other  
   
7d.   If you are „single‟ and with children are you?  
Widowed  
Divorced  
Separated  
 
 
 
 
 
 
 
 
 
 306 
 
 
SERVICE USE QUESTIONNAIRE 
 
These questions refer to the previous 3 months. 
 
USE OF HEALTH SERVICES (excluding specific treatment for depression 
problem) 
 
1. Have you visited a hospital as a patient during the last three 
months?  
Yes 
 
No 
 
Not Answered 
 
 
If “NO”, please skip to 1e. 
 
1a. Have you visited a hospital A & E dept in the last 3 months? 
 
Yes 
 
No 
 
Not Answered 
 
If “NO”, please skip to 1b. 
 
How many times?    
 
How many nights did you stay in total?    
 
How many times did you use an emergency  
(999 call) ambulance? 
   
 
1b. Have you visited hospital as an inpatient for a medical  
problem in the past 3 months?  (i.e. stayed overnight, but 
excluding A&E) 
Yes 
 
No 
 
Not Answered 
 
 
If “NO”, please skip to 1c. 
 
How many nights did you stay in total?    
 
1c. Have you visited hospital as an outpatient in the last 3 
months? 
Yes 
 
No 
 
Not Answered 
 
 
If “NO”, please skip to 1d. 
 
How many times?    
 
1d. Have you visited hospital as a day patient in the last 3 
months? 
Yes 
 
No 
 
Not Answered 
 
 
If “NO”, please skip to 1e. 
 
How many days?    
 
1e. Have you seen your GP or a practice nurse at the surgery in 
the last 3 months?   
Yes 
 
No 
 
Not Answered 
 
 
If “NO”, please skip to 1f. 
 
How many times have you visited the GP?    
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How many times have you visited the practice nurse? 
 
   
 
1f. Have you been visited at home in the last 3 months by a GP, 
practice nurse? 
Yes 
 
No 
 
Not Answered 
 
 
If “NO”, please skip to 1g 
 
How many times? GP    
 
Practice nurse    
 
 
1g. Have you contacted NHS Direct over the past 3 months? Yes 
 
No 
 
Not Answered 
 
 
If “NO”, please skip to 1h 
 
How many times?    
 
1h. Have you visited a walk in centre over the past 3 months? Yes 
 
No 
 
Not Answered 
 
 
If “NO”, please skip to 2 
 
How many times?    
 
MEDICATION 
 
2. Have you received any prescriptions in the last 3 months? Yes 
 
No 
 
Not Answered 
 
 
If “NO”, please skip to 3. 
 
How many?    
 
DEPRESSION SERVICES CONTACTS 
 
3. Have you received treatment for a depression over the last 3 months 
other than seeing the trial therapist? 
Yes 
 
No 
 
Not Answered 
 
 
If “NO”, please skip to 4. 
 
3a. Have you been prescribed medication in the past 3 months? 
 
Yes 
 
No 
 
 If so what was the name of the medication   
If “NO”, please skip to 3b. 
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What dose in mg per day?       
If current dose is 
unknown 
 
    tick this box.  
 
 
3b. Were you offered any other services for a problem with depression (such 
as seeing a counsellor, CPN, Psychiatrist etc)? 
 
Yes 
 
No 
 
If “NO”, please skip to 3c. 
 
Service  When and how long were the 
appointments 
 How many 
times 
       
 
       
 
       
 
       
 
3c. Were you prescribed any other medication for psychological problems 
(such as sleeping, anxiety etc)? 
 
Yes 
 
No 
 
If “NO”, please skip to 3d. 
 
Drug  Dose  No of 
prescriptions 
       
 
       
 
       
 
       
 
This section records other contacts with depression services over the last 3 months.   
 
3d. Have you been treated for a depression problem in the last 3 
months where you stayed in a hospital? 
Yes 
 
No 
 
Don‟t know 
 
 
If “NO”, please skip to 3e. 
 
How many times were you admitted?    
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How many nights did you stay in total?    
 
3e. Have you received specific counselling or advice in a 
specialist depression clinic? 
Yes 
 
No 
 
Not answered 
 
 
If “NO”, please skip to 3f. 
 
What type of counsellor did you see? Number of occasions 
seen 
Psychologist    
    
Keyworker/general counselling    
    
Social worker    
    
Psychiatrist    
    
Other (please specify):    
……………………………………………    
 
 
OTHER SERVICE RECEIPT 
 
4. Have you used any of the following services during the last 3 months? 
  Number of contacts 
(i) Advisor regarding state benefits or housing issues 
 
   
     
(ii) Social Worker (at home) 
 
   
     
(iii) Occupational Therapist (at home) 
 
   
     
(iv) Citizens Advice 
 
   
     
(v) RELATE 
 
   
     
(vi) Alternative medical practitioner 
 
   
     
(vii) Advisor on legal or debt issues 
 
   
     
(viii) A homeless persons agency 
 
   
     
(ix) An employment advisor 
 
   
     
(x) Other     
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(please specify………………………………….……….…………) 
 
EMPLOYMENT 
 
5a. Have you had a job in the past 3 months? Yes 
 
No 
 
Not Answered 
 
If “NO”, please skip to 5i. 
 
5b. How many weeks have you been working?   Not Answered 
 
 
5c. Have you been unemployed in the last 3 months? Yes 
 
No 
 
Not Answered 
 
 
5d. Do you currently have a job where you are on a contract and pay 
income tax?  
Yes 
 
No 
 
Not Answered 
 
 
If “NO” or “Not Answered”, please skip to 5e. 
 
If “Yes”, is it full time or part time?  
 
Full time 
 
Part time 
 
Not answered 
 
 
What is your weekly wage before tax?  
 
    
 
5e. Do you earn money from „cash in hand‟ work?  Yes 
 
No 
 
Not Answered 
 
If “NO” or “Not Answered”, please skip to 5f. 
 
 
If “Yes”, is it full time or part time?  
 
Full time 
 
Part time 
 
Not answered 
 
 
How much, approximately, do you earn per week from cash 
in hand work? 
    
 
5f. How many days have you been absent from work in the last 3 
months?  
   
 
5g. Do you think your performance at work has been affected by your 
depression in the past 3 months? 
Yes 
 
No 
 
Not Answered 
 
 
If “NO”, please skip to 5h. 
 
On how many days in the past 3 months has your 
productivity been affected? 
    
 
Was your productivity affected . . . . . .  Slightly  
 Moderately  
 Considerably  
 Extremely  
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Manual for the 12 session treatment protocol used in 
study 
 
Behavioural Activation for Depression 
Facilitated by Mental Health Practitioners 
 
 
 
Treatment Protocol 
 
 
 
 
 
 
 
 
 
 
This is a protocol for the delivery of Behavioural Therapy for Depression 
over 12 sessions. It draws heavily of work by C Martell, S Dimidjian, M 
Addis and N Jacobson 
(see Martell, C. R., Addis, M. E. and Jacobson, N. S. (2003) Depression in 
context: Strategies for guided action, W. W. Norton, New York) 
 
 
 There is also material adapted from the work of  D Hopko and colleagues 
(see Hopko, D., Lejuez, C., Ruggiaro, K. and Eifert, G. (2003) 
Contemporary behavioural activation treatments for depression: 
procedures, principles and progress. Clinical Psychology Review, 23, 699-
717).   
 
The content of each session is specified to ensure all aspects related to this 
treatment are covered. With many sessions there are associated diaries and 
exercise sheets that can be located in the appendix. The process should be 
followed. If there is any reason to deviate from the protocol this should be 
discussed in clinical supervision, deviation is acceptable if maintaining the 
protocol would be to the detriment of the patient. 
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Session 1 
 
Agenda for session 1 
 
 
Introductions 
 
Measures 
 
Rational for BA for depression 
 
Assessment information relevant to intervention 
 
Setting homework 
 
 
Introductions 
 
Introduce self and role (part of a team exploring the use of this evidence based 
intervention), that your role is as a therapist and this means your first priority is to 
work in partnership with patients to understand their experiences of 
depression/low mood and identify ways that should help to make it better over 
time. Emphasise that it is by working together that we will get the best out of the 
sessions. 
 
Outline the process, that you will meet for 12 weekly sessions that will be will be 
structured (using an agenda like this). That you hope the person finds the sessions 
helpful and are able to discuss any problems that arise in relation to how they are 
run, getting to them etc, so this can be worked out. Emphasise that the main 
person who can make changes is the patient and that there will be work to 
continue between the sessions that builds on what is covered within the sessions. 
This can be termed as homework (although some do not like that term), and it is 
the regular use of this homework that will make the most difference. 
 
Also point out that the sessions are focused upon this approach, and that as a 
therapist your job is to ensure they get the most out of each session by keeping 
focussed on the problems at hand. 
 
Make sure the person has contact details in case they need to make changes to 
appointments 
 
 
Rationale for BA treatment 
 
The treatment that we will be providing for you is based on the belief that the best 
way to reduce depressive symptoms and to make long-term changes in your life is 
by looking at how you spend your time, understanding what is important in your 
life (your values), relating this to the way you feel and then making appropriate 
changes to your daily activity. In other words, we are going to teach you a 
different way of structuring your days that will make it more likely that you will 
experience more positive situations and gradually reduce some of life‟s problems. 
It is much more difficult to feel depressed and have low self-esteem if you are 
regularly engaging in activities that bring you a sense of pleasure and/or 
accomplishment.  
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Keep in mind that it is possible for an individual to be quite active yet still 
depressed. This might occur when activities occur often but are not overly 
fulfilling or gratifying to an individual. In other words, the activities may be 
inconsistent with their life goals and values. For example, although a person may 
be active at work and complete chores at home, sacrificing time and activities 
with his/her child or spouse (an important life goal) may result in depressive 
emotions. Thus, it is not how often you engage in different activities, but rather 
how rewarding or gratifying these activities are for you and how you engage with 
them.   
 
Depression trap 
 
From what we have discussed, we can see there is a trap in depression; the lower 
you feel, the less energy you have and the less you do. This leads to a build up of 
problems, which in turn, make you feel worse and like doing less things. 
Eventually you end up avoiding many things in life you used to find pleasurable 
and rewarding. This again results in reduced mood.  
   
This treatment is behavioural in nature, which means that we will work toward 
changing your behaviour (how you spend your time) as a method for improving 
your thoughts, mood, and overall quality of life. We will be working on the here 
and now and making changes designed to improve the future. Some people seek 
to find a reason/explanation for depression in the expectation that that will make 
things better. Often these things are hard to identify, or even impossible, even if 
you do manage you still have to deal with the current situation you are in and 
make changes in order to move forward. Many individuals with depression often 
feel lethargic and lack the motivation to engage in various activities. In this 
treatment, behaviour is changed first, despite feelings of depression or anxiety. 
Once behaviour is changed, you‟ll then see fairly dramatic changes in your energy 
level, motivation, positive thinking, and better moods (less depressed and 
anxious). In focusing on behaviour change, we do not ignore thoughts and 
feelings. Instead, we suggest negative thoughts and feelings will change only after 
you change your behaviour and are experiencing positive events and 
consequences more frequently. We call this working from ‘the outside in’ rather 
than the „inside out’. 
 
 
 
Check out rationale with patient – “How does this sound to you?” 
 
 
 
Assessment of current depression and problems 
 
Start by asking about current problems in life. For many people, the 
beginning of depression is clearly related to stressful life events (e.g., loss 
of a loved one, financial difficulty, job loss, maybe being diagnosed with 
an illness). For others, the specific causes of depression may be unclear and 
it may occur from “out of the blue.” Relate to patient’s prior discussion of 
his/her depression. Whether it lasts a couple of weeks or as long as several 
years, depression may produce: 
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Significant problems in living (e.g., unable to work, cook, or take care of 
children). Individuals with depression also may isolate themselves from others, 
which may result in reduced social support from friends and family, divorce, 
decreased job satisfaction or unemployment, and educational failure. 
 
Get a picture of this for this person by using semi structured interview, this is 
major work for this session, take about 30 minutes. 
 
Then ask about depression symptoms. Ask how they have been feeling, use this to 
introduce the PHQ 9 and (other measures) and explain that you will be using this 
every session to review such symptoms in a standardised way. 
 
If there is any indication of suicide risk, explore this and check for any 
plans, intent, methods or contingencies (refer to risk protocol). If this is 
positive, you will need to inform/discuss this with your supervisor. If it 
presents in your view a high risk, follow Trust protocols for urgent 
assessment. 
 
Recap content of session so far. Check out understanding and any problems with 
the patient. Focus on the „outside in‟ nature of the approach. Recap some 
examples of this. 
 
Then introduce formulation template to begin collaboration and to lead into 
homework design. Note this is to share the ideas that have been generated via 
semi structured interview. This will be built on throughout treatment. 
 
Setting Homework 
 
First homework is to self-monitor activities and related mood over the coming 
week.  Emphasise that this does not have to be the whole week, but the more the 
better. Outline it is to start exploring the relationship between their day and their 
mood, and that this will help build a treatment plan relevant for them. Ask the 
patient to have a look at this before next session to see if they observe any 
patterns. 
 
Introduce Diary 1 (self monitoring) and in session firstly complete ‘two hours 
from 48 hours ago’. Then use to do „last 2-3 hours’. Discuss the difference in 
ability to complete with accuracy. Discuss the longer you leave it the more how 
you felt will be influenced by what has followed.   
 
Check out any questions re self-monitoring 
 
 
 
Use diary 1 in appendix 
 
 
Summarise session and confirm next appt 
 
 
 
 
 
 
Tools for use in this session 
 
 Semi Structured interview sheet 
 Formulation Template 
 Daily/Weekly activity schedule 
(DAS/WAS) 
 PHQ 9 (all standard measures for 
IAPTus) 
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Session 2 
 
 
Agenda for Session 2 
 
 
Measures 
 
Review homework: diaries, discuss any problems 
 
Behaviour-mood link and relate  to formulation 
 
Explore the concept of what is depressed behaviour and what are healthy 
behaviours and the reward that explains why behaviours continue (relief from 
feelings of pressure) (note positive/negative reinforcement) 
 
Treatment goals 
 
Homework 
 
 
Review diaries 
 
 
Look at this together; ask what patterns if any they see (what may be healthy or 
depressed behaviours, check out what this reveals to them, how others might feel 
if there range of activities were the same). How might that help us consider what 
changes may help? 
 
 
 
Introduce behaviour mood link 
 
 
Discuss that 
 
Often behaviour is out of awareness and is automatic 
 
Much is done due to habit 
 
To change you have to recognise the habit and its consequence so you know what 
and when to change. 
 
 
What types of behaviours were linked to what types of moods in diaries? Is this a 
common picture? 
 
Through discussion, distinguish between healthy and depressed behaviours in 
others or prior to depression. What are „depressed behaviours‟ (e.g., passivity, 
avoidance of situations, staying in bed) and what are „healthy behaviours‟ (dealing 
with jobs, meeting with friends, exercising etc)?  
 
Then look over diary and consider some examples of depressed and healthy 
behaviours from the week. What were the consequences of acting in each way?  
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Complete a contextual functional analysis (Antecedent/Behaviour/Consequence 
ABC) in session to look at examples of behaviour and emphasise consequences 
(and the reinforcing nature of short term relief). Then go back to behavioural 
activation formulation sheet used in last session and consider how relates. 
 
Use example such as staying in bed instead of getting up and having a 
shower 
 
Then discuss the function of behaviour. All behaviour serves 1 of 2 purposes, to 
obtain something positive or to escape something negative. Does it serve to 
reduce discomfort (avoidance) i.e. we eat dinner because it “feels good” to fill our 
stomachs and also to obtain essential vitamins and minerals and we can avoid the 
unpleasant feeling of being hungry, or even worse, starving. 
 
In the session, start to look at examples of depressed and healthy behaviours and 
what type of rewards were maintaining them (note that depressed behaviours can 
have a positive reward, such as obtaining sympathy, or increased contact, this can 
explain why they are hard to break). 
How might this help us work to break depression loops? What types of 
behaviours should be aimed for? Discuss this in session. 
 
Treatment goals 
 
To build on this, you need to consider what the goals are the person has for 
treatment (that relate to their values). Not „feeling less depressed‟ but what 
behaviours would they like to be doing in the medium term that would indicate 
things had improved. Use Goals sheet, explain the SMART (specific, measurable, 
achievable, relevant, timed) nature of goals. Create one in session and then give as 
homework. 
 
PHQ9 
 
Recap session and check understanding. Elicit any questions.  
 
Homework 
 
Self-monitoring, make notes of behaviour types (healthy/depressed) and the 
consequence of these. 
 
Goals sheet. 
 
 
Check out next session planning 
 
 
 
 
 
Tools for use in session 
 
 ABC formulation sheet 
 Behavioural activation 
formulation sheet 
 Goal sheet 
 WAS/DAS 
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Session 3 
 
Agenda for Session 3 
 
 
Measures 
 
Review Home Work 
 
Link findings to our understanding of depression 
 
Goals and how to move towards them 
 
Activity scheduling 
 
Home Work review 
 
Check out how it went, what observations were made? What different behaviours 
did they find in their time? Look at diaries together and discuss. 
 
Link findings to our understanding of depression 
 
How does this link to the depression cycle and the need to work from the „outside 
in‟? Link back to the rationale that depression is strongly linked to the way that 
we relate to our environment. If we are generally avoiding (due to escape from 
difficult feelings) and then having subsequent problems with an absence of 
positive or healthy experiences, this may help us to understand why such feelings 
are maintained. 
 
Therefore the patient needs to make some changes and start to schedule activities 
that will re-introduce such healthy behaviours in place of avoidant behaviours. 
 
Seven steps to change:      
      
Identify situations/behaviours that depress you 
 
Develop ideas of alternative behaviours 
 
Schedule alternative behaviours – small steps not giant leaps. Experiment with 
alternative behaviours 
 
Develop experimental attitude to depression, challenge negativity and try none the 
less 
 
Try out behaviours – attend to the action and not thoughts/evaluations. Keep 
trying  
 
Evaluate results 
 
Continue to experiment – no quick fixes. Examine results – place in schedule 2 – 
3    weeks 
 
Goals 
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We are now in steps 2-3.  
Look at homework goal sheet.  
 
Now look at alternative behaviours. Introduce activity sheets (routine, pleasurable, 
necessary)   and consider in relation to goals set for treatment. Start to generate a 
list of SMART behaviours in session that move the person towards goals. Do 
about 10, across all areas and then list in order of difficulty. 
 
Then in session you can use „behaviours that make me feel bad‟ exercise sheet 
and explore some options for behaviour change. Use self-monitoring sheets and 
discuss 2-3 situations and what may have been useful „alternative behaviours‟ 
using previous worksheet (remember in all these sessions you must be using 
collaborative discussion, getting the patient to generate ideas, not therapist‟s 
actions, your job is as a coach). 
 
 
Activity Scheduling 
 
Then introduce scheduling, ask patient to consider what would be the best time to 
schedule in some of the changes discussed in today‟s session. Then do for 2 of 
those days together considering alternative behaviours that are linked to the goals. 
Remind the patient of the „outside in‟ approach and that it is important not to wait 
to feel ready to do these things, but to do them to help feel better over time. 
Discuss this as an experiment, so on the days scheduled, follow plan and continue 
to monitor mood to see what happens. 
 
Finally recap what you have covered in treatment so far, how it links up to help to 
have a practical plan to overcome depression. Use this recap to highlight the 
structured step-by-step approach we are adopting, rather than the reactive to 
internal state approach (inside out). 
 
Before end of session complete PHQ9. 
 
Homework   
 
Follow scheduling and monitor. Continue to try to recognise what is depressed 
and what is healthy behaviour. Introduce alternatives if you can. 
 
 
Tools for use in session 
 
 Goal sheet 2, routine, necessary & pleasure 
 Behaviours that make me feel bad 
 Use self monitoring forms to schedule 
 PHQ9 
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Session 4 
 
Agenda for Session 4 
 
Measures 
 
Review homework 
 
Discuss changes made and the consequence of them 
 
TRAP and TRAC 
 
Home Work review 
 
What did they observe in relation to scheduling, what are the healthy behaviours 
that they endeavoured to use to replace depressed behaviours? Look through 
dairies/behaviours that make me feel bad worksheets together in discussion. 
Congratulate any success discuss any problems. Use results to consider in relation 
to treatment rationale. What may be the use of scheduling in relation to goals? 
Acknowledge how difficult it is to change and how it will have a mix of success 
and failure. Speak of using the approach to understand how best they can make 
changes in life to give “best chance of feeling better”. Look at where scheduling 
didn‟t work so well and consider what may be the explanation (are they working 
from the „inside out‟, waiting to feel ready, was the goal set too high, was it not 
specific enough, is it focussed towards a goal that is useful for them). 
 
Introduce the role of avoidance in depression maintenance, relate to the cycle of 
depression you have been using throughout sessions. Explain TRAP/TRAC: 
 
Trigger                                                                          Trigger 
 
Response                                                                      Response 
 
Avoidance                                                                     Alternative 
 
Pattern                                                                          Coping 
 
This framework can be used to look at where depressed behaviours exist and help 
explain why these become so entrenched; that is, the reward for a trap is initial 
relief from discomfort.  What however will be the long-term consequence on 
mood (discuss in session)? Helps us identify what are the things being avoided 
and why we are avoiding them. In session use 2 TRAP/TRAC sheets based upon 
previous weeks experiences as examples. Then give as homework to complete 
when engaging in depressed (avoidant) behaviour. 
Homework 
To schedule incorporating goal orientated activities. 
Use TRAP/TRAC worksheet when not engaging in scheduled activities. 
 
 Tools for use in session 
 
 Monitoring scheduling sheets 
 TRAP/TRAC forms 
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Session 5 
 
 
Agenda for Session 5 
 
 
Measures 
 
Review homework 
 
Getting on TRAC (Review again TRAP/TRAC) 
 
What have I learnt so far re my mood? 
 
Homework planning 
 
 
Homework review 
 
 
 
Look at scheduling and mood, discuss how using to move towards goals and the 
activities placed in line with this. Discuss how they have found doing this and 
what it may mean for managing depression in the future. 
 
Next look at TRAP/TRAC sheets and discuss how they help identify avoidances 
that are „blocking‟ access to new more adaptive and useful experiences. Review 
the role of negative reinforcement in increasing such blocks and how as you 
become aware of them you have some power in relation to change. 
 
Discuss how TRAC helps to overcome blockages and decide to do something 
different that increases interaction with important „events‟ in the environment 
hence increasing positive reinforcement and moving towards goals. Go over 2 
examples related to TRAP sheets for past couple of weeks together. 
 
Treatment review 
 
Next in session spend some time looking at outlining what you have covered in 
treatment and discuss what it means for the person. Introduce „what I have learnt 
about my depression so far worksheet‟ and ask for it to be reviewed during the 
following week. The aim is to spend some time to review the different approach 
to managing depression so the person can become their own therapist. 
 
 
Complete PHQ9 
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Homework  
 
Continue to schedule. Review how they are progressing in relation to task lists 
and goals. 
 
Using TRAP/TRAC sheets when noticing ‘depressed behaviour’ to help finding 
alternative behaviours. 
 
Spend time on ‘what I have learnt about my depression’ worksheets 
 
Tools for use in session 
 
 Self monitoring/scheduling 
 TRAP/TRAC sheets 
 What I have learnt about my 
depression  
 PHQ9 
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Session 6 
 
Agenda for Session 6 
 
Measures 
 
Review homework 
 
What TRAP/TRAC helped me do 
 
Using ACTION to help summarise 
 
Review homework as per previous sessions 
 
Look at „what I have learnt about my depression worksheet‟ and discuss findings. 
Anything that is not clear discuss openly. Discuss the role of changing avoided 
behaviours to improve how you feel and to deal with life problems. Consider any 
problems openly and discuss, recognise the powerful drive of responding to 
internal feelings, and how it explains reduced/avoidant behaviours. Remember to 
consider the pros & cons of choices made and how it is best to focus on own 
behaviours rather than others. Review examples of TRAP/TRAC sheets and 
discuss how these have been used. Then introduce the alternative behaviours 
worksheet to reduce need for writing. This however is to be used using the 
TRAP/TRAC process. 
 
Next introduce ACTION as a way of analysing response to situations: 
 
Remind that: 
 
Preparing to change: 
 
Open mind 
Experiment 
Small steps 
Expect ups and downs in process  
Not ‘Just do it’ as would have already.  
 
Assessing situations: 
 
Understanding patterns 
Recognising when happening 
 
Choosing alternatives:   
 
Recognise TRAPS and work out how to get on TRAC.   
Make choice based on knowledge. 
 
Try: 
 
Pick out time and day/s 
Put on schedule 
Expect to be hard 
Don‟t give up 
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Integrate: 
 
Try several times before making decision 
Expect some unexpected results 
 
Observe results: 
 
Get used to checking feeling – just before, during and after 
 
Now Evaluate/Never Give Up: 
 
Did behaviours help mood 
Did you manage 
Was it helpful within life 
Continue? 
What learned 
 
ACTION – reminder    
 
A    - Assess mood and behaviour 
C   - Choose alternatives 
T   - Try out 
I    - Integrate into life 
O  - Observe results 
N   - Now evaluate/never give up 
 
Go over steps and give sheet to person to use. Discuss how scheduling is at the 
core of behavioural treatment, and that TRAP/TRAC & ACTION are designed to 
help identify what to do in schedules to make things better. Revisit Goal sheet and 
re rate to assess progress towards them. You can use turning reactive-proactive 
behaviour sheet.  
 
Home Work 
 
Continue to schedule mix of activities. Use worksheets and learning to 
identify behaviours to incorporate and how to break down to small steps 
towards goals. 
 
 
Tools for use in session 
 Alternative behaviours worksheet 
 ACTION /reactive-proactive sheet 
 WAS 
 PHQ9 
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Session 7 
 
Agenda for Session 7 
 
 
Measures 
  
Review homework  
 
How to deal with depressed thinking/worry 
 
Homework  
 
Homework review. How do you schedule now, how do you choose what to 
incorporate. Reflect on tools used so far 
 
 
 
Review homework as per previous session 
 
 
Pay particular attention to progress towards goals linked to schedules. Discuss 
how using ACTION sheets and alternative behaviour sheets to consider how to 
plan each day. Reinforce valued direction and reflect on benefits of this. 
 
 
Worry and thoughts – How to respond 
Exercise in session can we control thinking: 
 
Use elephant exercise! 
 
If they can‟t stop such an inert thought what chance is there of doing so with 
emotional thought 
 
Content of thinking    ) 
                                  >    Distinguish 
Function of thinking   ) 
 
Commonly we focus on content but in this treatment we are most interested in 
function. 
 
Common examples of function: 
 
Try to figure why depressed, trying to solve it. 
Think about difficulties and feelings whilst in bed (rather than get up). 
Worry about possible bad events in the future, so as not to think about the present. 
Hold on to bad thoughts as to let go would be to give up / let others off the hook. 
 
Thinking in these situations can be seen as a behaviour you do, hence you could 
choose to do something else. 
 
 
Golden rule: 
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What is the thinking doing for you at a given time? 
Are you aware of it? 
What else is there to do? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rumination 
 
Outline rumination – dredging up and turning over such as worry, brooding, 
turning problems over and over, often about: 
 
Relationship problems 
Past hurts 
Future worries 
Money problems 
Bad decisions 
Feelings 
What others think 
 
 
Exercise in session: 
 
What do you ruminate on? 
 
Induce rumination on this subject for 2 minutes within session as a collaborative 
exercise. 
 
Then: 
 
 How do I feel when I do this? 
 
Then note rumination stops problem solving and leads to internal focus. This can 
lead to avoidance of actions that change the situation. 
 
Relate to noisy road example! 
 
 
  
 
 
 
 
 
A metaphor for thoughts and urges is traffic on a road. Engaging 
with thoughts is akin to standing in the road and trying to divert 
the cars (and getting run over) or trying to get one and find a 
parking space for it. However, even if one manages to divert or 
park one car there are always more to be dealt with. The goal is 
to acknowledge the thoughts but not to attempt to stop or control 
or answer back at them. The aim is to accept fully aversive 
thoughts and to „walk along the side of the road‟, engaging with 
life despite the traffic, which one can quietly ignore. (Taken from 
Veale 2008) 
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Homework 
 
Continue scheduling towards goals 
 
Monitoring rumination using worksheet 
 
Noticing rumination is the start – use examples of this 
 
 
Consider this when: 
 
You notice thinking over and over the same thing 
It doesn‟t give you any solutions 
 
 
After two minutes ask: 
 
 
Has it helped solve a problem? 
Do I have any new understanding? 
Am I less self critical/depressed? 
 
 
Tools for use in this session 
 
 WAS 
 Monitoring rumination sheets 
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Session 8 
 
Agenda for Session 8 
 
 
Measures 
 
Homework review 
 
Consider rumination, use diaries 
 
Introduce RCA 
 
 
Homework review as per previous sessions 
 
 
Go over scheduling and discuss any issues, review progress towards goals and 
consider blocks or developing further goals.  
 
Review rumination diaries 
 
 
Review rumination diaries and discuss the consequences of rumination on mood 
and activity. Where was attention focussed at this time? Even if active can be 
focussed on internal rather than external cues. Go back to discussion regarding the 
function/consequence of rumination and discuss. Review the noisy road metaphor. 
To lead on to RCA (Martell et al 2004). 
 
 
Introduce RCA 
 
Session theme RCA: 
 
Rumination 
Cues  
Action 
 
Rumination can make you feel worse, plus you have tried to get better at 
recognising so now practise changing. Use RCA. 
 
Remember the importance of attending to your experience. 
 
 
In session exercise: 
 
Fill out RCA form for three ruminating situations: 
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 Situation Rumination  Cues Action 
1    1. 
2. 
2     
3     
 
Use at home for others and practise. 
 
Negative thoughts 
 
Discuss the following: 
 
When they come: 
 
How do you feel? 
Do you try to debate, stop them? 
Does it work? 
 
Try to notice, label and move on. 
 
Remember focus attention on what is happening what you are doing, self-soothe 
through your five senses. Focus intensely on sights, sounds, smells, tastes, and 
touch. Appreciate and understand the world around you. Go through a practice 
exercise with the patient where you have them sit back and relax. Have them take 
a couple deep breaths. Then, have them describe everything they see, hear, smell, 
and feel (in great detail). At the end, ask the patient how this experience related to 
negative thoughts. Did they have any (very unlikely if they were doing the 
exercise correctly)? Ask the patient how this exercise might be incorporated into 
their daily life. When are the times (days, hours, or situations) when the patient is 
most likely to ruminate? Can you schedule activities at these times to minimize 
the likelihood of ruminative experiences? 
 
Note how this is different to ignoring thoughts, or dismissing them. It is about 
recognizing them, how they make us feel and deciding that rather then ruminate 
on them getting on with goal orientated activity is more likely to be productive, 
and help feel better. 
 
Home Work  
 
 Practise RCA alongside Scheduling. 
 
 
 
   
 
Tools for use in this session 
 
 Scheduling and goal sheets 
 Monitoring rumination 
 RCA sheets 
 Paying attention sheets 
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Session 9 
 
 
Agenda for Session 9 
 
 
Home Work review (RCA) 
 
Recap topics covered in treatment  
 
Problem solving 
 
Treatment review 
 
Recap what has been used in treatment up to this point (e.g. Cycle of depression, 
Reduced activity and avoidance, Mood and action, Working from outside in, 
Scheduling, Avoidance = TRAP/TRAC, ACTION, Thoughts and ruminations and 
depression, RCA) 
 
Here on in it is practise of building into daily life and accepting varied responses. 
Focus on small steps, one at a time. Do you need to wait for motivation? 
 
Establish if any area remains troublesome. Review goal list and progress towards 
this. What areas remain problematic? Return to and use tools relevant to this. 
 
 
How to solve a problem 
 
Review 7 stages of problem solving   
 
Identify problem 
 
Establish SMART goals 
 
Generate list of possible steps to meet goals 
 
Review pros & cons of each 
 
Pick one Outline detailed steps 
 
Do 
 
Evaluate 
 
Finally return to what induces my behaviours, and discuss with the patient the role 
of reactive/proactive behaviours. 
 
 
Use PST worksheet. 
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Home Work  
 
Schedule, use worksheets as needed to help have balance and goal orientated 
approach. 
 
Use problem solving sheets for difficulties in week 
 
 
 
Tools for use in this session 
 
 Scheduling/goals                 
 Any identified in treatment review 
 Problem solving sheet 
 PHQ9 measures 
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Session 10 
 
 
Agenda for Session 10 
 
 
Measures 
 
Review Home Work tasks 
 
Acting „as if‟ 
 
What I have learnt about depression 
 
 
Home Work review 
 
 
What did they use, what problems? Remember action and working from „outside 
in‟. Review any use of problem solving. 
 
 
Discuss the role of how we act in relation to how we feel 
 
 
Exercise in session: 
 
Role Play social situation. 1
st
 five minutes act as if low (poor eye contact, slow 
speech, etc), 2
nd
 five minutes act as if o.k.   
Compare and contrast. How will affect mood and goal attainment. What does this 
mean? 
 
 
What you have learnt about depression 
 
There are now only two more sessions. Emphasise that treatment is aimed at 
making them their own behaviour expert. Discuss continued rehab after treatment: 
 
Discuss treatment as road to recovery   
Plan what ongoing goals may be  
What have they learnt from sessions? 
How may this help with „life ahead‟ 
Learning to solve problems 
Seven stages of problem solving 
 
Introduce concept of flash card to manage mood in future. First step is to review 
what they have learnt about depression. Start worksheet in session and complete 
as homework. 
 
 
 
 
 
 
 332 
 
 
 
 
 
Home Work 
 
Problem solving and link to schedules 
 
Use acting as if and monitor outcomes 
 
Complete „what I have learnt about my depression‟ 
 
 
 
 
Tools for use in session 
 
 What I have learnt about my depression 
 WAS 
 Measures 
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Session 11 
 
 
 
Agenda for Session 11 
 
 
Measures 
 
Review Home Work 
 
Progress towards goals/Scheduling 
 
What I have learnt about depression 
 
Relapse prevention Flash cards 
 
 
 
Home Work review 
 
 
 
Any problems, solving/acting as if review outcome.  
 
Review „what I have learnt about depression‟ sheets and discuss how this differs 
from before treatment. Then link to the ‘Relapse Prevention flashcard‟. 
 
Give ‘Relapse Prevention flashcard’ to keep with what I have learnt flashcard. 
Discuss working on these over next week, do 1-2 examples in session. 
 
 
Home Work schedule 
 
 
Do the relapse prevention keycard 
 
 
Tools for use in session 
 
 Relapse prevention flashcard 
 WAS 
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Session 12 
 
 
 
Agenda for Session 12 
 
 
Measures 
 
Homework review 
 
Keycards and how to use them 
 
 
 
Home Work review 
 
 
Recap of treatment and what learning has taken place. Have full discussion on the 
process adopted throughout treatment. Explore goals set by person and how these 
have been progressed. At all times re emphasise that proactive, non-avoidant 
behaviour and working from the outside in has helped get things done, feel better 
although it is often hard and there is desire to withdraw. 
 
Note that all the tools used in treatment are there for future use, and keeping these 
up will help maintain a healthy mood in the future. Review keycards and how to 
use them. 
 
 
Inform the patient that they will be passed back to GP (or worker who referred 
them) and a brief letter will be sent, that will be copied to them. 
 
 
 
 
 
Take some time to say goodbye as this may be difficult for the person 
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Data error checklist 
Error Solution/ Action taken 
Different Freq employment scores 
between data sets  
Found inconsistencies (Subject No‟s 3, 18, 25, 
35 – was PT when referred, 45) and checked 
original file for correct data 
CSQ data inconsistencies Found errors (Subject No‟s 16 and 44), 
corrected according to original file. 
Basecsirdiag different Freq scores Found errors (Subject No‟s 3 and 18), corrected 
according to original file. 
BDIcatpre different Freq scores Found error (subject no 31), check BDI total to 
get correct categories 
BDIpostsev different Freq scores Found error (Subject no 35), checked BDI total 
to get correct category 
BDIpostcat different Freq scores Found error (subject no‟s 8, 15, 18, 38, 43) 
checked BDI total to get correct category 
CSQ1 and CSQ2 different Freq scores Could not find difference when reading data 
manually but could have been changed 
inadvertently when editing earlier data. 
CSQ6 different Freq scores Corrected subject 4‟s error by referring to 
original file 
CSQ8 Freq error Could not find difference when reading data 
manually but could have been changed 
inadvertently when editing earlier data. 
Referrer difference freq scores Could not find difference when reading data 
manually 
BDI1Month 3 Compared files, found errors (4, 24), and 
referred to original data. 
BDI1month17 Compared files, found errors (7), and referred 
to original data. 
onemonthwasa Compared files, found errors (3, 4, 9), and 
referred to original data. 
BDIpost all data Subject 9 all data entered incorrectly 
BDI9post Compared files, found error (28), and referred 
to original data. 
CSQ1, CSQ2, CSQ6 and CSQ8 Scores Could not find reason for differences in mean 
scores 
BDI Pre scores Compared files, found error (3, 4, 18), and 
referred to original data. 
basewasafull Compared files, found error (3, 4, 7, 9, 31, 45, 
47), and referred to original data. 
Basewasahome Compared files, found error (3, 4, and 31) and 
referred to original data. 
All 2month data Compared files, found errors, and referred to 
original data. 
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Appendix III: dissemination, research publications 
and subsequent research protocols 
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This research has been disseminated through conference presentations both 
nationally and internationally. It has also led to publication in high impact 
peer reviewed journals with an international audience. 
 
List of Conference presentations 
 
Meta Analysis 
 
2007 
 
British Association Of Behavioural and Cognitive Psychotherapies- July 
2007 Brighton UK. Oral presentation open paper session. BA for 
depression a systematic review.  
 
Network for Psychiatric Nursing Research-September 2007 Cambridge 
UK. Oral presentation symposium new approaches. A systematic review of 
BA treatment of depression and the potential relevance for psychiatric 
nurses. 
 
2008 
Australian College of Mental health Nurses-September 2008, Melbourne, 
Australia. Open oral presentation. Behavioural Treatments of Depression: 
Do they Work And Can Mental Health Nurses Deliver Them Effectively. 
 
Meta Analysis and Trial 
 
2009    
British Association Of Behavioural and Cognitive Psychotherapies- July 
2009, Exeter UK. Open oral paper presentation,. Behavioural Activation 
for depression summary of the evidence base and development in a 
randomised controlled trial by non specialists.  
 
2010 
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European psychiatric Nursing Congress. HORATIO. Aril 2010, Prague 
Czech Republic. Oral presentation.  Behavioural Activation for depression 
delivered by mental health nurses.  A systematic review of the evidence 
and controlled clinical trial. 
 
Royal College of Nursing Research Society.  International Nursing 
Research Conference. May 2010, Gateshead UK. Open oral paper.  
Behavioural Activation for depression delivered by mental health nurses.  
A systematic review of the evidence and controlled clinical trial. 
 
Health Care Events National Depression Conference June 2010 London 
UK. Oral presentation. Behavioural Activation for Depression. 
 
British Association Of Behavioural and Cognitive Psychotherapies- July 
2010, Exeter UK. Open oral paper presentation. Behavioural Activation for 
depression summary of the evidence base and results of a randomised 
controlled trial by non specialists.  
 
Network for Psychiatric Nursing Research-September 2010 Cambridge 
UK. Oral presentation. Behavioural Activation for depression summary of 
the evidence base and results of a randomised controlled trial by non 
specialists. 
 
York Primary Care Conference-March 2011 York UK. Oral Presentation.  
Behavioural Activation for depression summary of the evidence base and 
results of a randomised controlled trial by non specialists. 
 
3
rd
 International Nursing and Midwifery Conference- April 2011 Galway 
Ireland. Oral Presentation. Behavioural Activation for Depression by 
Mental Health Nurses. A randomised Controlled Trial of Clinical and Cost 
Effectiveness. 
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Publications from research  
 
Copies of papers are included below 
 
Ekers D, Richards D, Gilbody S. (2008) A Meta Analysis of Behavioural 
Therapy for Depression. Psychological Medicine; 38(5): 611-623. 
 
Ekers D, Richards D, McMillan D, Bland M, Gilbody S. (2011) 
Behavioural Activation delivered by the non specialist: phase II 
randomised controlled trial. British journal of psychiatry; 198(1): 66-72 
 
Contribution to new research development 
 
CASPER  
 
The Meta analysis was used in the design of the HTA funded multi centre 
study Collaborative care for screen positive elders: the CASPER Trial. D 
Ekers is a co applicant on this study due to experience and knowledge 
gained in BA as part of this thesis.  
COBRA 
 
 
The Meta Analysis and RCT have been developed into a large scale multi 
centre study design COBRA (Cost and Outcome of BehaviouRal 
Activation): a Randomised Controlled Trial of Behavioural Activation 
versus Cognitive Therapy for Depression. The COBRA study is designed 
to expand on the findings reported in this thesis as a definitive trial.  The 
results from this research form the basis of this study design and findings 
have informed sample size, recruitment intervention design and therapist 
issues. The relevant section of the COBRA protocol is included in 
appendix III. 
D Ekers is a co applicant of the COBRA study which has been submitted 
for HTA funding and has progressed to second stage review. 
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D Ekers is also on the advisory board of 2 further studies exploring 
dissemination of BA. Firstly to examine BAs effectiveness in Muslim 
communities and secondly adapting BA for delivery to children and 
adolescents. Both studies are in early phases of development and have been 
influenced by the research findings reported in this thesis.  
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Copy of Ekers et al 2008 A Meta Analysis of randomised 
trials of behavioural treatments of depression 
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Evidence based mental health review of Meta Analysis 
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Copy of Ekers et al 2011 Publication BA delivered  by the 
non specilaist: phase II RCT 
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COBRA study protocol section based upon research 
reported in thesis   
 
 
3.2.1 Preparatory work prior to the COBRA application.  
In preparation for the COBRA trial, we conducted a systematic review, meta 
analysis and phase II pilot trial of BA.1,2  
3.2.2 Systematic review and 
meta analysis: in our meta 
analysis of RCTs,2 we first 
found a clinical effect size in 
terms of a reduced 
depression score of −0.70 SD 
units from twelve studies 
(n=459; 95% CI -1.00 to -
0.39; p<0.001) comparing 
behavioural treatments to 
controls using experienced 
therapists (figure 1). We then 
found twelve studies 
comparing behavioural 
treatments with CBT (n=476) 
and showed that behavioural 
treatments had equivalent 
outcomes to CBT (pooled 
SMD 0.08; 95% CI -0.14 to 
0.30, p=0.46), (additional 
figure). In a subsequent meta-
regression analysis, these 
behavioural treatments 
demonstrated a greater level 
of effectiveness at more severe levels of depression (meta-regression b-coefficient -0.05; 
95%CI -0.10 to -0.01; p=0.04).  
However, many of the trials were of limited methodological quality, all were under-
powered for comparing treatments and most did not utilise diagnostic interviews for trial 
inclusion. Treatments in many cases did not conform to modern clinical protocols for BA. 
Long term outcomes were rarely reported with average follow-up only to four months. 
Therefore, the existing trial data are insufficient to provide certainty that BA should be a 
first line treatment for depression and these limitations led to NICE regarding the evidence 
for BA as equivocal and of insufficient strength to recommend BA for first-line routine 
NHS depression treatment.10 Consequently, NICE [p256] made a clear research 
recommendation “to establish whether behavioural activation is an effective alternative to 
CBT” using a study which is “large enough to determine the presence or absence of 
clinically important effects using a non-inferiority design”.10 
 
3.2.3 Pilot Phase II Trial: 
in order to test uncertainties 
around our main COBRA 
hypothesis – that BA will be 
equivalently effective to 
CBT and more cost effective 
– we piloted BA in a phase 
II RCT to examine the 
parsimony argument 
directly, i.e. whether generic 
mental health workers, 
without previous experience 
in therapy, can effectively treat depressed people using a full high-intensity BA 
therapeutic protocol.1 We compared BA against usual care. BA was delivered by NHS 
Figure 3: BA vs TAU
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AfC grade 5 mental health workers with no previous formal training or psychotherapeutic 
experience, who received five days training in BA and subsequent one hour clinical 
supervision fortnightly from David Ekers (nurse consultant, educator and COBRA 
applicant). Intention to treat analyses (figure 3) indicated a difference in favour of BA of 
−15.79 (n=47; 95% CI −24.55 to −7.02) on depression (Beck Depression Inventory-II), an 
effect size of −1.15 SD units (95% CI − 0.45 to −1.85). This compares favourably to the 
overall effect size of −0.70 comparing BA to controls using experienced therapists in our 
meta analysis above.2 The mental health workers demonstrated excellent fidelity to the 
protocol when audio recordings were assessed by independent accredited cognitive 
behavioural therapists with extensive experience in BA. 
3.2.4 Implications: the implications for COBRA are thus: we have demonstrated 
that data from a number of small trials indicates that BA and CBT may have similar 
effectiveness when delivered by specialist therapists; we have also demonstrated that 
generic mental health workers with no prior training in psychological therapies can deliver 
a full BA protocol and achieve results from treating patients with BA which are at least as 
powerful as those achieved by specialist workers compared to usual care. We now need to 
combine these research strands and test BA against CBT using generic mental health 
workers to deliver BA in an adequately powered non-inferiority RCT using gold standard 
diagnostic and depression severity outcomes. We need to include a cost effectiveness 
analysis to see if BA should join CBT as a first line treatment for major depression with 
additional cost advantages to the NHS. If CBT and BA are equally effective, then BA may 
be preferable because its simplicity in delivery and mechanism of change allows for more 
cost effective delivery by less specialised NHS mental health workers. We also need to 
plan a trial with sufficient length of follow-up to measure impact on long-term outcomes 
and costs. Finally, we need to ensure that the training, supervision and treatment fidelity 
checks ensure that the trial is an adequate test of the two interventions, BA and CBT. As 
noted by NICE [p256] “the results of this study will have important implications for the 
provision of psychological treatment in the NHS.”10  
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